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Abstract 
This thesis is concerned with the estimation of costs in economic evaluation. The 
thesis reviews the theoretical and applied literature on costing and highlights that 
studies generally ignore cost variation across health care settings. The thesis aims to 
assess why costs vary across health care settings, and the implications for economic 
evaluations. 
The study uses microeconomic theory to pose hypotheses for cost variation across 
health care settings and uses a consistent methodology to collect costs across a range 
of health care settings. The analysis uses multilevel models (MLMs) to test 
hypotheses concerning cost variation. Statistical theory suggests that MLMs 
accommodate the hierarchical structure of the data and may therefore be more 
appropriate than ordinary least squares (OLS) models for identifying reasons for cost 
variation across settings. The use of MLMs and OLS models for analysing reasons for 
cost variation are compared. The OLS models find that both patient and higher-level 
covariates are associated with length of hospital stay (LOS) and total cost, but these 
models overestimate the precision of the higher-level variables. By contrast, the 
MLMs show that none of the higher-level variables are associated with LOS, and the 
national level of spending on health care is the only higher-level variable associated 
with total cost. 
The empirical investigation also illustrates that using OLS regression analysis to 
report cost-effectiveness can lead to inaccurate estimates. By contrast, the MLMs 
recognise the structure of the data and accurately quantify mean incremental cost- 
effectiveness and the associated levels of uncertainty. 
The thesis concludes that ignoring cost variation across health care settings can lead 
to inaccurate estimates of cost and cost-effectiveness. Basing decision-making on 
inaccurate information can move the allocation of health care resources away from the 
target of allocative efficiency. This thesis presents a methodology for improving the 
conduct of cost analyses that future economic evaluations can adopt. 
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Chapter 1: Introduction 
1.0 Rationale for the thesis 
The last decade has seen important developments in the use of economic evaluation in 
policy-making. Governments in Canada, Australia, the UK, the Netherlands, Sweden, 
Finland and Portugal now use economic evaluations to decide which health care 
technologies to provide (Maynard and Kanavos 2000). The number of published 
economic evaluations has grown rapidly (Pritchard 2004), and the use of these 
evaluations in decision-making can potentially lead to the more efficient use of scarce 
health care resources. However, this objective will only be achieved if these studies 
use appropriate methodologies for measuring outcomes and costs. 
The methods used in economic evaluations have been severely criticised (Birch and 
Gafni 1992, Drummond et al. 1993, Hutton 1994, Gerard et al. 1999, Birch and Gafni 
2002, Drummond and Sculpher 2005). In particular, the methods used in published 
studies for measuring and analysing costs have been shown to be inadequate (Graves 
et al. 2002, Barber and Thompson 1998). Unless these methods are improved, the use 
of economic evaluations will not improve the efficiency of resource allocation. 
1.01 Economic evaluation and efficiency 
The main purpose of economic evaluation is to provide information that can lead to 
the more efficient use of health care resources (McGuire 2001). In the context of this 
thesis there are three different forms of efficiency that warrant consideration: 
technical efficiency, productive efficiency and allocative efficiency. Technical 
efficiency defines the minimum resource inputs required to produce a given output. 
Technical efficiency is necessary but insufficient for productive efficiency, which also 
depends on the relative factor prices of the different factor inputs. To achieve 
productive efficiency the costs of producing a technically efficient output are 
minimised, and so the combination of factor inputs chosen depends partly on their 
relative factor prices. 
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Technical and productive efficiency are pre-requisites for achieving allocative 
efficiency. This `higher level' notion of efficiency requires that the marginal benefits 
and marginal costs of different alternatives, each produced in an efficient way, are 
compared (McPake et al. 2002). Health care decision-makers can use the notion of 
allocative efficiency to choose which health care programmes to provide. The aim of 
this comparison is to identify those health care programmes that produce the most 
units of health gain from the given budget. This comparison might suggest that 
instead of using certain resources to produce for example stroke care, those resources 
could be redeployed to produce paediatric care, leading to a larger gain in health for 
the same cost. This would move the allocation of resources towards the target of 
allocative efficiency'. 
For cost-effectiveness analyses (CEA) to provide the information required to move 
resources towards the goal of allocative efficiency, they have to meet certain 
important requirements (McGuire 2001). For example, each CEA has to report the 
effectiveness of each health care programme by measuring outcomes on the same 
scale. Some commentators have argued that the quality-adjusted life year (QALY) is 
the most appropriate measure of outcome for CEA (Gold et al. 1996)2. Importantly for 
this thesis, a second requirement for CEA is that the costs of each health care 
programme must reflect opportunity costs (Birch and Gafni 2002). Opportunity costs 
are the costs of providing each health care programme in a way that is productively 
efficient (McPake et al. 2002)3. If an economic evaluation compares the costs and 
outcomes of a new intervention delivered in a way that is productively efficient, to an 
existing service delivered in a productively inefficient way, then the cost- 
1 Economists disagree about whether CEA are appropriate for this purpose (see Birch and Gafni 1992, 
Johannesson and Weinstein 1993, Birch and Gafni 1993). For the use of CEA to move resource 
allocation towards allocative efficiency, assumptions such as perfect divisibility of resource inputs, and 
constant returns to scale have to be made (Birch and Gafni 1992). 
2 It is argued that only under very restrictive assumptions is using QALYS as the outcome measure 
consistent with the goal of allocative efficiency (McGuire 2001). 
3 There are various ways in which the definition of opportunity cost can be applied to the use of 
economic evaluations. For example, opportunity cost may refer to the value foregone when the NILS 
does not provide certain health services (Birch and Gafni 2002. However, as this thesis is concerned 
with cost variation across settings the more relevant definition of opportunity cost is the cost of 
efficient production. Variation in costs observed across settings may arise because costs in some 
settings reflect productive inefficiency, and hence intervention costs do not represent opportunity costs. 
If the costs of either or both the health care alternatives under comparison are not opportunity costs, 
then using the resultant CEA may fail to move resource allocation towards allocative efficiency. 
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effectiveness of the new intervention may be overstated. Its implementation would 
then lead to further allocative inefficiency. 
As Tan-Torres Edejar et al. (2003) state: 
"It is not useful for policy-makers to know the cost-effectiveness of interventions 
undertaken in a technically inefficient manner.. " (Tan-Torres Edejar et al. 2003, p47). 
1.02 Measuring opportunity costs for the decision-making context 
It is desirable to measure the opportunity costs of each health care programme for the 
particular decision-making context. If CEAs are to be used to set national priorities 
then costs should represent the opportunity costs of providing each health care 
programme in the country concerned. It is now common for CEAs to collect costs 
alongside multicentre RCTs. These studies can measure resource use for each patient 
and calculate a mean cost for each health care programme. These evaluations can 
potentially estimate opportunity costs for a particular decision context, for example 
for a national decision-making agency such as NICE. 
However, multicentre CEAs may fail to measure opportunity costs because they 
ignore systematic cost variations across health care settings. In this thesis, a health 
care setting4 is defined as a health care provider in a particular geographical location. 
These health care providers may be located in different geographical locations in the 
same country or in different countries. This thesis uses the term `cost variation across 
settings' to refer to systematic variation in resource use and/or unit costs across health 
care providers. This form of cost variation may arise because of for example, 
differences in incentives to cost-minimise across health care settings. The problem is 
that even multicentre CEAs typically only measure unit costs in a single health care 
setting, and may only collect resource use data for a few patients in each health care 
setting. In these circumstances, it is difficult to establish which health care settings are 
4 Throughout the thesis the term 'setting' is used interchangeably with the terms 'centre' or 'health care 
firm'. Each of these terms refers to a particular health care provider or group of providers. 
s The term `cost variation' used in the thesis refers generally refers to the product of the resources used 
(e. g. the length of hospital stay), multiplied by their unit cost (e. g. the cost per hospital day). Where 
more specific reference is made to variation in resource use or unit costs this is made explicit. The costs 
referred to are generally health service costs, but where appropriate broader societal costs are 
considered. 
is 
efficient, and therefore which health care settings' costs represent opportunity costs. 
Studies cannot identify efficient production unless they measure costs in several 
health care settings, for example by comparing the costs of providing a particular 
technology in different geographical locations. 
Multinational economic evaluations can measure costs in several settings, however 
they tend to measure costs in one country and transfer them to another country 
(Schulman et al. 1996, Johannesson et al. 1997). Even if the costs estimated in one 
country represent opportunity costs, they are unlikely to represent opportunity costs in 
a different country, because of variations in for example, factor prices6. 
Thus, multicentre studies whether they are conducted on a national or an international 
basis have failed to identify reasons for cost variation across settings, and the 
difficulties this poses for the estimation of opportunity costs. 
Economic evaluations that measure costs in several health care centres have 
demonstrated wide variations in resource use and unit costs across the settings 
concerned, both within and between countries (Coyle and Drummond 2001, Johnston 
et al. 1998, Willke et al. 1998). However, these studies do not assess why these cost 
differences occur. In particular, these studies have not provided an empirical 
investigation of which factors are associated with cost variation. Instead, 
commentators have listed a priori reasons why costs may vary between health care 
settings in an ad hoc manner (O'Brien 1997, Mason 1997). For example, costs in a 
particular health care setting may be relatively high because the setting faces higher 
factor prices or has higher levels of productive inefficiency (O'Brien 1997). If the 
setting produces health care in a less efficient way7, then the costs of health care 
6 Factor prices may vary across international health care settings because for example restrictions in the 
labour market for health care professionals mean that the wages of health care professionals vary across 
countries. If health care firms aim to cost-minimise then theory suggests that where firms face 
differences in relative factor price they will adjust the mix of factor inputs used, As both factor use and 
factor price are components of unit cost, these between-country differences can lead to differences in 
unit costs, Firms may also adjust the resources used in providing each health care programme, 
according to the factor prices they face. Theory suggests that resource use and unit costs are also 
correlated. Thus if factor prices differ across countries then resource use, unit costs and total costs may 
vary across international health care settings. 
7 For example, because there is less incentive for the health care decision-makers to cost-minimise. 
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programmes in this setting do not represent opportunity costs. However, there is 
limited empirical support for these a priori reasons for cost variation. 
A thorough investigation is required that uses the relevant literature to identify a 
priori reasons for cost variation, collects costs in a range of health care settings and 
identifies which of the a priori reasons for cost variation are the most important. This 
investigation can provide guidance on the settings that economic evaluations should 
collect costs from to ensure that the programme's costs represent relevant opportunity 
costs. 
1.03 Identifying a priori reasons for why costs may vary systematically across 
health care settings. 
Insights from microeconomic theory can provide a priori reasons for why the costs 
observed may vary across settings. Production function theory states that firms in 
different health care settings can all produce a technically efficient output, but with 
varying combinations of factor inputs. Cost function theory suggests that if firms in 
different settings face different relative factor prices, then they will substitute those 
inputs with relatively low factor prices for those inputs with relatively high factor 
prices to achieve productive efficiency. However, firms in different contexts may vary 
in the extent to which they achieve technical or productive efficiency. 
To understand why health care firms may not choose efficient combinations of factor 
inputs an understanding of the health care context is important. Health care firms may 
be constrained from achieving efficient production by contextual factors such as local 
labour market regulations (Elliott 2003). For example, even if a hospital recognises 
that it is efficient to reduce the use of doctors' time, local labour market regulations 
may prevent this. The incentives and regulations provided by national decision. 
makers may also explain why the rate of diffusion of new technologies varies across 
countries. These contextual factors may partly explain why systematic cost variations 
are observed across health care settings. 
While some of the factors driving systematic variations in costs may operate at a 
national or centre-level, the health services research literature suggests that variations 
in individual patient characteristics across health care settings, may also be important 
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(Phelps and Mooney 1993). If the case-mix of patients attending a particular health 
care setting is more complex than average, then this may lead to higher resource use 
and unit costs. 
Empirical evidence is required to assess which of these a priori reasons are important 
for explaining variations in costs across health care settings. Before systematic 
reasons for cost variation can be identified, certain measurement and analysis issues 
that arise when comparing costs across health care settings need to be recognised. 
1.04 Measurement issues that arise when comparing costs across health care 
settings 
A study that attempts to compare costs across health care settings will encounter 
measurement issues. Most of these issues arise whether the study compares costs 
within or across countries. Previous attempts to compare costs across health care 
settings have not used a consistent costing methodology (Schulman et al. 1998, 
Willke et al. 1998); this makes it difficult to assess whether the observed cost 
differences are due to systematic variations in cost or inconsistencies in the costing 
methodology. In studies that have used aggregated datasets to assess cost variation, it 
is difficult to assess whether the costs are measured in the same way in each setting 
(Carey 2000). For example, the costs of hospital overheads are included in some 
settings but not others. The guidelines for economic evaluation suggest that measuring 
resource use and unit costs separately can assist with interpreting cost differences 
between settings (Drummond et al. 1997a). However, this level of disaggregation may 
be insufficient; it is difficult to interpret reasons for unit cost variation if the study 
uses aggregated measures of unit cost. Instead, if a disaggregated costing method is 
used differences in the individual components of unit costs, the factor prices and 
factor use, can be compared across health care settings. Price and volume indices can 
then be constructed to examine why unit costs vary by health care setting. These 
indices have proved helpful in other areas for interpreting factor use and factor prices 
differences across settings, and the implications for productive efficiency (Danzon 
and Chao 2000, van Ark et al. 1999). 
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A measurement issue that arises when comparing costs across international settings, is 
that costs have to be converted from local currencies into a common currency. A 
common approach is to use conversion factors based on purchasing power parity 
(PPP) indices, these indices aim to adjust for international differences in factor prices 
(Kanavos and Mossialos 1999). Studies estimating costs in different countries 
generally use Gross Domestic Product (GDP) PPP indices, that attempt to adjust for 
differences in the price of goods and services consumed in the entire economy. 
However, if these general indices are used to convert costs in a particular sector they 
may fail to adjust for differences in input prices (Wordsworth and Ludbrook 2005). 
Unexplained variations in costs across settings could relate to unmeasured differences 
in case-mix. This problem arises in studies assessing levels of inefficiency across 
health care settings. To estimate levels of inefficiency these studies require data from 
a large number of health care firms and therefore tend to rely on aggregated datasets 
(Newhouse 1994)8. Such datasets contain routinely collected data on costs, case-mix 
and outputs and encompass the whole of hospital production. Routine measures such 
as the Diagnosis Related Group (DRG) system of case-mix classification may fail to 
recognise differences in the case-mix of patients across hospitals (Iezzoni et al. 1996). 
It is therefore unclear how much reported variations in efficiency levels across 
hospitals represent actual efficiency differences, or variations in the case-mix of 
patients (Cowing and Holtmann 1983). 
A further measurement issue is whether the study has sufficient patients and health 
care settings to identify systematic reasons for cost variation. Some previous studies 
of cost variation have not sampled enough patients or health care settings to identify 
systematic variations across health care centres (Willke et al. 1998). These studies 
may have attributed unexplained variations to random variations when they reflect 
systematic differences that the study failed to detect. 
a Even the smallest hospital production studies use cross-sectional datasets from more than 20 health 
care firms. 
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1.05 The choice of statistical techniques for identifying reasons for cost variation 
and analysing multicentre cost-effectiveness. 
Studies could address the main measurement issues raised by collecting disaggregated 
data for sufficient patients and centres. However, decisions made at the analysis stage 
still determine whether the investigation makes an appropriate assessment of the 
reasons for cost variation. 
Ordinary least squares (OLS) regression analysis and multilevel models (MLMs) are 
two techniques that the analyst can use to identify factors associated with cost 
variation across settings. Previously, economic evaluations have used OLS regression 
models to identify reasons why costs vary between settings (Willke et al. 1998, Coyle 
and Drummond 2001). However, OLS models assume that individual observations are 
independent. This assumption does not appear plausible when analysing cost data 
from several settings, where there are a priori reasons for expecting differences in 
costs. For example, factor prices may vary across health care settings, and the cost 
data may therefore be clustered within health care settings. In this context, the use of 
OLS regression models to identify reasons for cost variation could lead to incorrect 
inferences. MLMs can acknowledge the hierarchical structure of data (Goldstein 
1995) and may therefore be more appropriate for analysing variations in costs across 
health care settings. However, they have rarely been used in health economics (Rice 
and Jones 1997), and their use for analysing costs and cost-effectiveness has not been 
explored. 
In summary, economic evaluations commonly fail to identify reasons for cost 
variations across health care settings. Some studies suggest that there are wide cost 
variations particularly across international health care settings (Schulman et al. 1998, 
Willke et al. 1998) but these studies fail to use appropriate methodologies. In 
particular, these studies do not use a priori reasoning to pose hypotheses for 
systematic variations in cost, they ignore measurement issues, and the analytical 
methods used do not recognise the clustering in the data. The importance of this gap 
in the literature was recognised by a commissioning brief from the NHS Health 
Technology Assessment Programme (NHS R&D Programme 1998), and recent WHO 
guidelines on generalisability (Murray et al. 2000). 
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An empirical study is needed to thoroughly assess the reasons why costs observed 
may vary across health care settings. This assessment needs to use a priori reasoning 
to identify factors that may be associated with systematic cost variation. The 
importance of these a priori reasons in explaining cost variations then needs to be 
tested. Such an empirical investigation has to tackle the measurement and analysis 
issues raised. Finally, once the study identifies reasons for systematic variations, the 
findings can inform the conduct and interpretation of economic evaluations. 
1.1 Aims and objectives 
The overall aim of this thesis is to assess why costs vary across health care settings, 
and the implications for the methodologies used in economic evaluation. The specific 
objectives are: 
1. To assess how economic evaluations currently consider cost variation across 
settings. 
2. To generate hypotheses for why costs may vary across health care settings. 
3. To identify which factors are associated with variation in resource use and cost 
using MLMs and OLS regression models. 
4. To compare the use of OLS regression models to MLMs for analysing 
multicentre cost-effectiveness data. 
The way the thesis considers each of these objectives is described briefly below: 
1. To assess how economic evaluations currently consider cost variation 
across settings. 
The literature review considers current practice in economic evaluation and examines 
both methodological guidelines and empirical studies. The review focuses on how the 
design and analysis of economic evaluations currently considers cost variation across 
settings. It highlights that there are important areas of omission in current 
recommended practice. For example, the guidelines provide scant advice for the 
analyst conducting a multicentre study on how to select the centres for cost 
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measurement. The guidance does not consider a priori reasons from the economics 
literature on why factor prices, factor use, and resource use may differ across health 
care settings. Moreover, there is little advice on how studies should identify 
systematic variations when analysing cost data, and how they should interpret 
differences in cost-effectiveness across health care settings. 
The thesis therefore identifies several gaps in the methodological literature on 
economic evaluation that the thesis can inform by identifying reasons for systematic 
variations in costs across health care settings. 
2. To generate hypotheses for why costs may vary across health care settings. 
The thesis identifies a priori reasons for systematic cost variation by reviewing 
relevant strands from the health economics, microeconomics and health services 
research literatures. Costs may vary systematically across health care settings because 
for example, health care firms face different incentives to cost-minimise, and this may 
lead to variations in levels of productive inefficiency. Observed costs may also vary 
because of systematic differences in case-mix. The identification of a priori reasons 
for cost variations across health care settings informs the design and interpretation of 
the empirical investigation. 
The empirical investigation extends an observational study that measures the costs 
and outcomes of stroke care across 13 centres in 10 different European countries. The 
study collects information on why costs may vary systematically across the different 
European centres. For example, the study gathers information on, factor prices, the 
incentives for each provider to cost-minimise, and the level of health care spending in 
each country. These data are used to establish whether the reasons for cost variation 
suggested in the literature review are supported by the empirical investigation. 
The empirical investigation takes a consistent, disaggregated approach to cost 
measurement in each setting. The study measures the use and price of factor inputs, 
and compares these parameters across the health care centres. The thesis considers the 
choice of currency conversion factor, by developing a technology specific measure of 
PPP based on factor inputs used to produce stroke care and their associated factor 
prices. 
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3. To identify which factors are associated with variation in resource use and 
cost using MLMs and OLS regression models. 
The empirical investigation recognises that multinational cost data may have a 
hierarchical structure with patients clustered within health care centres in different 
countries. In this context, the use of MLMs to identify systematic reasons for 
international cost variation is attractive. MLMs recognise the structure of the data, and 
may make inferences that are more correct. The thesis compares the use of MLMs 
with OLS regression analysis for identifying reasons for systematic cost variations, to 
see whether the choice of technique has an effect on the study's results. 
4. To compare the use of OLS regression models and MLMs for analysing 
multicentre cost-effectiveness data. 
Once a comprehensive assessment of the reasons for cost variation is undertaken, it is 
then possible to consider the implications for the conduct of economic evaluations. 
The thesis uses data from the costing study to generate a multicentre cost- 
effectiveness dataset. The analysis compares MLMs to OLS regression models for 
estimating incremental cost-effectiveness. The MLMs are extended to include 
covariates that adjust for systematic cost variations across health care settings. 
The discussion section of the thesis considers more generally the implications of the 
investigation of cost variation across settings for the design and analysis of economic 
evaluations. 
1.2 Structure of the thesis 
The thesis has two main sections: Chapters 2-5 cover the literature review and 
Chapters 6-9 the empirical investigation. 
The literature review starts by examining the relevant economic evaluation literature. 
Chapter 2 considers the methodological guidelines for economic evaluation with a 
focus on those aspects that are relevant for an investigation of cost variation across 
settings. Chapter 3 reviews how economic evaluations have traditionally considered 
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cost variations across settings, with a focus on multinational studies. Chapter 4 
reviews the relevant microeconomics, health economics and health services research 
literatures. The chapter begins by examining insights from the production and cost 
function literature, then moves onto consider contextual and patient factors that may 
explain systematic variations in costs across health care settings. The literature review 
also highlights measurement issues that arise when comparing costs across health care 
settings. Hypotheses are posed regarding potential reasons for cost variation. Chapter 
5 considers some of the techniques for identifying reasons for cost variation across 
settings. The chapter discusses issues that arise when using techniques for measuring 
efficiency, OLS regression analysis or MLMs for analysing cost variation. The review 
focuses on the issues that arise when using MLMs to analyse variations in cost and 
cost-effectiveness across health care settings. Chapter 5 concludes by offering an 
overall critique of the literature reviewed and provides the conceptual framework for 
the empirical investigation. 
Chapter 6 begins by considering how the conceptual framework applies to the 
empirical investigation and introduces the case study for the empirical study. The 
chapter describes the methods used to collect information on the patient, centre and 
national factors potentially associated with cost variation across settings. The 
methodology used to collect resource use data is described. The resource use data are 
presented and used in conjunction with the information on patient and contextual 
factors to pose hypotheses for resource use and cost variation. Chapter 7 describes the 
methods used to collect unit costs and explains how the empirical study addresses 
some of the measurement issues raised. It also describes how price and volume 
indices are calculated and used to analyse unit cost differences across the study 
settings. Unit costs for each health care setting are presented, together with the price 
and volume indices. The choice of conversion factor for translating costs to a common 
currency is considered, and the total costs are presented using different conversion 
factors. 
In Chapter 8 OLS regression analyses and MLMs are used to identify factors 
associated with systematic variations in resource use and costs across health care 
settings. The implications of the choice of technique are discussed. Chapter 9 
compares OLS regression analyses and MLMs for CEA using a multicentre dataset 
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developed from the cost data. Each of the techniques is used to estimate overall 
incremental cost-effectiveness. This chapter illustrates how using a MLM with 
covariates can recognise systematic cost differences across health care settings, when 
analysing cost-effectiveness. 
Chapter 10 summarises the main findings from both the literature review and the 
empirical investigation. The main themes to emerge from the thesis are discussed 
alongside the limitations of the approach. Chapter 11 presents the conclusions, 
recommendations for further research and the policy implications that arise from the 
thesis. 
1.3 Overall contribution of the thesis 
The overall contribution of the thesis is to raise awareness of current problems 
concerning the way costs in economic evaluations are measured and analysed. In 
particular the literature review highlights that previous studies have tended to 
disregard cost variation across health care settings. Ignoring this cost variation may 
lead to inaccurate estimates of the cost and cost-effectiveness of health care services. 
It is therefore a primary objective of this thesis to examine why this cost variation 
exists, and to examine the implications for economic evaluation. This thesis identifies 
a priori reasons for why costs may vary across health care settings. These reasons are 
grouped into patient factors (e. g. casemix) and contextual factors (e. g. the level of 
health care infrastructure in the setting concerned). 
Previous studies of cost variations across settings have used highly aggregated 
datasets, and the results have been difficult to interpret because measurement issues 
pervade these studies. The cost differences observed may simply reflect 
methodological inconsistencies in for example, the methods used to estimate unit 
costs. This thesis contributes to research in this area by using a disaggregated dataset 
to tackle the measurement issues raised. The methodology developed disentangles 
reasons for cost variation across international health care settings. Price and volume 
indices originally developed on time series data, are used to examine the role of price 
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and volume differences in explaining cost variation across health care settings. This 
disaggregated approach therefore extends traditional cost function studies (see for 
example Feldstein, 1967), and enables the thesis to identify a range of reasons for cost 
variation across settings. 
A key contribution of the thesis is to apply a method of analysis-- multilevel 
modelling that recognises that multicentre cost data are hierarchical. Although MLMs 
have been recommended for use in health economics (Rice and Jones, 1997), few 
studies have followed this approach. The empirical section of this thesis demonstrates 
that MLMs are more appropriate than OLS regression analyses for analysing reasons 
for cost variations across health care settings. In particular, the MLMs appropriately 
estimate the precision of the higher level variables associated with total cost. By 
contrast the thesis demonstrates that OLS regression analysis overestimates the 
precision of these higher-level variables and leads to incorrect inferences about which 
factors are associated with cost variation. The thesis also demonstrates that using OLS 
regression analysis in multicentre studies can lead to inaccurate estimates of mean 
incremental cost-effectiveness, and the associated uncertainty. 
The thesis concludes that ignoring cost variation across health care settings can lead 
to inaccurate estimates of cost and cost-effectiveness. Basing decision-making on 
inaccurate information can move the allocation of health care resources away from the 
target of allocative efficiency. While the focus of the empirical contribution is on 
observational cost data collected in a multinational context, the underlying 
methodological concerns raised by ignoring cost variation across health care settings 
apply more generally. This thesis presents a methodology for improving the conduct 
of cost analyses that future economic evaluations can adopt. 
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Chapter 2: Economic evaluation guidelines on 
costs and cost variation across settings 
2.0 Introduction 
As the demand for health care continues to outstrip the supply, information is required 
to assist policy-makers allocate resources in an efficient and equitable way (Maynard 
and Kanavos 2000). Economic evaluation provides a framework for presenting 
information on the costs and effectiveness of health care interventions, so that 
decision-makers can allocate resources in a way that maximises the population's 
health given resource constraints (Drummond et al. 1997a). Several countries have 
moved towards the statutory use of economic evaluation in setting health care 
priorities9. Yet for economic evaluations to make a useful contribution, these studies 
have to be conducted on a sound basis in accordance with economic and statistical 
principles. Otherwise, using these studies may fail to move the allocation of scarce 
health care resources towards the goal of allocative efficiency; decision-makers may 
become disillusioned with economic evaluations and return to using other ways to set 
health care priorities (Donaldson et al. 2002, Hutton and Maynard 2000). 
2.01 Improving the methodological quality of economic evaluations 
In an attempt to improve the quality of economic evaluations, methodological 
guidelines have been developed that give advice on how to conduct these studies. The 
guidelines consist of formal requirements issued by reimbursement agencies and more 
methodological advice published in academic journals. In part, these guidelines reflect 
recent methodological and empirical developments, and emphasise areas of agreement 
9 Economic evaluations are now used by governments in Canada, Australia, the UK, the Netherlands, 
Sweden, Finland and Portugal to inform decisions about which health care technologies are to be 
publicly provided (Hutton and Maynard 2000). 
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amongst health economists (Johnston et al. 1999). For example, there has been recent 
progress in the measurement and valuation of health outcomes (Brazier et al. 1999), 
and the development of methods to represent uncertainty (Briggs and Gray 1999, 
Fenwick et al. 2004). By contrast, less research resources have been devoted to 
improving costing methods in economic evaluation (Graves et al. 2002) and in 
particular to the issue of cost variation across health care settings. However, the issue 
of cost variation would appear important as many studies now rely on cost data 
collected alongside multicentre RCTs. In these studies, there are a priori reasons for 
expecting costs to differ across settings, because of for example variations in factor 
prices. 
The prior belief that costs vary across health care settings raises certain issues for the 
conduct of CEA. These issues include: in which centres should the study collect 
resource use and unit cost data? If the study is multinational, should the analysis pool 
cost data across different countries? How can a national decision-maker apply a 
multinational measure of cost-effectiveness to a particular country? Economic 
evaluations are required to consider these issues; otherwise, the results may not be 
relevant for decision-making. Decision-makers have stated that they may not use 
published evaluations if they do not believe that the results apply to their local context 
decision context (Drummond et al. 1997b, Weatherly et al. 2002). 
2.02 Purpose of the review of methodological guidelines 
The main aim of this chapter is to assess how methodological guidelines suggest 
economic evaluations should consider systematic variations in costs across settings. 
This review covers study design, analysis and presentation of results in economic 
evaluation. The review highlights where there are omissions or disagreements in the 
methodological literature relating to the issue of cost variation. The review also 
identifies aspects of the guidance that can be used to ensure methodological 
consistency when measuring costs across health care settings. The findings from the 
review can therefore inform the empirical investigation for the thesis. The empirical 
investigation needs to apply a standard costing method across different health care 
settings so that any differences in observed costs across health care settings can be 
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attributed to systematic variations rather than methodological differences in the way 
the costs are measured. 
2.1 Methodology used in literature review 
A structured review was conducted of the guidance issued for economic evaluations. 
The focus of the review was on methodological guidance that relates to cost variation 
across health care settings. The literature review covered advice for economic 
submissions to government agencies and general guidance published in peer-reviewed 
journals aimed at academic researchersto 
2.11 Data sources and search strategy 
The literature search located guidance from a range of sources. The Medline, BIDS, 
HEED, NHS NEED and EMBASE databases were searched using the search terms 
`costs and cost analysis', `economic eval*', `transferability', `generalisability', 
`generalizability', `multinational', and `multicentre' over the years 1990-2004. This 
strategy was supplemented by screening the bibliographies of recently published 
articles reviewing the methodology used in economic evaluations, reviewing the 
bibliographies of papers retrieved, searching library catalogues for relevant books, 
reviewing websites of institutions producing or using economic evaluations, and 
based on recommendations from colleagues working in this area. In addition to 
including published papers, the review also included `grey literature' in particular 
conference papers and working papers. Relevant electronic journals were searched to 
identify recent articles that were `in press'. 
Inclusion and exclusion criteria 
Titles, abstracts (if available) and full papers were examined to identify relevant 
sources for the purposes of this review. Sources were required that discussed aspects 
of study design, analysis or presentation of results related to cost variation across 
lo Although it is recognised that these are not formal guidelines, they are included in the general term 
'guidelines' used throughout this thesis. 
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settings". The review only included those guidelines published or produced after 
1990. Previous reviews of costing methods found guidelines prior to 1990, tended to 
ignore methodological issues (Wolstenholme 2001). This review was therefore 
limited to those guidelines that incorporated recent developments in the field. The 
review was also limited to English language sources. 
The findings from the review are reported in each of the three key methodological 
areas: study design (section 2.2), data analysis (2.3) and presentation and 
interpretation of results (2.4). 
2.2 Study Design 
The guidelines reviewed mostly include sections on framing and designing the study, 
inclusion of the relevant resource use items, and collection and measurement of 
resource use and unit costs. Each of these areas is reviewed below. 
2.21. Framing and designing the economic evaluation 
The guidelines emphasise that the study question has to be clearly defined. In 
particular, it is important to identify the relevant decision-maker, as this may 
determine many of the key methodological standpoints, as Torrance et al. (1996) point 
out: 
"... understanding the decision context will guide the choice of audience and the 
perspective of the study. " (Torrance et al. 1996, p54. ) 
Jonsson and Weinstein (1997) suggest that the perspective taken to the evaluation 
may differ across countries in a multinational CEA. For example while in England 
and Wales NICE recommends that CEA should exclude the costs related to lost 
11 Questions such as which form of economic evaluation to use are not relevant, as the issues raised by 
cost variation across settings apply whichever type of economic evaluation is chosen. For more general 
reviews on methodology in economic evaluations see the books by Drummond et al. (1997a) or Gold et 
al. (1996). 
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income, this may inappropriate for measuring costs in Germany as sickness funds 
have to meet the costs associated with lost income as well as health care costs. 
The decision context also has implications for the `vehicle' chosen for the economic 
evaluation; economic evaluations may use national RCTs, multinational RCTs or 
decision-analytical models12. In some decision contexts methodological guidelines 
have expressed a preference for CEA based on national RCTs (CCOHTA 1997). 
Nevertheless, whichever study design is preferred there are general issues to address 
about cost variation across settings. 
Most of the guidelines emphasise that analysts should carefully define the health care 
programmes under evaluation. So for example, the type of surgery or the dose and the 
duration of the drug regimen should be clearly stated. The comparators chosen should 
include current routine practice, which may vary depending on the decision context, 
for example the country concerned (Byford and Palmer 1998). The evaluation should 
define what `routine practice' means, for example if patients are routinely managed 
following a stroke, the evaluation should explain what resources use is involved. This 
can help a decision-maker understand what the baseline is for the analysis, and assess 
whether the results are likely to apply to their particular context. 
2.22 Including the relevant items of resource use 
The guidelines emphasise that all relevant items of resource use should be included in 
a cost analysis (Johnston et al. 1999, Drummond et al. 1997a). The items to include 
depend on the methodological standpoints taken including the study's perspective and 
time-frame. There are also empirical issues to consider, including the quantitative 
importance of the resource use items concerned, and their association with health 
outcomes (Johnston et al. 1999). 
12 Economic evaluations may also be based on observational studies, or use a combination of these 
different study designs, e. g. a model may use effectiveness data from a national RCT, but cost data 
from an observational study. 
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a) Perspective or viewpoint 
A primary consideration is whether the theory of welfare economics provides the 
basis for the study 13. The welfarist position provides a strong basis for including a 
wide range of programme costs irrespective of the agency upon which they fall 
(Johnston et al. 1999). From a welfarist perspective the costs to any public sector 
agency, the costs of lost production, the costs to patients and their carers and any 
other costs to society should be included. However, there is widespread disagreement 
about whether welfare economics should provide the basis for economic evaluation, 
and others recommend taking an extra-welfarist position and only including those 
costs that are relevant from the perspective of the decision-maker (Tsuchiya and 
Williams 2001). It is still possible that from an extra-welfarist standpoint the societal 
perspective is taken, for example the CCOHTA guidelines suggest taking the widest 
possible decision-making perspective, i. e. the societal perspective (CCOHTA 1997). 
This allows decision-makers to use the results from the perspective most relevant to 
them. As Brouwer et al. (2001) state: 
"Taking other perspectives like the health care budget perspective is therefore to be 
discouraged as being too narrow and not recognising that budgets are arbitrary 
divisions in how resources are organised. " (Brouwer et al. 2001, p70). 
Nevertheless, other guidelines do recommend taking a narrow viewpoint. For 
example, recent NICE guidance for submissions to the technology appraisal process 
suggests that a health and personal social service perspective (PSS) is appropriate 
(NICE 2004). Taking this perspective ignores all costs falling on other public service 
providers, patients, and on society from lost production. This has implications for 
ensuring consistency in cost analysis conducted or used in different settings. The 
boundaries between different agencies may vary across settings. For example, in some 
countries the health budget pays for the cost of nursing home care, whereas in others 
the social care budget or the patient may bear the cost. Taking a narrow perspective 
leads to inconsistent criteria being applied to the inclusion of resource use across 
13 Welfare economic theory rests upon economic models of individual behaviour. It is based on the 
assumption that individuals are the best judge of their own well-being and provides the theoretical basis 
for cost-benefit analysis. The theoretical basis of cost-effectiveness analysis is less clear, and has been 
subject to considerable debate in the health economics literature (McGuire 2001). 
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different contexts. One way to address this problem is to take a societal perspective to 
costing across all settings. 
b) Time-frame 
The choice of resource use items for inclusion in the cost analysis also depends on the 
study's time-frame. However, there is no consensus about which time-horizon is most 
appropriate. Torrance et al. (1996) recommend taking a long-term time-horizon, while 
the NICE guidelines suggest that the time-horizon should be sufficient for the 
evaluation to examine the full impact of the interventions on costs and outcomes 
(NICE 2004). The NICE guidelines suggest that when the evaluation is of 
technologies for chronic diseases, such as cancer, diabetes or ischaemic heart disease, 
this requires a lifetime time-horizon (NICE 2004). If the time-horizon is too short, the 
analysis may exclude important costs and outcomes associated with the intervention. 
This could be an important issue when collecting costs across several settings. If some 
settings treat the disease early and intensively, whereas in other settings, high-cost 
interventions are provided much later, then the time-horizon must be sufficient to 
avoid the inconsistent inclusion of costs. 
c) Quantitative importance 
Johnston et al. (1999) suggest that if there is no difference in a particular cost between 
the interventions concerned, then the analyst could exclude these costs. However, as 
Drummond and Davies (1991) point out in a multicentre study, even if costs are the 
same in both the treatment and control groups over all the centres included, there may 
be cost differences between the two groups within individual health care settings. It is 
therefore unwise to neglect context-specific cost differences when deciding on which 
resource use items to include. 
d) , Association with health outcome 
Although the focus of the thesis is on costs and cost variation, decisions about which 
resource items to include also need to consider patient outcomes. The costs included 
in an economic evaluation should be opportunity costs. Opportunity costs are the 
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costs of technologies that are produced efficiently, where productive efficiency refers 
to the minimum cost of producing a given output or outcome. Thus, if resource use 
that does not improve outcomes could be identified, the CEA could exclude these 
costs from the overall costs of the health care programmes. Including these costs 
would mean that the costs reported no longer reflect productive efficiency and 
opportunity costs. Some guidelines have suggested that the relevant outcomes are 
those that relate to health rather than utility, and therefore the relevant resource use 
items to include are those that improve health rather than utility (Culyer 1990). The 
guidelines do not explain how to identify those resource inputs that are associated 
with improvements in health outcome. To understand the relationship between 
resource inputs and health outcomes the study could estimate the likely production 
function for the disease and interventions in question (Brouwer et al. 2001). However, 
this may be difficult especially in a multinational context (Koopmanschap et al. 
2001). The relationship between resource use and health outcome may differ across 
settings, because of for example, differences in case-mix. Rather than just deciding on 
a standard list of resource use items for inclusion, studies should try to recognise these 
issues when identifying the relevant resource use to measure. 
2.23 Collection and measurement of resource use 
The guidelines all agree that it is necessary to present separate estimates of resource 
use and unit cost to help decision-makers understand whether the resource use and 
unit costs observed in the study setting will differ from their own (NICE 2004, Luce 
et al. 1996, Drummond et al. 1997a, CCOHTA 1997, Drummond and Jefferson 1996). 
However, there is a lack of definitive guidance on exactly how to measure resource 
use. Issues that are relevant for assessing cost variation across settings include: the 
source of resource use data, the numbers of patients to measure resource use for, the 
numbers and types of setting to include, and the level of aggregation to use. Each of 
these issues is now considered in turn. 
a) Source of resource use data 
An RCT, observational study, routine database or expert opinion can provide the 
source of resource use data. A cost-effectiveness model can use information from any 
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of these sources. Some of the guidelines state that the preferred source of data for 
resource use measurement is a pragmatic RCT (Mason 1997). Collecting data from 
pragmatic RCTs has the advantage of producing unbiased estimates of the differences 
in resource use between the interventions concerned, and it allows costs to reflect 
routine clinical practice. By contrast, Mason (1997) criticises explanatory RCTs14 for 
being atypical of routine practice because of protocol driven costs, and the inclusion 
of atypical patients and centres. 
A multicentre RCT has advantages over other forms of study design in that it can 
explore differences in resource use across centres, and has the potential to produce 
results that are more generally applicable. Drummond and Davies (1991) suggest that 
before the results from an economic evaluation alongside a multinational RCT can be 
applied to a national context, the pooled international estimates of resource use should 
be adjusted to each local context. Drummond and Davies (1991) demonstrate how 
expert opinion can be used to adjust resource use parameters collected in an 
international evaluation and make them more nationally relevant. However, Luce et 
al. (1996) highlight the potential inaccuracies of using expert opinion to estimate 
resource use and recommend using it as a last resort. 
Mason (1997) considers the problem of using observational data to compare resource 
use between treatment groups and discusses the bias that may arise according to the 
selection of patients. In a multicentre observational study, the selection of patients for 
each treatment arm may also vary by centre leading to differences in the degree of 
bias across the centres concerned. Mason (1997) does though acknowledge that 
observational studies are more likely to represent routine clinical practice than RCTs, 
and studies that use this study design may produce more generalisable cost estimates. 
Observational studies can therefore be used to establish why costs of routine practice 
may vary across health care settings in different geographical locations. 
14 Explanatory RCTs use highly regulated protocols, and involve blinding of patients and health care 
professionals. 
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b) Number of patients to include in the resource use measurement 
In an economic evaluation based on a RCT the study's power to detect differences in 
cost or cost-effectiveness between the interventions concerned partly depends on how 
many patients are included in the measurement of resource use. However, the 
guidelines are not prescriptive about recruiting sufficient numbers to detect these 
differences. Instead, the guidelines highlight the difficulties faced by economic 
analysts when trying to detect differences in economic endpoints, as sample sizes are 
usually determined by power calculations for the main clinical endpoint (Johnston et 
al. 1999, Briggs and Gray 1999, Gray et al. 1997). As there is often greater variability 
in costs than outcomes amongst patients, more cases are usually needed to detect 
differences in economic endpoints (Gray et al. 1997). Power calculations are also 
problematic because they require data on cost differences between interventions, and 
on the distribution and variability of costs, these data are usually unavailable ex ante 
(Johnston et al. 1999). 
In addition to variability in costs amongst patients receiving a health care programme 
within a particular setting, there may be differences in resource use and costs across 
settings. This may have additional implications for the study's ability to estimate 
accurately and precisely the incremental costs of an intervention for a particular 
decision context. The systematic differences in resource use across settings may be 
particularly large in an international study. In light of these systematic differences, it 
might be tempting to base power calculations on conducting country-specific 
analyses. However, if multinational economic evaluations are to recruit sufficient 
patients to detect country-specific differences then this would drastically increase the 
costs and duration of these studies. 
There is little advice in the guidelines on how many patients to sample when 
collecting data on resource use. This may depend on several factors including the size 
of the differences the study is aiming to detect, the sampling variation across patients, 
and particularly in an international context, any systematic variations that exist across 
patients and health care settings. 
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c) Number and types of setting to include 
In economic evaluations based around RCTs a potentially important issue is: from 
how many and which centres should resource use data be collected? None of the 
guidelines offer specific advice on the optimal number or location of sites for 
measuring resource use data. Coyle et al. (1998) suggest that: 
"... cost data from a single site participating in the study would be acceptable if it is 
demonstrated that the cost structure of the site is typical of all other sites within the 
study" (Coyle et al. 1998, p140). 
The authors do not explain why obtaining cost data from a `typical site' is desirable, 
or how it is possible to judge whether the cost structure is typical without measuring 
costs in all sites. Baladi et al. (1996) offer slightly more stringent criteria for centre 
selection and state that rather than being representative of the study sites, the 
centres(s) selected for resource use measurement should be representative of the 
setting in which the technology is going to be implemented; they state: 
".. for example if a technology is to be deployed in secondary level hospitals, costs 
should be derived from this particular hospital group and not estimated from tertiary 
teaching hospitals. " (Baladi et al. 1996, p4). 
They go onto recommend using costs based on routine clinical practice that are 
derived from a number of different institutions, rather than using costs from a 
particular institution for a specific purpose. 
While Drummond and Davies (1991) suggest that collecting data from all centres in a 
multicentre study could lead to more generalisable results they recognise that 
problems arise when measuring resource use in different settings. They cite instances 
in multinational studies where there are systematic differences in resource use across 
settings. In these circumstances, the analyst can either pool the results or report 
separate cost estimates for each setting. The problem with pooled results is that they 
may not represent the opportunity costs of the health care programmes in any 
particular jurisdiction. If the analysis reports separate costs for each setting, then there 
may be insufficient cases to assess differences in cost and cost-effectiveness between 
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the programmes concerned. Using country-specific results would also question the 
purpose of doing a multinational study in the first place (Drummond and Davies 
1991). Some of the guidelines suggest that there are circumstances where all the study 
centres should collect resource use data. For example, Johnston et al. (1999) 
recommend: 
"If centres are likely to differ in terms of their economic characteristics, then resource 
use should be collected from all centres.. " (Johnston et al. 1999, p4). 
The guidelines by Johnston et al. (1999) offer the most insight into the issue of site 
selection. They state that although it might be possible in the analysis to adjust for any 
observed heterogeneity in costs across the centres, crucial decisions made at the 
design stage regarding the centres included in the study determine the heterogeneity 
observed. Whilst Johnston et al. (1999) agree with previous guidelines that the centres 
chosen for resource use and unit costing should be `representative' of where the 
technology is going to be implemented, they also point out that a `representative' 
centre needs defining. 
Johnston et al. (1998) assess whether costs collected in a trial setting are 
representative of the programmes' costs in a more general health care context. They 
suggest `economic factors' that might be associated with cost variation across 
settings, which include whether a centre is urban or rural, has high or low occupancy 
rates, and is a teaching or non-teaching hospital. However, the guidelines do not offer 
a theoretical basis for these suggestions. 
To understand what constitutes a representative centre this thesis argues that insights 
from theory can identify the factors associated with cost variation across settings. 
None of the guidelines apply the notion of opportunity costs when deciding on which 
centres the resource use (and costs) should be collected in. Some centres may be 
producing the health care programmes concerned in an efficient manner, whereas in 
other centres, resources may be wasted. If the costs included are to represent 
opportunity costs then the costs from the efficient centres are those that are relevant. 
A study identifying efficient production would need to collect costs in several centres, 
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and conduct a thorough assessment using a consistent methodology to identify 
reasons for any variation in costs between settings. 
d) Level of aggregation in resource use measurement 
The guidelines highlight that there is wide variation across studies in the level of 
aggregation used when measuring resource use and unit costs. A gross costing or `top 
down' approach involves using an aggregated measure of resource use such as the 
length of hospital stay (LOS) and combining this with a similarly aggregated measure 
of unit cost, such as the cost per hospital bed-day. By contrast, a micro costing or 
`bottom-up' approach requires measuring the individual resource use items (e. g. 
individual blood tests) consumed during the hospital stay for each patient and then 
valuing these using the appropriate unit cost (e. g. cost per test). The guidelines do not 
offer any clear advice on which method is preferable. Indeed some of the guidelines 
ignore the issue completely (NICE 2004, Commonwealth Department of Human 
Services and Health 1995). 
The level of aggregation used in resource use measurement has implications for 
interpreting variability across settings. Measuring resource use at a highly aggregated 
level makes it difficult to assess why costs vary across health care settings. For 
example, just measuring hospital length of stay (LOS) does not enable a study to 
examine differences in the intensity of resource use across settings. Certainly, it is 
important for a study that aims to identify reasons for cost variation across 
international settings to use a disaggregated approach. This can help the study to 
describe differences across settings in the use of factor inputs and may improve 
understanding of why costs vary across settings. A study conceals these differences if 
it only measures resource use at a highly aggregated level. 
2.23 Collection and measurement of unit costs 
Some of the issues that arise when measuring resource use also apply when estimating 
unit costs. For example, if the study measures resource use at a highly aggregated 
level, then highly aggregated unit costs are also required. The following section 
discusses this and other issues arising in the measurement of unit costs across settings. 
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a) Sources of unit cost data 
Unit cost data can be taken from previously published costing studies, from national 
databases or by estimating costs specifically for the study. Some of the guidelines are 
quite prescriptive and suggest that evaluations use national estimates of unit costs and 
append these to the guidelines (CCOHTA 1997, Commonwealth Department of 
Human Services and Health 1995, Oostenbrink et al. 2000). In England, the 
Department of Health (DoH) and Personal Social Services Research Unit (PSSRU) 
both provide national cost estimates for hospital and community care (DoH 2002, 
Netten and Curtis 2002). These unit costs vary widely across settings, and estimates 
of the costs and cost-effectiveness of health care programmes could incorporate this 
variability. However, there are concerns about the quality of these unit cost estimates 
(Dawson and Street 1998, Bliss 1999). In particular, UK NHS reference costs use 
financial rather than opportunity costs. These reference costs take a highly aggregated 
approach to costing, so it is difficult to identify which resource inputs are included 
and whether they are measured consistently across health care settings. Thus, it is 
difficult to interpret whether any observed differences in unit costs reflect 
methodological inconsistencies or actual cost differences. 
b) Estimation of opportunity and marginal costs 
Some of the guidelines emphasise that unit costs should aim to measure opportunity 
costs (Drummond et al. 1997a, Luce et al. 1996, CCOHTA 1997). These guidelines 
point out that although in general market prices can represent opportunity costs, this 
might not be the case in health care, as many factor inputs are not delivered via a 
perfectly competitive market (Luce et al. 1996). Thus prices might not be available, 
and even where prices are available they may not represent opportunity costs. Luce et 
al. (1996) suggest that prices can be adjusted to make them representative of 
opportunity cost and in the United States cost-to-charge ratios have been used for this 
purpose (Luce et al. 1996). However, the extent to which health care prices diverge 
from opportunity costs is likely to differ across geographical health care settings, 
because of for example, different labour market structures. 
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As opportunity costs are not routinely available or easily calculated, economic 
evaluations may fail to use them (Walker et al. 1997). Indeed the guidelines offer little 
advice on how analysts should measure opportunity costs, as Birch and Gafni (2002) 
point out when offering a critique of previous NICE guidelines: 
"... a general problem that underlies many aspects of the guidelines relates to the 
limited attention given to the concept of opportunity cost.. . the solution to the problem 
of using market prices that do not reflect opportunity costs is to use other data which 
also do not reflect opportunity costs... " (Birch and Gafni 2002, p187). 
The most recent guidelines from NICE state that they prefer unit costs to reflect the 
financial costs to the NHS and PSS, rather than the opportunity costs. If economic 
evaluation aims to move resource use towards allocative efficiency then opportunity 
costs are required. Thus, the NICE position is inconsistent with economic theory. 
Using financial costs in economic evaluations and decision-making may lead to 
inefficient resource allocation. 
Another important example of where adopting different methodological standpoints 
can lead to variation in cost estimates comes in the debate about how to measure 
marginal costs. As economic evaluations usually aim to measure small changes in the 
mix of services provided, the relevant concept to use is marginal rather average cost 
(Goddard and Hutton 1991, Baladi et al. 1996, Jacobs and Baladi 1996)15. However, 
there is no clear consensus on how to measure marginal costs. 
Jacobs and Baladi (1996) state that marginal costs can be approximated by average 
costs. This assumes that marginal costs are constant and that total costs only include 
those items that may be regarded as variable for the time-period concerned. Such an 
approach requires identifying those factors of production that are fixed rather than 
variable. This assessment is subjective, may change over time, and would be 
particularly susceptible to local factors (Dawson and Street 1998, Drummond et al. 
1997a, Walker et al. 1997). One way of limiting this problem is to take a long-run 
is Marginal cost is the additional cost of a one-unit increase in output, whereas average costs reports the 
total cost divided by the total quantity produced. 
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perspective to cost measurement, in which case all cost items including overheads and 
capital costs should be included in total costs, and then long-run average costs 
approximate marginal costs. Following this approach would make the range of items 
included in unit costs more consistent across settings. However, to ensure 
comparability, studies that collect unit costs across settings also have to use the same 
methodology to measure this common range of cost items. 
c) Allocation of overheads and capital costs 
If the health care interventions under evaluation use different quantities of fixed 
inputs such as durable equipment or buildings, the CEA has to allocate the costs of 
these fixed inputs to the individual patients included in the treatment groups 
concerned. It is particularly difficult to apply the same methodology across settings 
when allocating the costs of overheads and capital to individual patients (Graves et al. 
2002). Although attempts have been made to try and standardise the way overheads 
are allocated (Jacobs and Baladi 1996), many economic evaluations rely on the 
attribution techniques used by finance departments in the institutions concerned which 
may differ according to the health care setting. 
d) Aggregated versus disaggregated unit costs 
Just as the guidelines did not define the appropriate level of aggregation for 
measuring resource use, they are also reticent about how aggregated the measure of 
unit costs should be, except to say that one will determine the other. Clearly, adopting 
a highly aggregated approach to unit costing makes it difficult to ensure resources are 
valued using marginal and opportunity costs (Walker et al. 1997). As Reid et al 
(2003) highlight using aggregated unit costs, for example DRGs ignores any 
variations in the intensity of care over an individual patient's hospital stay. It is also 
difficult to ensure that the same unit costs are included in each health care setting 
(Jonsson and Weinstein 1997). For example, unit costs based on Diagnosis Related 
Groups (DRGs) may include capital costs in one setting, but these may be excluded in 
another. The case-severity of patients included within a particular DRG may vary 
across health care settings within or across countries. Any study comparing costs 
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across different settings that uses a highly aggregated approach may struggle to 
disentangle measurement differences from systematic differences in unit costs. 
e) Number and characteristics of centres 
The guidelines disagree about whether studies should collect unit costs from all 
centres or countries participating in a multicentre study (Commonwealth Department 
of Human Services and Health 1995, Baladi et al. 1996). The guidelines argue that the 
centres selected should be `representative' for example Baladi et al. (1996) explain 
that: 
"... a site selection bias would result from the use of estimates derived from 
institutions that may not reflect the cost structure that prevails in the chosen 
perspective... " (Baladi et al. 2001, p4). 
While some of the guidelines highlight the desirability of just using a national or 
regional estimate of average unit costs (Commonwealth Department of Human 
Services and Health, 1995), the selection and measurement of a `representative' unit 
cost is not straightforward. As Brouwer et al. (2001) state: 
"... if one needs a national or regional average for the cost per unit of a service it is not 
easy to give a simple rule of thumb on the number of observations (sites) needed in 
order to get a robust estimate... the best provisional advice may be to use at least 
three to five observations for each specific organisational setting and to make overall 
estimates as a weighted average using the prevalence of the specific settings as well. " 
(Brouwer et al. 2001, p82). 
The way in which the centres chosen for unit costing are currently selected appears 
arbitrary or based on convenience (Pang 2002). As Glick et al. (2002) highlight centre 
selection is rarely driven by empirical or theoretical rationale: 
"The countries selected might be ones that enrol many patients in the trial, ones that 
represent the spectrum of economic development among countries that participated in 
the trial, ones in which the countries' regulators require a submission for 
reimbursement, ones for which unit costs are readily available, or ones in which the 
study sponsor wishes to make economic claims. " (Glick et al. 2002, p518) 
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The lack of consideration given in empirical studies to addressing this issue is not 
surprising given that previous guidelines have failed to offer clear advice on this 
issue. For example, Coyle et al. (1998) argue that if in a multicentre study detailed 
resource use data have been collected it may not be necessary to estimate unit costs in 
each centre. However, the authors do not offer any justification for making this 
recommendation. 
One concern about measuring unit costs in many health care centres is the additional 
research resources associated with approach. As Reed et al. (2003, p397) point out: 
"The costing methods must strike a balance between the high cost of data collection in 
a clinical trial, the availability of cost data, and the collection of sufficient resource 
use data to capture variation in costs between patients" 
While the opportunity costs of devoting research resources towards more extensive 
cost measurement should be recognised, the value of collecting this additional 
information must also be assessed. If a study only estimates unit costs in a single 
centre leading to an inaccurate estimate of the cost-effectiveness of the intervention 
then the value of acquiring more appropriate unit cost estimates may outweigh the 
additional research resources. 
2.3 Data Analysis 
A number of issues arise when analysing cost data that relate to cost variation across 
settings and these are discussed below: 
2.31 Calculation of total costs per patient 
Traditionally economic evaluations have not measured costs on an individual patient 
basis. Total costs per patient were calculated based on an `average' cost over the 
patients included, which gave no indication of the sampling variation, surrounding the 
mean estimate. Recently, there has been an increase in the number of economic 
evaluations undertaken alongside multicentre RCTs (see for example, Schulman et al. 
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1996, Glick et al. 1998). This study design allows resource use to be measured for 
each patient and multiplied by the appropriate unit costs to give the total costs per 
patient. Mean costs can then be reported with stochastic measures of uncertainty as 
recommended by the guidelines (Manning et al. 1996). Even in CEAs based on 
models, recent guidelines advocate the use of probabilistic sensitivity analysis (NICE 
2004). This requires a measure of the mean cost per patient and its standard error, to 
assess the impact of sampling uncertainty on the study's results. 
While it is desirable to estimate total costs per patient, decisions at the design stage 
about how to collect resource use and unit costs, may determine how exactly this is 
done 16. In particular, where an economic evaluation is based on a multinational trial, 
depending on how the study is designed the options available at the analysis stage 
include using: 
1. Mean trial-wide measures of resource use, with a single or average set of unit 
costs. 
2. Mean trial-wide measures of resource use data with country-specific unit 
costs. 
3. Country-specific resource use and unit costs. 
The guidelines do not offer advice on which of these options is preferable. The first 
two options would not provide an estimate of opportunity costs in any particular 
country or decision-context (Baladi et al. 1996). In option one neither the resource use 
nor the unit costs are likely to represent the levels of factor inputs or factor prices used 
in producing the health care programme in an efficient way in any particular country. 
Coyle et al. (1998) advise against taking this approach except under certain 
circumstances: 
16 Clearly, there are other issues that arise when analysing costs including how to deal with missing 
data. To consider these issues in more depth readers are referred to Manning et al. 1996, Briggs and 
Gray 1999, and Briggs et al. 2003. 
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"... cost data from a single country would be acceptable if it was demonstrated that the 
cost structure of the site is typical of all other sites within the study" (Coyle et al. 
1998, p140. ) 
However, the authors do not provide guidance on how to assess whether or not a site 
is `typical'. 
The CCOHTA guidelines suggest transferring the results of a multinational trial to a 
Canadian context by assigning Canadian unit costs to trial-wide resource use data 
(CCOHTA 1997) (option 2). In option two, although the unit costs used may be 
relevant to each decision context if they represent opportunity costs, the resource use 
measure may not be applicable. Jacobs and Baladi (1996) argue that to make a study 
applicable to the Canadian health care system it is insufficient to take a multinational 
RCT and `Canadianize it' by simply using Canadian price weights. They state that the 
analyst has to justify that the patterns of resource use for all the centres in the trial are 
the same as those in Canada. The analysts could do this using data just from Canadian 
centres if these are included in the study, or by using separate observational studies or 
expert opinion to adjust the results to the Canadian context. This approach fails to 
recognise the insight from economic theory that decision-makers may choose to 
adjust the combination of factor inputs used according to the local levels of factor 
prices (Raikou et al. 2000). Across international health care settings factor prices may 
vary widely because of for example, differences in the characteristics of the labour 
market. 
Theory would therefore suggest that the resources used are correlated with the unit 
costs and that these parameters should not be measured in separate locations. Option 
three is therefore most likely to provide relevant estimates of resource use and unit 
costs, that approximate opportunity costs. However, the problem with this approach is 
that there may be insufficient cases in the particular country to provide robust 
estimates of costs and cost-effectiveness (Drummond and Davies 1991, Brouwer et al. 
2001). 
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In general, there is a lack of advice in the guidelines on how international studies 
should calculate costs. This gap in the literature could partly reflect a lack of evidence 
on cost variation across health care settings (see Chapter three). 
2.32 Currency conversion factor. 
If resource use and unit cost data are collected for the country of interest, then the 
results can simply be presented in the local currency. However, if a multinational 
study requires a single measure of cost-effectiveness (as implied by option 1) it is 
necessary to convert prices into an appropriate reference currency (e. g. US dollars). 
Similarly if a study wants to compare costs across multinational health care settings 
this requires conversion of country-specific costs into a reference currency. There are 
various currency conversion factors available for this purpose including official 
exchange rates (OER), or purchasing power parities (PPP) based on general measures 
of GDP or medical prices. None of the more formal guidelines for economic 
evaluation offer guidance on the most appropriate method for currency conversion. 
This is a potentially important issue for any study aiming to compare costs across 
countries, and so this thesis reviews the health economics literature on currency 
conversion factors as part of the empirical investigation (Chapter 7). 
2.33 Dealing with skewed data 
CEAs alongside RCTs can estimate total costs per patient and then report mean costs 
per patient for each group. These costs can be presented with appropriate measures of 
precision to represent sampling variation (Barber and Thompson 1998, Thompson and 
Barber 2000). The guidelines recommend using statistical tests to report whether any 
differences in costs between treatment alternatives are statistically significant (Briggs 
and Gray 1999, Thompson and Barber 2000). The study can test for statistical 
significance using standard parametric methods such as t-tests. However, cost data are 
notoriously skewed (Gray et at. 1997, Briggs and Gray 1998, Briggs and Gray 1999, 
Barber and Thompson 1998), with a small number of patients accounting for a 
relatively high proportion of total costs; the assumption of normality required for 
parametric tests may not be valid for cost data. While transforming the data may gain 
extra power for detecting significant differences in costs between treatment 
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alternatives (Gray et al. 1997), recent guidelines recommend reporting mean costs on 
the untransformed scale (Thompson and Barber 2000, Briggs and Gray 1999). 
Thompson and Barber (2000) also point out that standard t-tests are reasonably robust 
when sample sizes are large, even in the presence of skewed cost data. Another 
approach that does not make such strong distributional assumptions is to use the non- 
parametric bootstrap (Efron and Tibshirani 1993). 
While there is a consensus in the methodological literature on some issues such as the 
reporting of mean costs, the guidelines do not offer advice on how the study should 
deal with any systematic variations in mean costs across settings. Using data from a 
multicentre study Nixon and Thompson (2005) present the use of a multilevel model 
(MLM) that recognises mean differences in costs and cost-effectiveness within UK 
health care settings. While the MLM described acknowledges variation across centres 
it does not examine whether there are systemic reasons for the variation observed. In 
multinational economic evaluations, there may be large systematic differences in 
costs across settings, because of differences in for example, relative factor prices. 
However, the guidelines reviewed do not suggest how the analysis should identify any 
systematic differences in mean costs across settings. In addition, the distribution of 
the cost data may vary across the countries concerned, but again it is unclear how the 
analyst should tackle this. 
2.4 Presentation and interpretation of results 
The relevant issues that arise when presenting and interpreting the results of cost 
analysis and CEA are discussed below. 
2.41 Resource use, unit costs and total cost 
The guidelines acknowledge the importance of presenting costs disaggregated into 
measures of resource use and unit cost for each of the technologies in question 
(Drummond et al. 1997a, Luce et al. 1996, CCOHTA 1997). This helps those using 
the evaluation to assess whether the results apply to their local context. However, 
whether this level of disaggregation is sufficient for identifying reasons for cost 
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variation across health care settings is questionable. Unit costs may vary across 
settings because of differences in factor use or factor price. However, the guidelines 
stop short of recommending that unit costs are reported in a more disaggregated way 
that would allow differences across settings in these components of unit cost to be 
recognised. 
2.42 Cost-effectiveness and sampling variation 
Recent methodological developments in this area have shown that the incremental 
cost-effectiveness ratio (ICER) is generally an inappropriate summary statistic for 
CEA. The problem is that the standard error of the ICER is often intractable and 
summarising the sampling variation surrounding the ICER using confidence intervals 
leads to problems of interpretation. Instead, incremental net benefits (INB) and cost- 
effectiveness acceptability curves (CEAC) have become the preferred measures of 
cost-effectiveness (NICE 2004). Where a CEA is based on a RCT, Hoch et al. (2002) 
suggest that net benefits (NB) can be estimated on the cost scale as net monetary 
benefits (NMB) where: 
NMBi= A Et-TC, 
A is the societal willingness to pay for a unit of health gain, Ei is the observed effect 
for an individual i, TC, are the total costs for individual i. The mean INB is then the 
mean NMB for the treatment group minus the mean NMB for the control group. 
The current methodological guidelines for submissions to the NICE technology 
appraisal programme recommend that if, the mean INB of a new intervention is 
positive at a threshold of £30,000 per QALY, then there is strong evidence in favour 
of its adoption (NICE 2004). However, it is important to present the uncertainty 
surrounding the cost-effectiveness estimate as this highlights the need for further 
research (NICE 2004). The advantage of using the INB is that as it is a linear 
expression, it does not suffer from the problems of the ICER, and the standard error of 
the INB can be estimated directly. The sampling variation surrounding the cost- 
effectiveness estimate can therefore be reported using stochastic measures of 
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uncertainty such as CEACs and 95% confidence intervals around the INB. Clearly the 
cost-effectiveness of a particular technology depends on the value used for '%, the 
societal willingness to pay for a unit of health gain. CEACs make this sensitivity 
explicit by plotting the probability that the intervention is cost-effective, given the 
data, against the value of the ceiling ratio A (Fenwick et al. 2004). However, simply 
presenting a CEAC does not highlight any systematic variations in cost or cost- 
effectiveness across health care settings; in effect the observed variation is all 
attributed to inter-patient variability, rather than any systematic differences across 
settings. 
Recent guidelines recommend that analysts should consider other forms of uncertainty 
(Briggs and Gray 1999). These forms of uncertainty can be defined as: 
methodological uncertainty, uncertainty related to patient characteristics, uncertainty 
related to extrapolation and uncertainty related to generalisability. 
2.43 Methodological uncertainty 
Much of this chapter has highlighted methodological issues that arise when estimating 
costs, and highlighted areas where there is a lack of methodological agreement, or 
lack of advice from the literature. To limit methodological variability across studies 
and enhance comparability, some guidelines have defined a reference case that 
stipulates particular methodological standpoints (Gold et al. 1996, NICE 2004). Other 
guidelines have stopped short of prescribing the use of particular methods, and have 
acknowledged that important areas of disagreement still exist (Johnston et al. 1999, 
Drummond et al. 1997a). Mason (1997) highlights that it may be difficult to use a 
consistent methodology across health care settings, particularly when measuring 
costs. For example, if highly aggregated cost estimates are used in different 
international settings, then the methods of cost allocation may differ leading to 
problems comparing results. For any study assessing cost variation across settings, it 
is necessary to minimise the methodological inconsistencies across the settings 
concerned. 
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2.44 Variability according to defined patient characteristics 
The cost-effectiveness of an intervention may vary according to particular patient 
characteristics. Recent guidelines recommend the use of sub-group analysis to present 
cost-effectiveness results for different patient groups (NICE 2004). Hoch et al. (2002) 
extended the net-benefit approach to include the use of patient covariates. This allows 
the INB of an intervention to be reported for different patient sub-groups. In a 
multicentre study, patient characteristics may differ across settings, and it may be 
important to allow for these inter-patient differences, when assessing cost- 
effectiveness. 
2.45 Variability according to the method chosen for extrapolating long-term 
cost-effectiveness 
There may be important uncertainty about the method to use for extrapolating results. 
For instance if a model has been used to extend the results from a trial, to present 
cost-effectiveness over a longer time-horizon, the method chosen for extrapolation 
may be an important determinant of cost-effectiveness. Clearly, the choice of 
extrapolation method may vary according to the health care setting, as for example the 
relationship between short and long-term outcomes may vary across international 
health care settings. Where there is uncertainty about the assumptions used in making 
such an extrapolation, the guidelines suggest using sensitivity analyses (Briggs and 
Gray 1999). 
2.46 Generalisability 
Briggs and Gray (1999) define generalisability as: 
"... the extent to which the results of a study, as they apply to a particular patient 
population or setting and/or a specific context, hold true for another population and/or 
in a different context. " (Briggs and Gray 1999, p7. ) 
The guidelines reviewed often highlight generalisability as a secondary issue to be 
addressed after the internal validity of the study's results has been established 
(Drummond et al. 1997a). Within the methodological literature on generalisability 
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there are three clear strands: the first refers to generalisability across different 
geographical settings (Glick and Cook 2003), the second relates to generalisability 
from studies based on RCTs to routine practice, (Mason 1997, Drummond and Davies 
1991) and the third relates to generalisability over time (Sculpher et al. 1997). The 
first form of generalisability is the one most relevant for this thesis; the methods used 
to analyse variation in cost and cost-effectiveness across geographical locations may 
have implications for tackling this form of generalisability. 
O'Brien (1997) and Mason (1997) suggest barriers to generalising results across 
different locations, which include: differences in the demography and epidemiology 
of disease, clinical practice and conventions, incentives and regulations, relative price 
levels, consumer preferences and opportunity costs and availability of alternative 
treatments. However, the authors do not provide a theoretical basis to justify why 
these particular factors may limit generalisability. 
Jian et al. (1998) highlight the importance of understanding cost variation before 
making general conclusions about the efficiency of health care interventions: 
"To identify the most efficient way of providing immunisation services.. a rough 
quantitative notion of the relative importance of factors contributing to cost variation 
is useful.. " (Jian et at. 1998, p7). 
However, a problem with assessing cost variation and its implications for 
generalisability is that there is a lack of evidence in the economic evaluation literature 
on why costs vary between different places (Goree et al. 1999). 
Most of the guidelines focus on tackling issues relating to generalisability in the 
reporting of the results. For example, Byford and Palmer (1998) emphasise the 
importance of describing treatment alternatives and reporting separate estimates of 
resource use and unit costs, to make results transparent so that they can be interpreted 
in a more general context. However, these suggestions do not themselves make the 
results of a CEA generalisable to a different context. O'Brien (1997) emphasises the 
52 
importance of carefully scrutinising the relevance of the comparators used, the 
practice patterns and the price weights before applying the results to a different 
context. 
Some of the guidance suggests dealing at the analysis stage with the problems posed 
by cost variation across settings. For example, although Jacobs and Baladi (1996) 
highlight the importance of trying to avoid bias when selecting the site for costing, 
they then suggest adjusting for this bias in the analysis. They recommend deriving this 
measure of bias by comparing the unit costs collected from the site in question with 
those used in national databases. Briggs (2000) suggests that where a study is aiming 
to produce a national estimate of cost-effectiveness it may be appropriate to use 
national estimates of unit costs. A model could then incorporate the variation in unit 
costs across settings as part of the overall estimate of uncertainty surrounding the 
study's results. Bryan and Brown (1998) suggest that it may be possible to make 
results from a study more locally applicable by re-analysing cost-effectiveness using 
local unit costs. 
All these approaches assume that national unit cost databases of appropriate quality 
are available. They also ignore differences in resource use across settings which may 
be more important than unit cost differences in determining cost variation. As 
Johnston et al. (1999) point out it may not be possible to adjust for site selection 
biases at the analysis stage. For example, an appropriate national unit cost database 
may not be available. In a trial-based evaluation, the choice of study sites for 
collecting resource use and unit costs may be of crucial importance in determining the 
study's results, and the extent to which it can consider cost variation across settings. 
As Briggs and Gray (1999) concede if suitable cost data are not available it may be 
difficult to use standard statistical techniques to address generalisability issues. 
Instead, analysts may rely on one-way sensitivity analysis to assess the applicability 
of results to different contexts. This would seem analogous to the situation before 
RCTs were used for collecting resource use data, when sampling variation was 
assessed using deterministic sensitivity analysis. The inadequacies of relying solely 
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on deterministic sensitivity analyses have been clearly highlighted (Manning et al. 
1996). The fundamental criticism of using deterministic analyses to assess sampling 
variability, namely that the ranges used are at the discretion of the analyst, also 
applies when using this method to try to improve generalisability. Suitable datasets 
are required so statistical techniques can be used to analyse reasons for cost variation 
and the implications for the generalisability of results. 
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2.5 Discussion 
This review of the methodological guidelines for economic evaluation had two main 
purposes. Firstly, the review aimed to identify gaps or areas of disagreement in the 
literature relating to the assessment of cost variation across settings. Secondly, the 
review tried to identify the key aspects of study design for an empirical investigation 
of cost variation across health care settings. 
Ideally, an economic evaluation should use costs that represent efficient production of 
the health care technologies under evaluation i. e. opportunity costs. However, costs 
may vary across health care settings, and one reason for this is that health care firms 
in different geographical locations may have different incentives to cost-minimise. 
However, this review found little evidence to suggest that the guiding principles for 
economic evaluation considered cost variation across settings, and identified health 
care settings where the costs observed represented departure from opportunity costs. 
If the costs used do not represent opportunity costs then the study may produce 
misleading estimates of the relative cost-effectiveness of each health care programme. 
The issue of how to ensure that the costs used in economic evaluations approximate 
opportunity costs was not addressed by many of the guidelines including the recent 
methodological guidance issues by NICE (NICE 2004). 
The conduct of an economic evaluation is in three main stages, the study design, data 
analysis and interpretation of the results. This review finds that at each stage there are 
omissions or disagreements in the guidelines about issues pertaining to cost variation 
across settings. At the design stage, while the guidelines highlight the appeal of using 
pragmatic clinical trials as a vehicle for measuring resource use data, there are still 
unresolved issues. For example, it is unclear how the number and type of centres for 
measuring resource use and costs should be determined. While there is some 
agreement that the centres chosen for resource use or unit cost measurement should be 
'representative' or `typical' of the context where the technology is going to be 
deployed, there is no clear definition of what constitutes a `representative' or `typical' 
centre. Recent guidelines highlight that more information is required on why costs 
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vary across centres. In particular, if costs vary because some centres are inefficient 
whereas others are relatively efficient, then it is inappropriate to use costs that are 
representative of all the centres concerned. 
The guidelines generally treat the choice of centres for collecting resource use and 
unit cost data as separate issues, and in some instances, recommend that analysts use 
different sources. For example, some of the guidance states that in a multinational 
study it is acceptable to rely on pooled measures of resource use, and only estimate 
unit costs specifically for the country concerned. If resource use and unit costs are 
measured in different settings this contradicts economic theory. Cost function theory 
suggests that relative factor prices (a component of unit costs) in a given setting are 
correlated with relative factor use (a component of unit cost and resource use). The 
only approach that allows the data structure suggested by theory to be maintained, is 
to estimate separate unit costs, resource use and cost-effectiveness in each centre or 
country. In general the guidelines do not recommend taking this approach, although 
Halliday and Darba (2003) do suggest differences across countries should be 
recognised in the presentation of results. Estimating unit costs and resource use in 
each country would increase the costs of a multinational study and presenting cost- 
effectiveness results for each country would reduce the study's power to detect 
differences in costs between treatment groups. Subsequent chapters in this thesis 
examine conceptual and empirical reasons for cost variation and aim to inform the 
choice of settings for collecting resource use and unit cost data. 
Some of the guidelines advocate the use of highly aggregated or national unit costs, as 
these have the potential to ensure that costs are `representative' of the jurisdiction 
concerned. However, it is unlikely that these costs meet some of the other 
methodological standards recommended by the guidelines. In particular, it is difficult 
to ensure that the items included in the measure of unit costs are consistent across 
settings and that the unit costs represent opportunity and marginal costs. If costs are 
measured at a highly aggregated level it may be difficult to assess whether any 
differences in unit costs between health care settings, reflect differences in 
methodology or real differences. As Sculpher and Drummond (2005) highlight: 
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".. the higher the degree of aggregation, the greater the chance of hiding various 
methodological flaws. " (Sculpher and Drummond 2005, p18) 
It therefore seems more appropriate to use a disaggregated approach in the empirical 
investigation to compare costs across health care settings. 
The guidelines fail to provide any clear advice on how the results should be analysed 
to consider reasons for cost variation across settings. In a multicentre study, either 
national or international, it is unclear how any systematic differences in mean costs 
across the centres should be identified. 
Analysts have made recent progress in the methods used to analyse and present 
uncertainty in CEA. This progress has informed the most recent guidelines that have 
recommended using CEACs and INBs to present the results of CEA (NICE, 2004). 
These techniques are useful for summarising the sampling variation across the 
patients included in the study. However, in an economic evaluation based on a 
multicentre RCT there may be wide systematic variations in costs and cost- 
effectiveness across patients recruited from different centres. The guidelines suggest 
that there has been a relative lack of development in methods for dealing with this 
form of uncertainty, beyond recognising that results may not be generalisable across 
settings. Studies may be unable to assess systematic cost variation across settings if at 
the design stage, the study does not use an appropriate methodology for collecting 
resource use and unit cost data. If the study recruits insufficient patients, or measures 
costs using an inconsistent methodology across health care settings, then the study 
will struggle to distinguish between methodological differences, sampling variation or 
systematic differences in costs across the study settings. 
A study of cost variation across settings can therefore inform methodological 
development in this area. This chapter also identifies methodological principles to 
inform the design of the empirical investigation. The study's perspective should be 
sufficiently broad, and the time-horizon long enough to capture a consistent range of 
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costs in each setting. The review also suggests that taking a disaggregated approach to 
costing could prove particularly helpful. Taking an aggregated approach would make 
any differences in unit costs across settings difficult to interpret. These differences 
could be due to inconsistencies in methodology, as opposed to systematic differences 
in factor use or factor price. Data from a multinational observational study or RCT 
could be used for comparing resource use and costs across international settings, but if 
data are collected from an observational study, it is particularly important to collect 
detailed information on patient factors, to minimise selection bias when comparing 
costs across countries. The review did not identify any guidance on how reasons for 
cost variation across settings should be analysed. 
2.6 Conclusions 
Concerns about the quality of economic evaluations have led to the development of 
guidelines aimed at improving the quality of these studies. The guidelines have 
generally reflected areas of agreement and recent methodological developments. The 
purpose of the more formal guidelines has been to standardise methods across 
different disease areas and interventions rather than across health care settings. For 
some of the policy-making guidelines, it is clear that economic evaluations are 
required that are sound and relevant for the national decision-making context. 
However, there are certain key areas of omission that a study assessing cost variation 
across geographical health care settings can usefully inform: covering the study 
design; analysis and interpretation of results (see Table 2.1). The lack of guidance 
may partly reflect, a lack of empirical work in the area of cost variation, and the next 
chapter reviews the relevant studies. There would seem scope for methodological 
development in this area that could inform subsequent guidelines, and help economic 
evaluations provide a sounder basis for health care decision-making. 
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Table 2.1: Areas where a study assessing cost variation across settings could 
inform the conduct of economic evaluations. 
Study Design 
" No centres for resource use or unit cost measurement? 
" Choice of centres for resource use or unit cost measurement? 
" Appropriate level of aggregation in resource use or unit cost 
measurement? 
Study analysis 
" How to pool resource use, unit cost or total cost data across settings? 
" How to analyse cost data to allow for differences in the mean and the 
distribution of costs across settings? 
" How to adjust the cost parameters in a model to estimate cost- 
effectiveness in different settings? 
Presentation of study results 
" How to present context specific results in multicentre studies? 
" How to use statistical methods to make results more representative of the 
decision-context? 
" How to consider the extent to which the results are generalisable? 
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Chapter 3: Evidence from the economic 
evaluation literature on cost variation across 
settings 
3.0 Introduction 
The previous chapter highlighted gaps in the methodological literature relating to cost 
variation across settings. This may reflect a lack of empirical evidence on reasons for 
cost variation. The aim of this chapter is to examine how published economic 
evaluations consider cost variation across settings by reviewing the relevant empirical 
evidence. Economic evaluations conducted alongside multicentre RCTs can collect 
resource use data from different locations; these studies can therefore consider cost 
variations across health care settings. In particular, if RCTs recruit patients from 
different countries, the accompanying economic evaluation may be required to 
present separate estimates of cost-effectiveness for different national decision-makers. 
These studies may therefore have an incentive to examine whether costs vary across 
international settings. In a cost-effectiveness analysis alongside a national multicentre 
RCT, if the results are intended for a national decision-making agency (for example 
NICE in England and Wales) then there may be less incentive to present setting- 
specific results. However, there may still be cost variations across settings in a 
national context, and this review considers some examples of studies that have 
considered this. 
Methodology used in the literature review of empirical studies 
This aspect of the literature review builds on the previous chapter by considering 
examples of how variation in costs, and cost-effectiveness across health care settings 
has been considered in the empirical literature. Rather than attempting to quantify the 
numbers of empirical studies that have used different methods, the purpose of the 
review was to provide examples of studies taking different methodological 
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standpoints in relation to the issue of cost variation across health care settings. These 
examples were identified by searching the PubMed and HEED databases using the 
search terms `multicentre', `multinational', `costs and cost analysis' and `econ eval' 
for the years 1990-2004. The bibliographies of the sources retrieved and from those 
articles included in the methodological review in Chapter 2, were reviewed to identify 
other relevant articles. 
The articles retrieved were examined to see whether they raised methodological issues 
related to the issue of cost variation. Studies were included that raised relevant 
methodological issues that may apply more generally to studies with similar overall 
designs. The study designs considered were multinational economic evaluations 
alongside multinational RCTs, multinational economic evaluations based on models 
and systematic reviews, and economic evaluations based on national multicentre 
RCTs. The review was therefore structured around these different forms of study 
design and included examples of economic evaluations in each category. Within each 
category only studies that met the criteria for a full economic evaluation- costs and 
outcomes measured for two or more alternatives (Drummond et al. 1997), were 
included. 
The first section of the review examines how economic evaluations alongside 
multinational RCTs consider cost variation across settings. Section two reviews 
studies that use cost-effectiveness models to see how they deal with cost variation 
across international health care settings. Section three reviews economic evaluations 
conducted alongside national multicentre RCTs. Section four describes the main 
methodological issues that arise, before section five discusses the gaps identified by 
the literature review. 
3.1 Multinational Economic evaluations based on multinational 
RCTs 
An increasing number of studies estimate the effectiveness of health care 
interventions using multinational RCTs (Cook et al. 2003) and many of these studies 
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now incorporate a multinational CEA (Reed et al. 2004, Lopez et al. 2003, Doyle et 
al. 2001, Rutten-van Molken et al. 1998, Schulman et al. 1996, Glick et al. 1998, 
Mark et al. 1995, Johannesson et al. 1993). These evaluations have the potential to 
measure the costs of the technologies concerned across a range of countries, and 
assess variation in costs and cost-effectiveness across international settings. However, 
as the previous chapter argues, decisions taken at the design stage, in particular the 
approach taken to unit cost and resource use measurement, may determine whether 
the study can investigate variations in costs across settings. The approaches taken to 
resource use and unit cost measurement fall into three broad categories: " 
1. Studies that combine mean trial-wide measures of resource use, with a single 
or average set of unit costs. 
2. Studies that combine mean trial-wide measures of resource use with country- 
specific unit costs. 
3. Studies that use country-specific resource use and unit costs. 
The following sections consider each of these approaches in turn using examples from 
the multinational economic evaluation literature. 
3.11 Studies that combine mean trial-wide measures of resource use, with a 
single or average set of unit costs. 
Some international CEAs have taken resource use estimates pooled over all the 
centres in the study and combined these with a single set of unit costs (Schulman et al. 
1996, Glick et al. 1998, Mark et at. 1995, Johannesson et al. 1993). This study design 
does not allow for the analysis of variations in resource use or unit costs across 
countries. It is unclear whether these unit costs are those associated with efficient 
production, and therefore represent opportunity costs. In the economic evaluation of 
the FIRST study Schulman et al. (1996) combined trial-wide resource use measures 
taken from European and US patients with unit costs from a single American teaching 
hospital. The study reported average costs per patient for each of the technologies 
"A fourth category of study allows outcomes to vary across settings. However, the role of outcome 
variation is outside the scope of the thesis. 
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concerned, and then incremental costs. The analysis ignored any cost differences 
across the international health care settings included in the study, and the unit costs 
were unlikely to apply to the European centres. The study could have collected unit 
costs from centres in each country and reported country-specific measures of cost- 
effectiveness. 
In an economic evaluation conducted alongside a multinational Phase III RCT Lopez 
et al (2003) compared the overall costs associated with different antibiotics using 
resource use data pooled over trial centres in South America and Mexico. Unit cost 
data were taken from secondary sources and it was unclear whether they represented 
unit costs in any of the countries included in the RCT. 
The 4S (Scandinavian Simvastatin Survival Study) (1994) recruited patients to an 
international RCT comparing simvastatin to placebo for secondary prevention of 
coronary heart disease. The trial included patients from Sweden, Norway, Finland and 
Iceland. The CEA collected highly aggregated unit costs from four hospitals in 
Sweden (Johannesson et al. 1997). The study estimated total costs per patient by 
combining these unit cost data with resource use estimates across all patients included 
in the multinational trial. The study presented estimates of cost-effectiveness that 
pooled costs across all the countries, and did not report any variation in the 
incremental costs or cost-effectiveness of the intervention across the countries 
concerned. 
Studies have also collected unit costs from several countries, calculated an average set 
of unit costs, and then combined these average unit costs with trial-wide measures of 
resource use (Glick et al. 1998). An international economic evaluation of tirilazad 
mesylate for patients with subarachnoid haemorrhage, recruited patients from 11 
countries covering centres in Australia, Europe and the United States (Glick et al. 
1998). The study estimated average unit costs using data from six of these countries, 
and combined these data with trial-wide resource use estimates. In the initial CEA, the 
authors reported a single cost-effectiveness measure pooled across all the study 
centres (Glick et al. 1998). Although an ordinary least squares (OLS) regression 
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analysis showed that differences in resource use led to cost variations across 
countries, the authors did not assess whether there were any international differences 
in incremental costs, or incremental cost-effectiveness (Glick et al. 1998). 
3.12 Studies that combine mean trial-wide measures of resource use with 
country-specific unit costs. 
A number of studies have collected unit costs for each country included in a 
multinational RCT and then combined these with trial-wide measures of resource use 
(Henderson and Brown 1999, Jansen et al. 2001, Casciano et al. 2001, Lorenzoni et al. 
1998). Some studies found that while unit costs varied widely across countries, 
estimates of incremental cost-effectiveness were more stable. In a coronary 
prevention study Henderson and Brown (1999) found that unit costs, in particular the 
costs of ICU, CCU and CABG'8, varied widely across countries, but the study used 
the same unit costs for the intervention in each setting and there were no significant 
differences across countries in the relative cost-effectiveness of the new treatment. 
In a study, comparing recombinant tissue plasminogen activator to streptokinanse for 
preventing coronary heart disease, Lorenzoni et al. (1998) combined trial-wide 
resource use with country-specific unit costs. Despite the observed variations in unit 
costs, the ICERs did not vary appreciably across the countries concerned. While the 
unit costs of the interventions differed by up to five-fold across the settings, it was 
unclear whether the study used a consistent costing methodology across all countries. 
Drummond and Davies (1991) demonstrated the importance of a consistent costing 
method using as an example a multinational economic evaluation of new procedures 
for cataracts. Although this study reported wide variations in unit costs across 
countries, these were based on professional fees that varied widely across settings. For 
example, the fee for enucleation ranged from $2000 to $6000. These differences 
reflected the inconsistent costing methodology used. In some centres, the fee may 
represent the opportunity costs whereas in others the fee may include profit to the 
provider. 
18 ICU: Intensive care unit, CCU: coronary care unit and CABG: coronary artery bypass graft. 
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Other studies found that cross-country variations in unit costs led to important 
variations in cost-effectiveness (Hull et al. 1981, Jansen et al. 2001, Henderson and 
Brown 1999). Hull et al. (1981) found that the cost-effectiveness of different ways to 
diagnose deep vein thrombosis, varied by country according to differences in unit 
costs. In a study estimating the cost-effectiveness of different strategies for treating 
cardiovascular disease, Brown et al. (2001) collected unit costs from several different 
centres. Even though a consistent method was used to measure unit costs in each 
setting, unit costs varied widely within and across countries. For example, the unit 
costs of a PTCA varied from 1380 to 2700 Euros within the UK and from 1850 to 
4000 Euros across the countries concerned. 
A multinational economic evaluation comparing Terbinafine and Itraconazole as 
interventions for toenail onychomycosis included centres in Finland, Germany, 
Iceland, Italy, the Netherlands and the UK and found that the cost-effectiveness of the 
intervention varied across countries (Jansen et al. 2001). Terbinafine was relatively 
cost-effective in all countries except Finland where Itraconazole was the most cost- 
effective option. The main reason for this was the relative price of the interventions; 
the relative price of Terbinafine was higher in Finland, than elsewhere. 
Each of these studies ignored any variations in resource use across the countries 
concerned, and any interrelationships between resource use and unit costs. The 
methodological issues this raises are considered in section four. 
3.13 Country-specific resource use and country-specific unit costs 
Several studies have used unit costs and resource use for each country (Willke at al. 
1998, Rutten-van Molken et al. 1998, Jansen et al. 1997, Stalhammer et al. 1999, 
Berger et al. 1998; Reed et al 2003). Some of these studies have collected resource 
use and unit cost data for each country but then failed to report country-specific 
measures of cost-effectiveness (Reed et al 2004; Rutten-van Molken et al 1998). For 
example, Rutten-van Molken et al. (1998) compared the relative cost-effectiveness of 
formeterol to salmeterol for patients with asthma. The study showed that unit costs 
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varied widely across countries, for example the costs of a visit to the emergency room 
varied from $16 (Italy) to $346 (Spain) which was partly caused by inconsistencies in 
the costing method used across the centres. Regression analysis demonstrated that the 
costs for the control group were different across the countries concerned, however, the 
study did not examine whether the incremental costs of treatment varied by country. 
The authors highlighted that relative prices differed across the countries and this could 
potentially have an impact on the relative cost-effectiveness of the interventions. For 
example, an intervention that reduced clinician visits would appear more cost- 
effective in Sweden where physician costs were relatively high compared to France 
where physician costs were relatively low. 
Several studies found that relative cost-effectiveness varied by country (Willke et al. 
1998, Stalhammer et al. 1999, Berger et al. 1998). Stalhammer et al. (1999) used data 
from a multinational trial to assess the cost-effectiveness of omeprazole and ranitidine 
for management of patients with gastro-oesophageal reflux disease. The base-case 
analysis used trial-wide resource use and country-specific unit costs. A sensitivity 
analysis used country-specific resource use and unit costs. While the pooled result 
suggested that omeprazole was the least-cost option there were important variations 
across countries; in France and Ireland ranitidine was the lowest cost option, whereas 
omeprazole was the least-cost option in Italy and Spain. 
Willke et al. (1998) examined the impact of using country-specific resource use and 
unit costs as opposed to pooled estimates. The authors extended the CEA of tirilazad 
mesylate for patients with subarachnoid haemorrhage (Glick et al. 1998). From the 11 
countries originally recruited to the study, unit costs were collected in five countries. 
The initial analysis pooled resource use, unit costs and outcomes across the five 
countries and estimated that the mean ICER was $45,892 per death averted (Glick et 
al. 1998). Willke et at. (1998) used OLS regression models to estimate separate mean 
ICERs for each country. These regression models were initially based on trial-wide 
resource use data and unit costs for each country. Allowing unit costs to vary across 
countries meant that the mean ICER for the intervention ranged from $46,818 in 
country 1 compared to $69,145 in country 4 (Table 3.1). However, when country. 
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specific resource use data were combined with country-specific unit costs, the ICERs 
varied considerably, in country 5 the intervention was dominant (better outcomes, 
lower costs) whereas in countries 2-4 the cost-effectiveness ratio exceeded $90,000 
per death averted. Thus, once the study used country-specific resource use and unit 
costs the countries fell into two groups: those where the intervention was on average 
cost-effective (countries 1 and 5) and those where the intervention may not be cost- 
effective (countries 2,3, and 4). The initial analysis that used average measures of 
resource use, and presented a pooled estimate of cost-effectiveness led to misleading 
conclusions (Glick et al. 1998). 
Table 3.1: ICERs ($ per death averted) for tirilazad mesylate compared to 
placebo for treating subarachnoid haemmorhage 
Country trial-wide resource use country-specific resource use 
country-specific unit cost country-specific unit cost 
1 46,818 5,921 
2 57,636 91,906 
3 53,891 90,487 
4 69,145 93,326 
5 65,800 *** 
Average 45,892 45,892 
*** Intervention has lower costs, improves outcomes and therefore dominates placebo, but the paper 
did not report ICER. Source: Willke et al. (1998). 
Willke et al. (1998) considered cost variation across international settings more 
carefully than the other studies reviewed. However, while this study demonstrates the 
importance of considering variation in resource use as well as unit costs across 
countries, it suffers from important limitations. A problem with presenting country- 
specific estimates is that the study loses power to detect differences in costs and cost- 
effectiveness between the treatment and control groups. By just presenting mean 
estimates this study fails to report sampling uncertainty. This is important as although 
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the between-country differences in the mean estimates appear large, they could just 
reflect random variations. 
The study does not consider whether there were any systematic reasons for the 
differences in costs and cost-effectiveness across the countries concerned. There may 
be differences in the characteristics of the providers or patients across these countries 
that lead to the observed differences in incremental costs, and incremental cost- 
effectiveness. Assessing the reasons for cost variation would allow the cost- 
effectiveness results to be stratified based on factors that define international 
differences in patterns of care across the centres. This would make the results more 
useful, for decision-makers not represented by countries included in the study. There 
may be circumstances where none of the study centres' costs are likely to 
approximate opportunity costs in a different decision context. In these circumstances, 
further primary data collection may be required. 
3.2 Multinational Economic evaluations based on models and 
systematic reviews 
Another form of study design that has the scope to consider cost variation across 
settings is when an economic evaluation is conducted using a model or a systematic 
review. Cost-effectiveness models have been recommended for transferring cost- 
effectiveness data to different decision contexts (Drummond and Davies 1991). For 
example, information on effectiveness and resource use might be available from a 
clinical trial in a different location to the decision context. A study may then collect 
specific unit costs for the study context and use a model to combine these unit costs 
with more general information on resource use and the effectiveness of the 
interventions. However, a problem in these modelling studies is that the costing 
methods used may be inadequate, in particular any correlation between resource use 
and outcomes, or resource use and unit costs may be lost if different elements of cost- 
effectiveness data are transferred from different contexts. Another problem with 
assessing cost variation in model-based economic evaluations is that these studies 
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may not use a consistent methodology in each health care setting (Barbieri et al, 
2005). 
There are examples in the literature of model-based CEA that use a pooled estimate of 
resource use from a multinational RCT, alongside country-specific unit costs. For 
example, Casciano et al. (2001) evaluated Doxezosin for controlling blood pressure 
and found that cost-effectiveness varied between the UK and Italy because of 
differences in unit costs. 
Other studies have used country-specific resource use and unit costs. Menzin et al. 
(1996) used a model to extend results from a US trial of rhDNase in adults with cystic 
fibrosis. The model assessed the cost-effectiveness of the intervention in France, 
Germany, Italy and the UK. Although originally the analysis used US resource use 
patterns from the RCT alongside country-specific unit costs, this led to inaccurate 
estimates of cost-effectiveness in each of the European decision-contexts. Instead, the 
authors used evidence from local observational databases to adjust the overall 
resource use estimates from the trial for each local context. The adjusted results were 
used in the model to provide country-specific estimates of the relative cost- 
effectiveness of the intervention. The country-specific estimates suggested that the 
intervention was more cost-effective in Germany where morbidity costs were higher, 
than in Italy and France where morbidity costs were lower. However, the study design 
did not consider differences in the way costs were measured in each country. For 
example, it was unclear whether the same resource use items were included in each 
setting. This makes it difficult to assess whether the differences in cost-effectiveness 
across the study settings were due to systematic differences or methodological 
inconsistencies. 
Jansen et al. (1997) found that meloxican was relatively cost-effective compared to 
diclofenac for treating osteoarthritis across all the countries included in the study. 
However, the cost savings were greater in France than in the UK or Italy. Heaney et 
al. (2000) compared four different antidepressants and found similar results across the 
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12 countries included in the study, even though there were inter-country differences in 
resource use and unit costs. 
De Pouvourville and Tasch (1993) used a model to estimate the relative cost- 
effectiveness of misoprostol compared to NSAIDs19 for treating gastrointestinal 
disease in Belgium, France, the UK and the United States. Although there were 
differences in clinical practice and costs across the countries included, this did not 
affect the relative cost-effectiveness of the respective interventions. Drummond et al. 
(1991) considered the methodological issues that arose when using a decision- 
analytical approach to estimate the cost-effectiveness of misoprostol in different 
countries. However, the study used Delphi panels to estimate resource use, which 
clearly limited the internal validity of the results. Unit cost data were taken from 
different sources in each country; the study used hospital charges for centres in 
Belgium and the US, whereas in France and the UK specific costing studies were 
conducted. This may partly explain the wide international variations in the unit costs. 
As the authors themselves state: 
".. the non-comparability of hospital finance systems is likely to be a serious 
impediment to cross-national comparison. " (Drummond et al. 1991, p678). 
There was international variability in both the duration and the intensity of resource 
use, with the US having shorter LOS but higher resource use during that stay. The 
intervention was more cost-effective in the US than in the other countries. However, 
whether robust conclusions can be drawn based on studies that take resource use data 
from expert opinion is doubtful. 
3.21 Systematic reviews of cost-effectiveness studies in different countries 
If the economic evaluation is conducted alongside a systematic review this raises 
further issues about how to incorporate cost variation across settings. An economic 
evaluation based solely on a systematic review requires that data are pooled across 
different studies. While this may be judged appropriate for the outcome data 
19 MAIDS: nonsteroidal anti-inflammatory drug. 
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methodological differences across these studies may lead to methodological problems 
with pooling cost and cost-effectiveness data. Jefferson et al. (1996) considered these 
issues when they reviewed economic evaluations of influenza vaccination. The review 
identified 10 economic evaluations in this area conducted across different 
geographical locations. The review considered methodological differences across 
studies including the choice of currency conversion factor, and inconsistencies in the 
methods used to measure costs. The study concluded that the choice of conversion 
factor made little difference to the results. Of greater concern was that in four out of 
the ten studies reviewed, different resource use items were included which partly 
explained the variation in the results. Of those studies that measured similar items of 
resource use there was considerable variability in the levels of resource use, in 
particular there were differences in hospital LOS that led to differences in the study's 
conclusions. 
In a systematic review, Späth et al. (1999) assessed whether published economic 
evaluations of adjuvant therapy for breast cancer could provide useful information for 
setting health care priorities in France. Although six studies met the review's 
inclusion criteria the authors found that, none of these studies could inform French 
decision-makers. The studies did not identify the resources use included or report the 
unit costs. The authors conclude that if secondary data cannot be transferred from the 
study setting to the decision-context, then a local economic evaluation is required. 
3.3 Economic evaluations based on national multicentre RCTs 
When economic evaluations are conducted alongside RCTs in a single country or 
jurisdiction they usually still recruit patients from several different centres (see for 
example UK Small Aneurysm Trial Participants, 1998). The same decisions about 
how and where to measure resource use and unit costs have to be faced as in a 
multinational study. However, there are a number of important differences in this 
context compared to the multinational setting. The most important difference is that 
these studies are more likely to be tailored to a national decision-making agency, for 
example NICE. Here it is more relevant to present a national estimate of the relative 
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cost-effectiveness of the intervention, rather than an estimate of the cost-effectiveness 
for each setting. However, even when it is desirable to present national estimates, the 
choice of centres for measuring resource use and unit costs could still be important in 
determining the results. 
A common approach in national multicentre economic evaluations is to measure 
resource use for each patient and combine this with an overall measure of unit costs 
(see for example MRC Laparoscopic Hernia group, 2001; Longworth et al. 2001; 
Elboume et al, 2002). These unit costs may be national estimates, averages across all 
the study centres, or specific estimates from a particular centre (UK Small Aneurism 
Trial Participants, 1998; Longworth et al. 2001; MRC Laparoscopic Hernia group, 
2001). Studies then presents an overall cost per patient for each treatment arm and 
then an incremental cost pooled over all the treatment centres. This approach does not 
allow any differences in resource use or unit costs across the centres to be identified 
and explicitly considered in the analysis. It is therefore difficult to assess whether the 
costs used represent the efficient provision of health care programmes. 
Following the recommendations of Drummond et al. (1997a) studies tend to report 
separate resource use and unit costs across all the centres (see Graves et al. 2002 for a 
review), and then use sensitivity analysis to test the impact of changing the unit costs 
used. For example, Coast et al. (1998) compared a hospital at home scheme with 
conventional care. In the main analysis, average unit costs were taken from a single 
national source (Netten and Dennett 1996), and then in the sensitivity analysis the 
robustness of the conclusions was tested by using different estimates for the cost per 
hospital day. Sculpher et al. (1993) took a similar approach when comparing the cost- 
effectiveness of abdominal hysterectomy with transervical endometrial resection for 
patients with menorrhagia. Resource use data were taken from a national RCT with 
unit costs collected from one hospital and applied globally. In the sensitivity analysis, 
high and low estimates of hospital per bed-day costs across all hospitals in the UK 
were used to test the robustness of the results. 
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In these examples, the issue of cost variation across settings is relegated to a one-way 
sensitivity analysis, which can limit the scope for fully addressing the impact of cost 
variability. To assess the impact of cost variation the studies only changed estimates 
of unit cost and ignored any interrelationship between resource use and unit cost. The 
analyst has completion discretion over the range of estimates used in the sensitivity 
analysis. The methodology does not allow the study to fully investigate cost variation 
across settings and the implications for the stability of the results. 
3.4 Methodological issues the review raises concerning cost 
variation across settings. 
The empirical studies reviewed were primarily concerned with providing estimates of 
cost-effectiveness, rather than addressing methodological issues related to cost 
variation. However, the review raised some important methodological issues for any 
study that attempts to identify systematic reasons for cost variation across settings. 
3.41 Ignoring interrelationships between factor price and factor use 
Raikou et al. (2000) highlighted the problems with using location-specific resource 
use but relying on average unit costs. They contrast this approach with one whereby 
resource use data for each patient are combined with setting-specific unit costs. While 
studies that use an average measure of unit costs may presume that the results would 
be similar compared to approaches that estimate unit costs for each centre, economic 
theory suggests that these approaches may generate different results. If relative factor 
prices differ across health care settings for example geographical locations, then 
individual health care firms may choose different combinations of factor inputs. 
Raikou et al. (2000) show that in this case using average unit costs would overstate 
costs compared to using setting-specific unit costs. Using average unit costs fails to 
allow for the substitution of those inputs that are relatively low cost for those that are 
relatively high cost. 
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Raikou et al. (2000) used simulated data to illustrate the likely differences between 
approaches using average and centre-specific unit costs. One situation where the two 
approaches led to similar results was when the change in resource inputs was highly 
stochastic. However, the authors conclude that in general there would be differences 
between the two approaches unless health care centres do not respond to differences 
in unit costs in a manner consistent with economic theory. To understand whether 
health care centres do respond to differences in unit costs in the way suggested by 
economic theory, the authors argue strongly that empirical studies are required; they 
state that: 
". These findings highlight the need for more caution in multicentre studies. They also 
emphasise the need for more and better information on the production process in the 
health care sector. Little is known about the degree of factor substitution in this 
sector. " (Raikou et al. 2000, p197). 
Goree et al. (1990) also emphasise the importance of recognising the potential 
relationship between resource use and unit costs, they state: 
"Drummond and Davies (1991) suggest that resource quantities and unit prices 
should be reported separately so that costs can be recalculated for settings where price 
levels differ..... this solution ignores the inseparability of prices and quantities .. 
" 
(Goree et al. 1999, p570). 
Economic theory would therefore suggest that it is more appropriate to collect 
resource use and unit costs in each health care setting, although there is a need for 
studies that consider whether health care firms do adjust factor use according to 
differences in factor price in the manner predicted by theory. 
3.42 Reasons for observed variations in unit costs across settings 
Several of the studies reviewed attempted to identify reasons for unit cost variation 
(Schulman et al. 1998, Johnston et al. 1998, Hutton 2001). Schulman et al. (1998) 
examined the reasons for unit cost variability across countries. In a further reanalysis 
of the study of tirilazad mesylate for the treatment of subarachnoid haemorrhage unit 
costs were estimated in seven out of the 11 countries included in the RCT. Where unit 
costs were unavailable in a particular country they were estimated using an imputation 
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method based on the relative unit costs in that country compared to the others. To 
improve methodological consistency across the countries, the study only included 
`variable costs' and excluded overheads, and capital costs. However, this definition of 
variable costs is arbitrary, and other costs (e. g. staff costs) may remain fixed in the 
short-term. Also, items that are defined as overheads in some countries may be 
included as consumables in another. A generalised linear regression model was used 
to try and establish reasons for variability in unit costs. The results showed that the 
type of procedure explained 44%, and country 11 % of the overall variation in unit 
costs. However, for certain procedures there were wide variations in unit costs across 
countries. The study did not examine why there may be international variations in unit 
costs across countries. The analysis did not estimate the effect of differences in case- 
mix, and the intensity of resource use across countries. 
Johnston et al. (1998) examined factors that may be associated with differences in unit 
costs between trial and non-trial centres providing a breast cancer screening program 
in the UK. The study examined what characteristics differed between trial and non- 
trial centres, and found that the trial centres were larger, had lower uptake rates, and 
had more highly skilled nursing staff. The study estimated the effect of these centre 
characteristics on unit costs. The results suggested that having a higher level of 
qualified staff and a lower uptake rate of the screening service led to higher unit costs 
for the trial centres. By assessing differences in the characteristics of the trial and non- 
trial centres the study provided an assessment of how `representative' the unit costs 
were from the trial centres. 
By identifying the centre characteristics that were associated with unit costs, the study 
was able to adjust unit costs to be more generally applicable. This study may therefore 
have identified unit costs that were more representative of the opportunity costs for 
the decision context (the UK NHS). 
Hutton (2001) conducted a detailed assessment of reasons for unit cost variation in a 
developing country context. The study used data collected alongside an antenatal trial 
that included centres in South Africa, Thailand and Cuba. The results suggested that 
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there were wide differences in unit costs across the study settings that were associated 
with differences in resource productivity, occupancy levels, staffing patterns, 
exchange rates, input mix and the size of health care facilities. However, the study 
had insufficient health care centres to identify which centres were the most 
productively efficient, and hence had the unit costs closest to opportunity costs. 
3.43 From how many centres should unit costs be collected? 
The number of centres or countries chosen for unit costing is often arbitrary. Unit 
costs are frequently only collected in a sub sample of study centres and it is unclear 
whether these unit costs represent opportunity costs. In a multicountry study, Glick et 
al. (2002) collected unit cost data in four countries (Belgium, France, Spain and the 
UK) for 47 different hospital diagnoses. The authors tried to estimate what the error in 
the cost estimates would be if unit costs were only collected from a sub sample of the 
countries. The unit costs collected from one or more of the countries were omitted and 
instead the analysis imputed these unit costs based on the costs from the remaining 
countries. The study assessed how many countries it was appropriate to collect the 
unit cost data from based on the level of error in the unit costs estimated; this error 
decreased according to the number of countries used for the imputation. The results 
showed that when the imputation was based on the results for only one country, the 
imputation error was high (87% of the mean unit cost estimate), whereas when the 
unit cost imputation was based on data from three countries, the error was 
correspondingly lower (68% of the mean unit cost estimate). Clearly, the imputation 
error even with using three countries to impute unit costs is still large and may have a 
bearing on the accuracy of the cost-effectiveness measure. The number of countries 
included in the analysis was relatively small for making any definitive conclusions 
about the number of countries required for estimating accurate unit costs. In addition, 
the study failed to identify reasons for the inter-country cost variation and the 
implications for measuring opportunity costs. 
3.44 From which centres should unit costs be collected? 
Goree et al. (1999) highlighted that as well as the number of centres, the 
characteristics of the centres are also important in determining unit costs. The authors 
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compared three methods for collecting unit cost data: one based on selecting the most 
convenient hospital, one based on selecting a sample of convenient hospitals and the 
third involved selecting a sample of hospitals by stratifying for factors potentially 
associated with cost variation. The costs per patient for different ways of inducing 
labour for pregnant women were reported for each of these strategies. The results 
showed that the median costs per patient for each strategy varied by about 30% 
according to the method used for collecting unit costs. In some cases, the ranking of 
the relative costs of the respective treatments varied according to the methodology 
used. The results confirm that the choice of methods for estimating unit costs can 
have an important impact on the absolute and relative costs of different treatment 
strategies. 
Goree et al. (1999) put forward a research agenda to try to address this gap in the 
methodological literature. They suggest that a better understanding of cost variation 
across hospitals is needed. They recommend that unit costs are collected from as 
many hospitals as possible. Multivariate analyses can then identify the important cost 
drivers, for example teaching status, urban or rural location and labour and capital 
mix may be associated with unit costs. The results from these studies could provide 
further guidance on the number or type of hospitals required for unit costing. 
3.45 Reasons for resource use variation 
Hutton (2001) examined reasons for resource use variability across health care 
settings using data from a multinational RCT. This study found that there were wide 
variations in resource use both within and across countries. The study used OLS 
regression methods to assess factors associated with resource use variation. The 
results found that these variations were associated with differences in case-mix, 
clinical practice and accessibility. However, most of the resource use variation was 
left unexplained. 
In a multinational study, Bennett et al. (1995) investigated the use of adjunct therapy 
for bone marrow transplantation using data from hospitals in Paris and New York. 
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The study found very different patterns of resource use across these settings, and 
attributed these differences to variations in practice patterns. However, as the study 
only included two countries it was not possible to undertake statistical analyses of the 
reasons for international resource use and cost differences. 
Holmes et al. (1997) compared the resource use following interventions for 
cardiogenic shock between US and non-US countries. The results showed that 
diagnostic and therapeutic procedures were used more frequently in the US than other 
countries, however no reasons were offered for the observed variations. 
3.46 Statistical Methods to analyse differences in costs and cost-effectiveness 
Multicentre studies that collect individual patient data can use statistical techniques to 
analyse variations across health care settings. In a re-analysis of the 4S cost- 
effectiveness study Cook et al. (2003) used statistical techniques to examine whether 
the cost-effectiveness of simvastatin compared to placebo varied across study centres. 
The study reported the incremental cost-effectiveness of simvastatin for each country 
using ICERs and incremental bet benefits (INB) on the cost scale20 (Table 3.2). The 
cost-effectiveness results showed that the overall incremental cost per additional 
survivor was $59,201. The mean ICERs ranged from $47,032 to $129,474 across the 
countries. The mean INBs were reported with 95% confidence intervals to summarise 
the sampling uncertainty. The results showed that with a ceiling ratio (? ) of $75,000 
per additional survivor, the mean INB was positive in three of the countries, but 
negative in Finland and Iceland. Cook et al. (2003) used tests for heterogeneity to 
examine whether there were significant interactions between treatment and country. 
20 Also known as net monetary benefits (NMB). 
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Table 3.2: Incremental cost-effectiveness of simvastatin compared to placebo 
Country N ICER Mean INB 
(95% CI) 
Denmark 355 47,032 1,208 (-2,648 to 5,065) 
Norway 511 43,526 1,371(-1,546 to 4,288) 
Sweden 845 58,208 542 (-1,626 to 2,711) 
Finland 433 120,363 -850(-3,414 to 1,714) 
Iceland 79 129,474 -637(-7,359 to 6,086) 
Overall 2223 525(-826 to 1,876) 
l=$75,000 per additional survivor. Source: Cook et at. (2003). 
The tests for interaction showed the mean INB did not differ significantly across the 
countries. The study concluded that the hypothesis that there was significant variation 
in the cost-effectiveness of simvastatin across the countries, could be rejected. 
Instead, the study suggested it was acceptable to pool these measures of cost- 
effectiveness across the countries concerned. 
A major problem in using these tests for interaction is that there may be insufficient 
cases to detect whether significant interactions exist. The authors concede that even in 
this CEA which had a relatively large sample size (n=2,223), the power of the tests to 
detect an interaction in the INB across countries was only 12.1%. The conclusion that 
there were no significant interactions and that it was acceptable to pool the results was 
limited by the study's lack of statistical power. Also, the results were based on unit 
costs collected in one country. Depending on the interrelationship between unit costs 
and resource use, the cross-country differences in the INB may have been 
underestimated. 
In a national multicentre economic evaluation, Coyle and Drummond (1998) tried to 
establish which factors were responsible for resource use and cost variation. They 
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used data from two trials comparing different methods of radiotherapy, one for 
patients with head and neck cancer the other for patients with cancer of the bronchus. 
The study measured unit costs and resource use in each centre. The results showed 
that in both studies there was significant variation in costs amongst patients in the 
intervention arm. The authors used OLS regression analysis to identify reasons for 
this variation. The results suggested that variables summarising overtime payments to 
staff, clinical practice differences and patient case-mix were significant. The use of 
OLS regression analysis meant the study could not reach definitive conclusions about 
which factors were most important. The OLS regression analysis assumed that each 
patient observation was independent, whereas patients may be clustered within health 
care centres. In their discussion the authors emphasise the exploratory nature of the 
work and that further research is required to consider the potential importance of 
centre characteristics in explaining cost variation. They suggest that: 
"it may be worthwhile that certain centre characteristics are recorded to assist the 
interpretation of multicentre data.... Given the results of this study collection of unit 
cost data from at least a sample of treatment centres is necessary for all studies based 
on a number of treatment centres.. " (Coyle and Drummond 1998, p162). 
In general, economic evaluations have not used statistical methods to assess variations 
in resource use, unit costs, total costs and cost-effectiveness across health care 
settings. This meant the studies reviewed could not make definitive conclusions about 
the factors driving cost variation across settings. 
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3.5 Discussion 
The purpose of this chapter was to consider how economic evaluations have 
considered cost variation across settings. The review found many examples of studies 
that have taken an international approach to economic evaluation. These studies 
covered different decision-making contexts and therefore had reason to consider cost 
and cost-effectiveness variation across settings. However, these studies failed to 
adequately assess this cost variation because of limitations in the studies' design. In 
particular, these studies did not measure unit costs in all centres using a consistent 
methodology. Unless unit costs are measured in the same way in each setting it is 
difficult to identify systematic differences in for example factor prices, or levels of 
technical efficiency across settings. Studies have generally included insufficient 
centres to identify reasons why costs vary across settings. These studies have failed to 
assess whether cost differences exist across centres because of variations in efficiency 
or because of other factors for example case-mix differences or random variation. It is 
important to identify those centres that produce care efficiently to ensure that the unit 
costs used in an evaluation represent opportunity costs. 
Another approach is where economic evaluations have measured setting-specific unit 
costs and combined these with general measures of resource use. Some of these 
studies found that there were important variations in unit costs that led to differences 
in the cost-effectiveness of the intervention. However, as Raikou et al. (2000) point 
out combining setting-specific unit costs with general measures of resource use may 
not be appropriate. Economic theory suggests firms adjust their use of factor inputs 
according to differences in factor prices. Thus, it is theoretically incoherent to collect 
unit costs and resource use from different settings and ignore possible correlation 
between the different parameters. 
A few multinational economic evaluations have demonstrated that cost variation 
across settings can lead to differences in cost-effectiveness. The Willke et al. (1998) 
found international variations in resource use and that using country-specific 
measures of resource use led to wide variations in cost-effectiveness. The pooled 
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results suggested the intervention was universally cost-effective whereas the country- 
specific results suggested that the centres could be divided into two groups based on 
cost-effectiveness. The study did not establish why these two groups had such 
different estimates of relative cost-effectiveness. 
Johnston et al. (1998) found that even within a particular decision context, for 
example a national health care system, there were important variations in cost. The 
choice of centres for cost measurement in national economic evaluations should be 
based on the principle of opportunity costs. The different forms of economic 
evaluation reviewed have neglected this and made arbitrary decisions about which 
centres to include in the cost analysis. 
None of the studies examined provided a comprehensive assessment of which factors 
were associated with resource use and cost variation. While commentators have 
provided a suggested list of factors (O'Brien 1997, Mason 1997) these did not feature 
in the empirical literature. It has been suggested that studies should collect data on 
covariates that capture variation amongst patients and centres (Brown et al 2004). 
However, it is not clear how these covariates should be identified when designing the 
study. 
Methodological failings limited the studies' scope for identifying reasons for cost 
variation. Often cost data were not collected in sufficient centres to examine reasons 
for cost variation. In both the model-based and the RCT-based evaluations, there were 
methodological inconsistencies in cost measurement across health care settings, 
especially where a highly aggregated approach was taken. Even in those studies that 
used a consistent methodology across settings only a small number of settings were 
included in the cost analysis (less than 7), an aggregated approach was taken to 
resource use and unit cost measurement, and an inappropriate statistical methodology 
was used. 
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To examine which factors are associated with cost variation studies are required that 
use insights from economic theory, and collect disaggregated cost data using a 
consistent costing methodology across a range of settings. However, these are 
necessary but insufficient criteria for identifying reasons for cost variation; an 
appropriate statistical methodology is also required. The study by Cook et al. (2003) 
presented a statistical methodology for assessing cost variation across settings using 
tests for interaction. However, this method had insufficient power to detect 
differences across setting even in a study with over 2000 cases. Coyle and Drummond 
(1998) used OLS regression methods to analyse variation in costs across settings. This 
approach assumes that the individual observations are independent. However, this 
assumption may be implausible in multicentre studies as patients may be clustered 
within settings. There is scope for methodological development in this area and 
Chapter 5 reviews different techniques for assessing cost variation. 
3.6 Conclusions 
While commentators suggest that costs are likely to vary across health care settings 
(O'Brien 1997, Mason 1997), this review found few empirical studies that have 
carefully examined cost variation across settings (Goree et al. 1999, Hutton 2001). 
Many of the studies reviewed suffered from serious methodological limitations that 
hindered cost comparisons across health care settings. Studies are needed that use 
appropriate methodologies that can identify reasons for cost variation. This 
methodology should be based on economic theory, use a disaggregated and consistent 
approach to cost measurement in sufficient health care settings, and rely on an 
appropriate statistical method. The seriousness of this gap in the literature is 
highlighted by a commissioning brief from the NHS Health Technology Assessment 
Programme (1998), and recent initiatives from the WHO that aim to analyse unit cost 
data across many different countries (Murray et al. 2000). The next chapter considers 
how relevant strands from microeconomic theory can inform methodological 
developments in this area. 
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Chapter 4: Review of theoretical and empirical 
evidence for cost variation across settings 
4.0 Introduction 
The previous chapter highlighted gaps in the economic evaluation literature on why 
costs may vary across health care settings and the implications for the design, analysis 
and interpretation of economic evaluations. This chapter reviews relevant theoretical 
and empirical literature to provide insights into the reasons for cost variability across 
health care settings. The review is divided into four sections; the first section 
considers production and cost functions, the second section differences in the health 
care context, the third section differences in patient factors, and the fourth section the 
measurement issues that arise when comparing costs across health care settings. For 
each of these areas the concepts are outlined, before the evidence on cost variation 
across health care settings is assessed. The aim of this chapter is to generate 
hypotheses for why costs may vary across health care settings, and to provide a 
theoretical framework for the empirical investigation. 
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4.1 Review of theoretical concepts on production and cost 
functions 
This chapter begins by reviewing the key concepts underpinning the production and 
cost function literature. The production function specifies the relationship between the 
inputs used and the level of output produced. The production function has been 
described as: 
"..... the core concept in the economic theory of production. It is critical to know how 
much output can be produced with certain inputs, and to know if there are alternative 
ways of producing the same product" (Heathfield and Vibe 1981, p4). 
The production function specifies a purely technical relationship between the quantity 
of inputs used and the level of output produced, under the assumption that the firm 
aims to minimise the costs of producing a given level of output. Where one 
homogenous output (q) is being produced from various inputs (v1..... v, ) then the 
production function may be stated as: q=f(v,.... v, ). Knowing the technical 
relationship between inputs and outputs is a necessary but not sufficient condition for 
cost minimisation, which also requires knowledge of relative factor prices. 
In the most basic production function, the factors of production are divided into two 
groups labour (vi) and capital (v2) producing a one dimensional, homogenous output 
(q). In the short-run capital is assumed to be fixed, whereas labour is variable, but in 
the long-run the levels of both factors can be varied. 
The production functions provide a way of defining the alternative production 
methods and specifying the range of technical possibilities that are open to producers. 
The notion that there are different ways of producing the same good is often ignored 
in industries such as health care where providers may subscribe to what Fuchs has 
termed the `monotechnic' view (Folland 1997). In fact different quantities of various 
care inputs: doctors' time, nurses' time, therapeutic interventions, and capital may be 
combined to produce a particular level of output. 
There is a wide literature documenting the variations in resource use that exist across 
health care settings, this literature is often termed the `practice variations literature' 
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(McPherson et al. 1982, Wennberg 1984, Phelps and Mooney 1993). Much of the 
literature comes from the US where large administrative databases have been used to 
compare resource use across different geographical areas (see the review by Phelps 
and Mooney 1993). The results have suggested that for some procedures the reasons 
for medical intervention seem clear and the level of intervention is similar across 
regions. For example, intervention for hip fracture or acute myocardial infarction (MI) 
is similar across different geographical areas (Phelps and Mooney 1993). However, 
variations appear much larger for non-surgical admissions to hospital (Phelps and 
Mooney 1993; Phelps and Parente 1990, Wennberg 1984, McPherson et al. 1982). 
Phelps and Mooney (1993) point out that hospital care for cardiac and mental illness 
seem to dominate lists of hospital admissions with high variability across regions. 
Beech et al (1996) documented wide variation in the LOS in the acute hospital 
following stroke across centres in Western European countries. Wolfe et al. (1999) 
showed that in centres with different ways of managing stroke care there were also 
variations in outcomes post-stroke. 
However, these studies tend to simply document that such variations exist without 
detailing why they might occur. One reason why variations in resource use might 
occur is if substitution is occurring. Often clinical practice variations are greatest 
when various alternatives exist. For example, within orthopaedics the rate of 
hospitalisation for hip fractures has a small coefficient of variation (COV)21, whereas 
for fracture of the forearm the COV is much higher, in part because more alternatives 
exist (e. g. ambulatory surgery, or direct treatment in an emergency room, Wennberg 
(1984). To assess reasons for variations a broad range of production processes have to 
be considered. 
4.11 Isoquants, factor substitution and technical efficiency 
Isoquants (meaning equal quantities) show the possibility of factor substitution in 
producing a given level of output. The slope of the isoquant illustrates the extent to 
which factor substitution is possible. The slope is the ratio of marginal products, so a 
change in the marginal productivity of labour or capital will change the slope of the 
21 In health care, there may be a lack of substitution because of regulations or incentives in the health 
care setting that prevent substitution taking place, these are reviewed in section 4.2. 
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isoquant, which will have implications for the input mix chosen. The isoquant 
represents a frontier of technically efficient production. Isoquants are commonly 
drawn with a negative slope and convex to the origin, to illustrate the diminishing 
returns from using a particular factor input. This arises when factors of production are 
imperfect substitutes for one another. As the proportion of say labour relative to 
capital increases, then assuming that the same level of output must be maintained, the 
amount of labour that can be traded-off for a given amount of capital decreases. 
However, if the factors of production are perfect complements, then one factor cannot 
be substituted for another. 
In certain areas of health care, it may be possible to choose different input mixes 
while still producing a technically efficient level of output. However, different factor 
mixes may also be signs of different levels of technical efficiency which can lead to 
differences in total cost. 
Some studies have used a production function framework to analyse differences in 
resource use or more specifically the mix of resource inputs used to produce a 
particular good. Jensen and Morrisey (1986) analysed the effect of physician inputs 
on the level of health care provided. They found that physicians had a strong positive 
influence on the productivity of other inputs and were substitutes for other resources. 
This study illustrated the importance of case-mix adjustment: after adjusting for case- 
mix the marginal product of labour increased relative to capital. The study also 
demonstrated that there was a high potential substitutability of nurses for medical 
staff. This theme has been followed up by a number of studies reviewed by 
Richardson and Maynard (1995) who suggested that between 30% and 70% of the 
tasks currently carried out by doctors could be done by nurses. However, the review 
criticised the design of the studies, in particular little account was taken of the 
outcome of care provided. Also, none of these studies evaluate why substitution may 
or may not occur. 
Parente (1989) examined substitution of outpatient for inpatient care for various 
clinical conditions, across different regions in the Rochester, New York area. The 
study found that outpatient care for knee procedures was negatively correlated with 
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the use of inpatient care across regions. However, for most of the other clinical areas, 
the use of inpatient and outpatient care was positively correlated, indicating that the 
services were complements rather than substitutes (Table 4.1). Similarly, Phelps and 
Mooney (1993) found positive correlation between the uses of particular procedures 
that could a priori be defined as substitutes. The only evidence of substitution was in 
the use of ICU and non-ICU bed-days for patients with MI, angina or chest pain. 
Table 4.1: Correlation of inpatient and outpatient resource use 
total urban rural 
Procedure 
Cataracts 0.38 0.43 0.00 
Glaucoma 0.44 0.40 0.99 
Tonsillectomy and 0.09 0.18 -0.17 
adenoidectomy 
Varicose veins 0.48 0.81 -0.22 
Haemorrhoids -0.09 0.13 -0.34 
Knee procedures -0.25 -0.72 0.12 
Source: Parente (1990) 
In their seminal paper using a production function framework to analyse the 
substitutability of various health care inputs, Cowing and Holtmann (1983) found 
substantial levels of substitution between nursing and professional workers, nursing 
and general workers, nursing and administrative workers and professional and 
administrative labour. While this study found some evidence inputs were 
complements, hospitals generally appeared to have good flexibility in substitution 
between different labour inputs, even in the short-run. More recently, Carr-Hill et al. 
(1995) examined the impact of changing the nursing skill-mix on the output of 
nursing care. They found that reducing the number of untrained nurses and increasing 
the number of trained nurses, led to higher outputs, for a given level of input. Despite 
the stated importance of understanding production processes in order to understand 
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the behaviour of health care firms, there are very few studies that have estimated the 
degree of factor substitution in health care (Raikou et al. 2000). 
4.12 Evidence on technical efficiency 
An important reason for assessing production processes is to estimate the extent to 
which firms are failing to achieve technical efficiency, that is they are failing to 
maximise output from a given set of inputs, or failing to use the minimum inputs 
required to produce a given output. In an early work, Feldstein (1967) used the 
residuals of the production function as a measure of technical efficiency. Thus a 
hospital with a residual of zero from the production function, had an average level of 
technical efficiency, whereas a hospital with a residual greater than zero was more 
technically efficient. This pioneering study demonstrated wide variation in technical 
efficiency across hospitals in the UK NHS. Valdmanis (1990) used Data Envelopment 
Analysis (DEA) to estimate technical inefficiency in not-for-profit and for-profit 
hospitals in the US. This study indicated that for-profit hospitals achieved higher 
levels of efficiency. A similar study by Register and Bruning (1987) found no 
significance difference in efficiency levels between for-profit and not-for-profit 
hospitals. 
More recently stochastic frontier analysis (SFA) has been used to measure efficiency. 
SFA attempts to counter the principle problem of DEA, which is its sensitivity to 
unobservable shocks22. Wagstaff (1989b) in a study on Spanish hospitals found that 
90% of observed inefficiency was due to random shocks, leaving only 10% due to 
actual inefficiency. Zuckerman et al. (1994) used SFA to analyse a group of US 
hospitals and found efficiency levels of between 80 and 88%, which were similar to 
the estimates Valdmanis (1990) found using DEA techniques. However, SFA 
struggles to distinguish between technical and productive efficiency. As Jacobs 
(2000) points out this is an important limitation as different forms of inefficiency may 
call for different policy responses. In a DEA study Maniadakis and Thanassoulis 
(2000) used DEA to estimate the impact of the UK NHS reforms on technical 
efficiency, and concluded that the incentives put in place by the `internal market' had 
22 Chapter 5 provides a review of these different techniques. 
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little impact on technical efficiency. The SFA by Folland and Hofler (2001) did 
provide separate estimates of technical and productive efficiency but concluded that 
the estimates of technical efficiency were heavily dependent on the methodology 
used. Each of these studies used highly aggregated datasets to estimate efficiency, and 
encountered measurement issues, these are considered in section four below, and in 
Chapter 5. 
4.13 Productive efficiency 
The point of productive efficiency can be found with reference to the firm's isoquants 
and to the isocost line (also known as the budget constraint). The isocost line 
represents all the combinations of factor inputs that can be purchased for a constant 
total cost. The cost-minimising point on the isoquant is where the isoquant is 
tangental to the isocost line. Health care firms in various settings who are producing a 
similar product may face similar isoquants but different relative factor prices. 
Different relative factor prices may arise because of differences in the characteristics 
of the local markets for factor inputs (see section 4.23). Theory suggests that firms 
who face different relative factor prices may choose different combinations of factor 
inputs. The extent to which firms respond to changes in relative factor prices is 
measured by the elasticity of substitution a: 
relative change in (Vi / V2) 
relative change in (PI / Pi) 
where V, /V2 denotes the technically and productively efficient ratio of factor inputs 
and P1/P2 the ratio of input prices. Q can be between 0 and oo. When a =0 the factors 
of production are perfect complements, and where a= oo the factors of production are 
perfect substitutes. 
Different forms of the production function make different assumptions about o. For 
example, the Cobb-Douglas production function assumes that a =1, the constant 
elasticity of substitution function assumes that a is constant for the same level of 
output, and the translog production function allows a to vary across different levels of 
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output. The implications of these assumptions are considered further in the section on 
measurement issues (4.3). 
For each level of output (go, q,.... qp) there is a ratio of factor inputs at which costs are 
minimised. The cost function summarises the relationship between total costs (TC), 
outputs (q) and input prices (pl)p2): TC=h(q, p,, p2). The total cost function can then be 
used to derive average and marginal costs. Just as the isoquant represents a frontier of 
efficient production with respect to output, so the cost functions represent points of 
efficient production with respect to cost (Call and Holahan 1983). 
4.14 Empirical evidence on factor substitution and productive efficiency 
There has been little empirical work on the extent to which substitutions of factor 
inputs occur in response to differing factor prices in the health care sector (Raikou et 
al. 2000). Feldstein (1967) estimated the elasticities of substitution across different 
groups of factor inputs in the UK NHS, and concluded that providers spent too much 
on doctors and drugs. However, the Cobb-Douglas functional form may have been too 
restrictive. Lavers and Whynes (1978) used the more flexible translog production 
function but also concluded that in general the UK NHS did not adopt the 
combination of factor inputs required to achieve productive efficiency. The study 
found that the ratio of doctors to beds was too high and the ratio of nurses to beds was 
too low. Maniadakis and Thanassoulis (2000) used DEA to estimate different levels 
of efficiency before and after the 1991 NHS reforms; they found that any 
improvements observed in efficiency were attributable to gains in productive 
efficiency. In a study of the relative efficiency of public and private health care 
facilities in Nigeria, Wouters (1993) found that public health care facilities were 
productively inefficient. However, this study was relatively small for assessing 
inefficiency. Those firms that `appeared' technically inefficient were deleted from the 
dataset, and then a cost function with the Cobb-Douglas functional form was used to 
estimate productive efficiency. 
All of the studies reviewed use aggregated datasets. This makes it difficult to assess 
case-mix and quality of care differences across the studies, and identify systematic 
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differences in productive efficiency; this issue is considered again in section 4.3 and 
in Chapter 5. 
Phelps and Mooney (1993) suggest that while providers should be influenced by the 
costs of using different combinations of factor inputs, it may be that providers do not 
have the information available to allow relative costs to influence their decisions. In a 
before-and-after study, looking at the impact of introducing information on costs, 
doctors significantly reduced the number of laboratory tests they requested in 
response to having information on the costs of tests. When this information was 
withdrawn the number of tests requested increased. 
4.15 Consideration of the short-run versus the long-run 
In order to understand why costs differ across settings it is important to distinguish 
between firms taking a short-run compared to a long-run perspective. 
The cost function in the short-run 
In the short-run it is assumed that the firm is only able to vary one input, usually 
labour, while the other (capital) remains fixed. For example, in Figure 4.1 the firm can 
reduce short-run average costs (SRAC) by increasing labour input until the cost 
minimising point on SRACI is reached at point A. If the firm is operating on the 
SRAC2 at point B, the firm may be underutilising the fixed input. Increasing the 
labour input to point C, by increasing labour input would mean the fixed input was 
more fully utilised and the SRAC falls. Different levels of under-utilisation may exist 
across health care settings depending on incentives to cost-minimise, and the extent to 
which inflexibilities exist in the various factor markets. In the short-run it is assumed 
that the level of capital is fixed, it is not possible to reduce the level of capital to cost- 
minimise. 
The impact of under-utilised health services has been widely quoted in the literature 
as having a significant impact on unit costs (e. g. WHO 1979). However, the evidence 
for this rests largely on descriptive data. For example, Berman (1986) concluded that 
differences in utilisation rates and programme management `probably' accounted for 
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most of the variation in unit costs across settings. The limited econometric work on 
the impact of under-utilisation on unit costs comes from studies whose estimates of 
technical inefficiency include a component that can be categorised as under- 
utilisation23. For example, Zuckerman et al (1994) show that their measures of 
efficiency are inversely related to occupancy rates. The elasticity of inefficiency with 
respect to the occupancy rate is about 20%. This implies that a 10% increase in the 
occupancy rate would reduce inefficiency by 2%. 
The cost function in the long-run 
In the long-run it is assumed that the firm can adjust the level of capital as well as 
labour to try and cost-minimise. For example, if the firm in Figure 4.1 starts at point 
A then to cost-minimise in the long run it has to increase the level of capital and move 
to the cost minimising point on the next short run average cost curve (SRAC2), at 
point C. 
Average 
cost 
(AC) 
LRAC 
output (q) 
Figure 4.1: Short-run and long-run average total cost curves 
The long-run average cost curve (LRAC) joins all the short-run cost minimising 
points, thus showing the least cost combinations for different levels of output. If 
economies of scale exist, then the LRAC is downward sloping. Health care firms in 
23 Strictly speaking underutilisation should not be counted as part of technical inefficiency, technical 
inefficiency refers to waste and failing to minimise the inputs required to produce a given output, 
whereas underutilisation is a short run concept and refers to the reduction in the cost per unit of output 
that would occur if output was increased, so that the labour available would be more fully utilised. 
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different locations may vary in the extent to which they can achieve economies of 
scale. 
Evidence on whether health care firms take a short-run or long-run perspective. 
The cost function literature defines the short-run perspective as being where one 
group of inputs (labour) is variable, while another input set (capital) is fixed. Clearly, 
this represents an unrealistic and highly simplified dichotomy when applied to health 
care. In the health care setting, many labour inputs may be regarded as fixed, whilst 
certain capital inputs may be regarded as variable (Dawson 1994). There is a 
continuum from the short-run to the long-run, along which each input in turn may 
change from being regarded as fixed to variable. As Gravelle and Rees (1982) 
explain, what this simplified definition of fixed and variable really relates to, is the 
cost of adjusting the level of the input concerned. Although in the short-run, the costs 
of increasing say the number of beds on a hospital ward may exceed the expected 
increase in revenue, these adjustment costs may be justified over the long-run. Health 
care firms in different contexts may vary according to whether they display short-run 
or long-run behaviour. If it cannot be assumed that all firms are operating from a 
long-run perspective and hence able in principle to adjust all factor inputs according 
to differences in factor prices, this makes it difficult to interpret cost differences 
between settings as being attributable to variations in productive efficiency. 
In the context of a competitive market situation, Cowing and Holtmann (1983) found 
that in the US the production of for-profit hospitals met the short-run conditions for 
cost-minimisation. They also found though, that the same hospitals did not meet the 
long-run conditions for cost-minimisation. Bilodeau et al. (2000) conducted a similar 
study but using cost data on not-for-profit hospitals in Canada. This study used data 
from all the hospitals in Quebec over a 12-year period and concluded that these 
hospitals also met the conditions for short-run but not for long-run cost-minimisation. 
Bilodeau et al. (2000) discuss whether this was because government rather than 
private sector decision-makers made investment decisions. However, the authors 
point out that their results are similar to those of Cowing and Holtmann (1983) and 
conclude that hospitals tend not to cost-minimise in the long-run irrespective of their 
ownership status. 
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4.16 Economies of scale 
A range of econometric studies have looked at the role of economies of scale in 
explaining differences in hospital costs (see review by Aletras 1999). The more 
reliable studies have found that the hospital of average size (one with 200-300 beds) 
faces constant returns or diseconomies of scale. Söderland et al. (1995) found that the 
total number of beds in the hospital was not significantly associated with hospital 
costs. However, when the analysis was conducted at the speciality level, the cost per 
episode was significantly associated with the number of beds. The use of highly 
aggregated data may therefore conceal the relationship between volume and output. 
4.2 Contextual factors 
The principles of the production and cost function literatures have been applied to 
health care delivery, to examine under what circumstances health care providers 
deliver services in a way consistent with cost-minimisation. This next section 
examines what contextual factors appear to be associated with differences in cost. 
This section focuses on the labour market for health care inputs to consider why 
differences in factor prices and factor inputs may arise. The review highlights that in 
the context of health care production, there be may restrictions on efficient production 
that differ across settings and these could be associated with cost variation. 
4.21 Incentives 
Much of the applied literature on cost and production functions has focused on 
analysing whether those health care providers with greater incentive to cost-minimise 
exhibit more efficient behaviour (Valdmanis 1990, Cowing and Holtmann 1983, 
Sloan 2000). The evidence suggests that even if providers have clear incentives to 
profit-maximise, it is unclear whether health care providers' behaviour is consistent 
with cost-minimisation in the long-run. Cowing and Holtmann (1983) compared the 
behaviour of for-profit and not-for-profit providers in the US and showed that in the 
short-run for-profit providers were aiming to cost-minimise. Not-for-profit hospitals 
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were using a higher quantity of inputs in the production process they were also 
producing a higher quality product than their for-profit counterparts24. Sloan (2000) 
highlighted the difficulty in adjusting for patient and provider factors when trying to 
estimate the effect of incentives on costs. For example, levels of teaching, research 
and case-mix may all vary according to the hospitals' ownership status, and may limit 
the comparability of costs. Following a comprehensive review of the literature on the 
effect of ownership on costs, Sloan (2000) concluded that: 
"Overall the empirical evidence demonstrates no systematic differences in efficiency 
between profit and not-for-profit hospitals" (Sloan 2000, p1168). 
The way in which providers are reimbursed may differ across health care settings, 
which may also influence the use of health care. The Copenhagen case study found 
that introducing fees paid to providers for delivering certain services increased their 
use (Krasnik et al. 1990). In the US, managed care has been shown to improve 
technical efficiency in hospitals (Miller and Luft 1997). One reason for this may be 
the lower rate at which technology is diffused in a managed care rather than a fee for 
service (FFS) setting. However, these studies have again struggled to recognise 
differences in case-mix and the quality of care across health care providers. 
Many countries have moved towards prospective payment systems for hospital 
reimbursement in an attempt to improve productive efficiency. In the USA, 
prospective payment systems based on Diagnosis Related Groups (DRGs) have been 
introduced to try and reduce costs. DRG information is used to categorise inpatients 
according to diagnosis and resource use, and the reimbursement rate per case is set to 
the average for the DRG. Providers have an incentive to reduce costs below the DRG 
reimbursement rate as they can keep any cost `savings' that arise. Variants on the 
DRG system have been introduced in many EU countries in an attempt to reduce 
hospital costs. However, it is uncertain whether introducing a prospective payment 
system does reduce costs (Ellis and McGuire 1986). Often the DRG reimbursement 
only covers hospital services, so hospital providers have a clear incentive to shift costs 
onto community providers, or the patient themselves. Another problem is that 
24 This raises measurement issues that will be discussed in the next section. 
96 
providers have an incentive to misclassify the diagnosis to try to receive additional 
reimbursement. Instead of offering financial incentives, governments may introduce 
targets to try and reduce costs. However, evidence from the UK suggests that such 
policies have had limited impact on efficiency (Jacobs and Dawson 2003). 
International studies suggest that overall health care expenditures are likely to vary 
according to incentives within the health care system to reduce health care costs. For 
example, Hurst (1991) found that under a system where physicians were paid by fee 
for service (FFS) and providers were retrospectively reimbursed, expenditure was 
generally higher than one where there were fixed budgets for hospitals and clinicians 
reimbursed by capitation fees or salaries. At a more micro level, McClellan and 
Kessler (1999) demonstrated that differing incentives across 16 countries were 
important in explaining the relative uptake of hi-tech interventions for cardiovascular 
disease. 
The introduction of user charges for health services may reduce the demand for health 
services and the extent to which patients in different health systems are required to 
pay for a given service may be important in explaining differences in resource use 
across settings. However, a review of studies examining the effect of user charges on 
the demand for health services found that the price elasticities of demand for health 
services were generally relatively inelastic (Folland and Stan 1990). In most 
European countries, patients have to pay a sizeable contribution towards social care 
services such as nursing homes or home help unless their assets are too low, or they 
fall below a needs-based threshold (Hantrais and Letablier 1996). Depending on the 
extent to which these social services may substitute for hospital services, higher 
copayments for social services may lead to higher use of hospital care. 
4.22 Technological progress and access to technology 
Firms may be constrained in their attempts to cost-minimise by the technological 
progress in their health care system. Technological progress occurs in an industry if 
new capital is developed or workers become more highly skilled. This may lead to 
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higher factor productivity, meaning that the same output can be produced with lower 
levels of factor inputs. While technology in general may be cost lowering, in health 
care, new technology often improves outcomes but at higher cost (Bradford et al. 
2001). Health care firms in different settings may have different levels of access to 
new technology, which explains why a higher output is produced from apparently 
similar levels of factor input. For example, a new pharmaceutical intervention, or 
highly trained health care professional may be available in one setting, but not others. 
This may partly reflect differences in the societal willingness to pay for a unit of 
health gain, which may depend upon national income, or relative preferences for 
health care versus other good and services (O'Brien 1997). 
Bradford et al. (2001) highlighted the importance of the `learning curve' in 
determining efficiency in production using as examples coronary bypass surgery 
(CABG) and balloon angioplasty (PTCA). The study found the average level of 
inefficiency for the established procedure, CABG was lower (8.7%) than for the new 
procedure, PTCA (38%). The authors go onto suggest that where hospitals are at 
different places on the learning curve this can have an important impact on the 
efficient use of a technology. 
The rate of uptake of new technologies may differ across international health care 
settings and this may hinder attempts to compare technical or productive efficiency. 
Dervaux et al. (2004) tried to compare technical efficiency between French and US 
hospitals, but concluded that there were substantial differences in the technologies 
used that meant problems arose when comparing estimates of technical efficiencies 
based on a general measure of technology. 
In a study comparing the use of new technologies following myocardial infarction 
(MI) across 16 countries, McClellan and Kessler (1999) reported wide variations 
across countries in the use of `high tech' costly interventions such as CABG and 
PTCA. The rate of adoption of these technologies varied according to the level of 
regulatory control on the introduction of new technologies in different countries. As 
McClellan and Kessler (1999) comment: 
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"countries such as the United States with relatively weak supply-side controls have 
relatively high growth rates.. " (McClellan and Kessler 1999, p37). 
4.23 Labour market characteristics 
The cost function literature tends to assume that although the level of technology and 
factor prices are determined exogenously, the firm can chose the factor-mix consistent 
with cost-minimisation. An issue this raises is whether firms in different health care 
settings do face different relative factor prices. As labour costs form an important 
component of total health care costs in most industrialised countries (OECD 2001), 
particular attention is now given to the labour market. In a perfectly competitive 
labour market, the wage rate would be determined by the intersection of the supply 
and demand for labour. Theory usually depicts the supply curve for labour as being 
upward sloping, with respect to price. The demand curve is usually downward sloping 
and depends on the marginal productivity of labour, and the price of the final product. 
As Figure 4.2 illustrates, if firms pay a wage (W! ) lower than the equilibrium wage 
(We) then workers will not supply their labour, and there will be vacancies equal to Le- 
Li. These vacancies would act as a signal for these firms to increase their wages, and 
supply would increase accordingly until an equilibrium wage and quantity is reached 
at E. 
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Li L. Quantity of Labour (L) 
Figure 4.2: Achieving equilibrium in a competitive labour market 
However, this model of the perfectly competitive labour market may not exist in 
health care. Labour markets in this sector are characterised by shortages of particular 
factor inputs in certain regions, which suggest that the market has rigidities and does 
not reach an equilibrium. For example, in the UK labour market the overall demand 
for nurses exceeds the supply, but in rural areas in the UK, the reverse is true (Elliott 
2003). There is wide variability in the supply of doctors across Western Europe. For 
example, the number of qualified doctors per 1000 of the population is 1.6 in the UK, 
compared to 5.5 in Italy (OECD 2001). This could reflect differences in the regulation 
of the labour market for physicians between these two countries. 
A perfectly competitive labour market would predict that in the long-run the level of 
wages would reach the same equilibrium wage across the health care settings 
concerned. However, international labour markets for health professionals appear to 
be in a permanent state of disequilibria, as wage rates differ across countries. 
Cromwell and Mitchell (1986) found that differences in wages explained up to 33% 
of the observed variation in costs across US hospitals. Fuchs and Hahn (1990) 
suggested the US had higher health care costs than Canada due to higher physician 
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fees. In Eastern Europe, the wages of health care professionals are much lower than in 
the West (ILO 2002). There has been a fall in real wages for public sector workers in 
ex-Soviet Union countries that have moved towards market economies (ILO 2002). 
An important reason why the conditions for a competitive labour market fail in health 
care is that there are insufficient buyers and sellers. In many countries, wages in the 
public sector are set by negotiation between one buyer (the government) and one 
seller for example, a national union acting on behalf of its members. Thus, the market 
may be characterised by having a monopolistic and monopsonistic structure. Wage 
rates may differ between countries depending on differences in the relative bargaining 
powers of these two parties. In some countries, there may be several buyers, for 
example, different health insurance firms and individual health care professionals may 
negotiate wages. This market characteristic may lead to differences in wages within a 
country or between countries with different characteristics. 
In some health care settings, the wage paid may only be a small consideration to the 
worker deciding whether to enter or remain in the particular labour market. Rosen 
(1986) highlights the importance of compensating differentials in understanding 
disequilibia in the labour market. Differences in the costs of living, the working 
conditions and the local environment may be important considerations when setting 
wages. In Eastern European countries, health care professionals may receive `under 
the counter' payments from the patient that partly compensate them for their low 
official wage (Thompson and Witter 2000). In addition, important state benefits may 
be provided for the employee including subsidies for childcare, housing, food and 
health care. Many employees also work in the private sector to increase their state 
income. In Lithuania, a survey of health care workers highlighted that flexible 
working hours were an important determinant of job satisfaction, and this policy may 
encourage workers to reduce the hours they work in the state sector (ILO 2002). In the 
UK, it has been demonstrated that the supply of health care professionals is quite 
inelastic with respect to price, and that many other factors including job satisfaction 
are important in determining nurses' decisions about whether to remain in the labour 
market (Elliott et al. 2003). In addition, the variability in vacancies for GPs across the 
UK was found to be independent of their wage, which is broadly similar across the 
101 
country (Elliott 2003). This indicates that factors other than the wage rate are 
important in determining where GPs choose to supply their labour. 
Barriers to entering and exiting the health care labour markets in different countries 
may also lead to differential factor prices. In some countries, for example the UK, 
doctors may be contracted to work for a five-year period, and in other countries the 
state may require training costs to be repaid by those leaving the labour market. While 
there is some evidence of labour market mobility across countries, for example in the 
UK more than 20% of doctors were trained elsewhere (Elliott 2003). In general, 
requirements to meet professional standards may differ across countries and may limit 
the transfer of labour. 
The perfectly competitive labour market also assumes that there is perfect 
information. However, in health care, the marginal productivities of different health 
care workers are often unknown. Similarly, the value of the product is often unknown 
as prices for many health care services are unavailable. This makes it difficult to set a 
wage that equals the marginal product. For a hospital looking to recruit health care 
workers from a different country, it may be difficult to assess what their wage should 
be, based on their likely marginal productivity. The extent to which the training and 
skills learnt in one context may be transferable to another may be unknown, and limit 
the transfer of workers between different settings. 
Labour markets and factor substitution 
Cost function theory suggests that when a factor price is relatively high in a particular 
setting, it may improve productive efficiency to use another input instead. Wagstaff 
(1989a) reviews econometric work conducted on the UK labour market and highlights 
the work by Gray et al. (1986) and Lindsay (1980) who both suggest that as the wage 
rates in the health care sector rises relative to the price of capital, there is a 
substitution of capital for labour. Lindsay (1980) also looked at the net emigration of 
physicians from the UK, and found that it was related to current and lagged values of 
rate of return to employment in medicine. However, in many instances, labour market 
restrictions may inhibit change from taking place. For example, professional bodies 
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may have strict guidelines that limit the substitutability of different labour inputs 
(Elliott 2003). Different labour markets have different regulations regarding the 
number of hours different health care professionals are allowed to work. For example, 
under the new contracts in the UK NHS junior doctors can work up to 48 hours per 
week, whereas in Germany regulations mean that doctors are not allowed to work 
more than 40 hours per week. Another restriction is that health care professionals 
usually have to receive an accreditation, which for some professions may be difficult 
to acquire in particular countries. Governments in Eastern Europe have only recently 
given accreditation to professions such as occupational therapists, and training 
colleges are rare. The supply of these inputs is therefore limited nationally and may 
constrain their use in local health care settings. 
Although production and cost function studies often presume that health care firms 
are acting from a long-run perspective, and therefore all factor inputs are variable, 
inflexibilities in the labour market may mean that firms in some settings fail to take a 
long-run perspective. Even for nursing inputs which due to the shorter training 
periods and relative flexibility of contracts, may be thought more adjustable, Carr Hill 
et al. (2003) reported a complete lack of flexibility in the deployment of nurses in 30 
UK hospitals. 
In summary, national labour market characteristics may determine the level of labour 
inputs deployed in local health care settings. Local decision-makers may have limited 
influence over the price and use of labour inputs. The price of labour inputs may 
differ across countries, as restrictions and inflexibilities in international labour 
markets mean that wages never reach equilibrium. 
4.26 Health care budget 
Several studies have highlighted that health care costs are correlated with national 
income (reviewed by Hutton 2001). For example, Barnum and Kutzin (1993) found a 
positive correlation between average health care costs and GNP per capita. These 
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findings reflect that labour costs are an important source of health care costs and wage 
rates are highly correlated with per capita income. 
Those countries with higher levels of national income tend to spend a higher 
proportion of their income on health care, that is health care has been shown to have 
the characteristics of a `normal' good (Gerdtham et al. 1992). The national level of 
spending on health care has implications for the factors of production that may be 
available to an individual health care firm. For example, the numbers of health care 
professionals that are trained and available to the labour market may depend on the 
national budget, and may be stipulated by a national decision-maker. Similarly, 
national decision-makers may decide whether or not to reimburse a new technology 
and this may depend on the budget available for health care. 
Phelps and Mooney (1993) discuss 'Roemer's Law' that suggests demand for services 
follow supply, whereas economic theory would suggest that supply follows demand. 
Differences in the resources available for health care may be an important determinant 
of the use of specific health services across settings in different countries. For 
example, in Western Europe the number of acute bed-days available per 1000 people 
ranges from a low of 2.2 in Turkey to a high of 7.0 in Germany (OECD 2001). This 
suggests that higher resource use of health services in Germany may partly reflect a 
greater availability of hospital resources. However, simply observing utilisation does 
not establish whether utilisation levels reflect supply or demand factors. 
4.27 Role of clinical decision-makers 
While in part, the use of factor inputs may be determined by the overall context within 
which the health care firm operates, the role of local decision-makers, in particular 
clinicians may be important. Reviews of the evidence on clinical practice variations 
have found that there are large differences in the way patients are managed across 
settings after adjusting for differences in patient factors (Folland and Stano 1990). 
There is considerable debate in the literature about which factors drive these 
`unexplained variations', Wennberg (1984) suggests that they reflect physicians' 
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uncertainty in diagnosis and treatment of specific conditions. However, Evans (1990) 
rejects the idea that the variation is explained by physician uncertainty and suggests 
instead that it reflects professional disagreement about what is best practice. Phelps 
and Mooney (1993) suggest that this variability reflects a lack of information 
available to the individual clinician about the effectiveness and cost-effectiveness of 
different procedures. 
4.28 Clinical guidelines 
In an attempt to reduce variability in clinical decision-making and to move towards 
best practice, various countries have introduced clinical guidelines. However, it is 
unclear whether these guidelines are based on evidence of clinical effectiveness let 
alone productive efficiency (Eccles and Mason 2001). The guidelines on best practice 
may differ, particularly across international health care settings. Even if the guidelines 
recommending `best practice' are consistent, the adherence to these guidelines may 
differ across health care settings leading to differences in resource use. There is little 
empirical evidence available on the extent to which guidelines are adhered to in 
different settings and the implications for observed resource use variation (Eccles and 
Mason 2001). 
4.29 Differences in the characteristics of individual health care providers 
Johnston et al. (1998) assessed why unit costs varied between trial centres and centres 
routinely screening for breast cancer in the UK. They found that the centres included 
in the trial differed in several ways to non-trial centres. Some of these differences 
were associated with unit cost variations, these included the location of the centre 
(urban or rural), and the throughput of screening cases. Cowing and Holtmann (1983) 
and Huttin and de Pouvourville (2001) found that hospitals involved with teaching 
and research had significantly higher unit costs than non-teaching hospitals. 
The level of access to health care workers with different levels of expertise may vary 
across settings, and this may lead to differences in resource use and costs. The study 
by Roos and Roos (1982) found that teaching hospital status and level of medical 
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experience reduced resource use. In the context of stroke care, the specialisation of 
the doctor is important, as there is evidence that neurologists provide more tests and 
investigations than general physicians do, but their patients have better outcomes 
(Mitchell et al. 1986). Other studies have shown that teaching hospital status leads to 
higher costs, but it is unclear whether outcomes are better than in non-teaching 
hospitals (Johnston et al. 1998). 
4.3 Patient factors 
4.31 Case-mix 
An important reason why the resources used to manage a particular patient group may 
vary across health care settings is that the case-mix of the populations concerned may 
differ. Case-mix may be defined as the characteristics of a single patient or group of 
patients seeking treatment (Söderland et al. 1996). Concepts such as diagnosis and 
severity, physical dependence and age, may all be regarded as part of case-mix 
(Söderland et al. 1995). Comparison of resource use or unit cost between health care 
settings needs to carefully adjust for case-mix, yet this may prove problematic when 
using the production function framework to pose hypotheses for cost variation, as 
such datasets have to analyse output and costs measured at a highly aggregated level. 
This issue is considered further in section 4.4 and in Chapter 5. 
4.32 Income and socioeconomic status 
Patients' access to and use of health services may partly depend on their income and 
socioeconomic group (SEG). In the UK, there is conflicting evidence on the effect of 
income and SEG on resource use. Davey Smith et al. (1990) found that those patients 
with the lowest incomes and in the poorest socioeconomic groups had the lowest use 
of health services and the worst health status. By contrast, O'Donnell and Propper 
(1991) found that those with lowest income made more use of health services. The 
difficulties in interpreting correlations between income and health are discussed by 
Deaton (2002) who suggests that even if access to health services is similar across 
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SEG the utilisation of those health services may differ leading to more effective care 
in those from higher SEGs. International comparisons of resource use have failed to 
develop consistent measures of SEG that can be applied across countries, and have 
ignored the role of SEG in explaining resource use differences (Beech et al. 1996). 
4.4 Measurement issues 
The literature on production and cost functions can be used to guide an empirical 
investigation into which factors are associated with cost variation across health care 
settings. However, considering cost variation across settings raises certain 
measurement issues. These measurement issues include: the assumptions made when 
estimating production and cost functions, and how best to measure case-mix, factor 
inputs, outputs, factor prices and random variation. These issues are considered in the 
following section. Chapter 5 consider the question of which technique is appropriate 
for analysing cost variation. 
4.41 Assumptions that are commonly made when estimating production and cost 
functions 
Certain assumptions are routinely made when estimating production and cost 
functions. Neoclassical production functions often make the assumption of 
homogeneity, which means that the elasticity of scale with respect to output is 
constant. For example, a production function that is homogeneous of degree one, 
exhibits constant returns to scale at all levels of output (Doll and Orazem 1973). The 
main advantage of estimating homogenous production functions is that the slopes of 
the isoquants depend only on the input proportions and are independent of the scale of 
production. The implication for estimating a cost function is that the input proportions 
required for cost-minimisation, only depend on factor prices and not the level of 
output. This makes cost functions based on homogenous production functions much 
easier to estimate. Empirical studies commonly make another restriction, that the 
production function is homothetic (Gravelle and Rees 1982). A production function is 
homothetic if it can be written as an increasing transformation of a linear homogenous 
function (Gravelle and Rees 1982). This is a more attractive property than 
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homogeneity as it allows for the advantages described in estimating the cost function, 
without making the restriction of constant scale elasticity. 
Within the group of production functions that are homothetic, a key determinant of 
the properties of the production function is the assumption made about the elasticity 
of substitution of factor inputs, a. The most flexible form of production function 
allows a to vary with respect to output. More recently, studies of hospital production 
have favoured using the fully flexible transcendental logarithmic form (Cowing and 
Holtmann 1983, Bilodeau et al. 2000, Rosko 2000). Such flexibility comes at a cost 
though, as it requires a relatively large number of parameters to be estimated. As 
Newhouse (1994) points out, an analyst may decide to estimate a function with 100 
input and output groups; this number of groups does not appear excessive to cover the 
whole of hospital production. However, using n=100 in the translog production 
function would require 5000 parameters to be estimated. In most hospital cost 'or 
production datasets there are insufficient degrees of freedom to estimate this number 
of parameters. Across the whole of the US for example, there are only around 5,000 
general hospitals. The problems posed by using the translog is clearly apparent in the 
studies by Cowing and Holtmann (1983) and Conrad and Strauss (1983), that both 
used translog production functions and relied on very crude measures of case-mix and 
output to adjust for differences across hospitals. As Breyer (1987) states: 
"an accurate reflection of patient heterogeneity seems to demand more variables than 
can be handled in a flexible functional form model., in existing studies either 
flexibility of the functional form or precision of the case-mix measure was sacrificed 
entirely" (Breyer 1987, p151). 
Some production function studies in health economics have assumed instead that the 
elasticity of substitution is constant with respect to output. Amongst the constant 
elasticity of substitution production functions, a further restriction is made by the 
Cobb-Douglas production function, which assumes a unitary elasticity of substitution 
between factor inputs. Some analysts have concluded that the Cobb-Douglas provides 
an adequate approximation to a more flexible functional form (Reinhardt 1970), 
whereas other studies in health care have disputed the assumption that the elasticity of 
substitution is unitary (Jensen and Morrisey 1986). 
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However, it is clear is that the more restrictive the assumptions made about the 
production function, the more degrees of freedom are available in the analysis, thus 
allowing potentially more careful adjustment for case-mix and output differences 
between settings. This highlights that given the existing size of the dataset, analysts 
have to decide upon the trade-off between making highly restrictive assumptions 
about the technology or about the homogeneity of the inputs and output measures 
used2S. 
4.42 The difficulties in measuring case-mix 
The assumptions made about production, are therefore important in determining the 
case-mix measures used. However even, if the most restrictive form of the production 
function is used, large numbers of health care firms and patients are required to 
estimate the relationships concerned. For example, in one of the smallest production 
and cost function studies reviewed, Wouters (1993) used the highly restrictive Cobb- 
Douglas production and cost functions to estimate efficiency of different health care 
providers in Nigeria. However, even this study included a total of 86 hospitals and 
relied on administrative data. Administrative datasets only contain measures of case- 
mix collected as part of routine practice. 
Most case-mix classification systems that are routinely used for administrative 
purposes are based on DRGs. As DRGs are routinely recorded they are available for 
many health care providers in the USA and have proved attractive measures of case- 
mix adjustment for production and cost function studies requiring data on large 
numbers of health care providers (Valdmanis 1990, Vita 1990, Vitaliano 1987). 
However, studies using routinely collected case-mix measures covering the full range 
of hospital production may have inadequately adjusted for case-mix differences across 
settings. For example, Newhouse (1994) points out that using DRGs to adjust for 
case-mix differences across hospitals assumes that within a DRG any cost variations 
across hospitals are random. If DRGs do not fully adjust for differences in case-mix 
25 This issue is considered further in Chapter 5. 
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across particular hospitals then cost variations may reflect unmeasured case-mix 
differences. 
Iezzoni et al. (1996) divided case-mix measures into two broad categories: general 
measures of case-mix that are routinely available and disease-specific measures 
collected from medical records. Within each of these broad categories, there are many 
different case-mix measures of varying degrees of sophistication (see Iezzoni 1997a 
for a comprehensive review). For example, in a UK context Söderland et al. (1996) 
compared measures of case-mix adjustment routinely available, including DRGs26, 
Health Care Resource Groups (HRGs) and a specialty classification, to predict 
variation in LOS and total cost. The results showed that while DRGs and HRGs 
generally explained a reasonable proportion of the variations in LOS, in some 
specialties for example geriatrics these measures left a high proportion of the variance 
unexplained (Söderland et al. 1996). 
Disease specific case-mix measures have now been developed for many diagnoses 
(see lezzoni 1997b). For some diagnoses, these measures do not explain any more 
heterogeneity than routinely collected measures. For example, Iezzoni et al. (1996) 
used 11 severity measures including both routinely collected and disease specific 
measures recorded from medical records. The study assessed how much variation in 
LOS following pneumonia each measure explained both amongst patients and across 
hospitals. The results showed that none of the measures explained substantial 
variation in LOS within or across hospitals. For all measures and both comparisons, 
the adjusted R2 was less than 0.20. The authors suggested that the case-mix measures 
examined may have been insufficiently sensitive to differences in patient 
characteristics, they also highlight that differences in provider characteristics were not 
considered and may well have been important. 
A number of studies found that disease specific measures of case-mix can explain 
more of the variation in resource use than routinely collected measures. Vos et al. 
(1994) found that for patients with acute MI more detailed clinical measures of case- 
26 Within the general term DRGs there are many different versions. 
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mix detected differences in resource use across hospitals for patients who fell into the 
same DRG. Escarce (1993) found that 43% of the observed variation in cataract 
surgery rates was explained by including economic and sociodemographic variables. 
In the context of stroke care, a range of case-mix measures have been developed and 
shown to partly explain variations in resource use, cost and outcome across centres. 
These measures include the sub type of stroke, whether or not the patient is continent 
at hospital admission, and whether or not the patient is paralysed at the time of 
maximum impairment from the stroke (Wade 1994, Davenport et al. 1996, Beech et 
al. 1996, Wolfe et at. 1999). Beech et al. (1996) used these measures of case-mix 
adjustment to compare LOS across a range of European centres. The study found that 
there were still wide variations in resource use after case-mix adjustment, which may 
be partly explained by unmeasured patient characteristics. However, this study did not 
consider the use of alternatives to hospital care or contextual factors such as the level 
of health care infrastructure in each of the countries concerned. 
The approach used to measure costs in particular the level of aggregation, has 
implications for understanding the role of case-mix in explaining cost variation. For 
example, if a highly aggregated approach is used, and number of hospitalisations are 
the resource use measure and cost per hospitalisation the unit cost, then patient 
characteristics may be important in determining unit costs. Söderland et al. (1995) 
used an aggregated approach to unit costing and found that case-mix explained 77% 
of the variations in costs per case across NHS providers in the UK. However, if 
instead a disaggregated approach is taken then the patient-mix may be more important 
in determining resource use than unit cost. 
In summary, the choice of case-mix measure is a key issue for any study attempting to 
estimate reasons for cost variation across settings. Highly aggregated measures of 
case-mix have been found to be inadequate for adjusting for differences in case-mix 
across different hospital providers. An empirical study of cost variation across settings 
should consider using disaggregated measures of case-mix. However, it should be 
recognised that for certain clinical areas, even using detailed case-mix measures may 
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still leave high levels of unexplained variation in resource use and costs across health 
care settings. 
4.43 Aggregation of factor inputs 
The diagrammatic representation of a production function often divides inputs broadly 
into labour and capital. When estimating production functions the problem of having 
sufficient degrees of freedom to estimate parameters, also restricts the numbers of 
parameters used to represent inputs and outputs. Hence, when estimating the inputs to 
the health care production function highly aggregated measures of input may be used 
such as the total number of employees in each hospital. When comparing the use of 
inputs across health care settings, this broad definition is unlikely to be sufficiently 
detailed as for example workers are likely to have different levels of skill and are 
therefore likely to have different marginal productivities. Firms may also differ in the 
quality of inputs they use in producing health services. For example, in the stroke 
literature, care in a specialised stroke unit improves outcomes for a given level of 
resource use, compared to care in general medical wards (Stroke Unit Trialists' 
Collaboration 1999). Comparison of costs across settings therefore needs to consider 
differences in the quality of factor inputs. 
Measures of unit cost may also have to recognise differences in the quality of inputs 27 9 
Berry (1973) found that quality enhanced hospital services cost 16% more per 
inpatient day than basic hospital services in the USA. Other studies have suggested 
though that improved quality of care led to lower unit costs particularly if it leads to 
reduced morbidity (Folland et al. 1997). Studies that compare costs across health care 
settings using highly aggregated datasets struggle to adjust for quality of care 
differences which may instead be attributed to differences in efficiency (Valdmanis 
1990, Aletras 1999). 
4.44 Aggregation of outputs 
The same problem of aggregation exists when comparing outputs across settings. 
Using an aggregated measure of output, may lead studies to ignore differences in 
27 This depends on the level of aggregation at which unit costs are measured. Highly aggregated unit 
costs e. g. costs per episode are likely to vary according to the quality of care provided. More disaggregated measures such as the cost of a blood test may be less susceptible to quality differences. 
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patient outcomes. The multi-product cost function literature has tried to compare both 
the quantity and quality of health care produced (Healey et al. 2000, Butler et al. 
1995, Cowing and Holtmann 1983). However, studies, which have attempted to 
compare output across health care providers, have often struggled to measure the 
quality of care provided and have often relied on aggregated measures of throughput 
for example the annual number of inpatient days (Folland et al. 1997). Using a narrow 
measure of throughput is likely to be inconsistent with health care providers' 
objectives which may for example be to maximise health from the resources available 
(Hurst 1991). If factor inputs fail to increase throughput but do improve health status, 
then their marginal productivity would be underestimated. This problem is likely to be 
greatest in production or cost functions, which take a flexible functional form and 
therefore include coarser classifications of case-mix and output (Newhouse 1994). 
While measurement and adjustment for differences in the quality of care is generally 
difficult, the use of patient-level measures of case-mix and outcome, may prove useful 
for considering the quality of care when comparing costs across settings, even if their 
use is not feasible within a cost function framework derived from a well-behaved 
production function. 
4.45 Accounting for random variation 
Another measurement issue that arises when comparing resource use across settings is 
that the differences observed in resource use may reflect random rather than 
systematic differences (Diehr et al. 1990). Variability in resource use across settings 
would be observed because of chance even if each health care provider was using 
identical production processes. McPherson et al. (1982) looked at differences in the 
rates of surgical procedures across several countries and found that random variation 
only accounted for 1-4% of total variance in Canada, and on average about 15% of 
variation in England and Wales. 
4.46 Consistent measurement of factor inputs, factor prices, unit costs or total 
costs 
In Chapter 2 it was emphasised that resource use and unit costs need to be measured 
across health care settings using a consistent methodology. This also applies to the 
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measures of factor inputs, factor prices, output and total cost covered in this chapter. 
This issue is often neglected by the cost and production function literature which 
tends to use highly aggregated administrative datasets to measure parameters across a 
large number of health care providers (Newhouse 1994). Different methods may be 
used in each health care setting for example to allocate costs. Any measurement 
inconsistencies may hinder attempts to identify systematic reasons for cost variations. 
4.47 Exchange rates 
To compare costs across international health care settings, local costs have to be 
converted into a common currency. This raises the question of which conversion 
factor is most appropriate. One alternative is to use the Official Exchange Rate 
(OER). However, a problem with using OERs is that they do not reflect the relative 
price of non-traded goods such as health care. Instead, Purchasing Power Parity 
indices (PPPs) may be used. PPPs aim to eliminate price differences across countries 
for both traded and non-traded goods and services (Kanavos and Mossialos 1999). 
There are different PPP indices that are available for converting goods and services 
produced or consumed in different sectors of the economy. The choice of conversion 
factor for comparing costs across international health care settings can have an 
important impact on the cost variations observed (Hutton 2001). This issue is 
considered further in the context of the empirical investigation (Chapter 7). 
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4.5 Discussion 
The aim of this chapter was to use conceptual and empirical literature to establish 
hypotheses for why costs may vary across health care settings. The literature reviewed 
considered four main areas: the cost and production function literature, context 
factors, patient factors and measurement issues that arise when comparing costs 
across health care settings. The main hypotheses to emerge from each of these areas 
are considered briefly below. 
The production function literature highlights that there may be different ways of 
producing the same output. In health care, clinical practice variations may be 
observed but these might not reflect differences in technical efficiency. The practice 
variations literature generally fails to identify reasons why clinical practice may differ 
across settings. In particular, the role of alternatives to hospital care is routinely 
ignored. Differences observed in resource use may indicate that each health care 
setting is producing care efficiently but faces differences in the technology available 
or in relative factor prices. Alternatively, variations across settings may reflect 
differences in technical, productive or scale efficiency. There is only limited evidence 
to suggest that differences in efficiency in the hospital sector may arise according to 
incentives to cost-minimise. 
Contextual factors that are likely to have an influence on production are often 
exogenous to the individual health care firm. The literature review suggested that 
factor prices may differ across settings, because of inflexibilities in international 
markets for good and services. This is likely to occur in the labour market for health 
care professionals which, even within a particular country, is known to suffer from 
rigidities and inflexibilities and remain in a state of disequilibrium (Elliott 2003). 
While individual countries may impose a bilateral monopoly and effectively 
establishing a uniform price across the country, international prices of labour inputs 
may differ even after adjustment using an appropriate conversion factor. Any 
comparison of factor prices across countries should recognise that such differences 
may remain because of compensating differentials; these include the possibility of 
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earning extra income from private practice, and satisfaction with the local working 
and living conditions28. 
Restrictions in the labour market may lead to differences in relative factor prices 
across health care settings. Insights from cost function theory would suggest that in 
response to different factor prices firms would choose differing factor inputs to 
maximise productive efficiency. However, the national availability of factor inputs 
and clinical guidelines may limit the power of individual health care providers to 
adjust factor use according to differences in factor price. National levels of income or 
the level of spending on health care may determine the national supply of particular 
inputs, or the availability and diffusion of new technologies. The extent to which 
clinical guidelines are followed, or health care professionals maintain control over the 
inputs used in production, will vary across settings and may be another important 
determinant of resource use and cost. 
The role of patient factors alongside contextual factors in explaining cost variation 
also warrants careful consideration. The literature has focused on either group of 
factors and studies have in general failed to consider both groups of factors together. 
lezzoni et al. (1996) highlight that including a range of patient and provider factors is 
important when comparing resource use across settings. 
This section of the literature review has posed some clear hypotheses as to why costs 
may vary across different health care settings (see Table 4.2 below). However, there 
are some challenges in applying the production and cost function literature to health 
care, and in testing these hypotheses. In particular, the studies reviewed struggled to 
separate systematic differences in inputs and outputs across health care settings from 
differences in the way these parameters were measured. A particular problem is that 
there is important heterogeneity in the case-mix of patients across settings even within 
particular DRGs. This patient-level heterogeneity may drive variability in resource 
use, factor inputs and outputs across settings. In production and cost function studies 
the less restrictive the assumptions made about the technology the higher the level of 
aggregation used in the measurement of case-mix and output. The greater the level of 
28 These issues are considered further in the discussion section of Chapter 7. 
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aggregation the more likely it is that cost differences across settings reflect 
unmeasured differences in patient case-mix, rather than differences in efficiency. It 
would seem most appropriate for studies identifying reasons for cost variation to 
measure case-mix at a patient level using disease-specific measures. 
4.6 Conclusions 
This chapter has considered concepts from the production and cost function literatures 
to provide a framework for identifying reasons for cost variation across health care 
settings. The review has identified contextual and patient factors that may be 
important in explaining resource use and cost variation. To test these hypotheses 
certain measurement issues have to be addressed, and the use of disaggregated data is 
appealing for this purpose. The challenges these measurement issues pose are 
considered further in the next chapter that reviews the techniques used to measure 
cost variation. 
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Chapter 5: Techniques to evaluate cost variation 
5.0 Introduction 
The previous chapter highlighted theoretical and empirical reasons why costs may 
vary across different settings. It was hypothesised that costs may vary because of 
differences in the use of factor inputs or resource use that may reflect differences in 
factor prices but also differences in technical or productive efficiency. Levels of 
technical or productive efficiency may vary according to the health care context, in 
particular according to the characteristics of the labour market and the method used to 
reimburse health care providers in the country concerned. Any study attempting to 
assess reasons for cost variation across health care settings encounters measurement 
issues in particular, it may be important to understand the role of case-mix, the quality 
of care and random variation in explaining observed cost differences. 
The aim of this chapter is to consider the appropriateness of some of the techniques 
available for analysing cost variation. This review covers the use of techniques to 
measure efficiency- including stochastic frontier analysis (SFA) and data 
envelopment analysis (DEA). These techniques have mainly been used in 
observational studies that describe associations. For example, studies have used these 
techniques to examine the association between the method of hospital reimbursement 
and the level of productive efficiency (Hollingsworth 2003). For analysing cost data 
in economic evaluation techniques such as ordinary least squares (OLS) regression 
models and multilevel models (MLMs) may be attractive as they can be used to 
evaluate the cost-effectiveness of an intervention recognising cost variation across 
health care settings. Examples of the use of these techniques are presented in health 
economics, but also in other areas of research such as health services and education 
research. The pros and cons of using each of these techniques for assessing the 
reasons for cost variation are examined. 
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This chapter is split into five main sections: section one provide an overview of 
techniques for measuring efficiency, section two reviews the use of OLS regression 
models for explaining cost variation; section three discusses in some depth the use of 
MLMs for both observational and evaluative studies. In section four, the implications 
of using each of these techniques for assessing cost variation are discussed. Section 
five summarises the main findings from the entire literature review and considers the 
implications for the empirical investigation. 
5.1 Methods for estimating technical and productive efficiency 
There has been much interest from national governments in using measures to identify 
inefficient performance (Smith 1995). For example, in the UK the Department of 
Health used performance indicators to identify those provider units that warrant 
further investigation (Audit Commission 1999). The methods for measuring health 
care efficiency can be divided into four main categories: OLS regression models, 
deterministic cost frontiers, stochastic frontier analysis (SFA) and data envelopment 
analysis (DEA). Each of these methods have been used to estimate efficiency using 
observational datasets. 
5.11 OLS regression models 
OLS regression models were traditionally used to estimate levels of technical and 
productive efficiency across different hospitals. In his pioneering work Feldstein 
(1967), used a cost function of the form: 
YJ=l0+El xjk+ui; (1) 
where yj is the cost for an individual hospital j, and xJk is the proportion of hospital j's 
patients in the kth case-mix category. Thus, the cost for treating a patient in case-mix 
category k is ß+A. From this model, Feldstein (1967) defined an efficiency index 
as: 
yr* yf t2) 
w yj+üi 
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Where y, and üj are the OLS fitted values and residuals. In this model, the residuals 
are used as measures of efficiency. Those hospitals with positive residuals have 
higher than average costs and are defined as performing in a relatively inefficient 
manner, whereas those hospitals with negative residuals are categorised as having 
above-average levels of efficiency. Central tendency measures produce an analysis of 
performance relative to average performance, not compared to the best performance 
amongst providers. The residuals are assumed to be distributed symmetrically around 
the cost function and they do not define a frontier of efficient production. While the 
residuals are used to define efficiency, they are also likely to include measurement 
error, or random variation. Despite these acknowledged problems, studies during the 
1970s and early 1980s tended to follow Feldstein's approach and used these 'non- 
frontier' OLS models to estimate efficiency (Hurst 1977, Culyer et al. 1978, Culyer 
and Drummond 1978, Steele and Gray 1982). 
5.12 Deterministic cost frontier (DCF) 
Deterministic cost frontiers attempt to tackle the problem that simply using residuals 
from an OLS model to define efficiency does not identify a frontier of efficient 
production (Aigner and Chu 1986). The DCF is defined as: 
yj=ß+Eßxjk+uj ; where ui z0 (3) 
In contrast to the previous model, the error term is constrained to be positive, and 
therefore the costs for each health care setting are above the deterministic cost 
frontier. The degree of inefficiency is therefore indicated by the size of uj. One 
estimator for the model is corrected OLS (Schmidt and Lovell 1979, Greene 1980). 
The drawbacks of this method are that it treats the most efficient hospital as 100% 
efficient, and the whole of the error term is assumed to reflect inefficiency. This 
ignores random noise due to measurement errors and any unobservable heterogeneity 
(Wagstaff 1989b). 
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5.13 Stochastic Frontier Analysis (SFA) 
SFA has been used to measure differences in efficiency across health care providers29 
and recognises that costs may vary randomly across providers. Compared to the OLS 
models, an additional error term v, is introduced (model 4). Thus, the overall error 
surrounding the estimates is split into two components: vj is a two-sided error term 
and captures measurement error and unobserved heterogeneity, and uj measures 
inefficiency relative to the stochastic frontier: 
yJ =ßo+Eßxjk+vf+uj where uj z0 
vj may be high if for example there are unexpected expenditures on hospital repairs or 
a temporarily high and unobservable level of disease severity. SFA mainly uses 
structural cost functions that are based on the dual of the production function (See 
section 5.23, and also Diewert 1982). 
(4) 
An important aspect of SFA is that particular distributions have to be assumed for the 
error terms, for example, Aigner et al. (1977) assume that v, is normal and u, is half 
normal. Newhouse (1994) criticised SFA for making these assumptions about the 
distributions of the residuals, as they are untestable. Commentators have criticised 
SFAs based on cross-sectional data for relying on skewness in the distribution of the 
residuals to estimate inefficiency, as Wagstaff (1989b) states: 
"Inefficiency is reflected in, and only in, skewness in the residuals, absence of 
skewness is construed as evidence of absence of inefficiency. " (Wagstaff 1989b, 
p664) 
This may be an important problem, especially as aggregated datasets are routinely 
used for SFA in health care. In these datasets, it is difficult to adjust for differences in 
case-mix and the quality of output across health care providers (Newhouse 1994). 
There may be omitted variables such as more detailed measures of case-mix that 
could potentially lead to skewed residuals. In these circumstances, SFA could 
incorrectly attribute unmeasured case-mix differences across providers to differences 
in efficiency (Wagstaff 1989b, Dor 1994). Using the level of skew in the residuals to 
29 SFA usually measures the sum of both technical and productive inefficiency, though analysts 
sometimes assume zero productive inefficiency and attribute all the observed inefficiency to technical 
inefficiency (Jacobs 2000). 
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define efficiency, may also lead to difficulties concerning the choice of functional 
form for the cost data. For example, Street (2004) illustrated a situation where the 
original analysis found that the residuals were skewed, and part of this skew was 
attributed to inefficiency. However, once the data were transformed using a 
logarithmic transformation the residuals were approximately normally distributed. In 
this situation, it is not possible to identify inefficiency across the provider units. 
While SFA allows for stochastic or random variation, the efficiency estimates for 
individual firms are routinely presented as point estimates. Street (2004) found that 
once sampling variation across hospital units was acknowledged, it was difficult to 
make firm conclusions about the relative inefficiency of different hospitals. 
More recent applications of SFA have used panel, rather than cross-sectional data 
(Koop 1997). In this case assumptions are no longer required about the distribution of 
the error term. However, these models have routinely assumed that inefficiency 
remains constant over time which may not be plausible in an industry such as health 
care, where technological development is ongoing. Battese and Corelli (1995) relax 
the assumption of constant efficiency over time; their model makes the weaker 
assumption that the rate of change in efficiency is common across health care units. 
5.14 Data envelopment analysis (DEA) 
DEA is a non-parametric, deterministic technique, that aims to measure efficiency for 
each firm relative to the most efficient unit(s) that form the efficiency frontier (or 
envelope) and are assumed to be 100% efficient (Farrell 1957). Efficiency in DEA is 
defined as the weighted sum of outputs to the weighted sum of inputs (Hollingsworth 
and Parkin 1998). DEA can measure relative levels of technical, productive, allocative 
or scale efficiency. The main problem with DEA is that it does not allow for 
measurement error or random fluctuations. The main advantage of DEA is that unlike 
SFA it does not have to make parametric assumptions that may not be supported by 
the data. In general, this means that DEA does not require as many health care units as 
SFA. However, as DEA still requires sufficient observations to make plausible 
assumptions about the underlying production technology and to avoid the results 
being driven by outlying observations. DEA has therefore mainly been used on 
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administrative datasets with many observations (see reviews by Jacobs 2000 and 
Hollingsworth 2003)30. There are many recent examples of the use of DEA in the cost 
function literature that use aggregated datasets (Hollingsworth and Parkin 1998, 
Söderland and van der Merwe 1999, Morey and Dittman 1996), but only a few 
examples of DEA that aim to inform the economic evaluation literature (Hutton 2001, 
Johnston and Gerard 2001, Valdmanis et al. 2003). 
5.15 Comparisons of DEA and SFA 
Recent studies have compared DEA with SFA, to see how sensitive estimates of 
technical efficiency are to the method used. Studies using cross-sectional data have 
found that these estimates are highly sensitive to the choice of technique and have 
suggested that it is not possible to make robust conclusions about the levels of 
technical efficiency from the use of either method (Jacobs 2000, Wagstaff 1989b). 
Jacobs (2000) found that where there are high levels of random noise the different 
techniques are likely to diverge in their estimates of efficiency. The more recent 
comparisons of the techniques using panel data have found much less variation 
according to the methodology used; Linna (1998) used SFA and DEA methods on 
panel data and concluded that the correlation between the results from the different 
methods was high. 
A consensus is emerging in the literature that suggests panel data estimates are useful 
for highlighting changes in efficiency over time. Analysis of these data may also help 
establish whether outliers identified in cross-sectional data represent one-off data 
anomalies or consistent differences in levels of efficiency. 
5.16 General problems with using techniques of efficiency measurement to 
identify reasons for cost variation 
In health care a range of studies have used either DEA or SFA to assess which 
provider characteristics are associated with differences in efficiency (Hollingsworth 
2003, Linna 1998, Vitiliano and Toren 1994, Rosko 1999). A central problem for 
these studies is how to make plausible assumptions about the underlying production 
30 Most of the DEA studies reviewed have datasets with at least 20 observations at the provider level. 
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technology while correctly estimating the effect of patient and centre-level 
characteristics on observed levels of inefficiency. 
Breyer (1987) suggests that studies measuring efficiency can be divided into two 
broad groups depending on their general approach to this problem: those studies that 
specify a behavioural cost function and those that estimate a structural cost function. 
The models that used behavioural cost functions included a range of variables to try 
and explain cost variation across settings (see for example Evans 1971, Lee and 
Wallace 1973 and Lave and Lave 1970). Wagstaff (1989a) has criticised these 
behavioural cost functions: 
"The observation by Evans (1971) that the absence of incentives to minimise costs 
means cost functions need to be interpreted as `behavioural' rather than 
`technological' has tended to result in an `anything goes' attitude to model 
specification. " (Wagstaff 1989a, p14). 
Wagstaff (1989a) highlights that analysts have often ignored economic theory when 
deciding on which explanatory variables to include in a behavioural cost function. For 
example the stock of beds, case flow, occupancy rates and LOS were all included in 
cost functions, despite theory suggesting that they would be correlated with each 
other. 
During the 1980s, there was a move away from the behavioural cost function 
approach and more studies used structural cost functions (see for example Conrad and 
Strauss 1983, and Cowing and Holtmann 1983). A structural cost function is defined 
as one that describes the minimum cost of providing a given output, as a function of 
an exogenous vector of factor prices (Breyer 1987). This implies that the explanatory 
variables included should only relate to output and price. Using structural cost 
functions also limits the choice of functional form in SFA, as the cost function should 
be the dual of the underlying production function (Diewert 1982). 
Often though the form of the production function is unknown, and this has led 
analysts using SFA to specify the cost function with a flexible functional form 
(Breyer 1987). As Newhouse (1994) points out this flexibility comes at a price 
though, as using this functional form increases the number of parameters that have to 
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be estimated 31. This makes anything other than crude adjustments for differences in 
case-mix and the quality of outputs across providers difficult (see Chapter 4), even 
when the datasets concerned include data for hundreds of provider units. 
The analyst is therefore faced with a choice between making assumptions that may 
adequately represent the characteristics of the underlying technology or specifying 
cost functions that are able to detect differences in patient characteristics, inputs and 
outputs across health care settings. Studies estimating efficiency using DEA or SFA 
have tended to take the former approach and relied on using large datasets, with 
highly aggregated measures of case-mix, inputs, outputs and costs that encompass the 
whole of hospital production (Caves et al. 1980). Using these measures clearly leads 
to measurement issues, for example costs may be measured using different 
methodologies across health care settings and case-mix measures may be too crude to 
detect differences in case-severity across hospitals. Thus, any attempt to establish 
reasons for cost variability that uses aggregated datasets may struggle to correctly 
identify systematic reasons for cost variation. 
In a comprehensive review of the recent literature using both parametric and non- 
parametric studies Hollingsworth (2003) identified 188 published papers on efficiency 
measurement in health care. The review suggested that 25% of these studies used 
DEA in combination with regression analysis in a `two stage' approach to identify 
reasons for differences in efficiency. Under this approach the analysis initially uses 
DEA to calculate mean efficiency scores for each health care provider. These scores 
are then used as a dependent variable in a regression equation to identify those 
provider characteristics associated with differences in efficiency. This approach 
ignores any variability in efficiency within each health care setting. In addition, this 
study design only allows for aggregated measures of case-mix to be used in the 
analysis. 
31 Although DEA studies avoid the problems associated with specifying a particular functional form the 
technique still requires large numbers of observations to avoid outlying observations having a 
disproportionate impact on the results. Therefore, DEA has seldom been used on datasets with fewer 
than 20 observations at the provider level (see Hollingsworth 2003). 
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As SFA and DEA both tend to rely on aggregated datasets to measure efficiency these 
techniques tend to ignore the hierarchical structure of cost data drawn from different 
settings. In this context, patients may be clustered within health care settings, and 
ignoring this clustering may mean that these analyses make incorrect inferences (see 
section 5.21 for a fu ther explanation). 
Most of the studies reviewed were conducted within a single country and did not have 
to consider the methodological issues that arise when comparing costs across health 
care settings in different countries. Adam et al. (2003) demonstrated the use of an 
OLS cost function to compare costs across countries. However, the study suffered 
from methodological shortcomings: it paid little attention to variation in factor prices, 
it used highly aggregated data, and did not consider clustering within countries, and 
the implications for the significance of the variables included in the cost function. 
The techniques for measuring efficiency are not appropriate for identifying reasons 
for cost variation, using datasets of the size routinely used in economic evaluations. 
However, some of the issues discussed during the development of these measures, 
notably the choice of explanatory variables, and the interpretation of residual variation 
may also apply to other techniques for identifying reasons for cost variation. 
5.2 OLS regression models for identifying reasons for resource use 
and cost variation. 
The previous section illustrated the problems with using OLS regression models for 
comparing efficiency across health care providers using observational datasets of 
hospital costs. OLS regression models have also been used in observational studies in 
particular clinical areas such as stroke and coronary heart disease to identify which 
patient characteristics are associated with cost variation (Lipscomb et al, 1998, 
Adams-Dudley et al. 1993). However, these models can also be used in an evaluative 
context to address particular methodological issues. For example, OLS regression 
models have been used to identify which costs are important to measure in a CEA 
based on a RCT. Whynes and Walker (1995) used OLS regression analysis to 
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establish whether the costs of colorectal cancer could be approximated using a 
`reduced list' of resource use categories. Studies have also used OLS regression 
analysis to tackle the same methodological issue in the areas of mental health (Knapp 
and Beecham 1993) and adult intensive care (Elliott and Buxton 1998). In an 
evaluative context, Hoch et al. (2002) used OLS models to estimate how cost- 
effectiveness varied according to patient characteristics. However, none of these 
studies examined why costs or cost-effectiveness vary across health care settings. 
A few studies have used OLS regression analysis to estimate variation in cost- 
effectiveness and more specifically costs across health care settings using data from 
multicentre RCTs. Willke et al. (1998) used an OLS regression model to present a 
different measure of cost-effectiveness for each country in a multinational study. 
Hutton (2001) used OLS models to estimate the variation in unit costs and total costs 
between centres in different countries. Coyle and Drummond (1998) used an OLS 
model to identify factors that drove cost variation amongst health care centres in the 
UK. Each of the costing studies reviewed used patient-level cost data, and here an 
OLS model may take the form: 
Yr ° Qo + ßi xi + ei ; ej - Normal(0, o2) (s) 
where yi is the cost for the ith individual; xi is a patient-level explanatory variable, 
with associated slope coefficient ßl; A is the intercept and e, the error term, which 
represents unexplained variability between individuals, is assumed to be normally 
distributed with a mean of zero. The use of these patient-level data means that the 
model has the potential to adjust for differences in case-mix, and quality of outcome, 
when assessing cost variation across settings. 
5.21 A key statistical assumption in OLS regression models 
A key statistical assumption made by these OLS models is that observations across 
patients are independent and have a common variance. This assumption may be 
violated when analysing cost variation, as cost data may be hierarchical with patients 
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nested within centres and centres nested within countries. This concern may arise 
when analysing data from a RCT or an observational study. In either context patients 
may be nested, if the characteristics of patients attending the same health care centre 
are similar compared to those attending a different health care centre. The data may 
also be clustered within health care settings if there are other cost drivers for example 
relative factor prices or the level of technological development that operate at a centre 
or a national level. Thus, costs may have a hierarchical structure as illustrated in 
Figure 5.1. 
Level 3: Countries f technological development 
Level 2: Centres Relative factor prices 
Level 1: Patients Case-mix 
Figure 5.1: Typical hierarchical structure for cost data, with examples of factors 
that are potentially associated with cost variation at each level of the hierarchy. 
The remainder of this section focuses on the use of OLS regression analysis when 
patients' costs are clustered within health care centres32. In this context, the OLS 
model (5) estimates a single intercept and regression line for the relationship between 
x and y, ignoring the nesting of patients within heath care centres. 
By ignoring the data's structure, an OLS model may report biased estimates of the 
patient-level explanatory variables. In an evaluative context, an OLS regression 
analysis may therefore report a biased estimate of the effect of treatment on costs: the 
incremental costs. The bias tends to be worst when the analysis estimates an overall 
effect but where the study design is `unbalanced'. For example, in a multicentre study 
comparing `treatment' to `control' an OLS estimate of the overall treatment effect 
32 Health care centres may in this context refer to different hospitals, nursing homes or primary care 
providers. 
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may be biased if the characteristics of the patients in the treatment and control groups 
differ across the centres. However, even if the study design ensures a balanced 
allocation across the treatment groups and centres, the costs in the control group and 
the incremental costs of treatment may differ across centres. Here, an OLS regression 
analysis that does not allow for this heterogeneity and simply reports the overall effect 
of treatment on costs, could report a biased estimate. To avoid this bias separate OLS 
analyses could be run for each centre. However, this approach lacks statistical power 
and does not identify reasons for variation in costs or cost-effectiveness. 
5.22 Inclusion of centre-level variables 
In either an observational or an evaluative context it may be desirable to include 
centre or national level variables to try and identify reasons for variation in costs or 
cost-effectiveness across health care settings. The OLS model (5) may be extended to 
include a centre-level variable zj, for example the size of the hospital concerned, 
measured by the total number of beds. An OLS model may then take the form: 
YI=/o +ßß xi+ß2Z, +ei; ei-Normal(0,02) (6) 
Here, the centre-level variable is included as if it was measured at a patient level, thus 
spuriously inflating the amount of information supplied; the precision of the centre- 
level estimate is therefore overestimated. Take as an example an OLS regression 
model with total cost per patient (y, ) as the dependent variable with x, estimating the 
effect of case-mix, measured at a patient level and zi estimating the effect of hospital 
size, measured at a centre-level. Suppose this observational dataset includes 10,000 
patient episodes of care in five hospitals. If hospital one has 400 beds and 1,000 
patient episodes, then each of the 1000 patient episodes would be given a value of 400 
for the number of beds in the hospital33. This ignores the clustering of patient episodes 
within each hospital. The OLS analysis would therefore overestimate the precision of 
the estimated effect of hospital size (z) on total cost (y) (Figure 5.2). 
" Similarly, if hospital 2 had 500 beds and 2000 patient episodes each of these patient episodes would be given a value of 500 etc. 
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'"* each centre 
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Figure 5.2: OLS estimate of the effect of hospital size(z) on total cost per patient 
episode (y) that assumes each patient episode is independent. The dotted lines 
show 95% confidence intervals. 
Rather than including a centre-level covariate, the OLS model could include a dummy 
variable zy, for each centre (j). This produces a fixed effect of the estimate of the 
average cost per patient in each centre (model 7): 
YI=ß +ßtXy+ß2 ZU+Ei; n- Normal(0, o2) (7) 
This approach provides unbiased estimates of the effects of both the patient covariates 
and centre per se. In an evaluative context, Willke et al. (1998) took a similar 
approach in their estimation of country-specific cost-effectiveness ratios. To allow for 
heterogeneity in the cost-effectiveness of a new intervention across countries they 
included a country by treatment interaction term in the model. However, one 
disadvantage of this model is that it is not possible to include centre-level covariates 
alongside dummy variables for centre-effects, thus this model cannot be used to 
examine, why costs may vary across different centres. Another problem is that this 
model is inefficient, it is necessary to estimate separate parameters for each centre, 
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and there may be insufficient cases to detect differences in effect sizes across the 
centres (see section 5.34). 
5.3 Multilevel models (MLMs) 
MLM is a generic term that encompasses random effects models, random intercept 
and random slope models, hierarchical models, and random effects meta-analyses 
(Goldstein 1995). MLMs incorporate the hierarchical structure of data and enable 
those factors that are associated with cost variation to be modelled directly. The use of 
MLMs would seem consistent with the findings from the review of economic theory 
(Chapter four), that suggested factors driving cost variation could operate at different 
levels of a hierarchy (Figure 5.1). By recognising this hierarchy, MLMs should 
provide more appropriate estimates of individual and higher-level effects and their 
variances, than OLS regression models. They could therefore prove useful in either 
descriptive or evaluative studies. 
Much of the pioneering work on the development of MLM has been conducted in the 
field of education (Goldstein 1992, Goldstein et al. 1993, Goldstein and Spiegelhalter 
1996). Here there has been particular interest in separating out the effects of school 
characteristics such as class size, and pupils' characteristics such as gender, on the 
level of educational attainment. The results from these models have contributed to the 
debate over the effectiveness of schools in the UK, and have been used to construct 
league tables of educational performance (Goldstein 1992, Goldstein and 
Spiegelhalter 1996). Other applications of MLMs are found in the social science 
literature, for example, Kreft and de Leeuw (1998) describe a MLM to examine the 
association of workers' education level with income in 12 different industries. The 
results showed that the workers within each industry were more similar than workers 
in different industiies. The MLM found that the effect of education on income 
differed according to each of the industries concerned. The authors reported that using 
a MLM enabled both industry and individual effects to be accurately estimated and 
therefore produced more appropriate estimates than using OLS models. 
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Rice and Leyland (1996) reviewed the use of statistical methods in health services 
research (HSR) and found that the clustering of observations is commonly ignored. 
This may reflect the lack of attention given to the development of MLM in this 
literature, the lack of statistical expertise applied to HSR, and the absence until 
recently, of suitable software (Localio et al. 2001). There are still plenty of examples 
of MLMs in the HSR literature for example Goldstein and Spiegelhalter (1996) 
demonstrated the importance of recognising the hierarchical structure of outcome data 
when comparing the performance of hospitals, and Rice (2001) illustrated the use of 
MLM to investigate equity in health care. MLMs have been used to perform meta- 
analyses that allows for random variation between studies (Thompson 1993). Recent 
developments in this area have included extending the use of random effects meta- 
analyses to examine why effect sizes may differ across studies (Thompson and Sharp 
1999). 
While health economists often have to work with clustered data, there are few 
examples of the use of MLMs in the health economics literature in either descriptive 
or evaluative studies (Rice and Jones 1997). A recent observational study used a 
MLM and a OLS regression model to estimate the effect of managed care on health 
service costs in the US. The results demonstrated that the MLM provided more 
appropriate estimates of why costs varied between managed care and fee for service 
providers (Carey 2000). Burgess et al. (2000) used a MLM in an observational study 
to distinguish between systematic differences in hospital performance and random 
variation owing to small numbers in particular hospitals. They acknowledge that an 
important limitation of their study was the lack of patient-level data, which meant the 
MLM was not able to adjust for case-mix differences across the hospitals. 
Scott and Shiell (1997) used a MLM to estimate the effect of changing the way 
Australian GPs were reimbursed using a dataset consisting of over 4000 consultations 
nested within 400 GPs. The results showed that drug prescribing was reduced 
following the change in reimbursement. Cairns and van der Pol (1997) used a MLM 
to estimate intertemporal preferences for future health. Respondents were asked to 
identify what future level of benefit made them indifferent between a benefit to be 
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received in one year's time, and a more distant delayed benefit, for two different 
periods of delay. Both MLMs and OLS regression models were used to estimate what 
factors were associated with the discount rates implied from the individual's 
responses. The results suggested that the standard errors for the explanatory variables 
were underestimated in the OLS model. In addition, the MLM demonstrated the 
variation that existed both amongst individuals' responses and across individuals. 
Carey (2000) suggests that the lack of suitable, micro datasets has constrained the use 
of MLMs in health economics, but as Phelps (1995) points out economic evaluations 
are available that contain data on both patient and institutional characteristics; these 
datasets may be appropriate for using MLMs to analyse what factors are associated 
with cost variation. In addition, panel datasets, that allow MLMs to assess variability 
within and across individuals, are becoming increasingly available for health 
economic analyses (Jones 2000). 
There would seem to be two forms of MLM that are particularly appropriate for 
analysing hierarchical cross-sectional cost data, the random intercept and the random 
intercept and slope model. Each of these are considered below: 
5.31 Random intercept models 
Moving from an OLS regression model to a MLM structure changes the way the 
unexplained variation, the random error term is modelled. The most basic MLM, the 
random intercepts model, includes an additional term, which represents the 
unexplained variation that exists amongst higher-level units. Therefore, in the 
example of a two level model where individuals are clustered within centres, using 
subscripts i and j for the ith individual in thejth centre, the model may be written: 
yu=, go +ßlxy+uj +6u; ev-Normal(0, o2), ul -Normal(0,1) (8) 
where A is the mean cost when x f-0, uj is a random variable with zero mean and 
constant variance (ý) which applies to all the cases in a particular centre, and eu is a 
random error term that represents the unexplained variation for individuals within a 
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centre. uj indicates the effect of centre on the average cost per patient, over and above 
that explained by the set of independent variables. The intercept for the jth centre 
(previously given as ß) is now given as a fixed component (ß) plus a random 
component (uj). So in the example below (Figure 5.3), the relationship between case- 
mix (x) and total cost per patient (y) for the reference centre, is given by the bold line 
yj=, 6 + 61 x y. The relationships for each of the other centres are given by parallel 
lines, these differ from the bold line according to the centre level residual, uj. 
Y 
x 
_A+U2+PIXY 
-ßo+U, +PIXY 
Qo+Ax1i 
=ßo + u3 + ßixu 
=A+U4+A; 
Figure 5.3: Random intercepts model for the relationship between case-mix (x), 
and total cost per patient (y) 
In this model, any variation between the centres, after adjusting for case-mix 
differences are recognised by allowing each centre to have a different intercept. This 
improves on the OLS model (5) with a patient-level covariate, by avoiding any bias 
from ignoring unexplained differences across the centres. The impact this has on the 
estimated effect of a patient-level covariate depends on the distribution of the data. 
There may be circumstances where patient-level estimates are similar from both the 
OLS and random intercepts models. In for example a CEA alongside a RCT, if 
patients in each centre had similar characteristics in the treatment and control groups 
and the mean costs in each group did not vary across the centres, then the OLS and 
MLM estimates of incremental cost would be similar. However, there may be 
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circumstances, as in Figure 5.4, where the effect for a patient level covariate- x differs 
between the random intercepts and the OLS estimates. This could be illustrative of a 
situation in an observational study where for example there is interest in the 
relationship between age (x) and cost (y). However, one problem may be that if the 
age of patients differs across the centres, then the OLS analysis estimating the overall 
effect of age on cost may be inappropriate. Here the OLS estimate of the effect of x on 
y is the bold horizontal line indicating that when the clustering in the data is ignored, 
the effect of x on y is approximately zero. However, once the intercepts are allowed to 
vary by centre as in the MLM, then there is a positive relationship of x with y. 
MLM 
v *** raw data for 
each centre 
OLS 
x 
Figure 5.4: A comparison of the effect of a patient-level explanatory variable (x) 
on cost (y) using an OLS vs MLM (random intercept). 
Similarly in an evaluative context the effect of a patient-level covariate, for example, 
treatment group, may differ between a MLM and a OLS regression analysis. This 
could happen if either the treatment groups were not balanced in each centre, or if 
incremental costs differed across centres owing to differences in for example relative 
factor prices. In these circumstances the estimates from a random intercepts model 
that adjusts for these differences across the centres would differ from OLS estimates 
that ignored these variations. 
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5.32 Random intercepts model with a centre-level covariate 
When using data from either observational or intervention studies this MLM can be 
extended to include additional explanatory variables at the level of the individual or 
the centre. For example, a centre-level variable, zj can be added as in the equation 
below. 
yif = flo + Q, x,, +ß2 zj +uj+E, j; E, j- Normal(0,02), uj - Normal(0, 
ý) (9) 
In a MLM including a centre-level covariate, the major difference compared to the 
corresponding OLS model (model 6), is that the MLM correctly recognises that each 
centre is effectively only providing one data point, and therefore correctly recognises 
the variance structure. Using the earlier example looking at the effect of hospital size 
on total cost per episode, a MLM would recognise that hospital size was measured at 
a centre-level. The MLM would therefore treat the cost data as if there were five data 
points, rather than 10000 in the five centres and would effectively estimate the effect 
of hospital size on the average cost per patient in each centre. The level of precision 
surrounding the estimated effect of hospital size on cost, would be reduced 
accordingly, so that compared to the OLS model, the confidence intervals surrounding 
the estimated effect are much wider in Figure 5.5 compared to those in Figure 5.2. 
An appealing feature of an MLM is that it allows the effect of including additional 
explanatory variables on the extent of unexplained variation between centres (z2) to be 
estimated. In addition, the relative degree of dependency amongst observations within 
a setting can be measured by the intra-class correlation coefficient (p) defined as 
This reflects the strength of `nesting' within the data hierarchy. For 
example, in a MLM evaluating the effect of managed care on patient costs, most 
unexplained variation was found at the level of the patient rather than the health care 
centre (Carey 2000). 
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-"`., ** raw data for 
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x 
Figure 5.5: Estimated effect of hospital size (z) on total cost per patient (y) using 
a MLM, that recognises patient episodes are clustered within hospitals. 
5.33 Random intercept and slope models 
A MLM can account for variability in the effect of covariates across higher level 
units, by using a `random intercept and slope model' (Leyland and Goldstein 2001). 
These models are common in the education literature where for example, the aim may 
be to examine the differential effect of the school attended over time (Goldstein 
1995). The pupils' ability at intake can be adjusted for using the random intercept 
model described above. The differential effect of school attended on attainment over 
time can then be modelled by allowing the effect of time to vary randomly across the 
schools- a random intercept and slope model. This requires an additional error term, 
of to be included, which represents a different slope for each school. The effect of 
time on educational attainment for each school is therefore A+ uU where /31 is the 
overall effect of time on attainment and uj is the mean difference in attainment for the 
individual, jth school. uy is routinely assumed to be normally distributed with a mean 
of 0 and variance rig (model 10). This model also requires the covariance between the 
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slope and intercepts error terms to be estimated. There is interest in the size of the 
between-school variance or level of heterogeneity, u, j 
yij = AOi +uoj+ (ßi + uv) xy + Ey ;gy- Normal(O, a2) uo - Normal(0, r02) (10) 
u jý - Normal(0, zý2) cov(uoy u, j)= zo1 
This model was used by Carey (2000) when assessing the effect of managed care on 
costs. Here relationships between cost and both risk status and age were allowed to 
vary across the health care centres. This model could also be used in the context of a 
multicentre CEA. Here there may be differences in incremental costs across centres. 
Including a random slope can recognise this variation across the centres. This form of 
MLM can also allow for the inclusion of centre-level variables to assess the reasons 
for this variation in incremental costs or cost-effectiveness across settings. These 
MLMs can also provide shrinkage estimates for individual centres in the study. 
5.34 Shrinkage estimates for individual higher level units e. g. centres 
The discussion of OLS models highlighted that when these are used to analyse 
multicentre data, one approach is to just estimate the overall effects of covariates on 
the dependent variable (model 6) which can lead to biased estimates. An alternative 
approach is to use separate OLS regression models for each centre (model 7). So for 
example, the incremental cost-effectiveness of a new intervention could be estimated 
separately in each setting. The main problem with this approach is that it leads to an 
imprecise estimate of cost-effectiveness in each setting i. e. the estimates are 
statistically inefficient. MLMs offer a further possibility by reporting `shrinkage 
estimates' for each higher level unit in this case for each centre. Shrinkage estimators 
combine the advantages from using the overall mean estimate (greater power and 
using all information) and the centre-specific estimates (unbiased estimates). These 
estimators shrink the individual centres' estimates (for example the mean cost in each 
centre) in towards the overall mean. The estimate for an individual centre therefore 
uses all the information available and `borrows strength' from the estimates in other 
centres. This leads to increased precision and the sharing of information between 
centres (Rasbach et al. 2002). 
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The extent to which an individual centre's estimate `shrinks in' depends on the level 
of within and between-centre variability. Shrinkage has the greatest impact when a 
centre's estimate has a high level of within-centre variability and is then `moved in' 
towards the mean in those centres with more precise estimates. If the level of 
between-centre variance is high, the shrinkage estimates have less impact than when 
the between-centre variance is small. Indeed if there is no between-centre variability, 
the centre-specific estimates are all the same: i. e. they shrink in completely to the 
overall mean. 
Shrinkage estimators have been used in HSR to provide context specific results, and 
improve precision (Goldstein and Spiegelhalter 1996). For example in a study 
estimating immunisation rates in different GP practices, certain individual practices 
may have very imprecise estimates owing to the small numbers of patients 
immunised. For these practices a shrinkage estimator would shift the estimated 
immunisation rate towards the overall mean estimate (Rice and Leyland 1996). The 
estimates for the smaller practices have `borrowed strength' from the larger practices. 
5.35 Assumptions made in MLMs 
While MLMs are appealing for the analysis of hierarchical cost data, certain 
assumptions have to be made which warrant careful consideration. The most relevant 
assumptions for the analysis of resource use and cost data are discussed below. 
Effects are random not fixed 
When considering the use of MLMs versus OLS regression models for analysing cost 
variation, the relative desirability of fixed versus random effects may be important 
(Thompson 1993). OLS estimates are always fixed, that is the coefficients estimated 
only refer to the study sample and not to some wider population from which the data 
are drawn (Kreft and de Leeuw 1998). In some cases, a fixed effect may be most 
appropriate, for example, if a RCT compares a high dose drug to a low dose drug, 
then the estimated effect from the cases sampled may be all the information required. 
In a MLM, while some coefficients may be fixed, other estimates consist of both a 
fixed component and a random component representing random variation across the 
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higher-level units34. The use of a random effects estimate infers that the estimates 
from the centres sampled are representative of the overall population which the study 
centres are drawn. In some instances, this may be more appropriate; for example, if a 
MLM is used to estimate the effect of centre on total cost, a random effects estimate 
suggests that the estimate from these centres represents the overall effect in the whole 
population. The random effects estimate would potentially be more generalisable than 
a fixed effects estimate, as it goes beyond those centres included in the study sample. 
The specification of random effects does rest on the premise that higher-level units 
are selected at random from the population concerned. However, in economic 
evaluation the centres chosen for costing are rarely selected at random. Random 
effects also assume that the data are exchangeable, i. e. that the data from one centre 
could be `exchanged' for the data from another centre (Spiegelhalter et al. 2000). 
However, if there are systematic cost variations across the health care centres as 
suggested by economic theory (see Chapter 4), then assuming exchangeability across 
the centres may not be plausible. Careful consideration of the link between economic 
and statistical theory would therefore seem warranted when using random effects 
estimators for analysing cost variation. 
Dependent variable is normally distributed 
Previous MLMs in health economics (Carey 2000), in health services research 
(Marshall and Spiegelhalter 2001) and in other sectors such as education (Goldstein 
1995) have assumed that the residuals are normally distributed. However, resource 
use and cost data are usually skewed and the error terms may not be normally 
distributed (Briggs and Gray 1999). One remedial approach is to use a simple 
logarithmic transformation, as the distribution of the residual may then be more 
normally distributed. This method has been used when analysing single-level (Forbes 
and Dennis 1995) and multilevel cost data (Carey 2000). However, a problem with 
this approach is that, back transforming the coefficient, provides an estimate of the 
geometric mean, rather than the arithmetic mean estimate required for policy purposes 
(Barber and Thompson 1998). More recently, Generalised Linear Models (GLMs) 
34 This characteristic of MLM having both a fixed and a random component often leads to them being termed mixed models. 
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have been recommended for analysing cost data (Barber and Thompson 2004), as a 
variety of non-normal distributions can be specified but, unlike data transformations 
in OLS regression, they make inferences about the arithmetic mean cost directly. 
Non-parametric bootstrapping has also been recommended for analysing cost data 
(Barber and Thompson 2000). However, neither GLMs nor non-parametric 
bootstrapping has been used in hierarchical models for analysing cross-sectional cost 
data35. 
GLMs are characterised by two essential features: firstly, they have a distribution 
function (F) that describes the distribution of the independent variable (y) in this case 
cost per patient. Secondly, they have a link function (g) that describes the scale on 
which the covariates are related to the mean of this distribution. Suppose yi is the 
observed cost for individual i, and u1 is the expected mean cost from the model E(yl), 
then if there is a single covariate xr representing patient case-mix the general form of 
the GLM is: 
g(ul)= ßn + ßßi xi where yi -F and E(y1)=pi (10) 
GLMs are particularly appealing for the analysis of cost data as the focus is always on 
the arithmetic mean p1. In addition, the distribution function F can be chosen from any 
of the exponential group of distributions (McCullagh and Neider 1989). This is 
attractive for the analysis of cost data where the choice of a skewed distribution may 
be appropriate. Briggs et al. (2005) have shown that choosing the correct distribution 
for analysing cost data is vital, otherwise the mean estimates may be biased, and the 
estimate of precision may be statistically inefficient. 
The most straightforward of the GLMs is the standard OLS model, that has a normal 
distribution function and an identity link function. When a patient-level covariate is 
the only independent variable this model is the same as the OLS model 5. The identity 
link means that the covariate acts additively on the dependent variable. If for example 
35 Seshamani and Gray (2004) use both these techniques to analyse panel data. 
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the model includes age (in years) as a continuous independent variable, the model 
estimates the mean change in total costs as age increases by one year. The main 
purpose of using GLMs for the analysis of cost data is usually to deal with skewed 
data where the assumption that the residuals are normally distributed is not 
appropriate. Here a skewed distribution function may be chosen for example, the 
Gamma distribution (McCullagh and Nelder 1989). If the Gamma distribution is 
chosen but the identity link is maintained then the interpretation of the coefficients is 
the same as in the OLS model 536 
Generalised linear mixed models (GLMMs) like MLMs are able to accommodate the 
hierarchical structure of the data and can specify random intercept or random intercept 
and slope models. GLMMs share with GLMs, the advantage of being able to make 
inferences directly about the arithmetic mean, while allowing for non-normal 
distributions. 
Within the group of GLMMs a particularly attractive model for analysing hierarchical 
cost data is the Gamma model that has a random mean p y, and allows for different 
shape parameters (0j) across the centres (model 11). 
Yi -Gamma(U, 0'), Ny°A+Qixu+uj; 
ui - Normal(O, Z2) (11) 
This model uses an identity link so that the coefficients can be interpreted on the same 
scale as the corresponding MLM- the MLM with a patient-level covariate and random 
intercept (model 8). This model can be easily extended to include higher-level 
covariates e. g. hospital size, or additional patient-level covariates. 
Barber and Thompson (2004) demonstrated that using GLMs rather than OLS models 
for analysing the effect of patient covariates on LOS and total cost, was more 
appropriate and fitted the data better. Manning and Mullahy (2001) compared GLMs 
36 Rather than using an identity link, alternative link functions such as the log link can be chosen. If the log link is used the covariates will act multiplicatively on the mean. 
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with using logarithmic transformations combined with `smearing' techniques for 
analysing cost data. They concluded that the choice of method was not clear-cut, and 
that there were important tradeoffs in terms of bias versus precision, between the 
different techniques. In the context of performance measurement in education, 
Carpenter et al. (2003) used a non-parametric bootstrap procedure to analyse 
hierarchical data on educational performance. They found that in this context the non- 
parametric bootstrap allowed accurate confidence intervals to be estimated without 
having to transform the data. 
There is a lack of previous research examining the choice of model for estimating 
factors associated with cost variation, using cross-sectional hierarchical datasets. For 
these data, it would seem important to compare the use of MLMs that assume a 
normal distribution with GLMMs that assume skewed distributions, or the non- 
parametric bootstrap. This comparison could reveal which technique may be more 
appropriate for dealing with skewed, hierarchical cost data. 
Higher-level residuals are independent from the explanatory variable, xU 
MLMs assume that the fixed effects for the independent variables are not correlated 
with the random effects. If this is the case then the effects estimated are consistent37 
(i. e. reliable), but when xy and uj are correlated, then the estimates may be inconsistent 
(Blundell and Windmeijer 1997). Blundell and Windmeijer (1997) show that even 
where there is correlation between the xU and the uU, then the use of random effects 
could still be appropriate. In their example, there were approximately 5000 
observations and 200 centres. The number of observations per centre ranged from 6 to 
95. They concluded that in this instance there were sufficient observations in each 
group for the MLM to produce consistent estimates for both the fixed and random 
effects. They suggest that in other circumstances where the number of groups is large, 
and the numbers in each group are small as is often the case in panel data, then the 
estimators for the parameters will become inconsistent (i. e. unreliable). In these 
circumstances, Blundell and Windmeijer (1997) suggest the choice of a fixed effects 
37 Gelman et al. (1998) define consistency as being when n-+ao the sample mean asymptotes towards the population mean. 
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specification would produce more consistent results and would be preferable. 
However, as Rice and Jones point out (1997), there may be considerations other than 
consistency that govern the choice of a fixed versus random effects model. There may 
be interest in the parameters associated with the higher-level variables, and then it 
would be undesirable to just regard such variables as nuisance variables to be adjusted 
for using fixed effects estimators. The random effects estimate is also more 
statistically efficient, as it requires fewer parameters to be estimated. 
Measurement error 
Measurement error is a common problem in econometrics and may pervade the 
measure of either dependent or independent variables (Gujarati 1988, Jones 2000). 
Measurement error may occur when for example, there is observer error when 
recording costs during an interview. Aggregated datasets have been criticised for 
being especially prone to measurement error, as they often rely on routine or 
administrative data (Newhouse 1994). In the context of naturally hierarchical data, 
measurement error often arises as characteristics measured at an individual level are 
aggregated to give mean estimates for higher-level units. For example, where 
individual data are missing, or sample data has been collected by for example, only 
surveying a sub sample of households, then the compositional variable derived at an 
aggregate level is measured with error (Goldstein and Leyland 2001). The 
development of approaches for dealing with measurement error in hierarchical models 
involves adding in reliability measures, however, this work is at an early stage and 
further research is needed (Goldstein and Leyland 2001). 
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5.4 Discussion 
The aim of the thesis is to evaluate reasons for cost variation across settings and 
examine the implications for economic evaluation. OLS regression analysis or MLMs 
are more appropriate techniques for this purpose than DEA or SFA that are used to 
measure efficiency. Techniques for measuring efficiency tend to require data on large 
numbers of centres, and usually rely on routinely collected, aggregated costing 
datasets. Using aggregated datasets to compare costs across health care settings is 
fraught with measurement issues. In particular, the aggregated case-mix measures 
used in hospital efficiency studies have been severely criticised for failing to adjust 
for case-mix differences between different hospitals (Newhouse 1994), and therefore 
provide inaccurate estimates of inefficiency. The reliance on techniques that require 
the use of aggregated datasets is not appropriate for addressing the thesis' objectives. 
Instead, further consideration will be given to those techniques that can analyse cost 
variation using more disaggregated datasets from observational and evaluative 
studies. 
Economic evaluations now routinely collect patient-level cost data. The development 
of these patient-level datasets enables OLS regression analyses to estimate how costs 
(Coyle and Drummond 1998) and cost-effectiveness (Hoch et al. 2002) vary 
according to patient characteristics. While OLS regression analysis appears a 
promising technique for analysing cost variation, its use for analysing hierarchical 
cost data is potentially problematic. OLS regression analysis assumes that individual 
observations are independent, which is not the case if patients are nested within for 
example hospitals. There are two strands of a priori reasoning to suggest that this 
clustering exists, firstly patients attending a particular setting may be more similar to 
one another, than those attending a different setting. Secondly, factors operating at the 
level of the health care setting, for example factor prices, may differ across settings 
(see Chapter 4). OLS regression analyses that ignore this clustering of observations at 
different levels of the hierarchy may provide biased estimates. In this context the 
problem of bias can arise when analysing data from a RCT or an observational study. 
Although an RCT can ensure that the treatment groups are `balanced' there may still 
be differences in for example the incremental costs of a new intervention across the 
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study centres. An OLS regression analysis that simply estimated the overall 
incremental cost-effectiveness across the centres, would ignore this clustering and 
could therefore lead to biased results. 
In the context of a CEA of different health care interventions where data are collected 
from several health care settings, a MLM may therefore be more appropriate. In 
particular a MLM that uses a `random slope' can be used to recognise the clustering 
in the data, and expose the variation in incremental costs or cost-effectiveness across 
study centres. By recognising this variation the MLM would avoid the potential bias 
in the OLS regression analysis. This MLM can also be expanded to include patient 
and centre-level covariates that may explain why costs and cost-effectiveness may 
vary across health care settings. A serious problem with using OLS regression 
analysis to examine the reasons for variation is that by disregarding the hierarchical 
structure of cost data the significance of higher-level variables may be markedly 
overstated. Thus OLS regression analyses that have used contextual variables in a cost 
function without allowing for the clustering of observations within health care centres, 
may have overestimated the precision of these higher-level estimates. 
MLM regression analyses are amenable to the analysis of patient-level data, and do 
not require vast numbers of higher-level units to evaluate provider characteristics that 
may be associated with cost variation. The main advantage of using MLMs compared 
to OLS regression analyses is that they recognise the hierarchical nature of cost data. 
MLMs can therefore provide more accurate estimates of those factors associated with 
cost variation and their standard errors. MLM also have the advantage that they can 
decompose the total variation according to the level of the hierarchy at which it 
occurs. As Leyland and Goldstein (2001) point out: 
"The questions facing researchers concern the degree to which observed differences at 
the macro-level, typically hospitals or areas- reflect genuine contextual differences at 
the macro level, or whether they do little more than reflect the composition of those 
areas in terms of the micro-level, typically the individual. " (Goldstein and Leyland 
2001, p181) 
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This would appear to be an important advantage given, that the review of economic 
theory suggested that factors explaining cost variation would operate at different 
levels of the data hierarchy (Chapter 4). While MLMs have theoretical appeal for 
analysing reasons for cost variation, their use in health economics has been limited 
(Rice and Jones 1997, Jones 2000, Seshamani and Gray 2004). In general, the cost 
datasets routinely available are highly aggregated, and not amenable to hierarchical 
modelling, that requires data at more than one level of the data hierarchy. The recent 
growth in economic evaluations conducted alongside multicentre RCTs provides an 
opportunity to use MLMs to establish why costs and cost-effectiveness varies across 
health care settings (Manca et al. 2005). 
A number of challenges have been raised concerning the use of MLMs for analysing 
cost variation. MLMs in other areas have generally assumed that the error terms are 
normally distributed (Goldstein 1995, Marshall and Spiegelhalter 2001), an 
assumption that may not be appropriate for the analysis of cost data (Barber and 
Thompson 1998). A potential solution to this problem would be to use GLMMs. Like 
MLMs, GLMMs can accommodate the hierarchical structure of data, but they can 
also allow for non-normal distributions (Barber and Thompson 2004). GLMMs have 
been used for analysing hierarchical cost data, but in the context of a panel dataset 
(Seshamani and Gray 2004). However, GLMMs have yet to be used for analysing 
cross-sectional hierarchical cost data. The use of GLMMs in this context would 
appear to warrant further investigation. Similarly while the non-parametric bootstrap 
has been used to analyse single-level cost data (Surf et al. 2001), and multilevel data 
in the education sector (Carpenter et al. 2003), its use for analysing multilevel cost 
data needs investigation. 
A further issue in the use of MLMs concerns the interpretation of residual variation, 
in particular the unexplained variation that exists across health care firms. Just as with 
OLS cost functions, the residuals estimated for each centre, are both above and below 
the the mean, therefore the residuals cannot be interpreted as measures of efficiency. 
It is likely that residual variations in cost are likely to reflect measurement errors and 
random variation, as well as efficiency differences across centres. The recognition of 
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the role of measurement error and random variation would appear important for any 
technique, including MLM that aims to compare costs across health care units,, even 
those that use more disaggregated datasets. 
There are lessons to be learnt from the debate in the hospital cost function literature 
about the use of behavioural versus structural cost functions. Although specifying a 
structural cost function would appear desirable as it is underpinned by production 
function theory, it has led researchers towards the use of highly aggregated datasets 
and the ensuing cost functions have been parsimonious with few explanatory 
variables. By contrast the `anything goes' approach of the behavioural cost functions 
can easily be criticised for its disregard of economic theory (Wagstaff 1989a). When 
analysing the reasons for cost variation using micro datasets it may not be feasible to 
maintain the theoretical rigour of the structural cost function, but it is still important to 
use insights from economic theory to decide which explanatory variables to include. 
In conclusion, this review found that the use of MLMs is potentially appropriate for 
analysing factors associated with cost variation and for use in CEA. A MLM can 
evaluate cost variation in a manner broadly consistent with economic theory, which 
suggests that reasons for cost variation may operate at different levels. The use of 
OLS regression analysis may lead to biased estimates, and the significance of 
contextual variables may be overstated. It is unclear whether OLS regression analyses 
are an adequate approximation for MLMs in the context of cost and cost-effectiveness 
analysis, as the lack of suitable, disaggregated datasets has limited the use of MLMs 
for these purposes. A careful investigation of the use of MLMs compared to OLS 
regression for analysing the reasons for cost variation is therefore warranted. 
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5.5 Summary of the central issues emerging from the literature 
review 
5.51 Limitations in the methods currently used in economic evaluations 
The literature review highlights that economic evaluations commonly ignore cost 
variation across settings at both the design and analysis stages. Health care providers 
in different settings may face different levels of factor prices, use various 
combinations of factor inputs and differ in the observed costs of producing health care 
programmes (Chapters 2 and 3). The review suggests that economic evaluations make 
fundamental decisions at a design stage that limit the consideration of these and other 
reasons for cost variation. For example, if studies only measure costs in one health 
care setting, it is unclear whether the costs measured are those of efficient production 
and therefore represent opportunity costs for the decision context concerned. Unless 
the costs used in economic evaluations represent opportunity costs, the evaluations 
may make inaccurate estimates of the relative costs and cost-effectiveness of different 
health care interventions. The use of inappropriate cost estimates can hinder moves to 
improve the allocative efficiency of resource allocation. Studies are required that 
assess reasons why costs vary across health care settings, and identify circumstances 
where costs may depart from opportunity costs. An assessment of cost variation 
across settings can provide guidance on the numbers and characteristics of health care 
settings that should be used in an economic evaluation to ensure that the costs 
collected represent the opportunity costs for the decision context concerned. 
Recent multinational economic evaluations have found that costs may vary widely 
across health care settings, and that ignoring this variation can lead to inaccurate 
estimates of cost-effectiveness (Chapter 3). However, these studies have suffered 
from serious limitations. These studies have not used economic theory to pose 
hypotheses for why costs may vary, the studies have failed to address measurement 
issues that pervade the comparison of costs across health care settings, and the 
analytical methods used have not recognised the hierarchical structure of these cost 
data. 
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5.52 A framework for assessing cost variation 
Insights from the production and cost function literatures 
The production and cost function literatures provide a useful framework for 
considering why systematic variations in cost may occur across health care settings 
(Chapter 4). The production function literature highlights that health care firms may 
choose different combinations of factor inputs and still maintain technical efficiency. 
The cost function literature suggests that firms may adjust the mix of factor inputs 
used in production according to differences in relative factor prices. Thus, a 
comparison of observed costs across settings may find that firms across various 
locations have different factor inputs, and total costs, but each firm is responding to 
differences in relative factor prices, in a way that is still productively efficient. 
However, there may be contextual factors that prevent health care firms from 
achieving productive efficiency. 
Consideration of contextual factors 
The review used various strands from the literature to identify some of the contextual 
factors that may be responsible for systematic variations in costs (Chapter 4). Health 
care firms across international settings may face different incentives for achieving 
productive efficiency. For example, some countries have introduced prospective 
reimbursement for hospital services, this provides a stronger incentive for hospitals to 
minimise costs than retrospective reimbursement. National governments usually try to 
regulate the overall number of health care professionals employed in each country. 
The numbers of different health care professionals available to an individual firm may 
depend partly on the structure of the national labour market. Individual health care 
centres may also have limited scope for choosing to adopt new health care 
technologies. National governments may try to control the national levels of public 
spending on health care, by limiting the rate at which new technologies are 
introduced. Decision-makers in individual health care settings, for example hospitals 
may not be able to adjust health care inputs to achieve productive efficiency. Thus, 
the national level of spending on health care may provide a proxy for the level of 
health care infrastructure that is available at the national level, but also at the level of 
the individual health care centre. An investigation of cost variation across health care 
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settings should use the contextual factors identified in the literature review to pose 
hypotheses for why costs may vary across health care settings. 
Measurement issues 
The methodological guidelines for economic evaluation have not carefully considered 
the measurement issues that arise when comparing or using cost data collected from 
different health care settings (Chapter 2). For example, the guidelines are not 
prescriptive about the appropriate level of aggregation to use when measuring 
resource use or unit costs. However, where studies have taken an aggregated approach 
to cost measurement, it is unclear whether the same items are included in the unit 
costs or resource use measured in each health care setting (Chapter 3). An empirical 
investigation of cost variation across health care settings needs to use a consistent 
method of cost measurement in different contexts. The review suggests that to reduce 
methodological inconsistencies between study settings a disaggregated approach to 
cost measurement is preferable. 
The review of the applied cost function literature emphasises the importance of 
adjusting for differences in case-mix, when comparing costs across health care 
settings (Chapter 4). Studies that have aimed to estimate differences in technical and 
productive efficiency across health care settings have required data from many health 
care units. These studies tended to use routine datasets to compare costs across the 
entire range of hospital production. For example, the DRG system of case-mix 
classification has been used, to adjust for case-mix differences that exist across health 
care providers. Using these highly aggregated measures of case-mix means that 
observed cost differences across health care settings could reflect unmeasured 
differences in the patient case-mix. Studies of cost variation across settings therefore 
need to use appropriate datasets that collect sufficiently detailed measures of patient 
case-mix to explore the role of differences between patients in explaining cost 
variation. 
The economic evaluations that have considered cost variation across settings have not 
included sufficient cases or centres to identify systematic reasons for cost variation 
across health care settings (Chapter 3). The literature review did not find definitive 
guidance on how to calculate the numbers of patients or centres required to detect 
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systematic cost differences. However, any study comparing costs across settings 
should consider whether there are sufficient patients and settings to identify 
systematic cost differences. Empirical investigations are required to provide guidance 
on how many centres should be included in economic evaluations, so that systematic 
reasons for cost variation across settings are identified. 
Analysis and presentation of results 
The reviews of both the methodological and applied literatures on economic 
evaluation highlighted that inadequate consideration has been given to the techniques 
used to analyse variation in costs and cost-effectiveness across health care settings 
(Chapters 2 and 3). The literature review described alternative statistical methods for 
analysing resource use, cost and cost-effectiveness variation (Chapter 5), in particular 
the use of OLS regression analysis and MLMs were considered in detail. While 
economic evaluations have previously used OLS regression analyses to identify 
reasons for cost variation, the review found that there may be a fundamental problem 
with using these techniques for this purpose: OLS regression analysis assumes that 
individual observations are independent. However, the examination of contextual 
factors in Chapter 4 suggested that cost data may be clustered within each health care 
setting as for example patients in a particular health care setting face more similar 
factor prices, than patients in other health care settings. As MLMs can acknowledge 
the hierarchical structure of these data, their use may be more appropriate for 
identifying systematic reasons for variation in costs and cost-effectiveness. MLMs are 
able to recognise that reasons for cost variation may operate at different levels, for 
example observed costs may vary between health care settings because of differences 
in factors that operate at a patient-level (e. g. case-mix) or because of factors that 
operate at a higher-level (e. g. characteristics of health care providers). If cost data are 
clustered within health care settings, then cost-effectiveness data may also have a 
hierarchical structure. MLMs are therefore attractive in an evaluative context for 
analysing cost-effectiveness data collected from several different locations. However, 
the use of MLMs in health economics has not been carefully explored, and empirical 
studies are required to assess whether MLMs should be used to analyse costs and 
cost-effectiveness. 
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While the measures of costs and cost-effectiveness presented clearly have to apply to 
the local decision context, methodological guidelines do not clarify how this should 
be achieved. In particular, where an economic evaluation has been conducted 
alongside a multicentre RCT the guidelines do not explain whether the results should 
be presented for different locations or whether it is acceptable to just present measures 
of cost and cost-effectiveness that are pooled over all the study centres. An empirical 
investigation should consider the most appropriate way to present the results of a 
multicentre cost-effectiveness study. The way the results of an economic evaluation 
are presented may have an impact bearing on whether they are useful for policy- 
making and move resource allocation towards allocative efficiency. 
5.6 Conclusions 
The literature review has assessed how economic evaluations currently consider cost 
variation across settings, and has identified gaps in the literature. The review has also 
identified a priori reasons why costs may vary across settings. Finally, the literature 
review has found that there are important measurement and analysis issues that arise 
when comparing costs across health care settings. An investigation is therefore 
required that uses a priori reasoning and recognises these measurement and analysis 
issues. This investigation can enhance understanding of why costs vary across health 
care settings. The next chapter introduces the empirical investigation. 
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Chapter 6: Introduction to the empirical 
investigation: conceptual framework, resource 
use measurement, data description and 
hypothesis generation. 
6.0 Applying the conceptual framework in the empirical 
investigation. 
The literature review identified fundamental gaps in the economic evaluation 
literature. The methods used in economic evaluation need to be informed by empirical 
studies that assess why costs may vary across health care settings. The results from 
these studies could address a range of issues that arise in the design and analysis of 
multicentre economic evaluations38. The empirical investigation in this thesis attempts 
to address some of the questions raised. These questions include: which centres 
should costs be collected from in a multicentre economic evaluation? Does using 
MLMs rather than OLS regression models for identifying factors associated with cost 
variation lead to different results? How should economic evaluations present results to 
make systematic variations in costs across health care settings transparent? The 
empirical investigation attempts to consider these issues by addressing the following 
specific objectives: 
1. To generate hypotheses for why costs may vary across health care settings. 
2. To identify which factors are associated with variability in resource use and 
costs using MLMs and OLS regression models. 
3. To compare the use of OLS regression models with MLMs for analysing 
international cost-effectiveness data. 
38 For a more complete list of issues that could be addressed by empirical studies of cost variation see 
Chapter 2, page 57. 
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To address the first of these objectives the empirical investigation has to gather data 
that can generate hypotheses for why costs may vary across health care settings. The 
empirical investigation therefore has to measure resource use and unit costs across a 
broad range of health care settings. The study also has to collect data on the factors 
that are potentially associated with cost variation across settings. The literature review 
identified a priori reasons why costs may vary systematically across health care 
settings and grouped these reasons into patient and contextual factors. The empirical 
investigation therefore collects data on patient factors such as case-mix and on a range 
of contextual factors (Chapter 6). The contextual factors suggested by the literature 
review (see Table 4.2 in Chapter 4) include the characteristics of the labour market, 
the % of GDP spent on health care, the way health care providers are reimbursed and 
the level of patient copayments. Within this chapter (section 6.4) information from the 
empirical study on resource use (6.41) and a range of patient (6.42) and contextual 
(6.43) factors that may be associated with resource use variation. These data are then 
used to pose about hypotheses about the reasons for resource use variation (6.5). 
The literature review suggested that factor prices and factor inputs may vary across 
health care settings. This may lead to differences in unit costs, and measurement 
issues when comparing costs across health care settings. Chapter 7 considers the 
variation in factor prices and factor volumes across the settings included in the study 
(see section 7.5). Where cost data are collected across international health care 
settings with differing factor prices, this has implications for the choice of currency 
conversion factor. Chapter 7 address this specific measurement issue and presents cost 
estimates using different currency conversion factors. 
To provide an assessment of the reasons for systematic cost variations, the empirical 
investigation has to address the measurement issues raised in the literature review. In 
particular, the empirical investigation must use a consistent costing methodology 
across a range of health care settings. The study should take a sufficiently broad 
perspective to cost measurement and record costs over an adequate time-horizon. The 
literature review suggested that the empirical investigation should measure costs in a 
disaggregated way and distinguish between differences in factor inputs and factor 
prices. The empirical investigation therefore considers the potential role of these 
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measurement issues in explaining resource use (Chapter 6) and cost (Chapters 7 and 
8) differences across the settings included in the empirical investigation. 
Even if a detailed approach to measurement is used, this does not mean that the 
empirical investigation should only measure costs in a few health care settings. 
Clearly there are trade-offs between avoiding the measurement issues that arise when 
taking a more aggregated approach and measuring costs in sufficient settings to 
identify systematic variations in cost. The literature review suggested that where 
economic evaluations have compared costs across just a few health care settings 
(n<7), they have been unable to identify systematic reasons for cost variation (Chapter 
3). An important challenge for the empirical investigation is to avoid inconsistencies 
in the measurement of costs but also to collect data from sufficient centres to identify 
systematic variations in costs. 
The second objective of the empirical investigation is to consider the use of MLMs to 
identify reasons for systematic variations in costs (Chapter 8). As previous studies 
have used OLS regression analysis to assess cost variation, it is important to compare 
the use of MLMs to OLS regression analyses. This comparison needs to assess 
whether the use of MLMs rather than OLS regression analyses leads to different 
results. The empirical investigation also has to consider whether assumptions made 
when using MLMs in other sectors, namely that the residuals are normally distributed, 
are plausible in this context. 
Finally, as the aim of the thesis is to inform the conduct of economic evaluations, the 
thesis has to consider the implications of the results of the empirical investigation for 
the design and analysis of economic evaluations. In particular, the empirical 
investigation also has to compare the use of OLS regression analysis to MLMs for 
analysing multicentre cost-effectiveness data. The literature review raised issues 
concerning the use of MLMs in this context, namely whether the assumption of 
exchangeability applies when analysing cost data from different health care settings 
(Chapter 9) 
For the empirical investigation to meet the objectives described, a case study is 
required that that can address the measurement and analysis issues identified. The 
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next section explains the rationale behind the choice of case study for the empirical 
investigation. 
6.1 Choice of case study for the empirical investigation 
To meet the thesis' objectives the empirical investigation has to use an appropriate 
case study, one that possesses the features defined in the conceptual framework. The 
case study chosen for the empirical investigation was the EU funded Biomed II stroke 
study (McKevitt et al. 2000). I was the network health economist on the Biomed II 
stroke study from 1995-1999, and over this period the work presented in this PhD 
thesis was commenced39. The Biomed II stroke study is an observational study that 
measures the costs of stroke care for 1757 cases managed in 13 centres in 10 
countries. Previous studies have shown that the burden of stroke is large (Bosanquet 
and Franks, 1998) and that there are important variations in the way stroke care is 
provided across European centres (Beech et al. 1996). The Biomed II stroke study 
aimed to measure the resource use, costs and outcomes associated with various ways 
of managing stroke patients (McKevitt et al. 2000). As part of this study, information 
was therefore collected on many of the patient and contextual factors that the 
literature review suggested could be associated with variation in resource use, unit 
costs and total costs. This study was therefore judged suitable for use in the empirical 
investigation. The empirical investigation of the thesis extended the Biomed II study 
to address the measurement and analysis issues outlined in the conceptual framework 
for the thesis and consider the methodological implications for economic evaluations 
(Chapter 5). 
In the Biomed II study resource use and unit cost data are collected in each centre 
using a standardised costing methodology (see Chapters 6 and 7). The study included 
sufficient patients and centres to allow for a thorough investigation of systematic 
reasons for cost variation as part of this thesis. These features made the Biomed II 
study more appropriate for the empirical investigation, than many of the economic 
evaluations based on multicentre RCTs that had been conducted at the 
39 Some of the results have been published in peer-reviewed journals (see the publication list at the beginning of the thesis). 
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commencement of this thesis or have been conducted since (see Chapter 3). These 
studies included fewer cases in each centre, only collected unit costs in a small 
number of centres and did not use a consistent disaggregated approach to cost 
measurement. 
The Biomed 11 stroke study provides an appropriate context for testing whether using 
MLMs is more appropriate than using OLS regression analyses for identifying 
reasons for cost variation (Chapter 8). There are a priori reasons for expecting that the 
costs of stroke care are clustered within health care centres (see Chapter 4), but it is 
unclear whether the use of MLMs, rather than OLS analysis would lead to different 
conclusions. 
The empirical investigation for this thesis aims to inform the methodological debate 
about how economic evaluations should be conducted. To consider the specific issue 
of whether MLMs are more appropriate than OLS regression analysis for analysing 
multicentre cost-effectiveness data, a multicentre cost-effectiveness dataset is 
required. As appropriate empirical datasets were not available, the results from the 
cost analysis are used to extend the observational stroke to generate a cost- 
effectiveness analysis (Chapter 9). This generated dataset mimics a multinational 
cost-effectiveness study in this disease area and provides a vehicle for comparing the 
use of OLS regression analysis versus MLMs for analysing cost-effectiveness. 
To summarise, to address the issues raised in the literature review an empirical 
investigation was required. The empirical investigation in this thesis extends the 
Biomed II stroke study and provides a case study for examining reasons for cost 
variation across health care settings. By extending the Biomed II stroke study the 
empirical investigation addresses measurement issues that arise when comparing costs 
across settings. 
This chapter introduces the methodology used to measure the resource use data, 
describes these data, and poses hypotheses for resource use variation, Chapter 7 
describes the methods used to collect unit costs, analyses why the unit costs may vary 
across health care settings and presents the unit costs and total costs. Chapter 8 tests 
the hypotheses for why resource use and total costs may vary across the health care 
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settings included in this study using OLS regression analysis and MLMs. Chapter 9 
extends the results from Chapter 8 to generate a cost-effectiveness dataset. This 
chapter then compares the use of OLS regression analyses with MLMs for analysing 
multicentre cost-effectiveness data. 
6.2 Chapter overview 
The aim of this chapter is to detail the methodology used to measure resource use, to 
describe the resource use data, and the factors potentially associated with resource use 
variation, and then to use these data to pose hypotheses for why resource use might 
vary across different health care settings. Identifying reasons for resource use 
variation is an important prerequisite for understanding why costs vary across health 
care settings. The next section of this chapter describes the methodology used to 
measure resource use and the factors associated with resource use variation. Section 
6.4 describes the data and highlights variations across the centres in resource use and 
in factors potentially associated with resource use variation. Section 6.5 poses 
hypotheses regarding resource use variation. Finally, section 6.6 discusses the data 
presented in this chapter and identifies any issues raised by the resource use 
methodology for the subsequent interpretation of results. 
6.3 Measurement of resource use and factors associated with 
resource use variation 
6.31 Centres included in the study 
The empirical investigation measures resource use for each patient attending each of 
the centres included in the study. The term `centre' refers to the health and 
community care providers delivering stroke care. Each centre consists of an acute 
hospital that takes stroke patients as direct admissions, and the majority of these acute 
hospitals are teaching hospitals. Table 6.1 lists the location of the centres, and the 
main characteristics of the acute hospitals included in the study. There are some 
similarities between the centres included; each of the acute hospitals is a publicly 
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funded hospital, and pays employees by salary rather than according to the volume of 
patients seen or the number of procedures completed. Each of the acute hospitals 
takes patients as direct admissions, does not use a triage system for selecting cases, 
and provides routine acute care to the local community. 
However, these centres were not selected because they were similar, but to compare 
the different ways in which stroke care may be provided across Europe. Previous 
research found that there were differences in the duration of acute hospitalisation and 
the main department where patients were managed (Beech et al. 1996). Site visits 
were undertaken at the start of the Biomed II study to collect more detailed 
information on the way stroke care is produced in each centre. The site visits found 
that the centres also differed in the services provided post discharge, for example 
some centres had additional inpatient care provided in a separate rehabilitation 
hospital (McKevitt et al. 2000). It was therefore important to collect data that allowed 
the different production processes in the centres to be described and to generate 
hypotheses for the reasons for resource use and cost variation. 
Table 6.1: Centres included in the study 
Centre Country Definition 
of acute 
Hospital' 
Main department 
managing stroke 
patients 
Separate 
rehabilitation 
hospital? 
Almada Portugal Teaching General Medicine No 
Menorca Spain Teaching General Medicine No 
Florence Italy Teaching Neurology Yes 
Dijon France Teaching Neurology Yes 
Copenhagen Denmark Teaching Neurology Yes 
Kuopio Finland 1 Teaching Neurology Yes 
Turku A Finland 2 Teaching Neurology Yes 
Turku B Finland 3 District General Medicine Yes 
London UK Teaching Elderly Care No 
Warsaw Poland Teaching Neurology No 
Kaunas A Lithuania 1 Teaching Neurology Yes 
Kaunas B Lithuania 2 District Neurology Yes 
Riga Latvia Teaching Neurology No 
Source: McKevitt et al. (2000)'. Teaching hospital, defined as a hospital which has an accredited 
medical school, district hospital defined as hospital without a medical school. 
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6.32 Patients included in the study 
Each centre prospectively recruited, over a one-year period, patients who had suffered 
a first-ever stroke, defined using the WHO criteria (Hatona 1976), and were admitted 
to hospital. Patients who suffered a stroke but were not admitted to hospital were 
excluded from the study. Patients who had a subarachnoid haemorrhage were 
excluded, as well as 31 patients who refused consent to participate in the study. A 
total of 1981 patients were registered for inclusion in the study, of whom 134 were 
missing key case-mix variables and 127 follow-up data. The dataset considered for 
use in this thesis consisted of those 1757 cases with complete information. 
The exclusion of decedents from the resource use and cost analysis 
The primary outcome measure in the Biomed II study was survival up to three months 
post stroke. A priori reasoning suggests that over a three month period those patients 
who died would consume less resources than those patients surviving the strokeao 
The survival analysis for the Biomed II study showed that there were differences in 
survival following stroke across the centres after adjusting for differences in patient 
factors (Grieve et al. 2001 a). This raises the question: would any cost variation across 
the centres simply reflect between-centre differences in survival? More specifically, 
does higher cost in certain centres simply reflect lower mortality in these centres? 
One way of considering this issue would be to include death as a variable in a cost 
function. However, this would lead to problems of interpretation. Firstly, including 
death alongside patient-level characteristics (see section 6.34) would be problematic. 
These covariates such as incontinence, are associated with survival as well as cost and 
hence there would be multicolinearity amongst the independent variables (Gudjarati 
1988). A more fundamental problem is that it would be difficult to interpret the 
potentially endogenous relationship between death and cost. It may be that those 
patients who died consumed fewer resources, it may also be true that those patients 
who had access to fewer resources were more likely to die. Disentangling this 
association is particularly problematic in a multicentre context where some centres 
have access to more resources and this may be associated with lower mortality. 
40 While there is a growing literature suggesting that in more general populations proximity to death is 
strongly associated with increase in costs, in stroke care less resources are consumed by those dying in 
the first three months post stroke, than by those surviving this period (Grieve et al, 2001b). 
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A potential solution to this endogeneity problem is to use an instrumental variable 
approach. Here, a set of variables are identified that are associated with the variable in 
question, and are then used instead of the endogenous variable in the original model 
(McCellan and Newhouse 1997). A key challenge with this approach is to identify a 
suitable instrument. This requires finding covariates that are associated with the 
endogenous variable but which are not independently associated with the outcome 
variable. So in the context of this investigation, the variables concerned would need to 
be associated with death but not cost. The covariates collected in the study (e. g. 
incontinence) were generally associated with both cost and survival and hence it was 
not possible to identify an appropriate set of variables to act as an instrument and 
avoid the endogeneity problem. 
Instead a pragmatic approach was taken to this problem and patients who died were 
excluded from the resource use and cost analysis (chapters 6-8). The subsequent 
analysis of the reasons for resource use and cost variation are explored for those 
patients who were still alive at three months post stroke (n=1298). In the cost- 
effectiveness study in chapter nine it is possible to include both decedents and 
survivors (n=1757) in the analysis (see also page 180). 
6.33 Resource use measures 
To ensure comparability across the centres it is important to address some of the 
measurement issues raised in the literature review, in particular it is necessary to 
adopt a sufficiently broad perspective and measure a wide range of costs. A hospital 
and community health service perspective was therefore taken to resource use 
measurement. The use of all hospital and community services was recorded for three 
months post stroke. Costs to patients and their carers and the costs of lost production 
were not measured in the study. However, information was collected on whether there 
was input from the patient's carer, for example with assisting the patient with their 
activities of daily living. This enabled the analysis to examine whether informal care 
inputs were either a substitute or a complement to hospital or community services (see 
below). 
164 
The length of hospital stay in each hospital, by ward type were recorded for each 
patient (intensive care unit [ICU], neurology unit, dedicated stroke specific unit, or 
general medical ward) in each hospital. The total length of stay (LOS) per patient was 
calculated by summing the length of stay in each hospital. The use of diagnostic 
investigations was recorded for each patient from medical records. 
The literature review suggested that the quality of care may be associated with the 
cost of care. Care, which meets the definition for organised stroke care, 
41 is associated 
with better outcomes and reduced LOS, and may be defined as better quality care than 
routine stroke care (Stroke Unit Trialists' Collaboration 1999). During site visits to 
each centre, care provided on each ward was categorised according to whether it met 
the criteria for organised stroke care (Stroke Unit Trialists' Collaboration 1999). 
The use of outpatient and community services (hospital clinics, therapy, GP visits, 
home carers, nursing and residential homes), was recorded during interviews 
conducted by clinical investigators in each centre with the patients and their carers at 
three months post stroke. The use of outpatient and community services was then 
summarised as a categorical variable42. This variable identified those patients for 
whom alternatives to hospital care such as home help or home nursing clearly existed. 
Similarly, for each patient it was recorded whether there was any care input provided 
by the patient's family, and a separate categorical variable was defined for family 
support. These two variables are used to identify those patients for whom an 
alternative to hospital care existed. The literature review suggested that the 
availability of care alternatives may be important in determining the duration of 
hospitalisation. So as well as being resource use measures themselves, these variables 
could be considered as factors potentially associated with hospital resource use. 
41 The criteria for organised stroke care relate to the level of training and education for different 
members of staff, the extent to which multidisciplinary teamwork is practised, and whether care is led 
by a clinician with a particular interest in stroke (Stroke Unit Trialists' Collaboration 1999). 
42 where 1=no use of community services, and 2= use of community services. 
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6.34 Patient factors potentially associated with resource use variation 
Hospital-based stroke registers were established for one year during 1996-7. 
Designated investigators at each centre completed standard forms to record baseline 
information. Individual patient data were collected on patient characteristics (sex, age, 
pre-stroke living conditions) and stroke severity measures (incontinence during the 
first week after stroke, paralysis at hospital admission; stroke subtype [cerebral 
infarction, intra-cerebral haemorrhage, or unspecified stroke]). These patient 
characteristics had not previously been shown to differ across European health care 
settings, and may be associated with differences in resource use, cost and outcome 
(Beech et al. 1996, Wolfe et al. 1999). 
6.35 Contextual factors potentially associated with resource use variation 
In this section the term contextual factors refers to factors that may operate at the 
level of the ward, department, hospital, centre, region or national health care system. 
In general, these factors are also measured at the centre or national-level. For some of 
these factors however, the best data was measured at a patient-level. 
One factor that may be associated with the level of resource use is the patients' 
geographical access to hospital care. The level of access to hospital may depend on 
factors such as the density of hospitals within a particular region. For this dataset the 
best data collected on access to care was the time from stroke onset to hospital 
admission, which was reported for each patient. Similarly, the level of access to 
specialist facilities, in particular neurologists input, or the use of inpatient 
rehabilitation facilities may determine resource use. During site visits to each centre, 
information was collected on whether neurologists were involved in providing care on 
each of the wards managing stroke patients. Data were also collected on whether 
separate inpatient rehabilitation services were available at other hospitals following 
discharge from the acute hospital. These data were used to define for each patient in 
the dataset whether they had access to input from a neurologist or utilised a 
rehabilitation hospital during their stay. 
For each hospital, information was collected on the bed-occupancy and the number of 
beds on the wards where stroke patients were managed. Information was gathered in 
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each centre on whether there was prospective reimbursement for hospital services 
through a Diagnosis related group (DRG) system. It was recorded in each centre 
whether patients were required to make copayments for their acute care, and what the 
nature of these copayments was. For example, it was noted whether patients were 
charged a fixed amount or whether the copayments was linked to the LOS. Each of 
these variables was recorded at the level of the health care centre. 
Finally, information was gathered from the literature on the national GDP per capita, 
and the national public health care expenditure as a% of GDP. These measures 
provide an indication of the national level of health care infrastructure, as this may be 
associated with resource use differences across the centres (OECD 2000, OECD 
2001, Karaskevica and Tragakes 2001, Karski et al. 2002, Cerniauskas and 
Murauskiene 2002). 
To summarise, data on hospital and community resource use were collected for three 
months post stroke for each patient in each centre. As survival varied across the 
centres, the main analysis for the thesis uses those patients surviving up to three 
months post stroke. The focus of the analysis will be on which factors are associated 
with resource use variation. Information is therefore recorded on patient 
characteristics for each patient. Data on contextual factors such as the method of 
reimbursement for hospital services were collected on site visits to each centre and 
from the literature review, and are reported at the level of the health care centre or 
country concerned. The next section describes the key resource use data and the 
patient, centre and national-level factors that are potentially associated with resource 
use variation. 
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Table 6.2: Summary of variables collected in the study that are used to 
investigate resource use variability. 
Groups of variables Specific Variables Level Source 
measured at 
Patient factors Patient case-mix, age Patient Project database 
Contextual factors 
access to neurologists? Patient Project database 
rehabilitation hospital? Patient Project database 
DRG system? Centre Site visits 
Patient copayments Centre Site visits 
% GDP on health care National Literature 
Resource use LOS, number CT scans Patient Project database 
measures 
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6.4 Data description: Resource use and factors associated with 
resource use variation 
This section begins by presenting resource use differences across the centres. 
Following this, data are presented on the patient and contextual factors that may be 
associated with resource use variation. Differences in resource use and in patient-level 
factors are compared across the centres using statistical tests. The chi squared (Z) test 
is used to establish if there are statistically significant differences across the centres 
for categorical variables. For continuous variables ordinary least squares (OLS) 
regression analysis is used with the resource use or patient factor as the dependent 
variable and dummy variables for each centre as the independent variables. The 
corresponding ,F statistics and p values are reported for each measure of resource 
use and for each of the patient factors. 
6.41 Description of resource use differences 
In this section the resources used in producing stroke care in the different centres are 
described. The resource use measures selected are those that are likely to be important 
determinants of total costs, and also those that demonstrate possible substitutions in 
the production of stroke care, across the centres. 
The first comparison of resource use across the centres uses aggregated measures: the 
total LOS in hospital, the days in institutions (residential and nursing homes), and the 
proportion of cases visiting a physician in the outpatient department in the three 
months post stroke. The comparisons demonstrate that important differences exist in 
these resource use measures across the centres (Table 6.3). For example, although the 
average total LOS in hospital is 27.3 days, the mean ranged from 7.8 days in the 
Spanish centre to 39.3 days in the UK centre. Similarly, the mean LOS in institutional 
care ranged from 0.2 days in the Danish centre to 18.5 days in the Finnish centre. The 
proportion of patients who visited outpatients in each centre ranged from 4% to 71 %. 
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Table 6.3: A comparison of mean resource use across centres 
Centre N Mean (SD)total 
LOS in hospital 
[days] 
Mean (SD)days in 
institutional care 
% visited 
outpatients 
Portugal 73 13.0(14.2) 3.4(16.3) 71 
Spain 32 7.8(6.4) 2.3(12.7) 66 
Italy 109 20.2(23.0) 5.2(19.2) 17 
France 105 24.2(27.5) 5.2(19.4) 30 
Denmark 246 37.1(33.7) 0.2(2.1) 52 
Finland 1 37 19.1(20.2) 1.1(6.9) 22 
Finland 2 81 36.5(31.1) 7.5(17.9) 32 
Finland 3 57 37.4(29.0) 18.5(25.8) 9 
UK 73 39.3(33.8) 1.3(7.6) 49 
Poland 92 25.5(15.9) 1.6(9.3) 72 
Lithuania 2 186 26.5(16.6) 1.6(9.8) 4 
Lithuania 1 62 28.0(13.5) 0.6(4.5) 48 
Latvia 145 18.7(11.1) 2.8(12.8) 4 
ALL 1,298 27.3(25.6) 3.2(13.7) 34 
F(12,1285)=13.33 F(12,1285)=11.92, (12)=336, 
P<0.001 P<0.001 p<0.001 
As the resource use measurement was for up to 90 days post stroke, any resource use 
after this time point was excluded from the analysis. To consider the potential impact 
this may have on the results, the patients' place of residence at three months post 
stroke is presented below (Table 6.4). The majority of patients were in their own 
home by three months post stroke. While further resource use attributable to the 
stroke may have occurred after this time point, for these patients this would only 
relate to hospital readmissions or to the use of outpatient or community services. 
Previous research has shown that both of these items are small components of the 
overall costs of stroke care (Porsdal and Boysen 1997). For those patients who are 
still in hospital, nursing or residential homes at 90 days post stroke, the further 
resource use that is excluded may be an important component of total costs. In the 
context of this investigation, the concern is whether limiting the time-period would 
have an impact on the comparison of costs across the centres. The centres where most 
patients were in hospital or institutional care at three months were in Denmark, 
Finland (2 and 3) and the UK. These centres were those with the longest LOS, and so 
limiting the time-frame to 90 days is likely to lead to an underestimation of 
differences in total costs across the centres. 
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Table 6.4: Place of residence at three months post stroke (% in each place) 
Country N Home Hospital Nursing Residential Sheltered 
home care home accommodation 
Portugal 73 95 1 4 0 0 
Spain 32 97 0 0 0 3 
Italy 109 93 2 0 0 6 
France 105 86 5 2 0 8 
Denmark 246 76 22 0 0 2 
Finland 1 37 97 3 0 0 0 
Finland 2 81 72 14 12 2 0 
Finland 3 57 56 5 28 11 0 
UK 73 74 15 11 0 0 
Poland 92 96 1 3 0 0 
Lithuania 1 62 100 0 0 0 0 
Lithuania 2 186 98 1 1 0 0 
Latvia 145 98 1 3 0 0 
ALL 1,298 87 7 5 1 0 
(12)=11.92, p<0.001 
More detailed comparisons of resource use within the hospital suggest that there is 
considerable variation both within and across centres in the resources used to produce 
stroke care. For example, in each hospital patients may stay on general medical, ICU, 
stroke units, elderly care units, rehabilitation units or neurology wards. The main area 
for caring for stroke patients varied according to the centre. In Table 6.5 the average 
number of days patients spent on each ward are presented for each centre. Over all the 
centres, the mean LOS was highest on the rehabilitation wards, however in certain 
centres (UK and Poland) the mean stay was highest on dedicated stroke units, whereas 
in the centres in Portugal and Finland, most days were spent on general medical 
wards. The relative number of days patients stay on each ward may be an important 
determinant of the overall cost variability both within and across centres. The results 
also show that there was variability in the quality of care provided across the centres 
according to the average number of days the patients received organised stroke care. 
Organised stroke care has generally been associated with better outcomes and shorter 
LOS than conventional care (Stroke Unit Trialists' Collaboration 1999). 
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Table 6.5: Mean days stayed on each ward, and mean (SD) total days 
Centre ICU Neurology Stroke uni Rehabilitati General Total days 
medical 
Portugal 0 6.4 0 0 6.6 13.0 (14.2) 
Spain 0.1 0 0 0 7.8 7.9(6.3) 
Italy 0 0 6.3* 9.7* 4.1 20.2(23.0) 
France 0.4 9.0* 0 14.0* 0.9 24.2(27.5) 
Denmark 0.4 6.3* 9.6* 12.2* 8.6 37.1(33.7) 
Finland 1 0 9.4* 0 9.6* 0 19.1(20.2) 
Finland 2 0 14.4* 0 18.7 3.4 36.5(31.1) 
Finland 3 0 0.2 0 11.2 25.9* 37.4(29.0) 
UK 0.7 0 19.3* 13.8* 6.2* 39.3*(33.8) 
Poland 2.5 0 22.1* 0.9 0 25.5(15.9) 
Lithuania 1 0 17.6 0 9.6* 1.2 28.0(13.5) 
Lithuania 2 0.3 16.0 0 7.1 * 3.2 26.5(16.6) 
Latvia 3.3 12.8 0 1.4 1.1 18.7(11.1) 
ALL 0.7 8.0 5.0 8.6 4.9 27.3 
F=8.841 F=31.74 F=39.39 F=9.11 F=23.19 F=13.33 
P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 
* the ward meets the criteria for organised stroke care. The F statistics are calculated based on an OLS 
regression of centre on LOS with n=1,298 and 13 parameters there are 1,285 degrees of freedom. 
The final measures of resource use are the mean number of CT scans (Table 6.6) and 
the proportion of patients having a carotid doppler. Again these show wide variation 
between the study centres (p<0.001). 
These resource use measures suggest that there were differences in the way stroke 
care was produced across the centres. The patient and contextual factors that may be 
associated with these resource use differences are described in the next section. 
172 
Table 6.6: Use of CT scans and carotid doppler investigations 
Centre Mean (SD) CT scans % having carotid Doppler 
Portugal 1.23(0.57) 40 
Spain 1.06(0.35) 6 
Italy 1.31(0.73) 60 
France 1.43(0.68) 82 
Denmark 1.17(1.05) 49 
Finland 1 1.16(0.60) 0 
Finland 2 1.36(0.68) 0 
Finland 3 1.18(0.50) 0 
UK 1.07(0.25) 14 
Poland 1.31(1.10) 100 
Lithuania 1 0.97(0.63) 48 
Lithuania 2 0.19(0.54) 5 
Latvia 1.24(0.52) 48 
ALL 1.08(0.82) 40 
F=28.76 (12)=496 
P<0.001 P<0.001 
6.42: Description of patient factors potentially associated with resource use and 
cost variation 
The patient factors measured in this dataset that are potentially associated with 
resource use and cost are described below. 
Patient characteristics 
The characteristics of the patients included in the study are presented in Table 6.7. 
There were differences across the centres in the mean age of the patients, the 
proportion of patients living alone at home before they had the stroke, and in the 
proportion of patients who were independent before the stroke. 
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Table 6.7: Age and Pre-stroke status 
Centre N Age at stroke 
Mean (sd) 
Residence pre-stroke 
Home Home with Nurs 
alone partner (%) home 
(%) (%) 
Indepen 
pre-stroke 
(%) 
Portugal 73 64.5(11.5) 10 88 4 99 
Spain 32 72.3(8.4) 28 72 0 88 
Italy 109 74.2(11.0) 9 87 4 95 
France 105 71.0(17.6) 34 61 5 95 
Denmark 246 67.6(13.9) 48 51 0 79 
Finland 1 37 72.9(9.4) 38 62 0 91 
Finland 2 81 70.1(11.6) 42 58 0 70 
Finland 3 57 80.8(7.3) 77 14 9 95 
UK 73 71.3(11.8) 37 53 10 81 
Poland 92 69.6(11.6) 24 75 1 97 
Lithuania 1 62 66.9(10.5) 6 94 0 98 
Lithuania 2 186 69.9(11.0) 11 89 1 99 
Latvia 145 62.7(10.0)) 11 88 1 97 
ALL 1,298 69.3(12.7) 11 88 1 91 
F=158 )e=283, p<0.001 x=125 
n<0.001 n<0.001 
Independ: Independent, Nurs: nursing 
Stroke severity 
The severity of the stroke varied across the centres (p<0.001 for all variables), with 
the proportion of patients who were incontinent at admission ranging from 12% for 
the centre in Latvia compared to 42% for the centre in Finland 3 centre (Table 6.8). 
Stroke is a heterogeneous condition encompassing both cerebral infarctions and intra- 
cerebral haemorrhages that differ in the way they are managed (Wade 1994). The 
distinction between different subtypes of stroke is usually made by CT scan. In one of 
the centres (Lithuania 2) where the CT scan rate was very low, the majority of strokes 
were therefore unclassified. In the remaining centres where most patients had a CT 
scan, the proportion of cases with cerebral infarction ranged from 68% to 97%. 
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Table 6.8: Measures of stroke severity (n=1298) 
Centre Incontinent' (%) Paralysed` 
(%) 
Infarction 
(%) 
Stroke subtype 
Haemorrhage 
(%) 
Unknown 
(%) 
Portugal 25 84 75 15 10 
Spain 28 84 81 16 3 
Italy 40 81 78 18 4 
France 18 69 96 3 1 
Denmark 33 70 75 11 14 
Finland 1 19 65 97 3 0 
Finland 2 35 74 86 12 1 
Finland 3 42 60 89 11 0 
UK 26 67 89 11 0 
Poland 20 95 91 8 1 
Lithuania 1 16 68 68 15 18 
Lithuania 2 25 89 9 5 87 
Latvia 12 82 81 16 3 
ALL 26 77 72 11 18 
)e(12)=52 x2(12)=68 x(12)=775 
p<0.001 p<0.001 p<0.001 
first week after stroke, `At 
6.43 Description of contextual factors potentially associated with resource use 
and cost variation 
Details were recorded on differences in access to care, the way stroke care was 
produced in each centre, incentives to reduce hospital costs and proxies for national 
levels of health care infrastructure. Each of these contextual factors can be used to 
offer insights into why there are resource use variations across the centres. While 
these factors are all grouped under the general heading of contextual factors this is 
simply to define these factors as operating at the level of the health care centre or 
country concerned, rather than at a patient-level. The definition of contextual or 
higher-level factors therefore refers to the level at which these factors were assumed 
to operate. In this dataset, some of these factors such as time from stroke onset to 
admission were measured at a patient-level whilst others such as the method of 
hospital reimbursement or level of health infrastructure were measured at a centre or 
national-level. 
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Access to hospital care 
One hypothesis from the literature review was that those with better access to care 
might consume higher levels of health care. In this study all the patients included are 
admitted to hospital, so by definition, they have been able to access hospital care. 
However, barriers to care may exist in some of the centres, and there may be a delay 
to hospital admission. The time between onset of stroke and admission varied across 
the health care settings (Table 6.9). For example, 14% of the stroke patients in the 
Polish centre arrived at the acute hospital at least seven days after the stroke. By 
contrast, the majority of the patients in the centres in Spain, Italy, Finland 2, and 
Lithuania were admitted to hospital within 6 hours post-stroke. 
Table 6.9: Time from stroke onset to admission (n=1,298): % in each category 
Centre <6 hours 6-24 hours 1-7 days >7 days unknown 
Portugal 44 40 16 0 0 
Spain 56 16 16 6 6 
Italy 57 28 14 1 1 
France 42 37 17 2 2 
Denmark 34 21 19 5 21 
Finland 1 46 19 8 0 27 
Finland 2 58 23 16 0 2 
Finland 3 46 30 16 0 9 
UK 45 16 27 0 11 
Poland 45 29 12 14 0 
Lithuania 1 52 29 13 2 5 
Lithuania 2 45 31 19 4 1 
Latvia 30 27 29 10 4 
ALL43 43 27 18 4 7 
y (12)=241, p <0.001 
Access to neurologist and utilisation of rehabilitation hospitals 
Almost all of the patients in the Eastern European centres had access to neurological 
care (Table 6.10). The centres in Italy, France, Denmark, and Finland generally had 
access to both neurologists and rehabilitation hospitals (Table 6.10). For patients in 
the UK, Spain and Portugal access to neurologists was either low or non-existent, and 
in these centres there was no use of separate rehabilitation hospitals. In the UK centre, 
inpatient rehabilitation was delivered in the acute hospital, whereas in the centres in 
Spain and Portugal, inpatient rehabilitation was not available for the majority of the 
43 Owing to rounding the numbers in this row do not sum to 100% 
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patients. This provides a clear example of stroke care being produced in different 
ways across centres within Western Europe, and may offer helpful insights into why 
resource use differs across the Western European centres. 
Table 6.10: Access to neurologists and inpatient use of rehabilitation hospitals 
(n=1,298) 
Centre % access to neurologists % transferred to rehabilitation 
hospital' 
Portugal 32 0 
Spain 0 0 
Italy 68 21 
France 93 28 
Denmark 76 27 
Finland 1 100 30 
Finland 2 91 48 
Finland 3 23 30 
UK 0 0 
Poland 92 4 
Lithuania 1 100 44 
Lithuania 2 91 29 
Latvia 94 3 
ALL 75 20 
j (12)=615 J(12)=175 
p<0.001 n<0.001 
'In Poland, Latvia, Spain there were no inpatient rehabilitation hospitals in the local area, and any use 
of rehabilitation hospitals came from patients being transferred to hospitals in other regions 
Alternatives to hospital care 
The table below (Table 6.11) shows that on average 19% of patients used community 
support services (home help, home carer, district nurse) after hospital discharge, and 
35% of patients had support or help from their family to assist with activities of daily 
living. Again there was important variability across the centres, a high proportion of 
patients in the Polish centre had family support (71%) compared to the UK and 
Danish centres, where none of the patients had family support in the three months 
following the stroke. 
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Table 6.11: Alternatives to hospital care (n=1,298) 
Centre % community support % family support 
Portugal 10 30 
Spain 38 41 
Italy 5 50 
France 37 35 
Denmark 27 0 
Finland 1 30 43 
Finland 2 14 35 
Finland 3 37 55 
UK 21 0 
Poland 21 71 
Lithuania 1 3 48 
Lithuania 2 14 36 
Latvia 6 62 
ALL 19 35 
e(12)=105 (12)=298 
p<0.001 p<0.001 
Reimbursement of inpatient hospital services, bed-occupancy and patient 
copayments 
Most of the hospitals in the study (Table 6.12) received a global budget to provide all 
inpatient and outpatient services. This may limit the level of stroke care that can be 
supplied. The extent to which this provides an incentive to minimise costs, depends 
on many factors including whether the demand for hospital services, for example for 
inpatient stroke care, exceeds the supply. Under global budgets if demand for 
inpatient care does exceed supply then there may be a greater incentive to discharge 
patients from hospital than when there is excess capacity. The table below (Table 
6.12) provides some indication of the spare capacity on the ward where most stroke 
patients in each hospital are managed, by reporting the bed-occupancy. Those centres 
that have global budgets and low bed-occupancies for example, Finland 1 and 2, and 
the UK centre may have weak incentives to discharge the patients from hospital. 
Diagnosis related groups (DRGs) are a prospective payment system whereby hospitals 
are reimbursed in advance for the cost of treating patients with a particular diagnosis. 
Hospitals have an incentive to minimise costs, as if the costs are lower than the DRG 
reimbursement rate, the savings are kept by the hospital. DRGs may therefore provide 
a more direct incentive than global budgets for reducing LOS, However, unless DRGs 
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cover the entire range of disease costs, they may lead to costs being shifted to a 
different provider. For example, in the French centre in this study, the DRG system 
does not cover the costs of the rehabilitation hospital, so cost shifting may occur. The 
incentive to minimise the total costs of hospitalisation may not be as strong as for the 
other centres reimbursed by DRGs, where the DRG covers the majority of stroke care 
costs. 
Table 6.12: Centre factors: patient copayments, reimbursement of hospital 
services and bed-occupancy on main ward managing stroke patients in each 
centre 
Centre Patient 
copayments? 
(acute care) 
Reimbursement of 
hospital services 
Bed occupancy' No. beds on main 
ward for stroke 
patients 
Portugal No DRG 0.94 28 
Spain No Global budget 0.81 31 
Italy No DRG 0.90 4 
France Yes DRG 0.80 25 
Denmark No Global budget 0.94 15 
Finland 1 No Global budget 0.75 23 
Finland 2 No Global budget 0.75 28 
Finland 3 No Global budget 0.99 28 
UK No Global budget 0.80 12 
Poland No Global budget 0.81 16 
Lithuania 1 No DRG 0.92 40 
Lithuania 2 No DRG 0.87 80 
Latvia Yes DRG 0.91 78 
' Calculated over the financial year 1997-1998, by dividing the total number of occupied bed-days by 
the total number of available bed-days. 
Presence of copayments 
In the centres in Latvia and France, patients were asked to make a small contribution 
towards the cost of each day in hospital to cover for example, food costs. The 
presence of these payments may therefore provide a small incentive for the patients to 
seek earlier discharge from hospital. 
Proxy measure for the national level of health care infrastructure 
The literature review suggested that the level of health care infrastructure in the 
country concerned, could be important in determining the resources used at a local 
level. Various alternative measures could be used to proxy the level of health care 
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infrastructure available. Table 6.13 presents two such measures: the GDP per capita, 
and the proportion of GDP spent on public health care. As the data show GDP per 
capita varies seven fold across the countries with centres included in this study. GDP 
per capita is not used as the measure of health care infrastructure in the subsequent 
analysis of resource use variation, as it is important to include price as an independent 
variable, and price is strongly correlated with GDP. So using GDP per capita as a 
measure of national health care infrastructure alongside measures of factor price could 
lead to problems of multicollinearity. Instead an alternative measure is used, the 
proportion of GDP spent on public health care. This measure is less likely to be 
correlated with factor prices. The percentage of GDP spent on health care also varied 
across the centres included in the study, with those centres in Eastern Europe 
generally spending a lower proportion of their national income on health care. As 
health care is a normal good those countries with higher GDP per capita generally 
tend to have higher levels of health care spending, this may lead to higher resource 
use and unit costs in these countries. 
Another alternative is to use the level of health care infrastructure that is available 
locally in each health care centre. This could be proxied by for example, the budget of 
each acute hospital. However, the budget facing the individual hospital would be 
directly correlated with both the resource use measure (the outcome variable) and the 
price variable in the subsequent regression equations analysing resource use variation. 
While the % of GDP spent on health care was chosen as the measure of health care 
infrastructure, the choice of this variable had implications for the selection of other 
variables for the regression analysis. In particular this variable was correlated with 
measures of the production processes in each centre such as access to neurologists or 
use of rehabilitation hospitals. Thus, when specifying the relationship between the 
various factors and resource use (Chapter 8) it will be necessary to choose carefully 
the variables for inclusion in the regression equations. 
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Table 6.13: Measures of national health infrastructure for each centre in the 
study 
Centre National GDP/head 
(1997/$PPP) 
National Public 
Health expenditure 
% share of GDP 
Portugal 13,840 5.2 
Spain 15,720 5.4 
Italy 20,060 5.7 
France 21,860 7.3 
Denmark 22,740 6.8 
Finland 1 18,980 5.3 
Finland 2 18,980 5.3 
Finland 3 18,980 5.3 
UK 20,520 5.6 
Poland 6,380 4.7 
Lithuania 1 4,510 5.1 
Lithuania 2 4,510 5.1 
Latvia 3,650 3.9 
Sources: OECD (2001), World Bank (2000) Cerniauskoas and Murauskiene (2002), Karaskevica and 
Tragakes (2001), Karski et at. (2002) 
6.5 Hypotheses generated about factors associated with resource 
use variation 
The data described in the previous section are now used to generate hypotheses about 
factors associated with resource use variation. OLS regression models are used with 
LOS as the dependent variable. The first model includes the patient factors described 
as independent variables, and describes their association with LOS. The second model 
includes dummy variables for each centre, apart from the Latvian centre which was 
taken as the reference centre. The third model considers whether there were still 
variations in LOS across the centres after adjusting for patient factors by including 
patient factors alongside dummy variables for each centre. 
Table 6.14 presents the regression coefficients from the three models. The data 
described by model one show that for example, patients who were independent pre- 
stroke stayed in hospital for on average six days less than patients who were 
dependent pre-stroke. Patients who were incontinent stayed in hospital for on average 
19 more days than patients who were continent pre-stroke. Patients for whom the 
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delay between onset of stroke and hospital admission was unknown, had a LOS that 
was on average 10 days longer than those who were admitted within 6 hours. 
The results from model 2 suggest that there are important variations in the mean LOS 
across the study centres ranging from the Spanish centre, where patients had a LOS 
on average 10 days shorter than in the Latvian centre, to the UK centre where the 
mean LOS was 21 days longer than in the Latvian centre. 
The estimates from model 3 show that including patient factors improved the fit of the 
model, the adjusted R2 increased from 0.10 in model 2 to 0.45 (likelihood ratio test, 
p<0.001). This suggests that including patient factors is important in explaining the 
overall variation in LOS. Allowing for differences in patient factors across the 
centres, also has a small impact on the relative LOS across the centres. Those centres 
with more complex than average case-mix had smaller coefficients after adjusting for 
patient factors. For example, the Finland 3 centre originally had the second highest 
LOS (model 2) relative to the Latvian centre, but as this centre had more complex 
case-mix, adjusting for patient factors meant that this centre's LOS after adjustment 
(model 3) fell compared to other centres, Similarly, the Italian centre had shorter 
relative LOS after adjusting for patient factors reflecting the relatively complex case- 
mix in this centre. In general though, while including patient factors reduced the 
variability in LOS left unexplained by the model, there was still wide variability in 
LOS across the centres concerned. 
The descriptive information previously provided on the way stroke care is produced in 
the different centres offers some insights into why there may be outstanding 
variability across the health care centres, after adjusting for differences in patient 
factors. Those centres that had higher LOS after adjusting for patient factors, were 
generally the centres with low levels of family or community support (e. g. UK and 
Denmark), and high levels of input available from neurologists and rehabilitation 
hospitals (Denmark, Finland 2 and 3). Those centres with low LOS were generally 
those where rehabilitation hospitals (Spain, Portugal, Latvia), and neurologists (Spain 
and Portugal) were not available, but there were relatively high levels of community 
(Spain) and family support (Latvia). Some of the individual centre rankings may not 
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follow from consideration of the factors listed. For example, the centres in Finland 1 
and Italy had low LOS despite having high levels of availability of neurologists and 
rehabilitation hospitals. Despite those exceptions, a general hypothesis to emerge 
from this data description is that the level of resource use variation between the 
centres may partly reflect differences in patient characteristics, but also differences in 
production processes and resource availability across the centres. Other variables such 
as the level of family support, the level of relative factor prices, the presence of 
patient copayments or a DRG system may also be important determinants of resource 
use. The literature review also suggested that these factors may be associated with 
resource use. These hypotheses are tested in subsequent chapters. 
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Table 6.14: Description of different factors association with LOS, coefficients 
(standard errors). 
Model one: Model two: Model three: 
Patient Centre dummy Centre dummys 
characteristics variables patient factors 
Constant term 22.35 (12.6)** 18.70(2.01)** 6.23(13.21)** 
Patient factors 
Age -0.13 (0.05)** -0.07(0.05) 
Independ. pre-stroke -5.97 (2.37)** -3.03(2.32) 
Living alone Reference 
Living with others -7.71 (1.50)** -4.84(1.56)** 
Living in nursing h -9.85 (4.60)** -8.50(4.44)** 
Incontinent 19.33 (1.56)** 18.77(1.49)** 
Paralysed 7.03 (1.55)** 8.59(1.51)** 
Ischaemic stroke Reference Reference 
Haemorrhagic stroke 5.37 (2.13)** 5.82(2.04)** 
Unknown stroke type -1.99 (1.72) -8.08(2.51)** 
Ons to admiss <6 hr Reference Reference 
Ons to admiss 6-24 hrs -0.57 (1.58) 0.64(1.52) 
Ons to admiss 1-7 days -0.93 (1.80) -0.71(1.73) Ons to admiss >7 days -1.12 (3.28) -0,77(3.17) Ons to admiss unk. 10.35 (2.64)** 7.98(2.60)** 
Centres 
UK 20.59(3.48)** 20.46(3.36)** 
Finland 3 18.68(3.79)** 14.38(3.14)** 
Denmark 18.38(2.53)** 16.23(2.64)** 
Finland 2 17.85(3.36)** 14.06(3.71)** 
Lithuania 2 7.83(2.68)** 14.21(3.20)** 
Lithuania 1 9.30(3.68)** 11.53(3.35)** 
Poland 6.81(3.23)** 5.36(2.95) 
France 5.52(3.11) 8.19(2.94)** 
Italy 1.47(3.07) -2.55(2.87) 
Finland 1 0.35(4.46) 0.29(4.15) 
Latvia Reference Reference 
Portugal -5.67(3.48) -6.11(3.19) Spain -10.82 (4.73) -12.28(4.33)** F statistic 27.68 13.33 21.6 
P value <0.001 <0.001 <0.001 
Adjusted R2 0.20 0.10 0.45 
** p<0.05, *p<0.10, Independ: independent, h: home, hrs: hours, unk: unknown 
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6.6 Discussion 
This chapter described the data collected in the empirical investigation on resource 
use and factors potentially associated with resource use variation in 13 different 
European health care settings. These data can be used in conjunction with the findings 
from the literature review, to pose hypotheses for why costs vary across health care 
settings (see Table 6.15). In general, for the factors operating at a patient level the 
hypotheses posed by the data were similar to those suggested by the literature. 
However, the data provided some specific hypotheses not suggested by the literature 
review. For example, the literature review suggested that older stroke patients were 
more dependant and therefore likely to consume more resources44. The data in this 
study suggest that those older patients who survive the stroke may use fewer 
resources than younger patients, although the effect was small and non-significant. 
The data described illustrate the variability across the centres in the patients' resource 
use. The regression models highlight variability in LOS across the study centres, after 
adjusting for differences in measured patient factors. This unexplained variability 
could reflect differences in the way these centres produce stroke care. In particular, 
there are differences amongst the centres in the levels of input from community 
support services and patients' carers (Table 6.15). The literature review also 
suggested that certain ways of managing stroke patients, in particular, neurologist led 
stroke care, were associated with higher resource use. These literature-based 
hypotheses were then used in conjunction with the differences described in the data, 
to pose hypotheses as to why LOS varied across the centres. For example, the reason 
why certain centres had higher resource use may be that their patients had better 
access to neurologists or to rehabilitation hospitals (Table 6.15). The general health 
economics literature suggested that the way hospitals are reimbursed, and level of 
patient copayments may also be associated with resource use (Chapter 4). The data 
described showed that these factors differed across the centres included in the study, 
and so the subsequent analyses consider these contextual factors when analysing 
resource use and cost variation (see Chapter 8). 
44 There is also a growing literature on the effect of proximity to death on resource use (see for example 
Seshaniani and Gray (2004). For these data the hypotheses posed by this literature are not considered as 
all the patients chosen for inclusion survived up to three months post stroke. 
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The literature review also suggested that the national level of health care spending 
could act as a proxy for the level of health care infrastructure in the country 
concerned. A hypothesis from the data is that those centres in countries with high 
levels of health care spending have better access to specialised personnel and use 
more advanced technology which leads to higher levels of resource use in these 
centres. 
The objective of this thesis is to examine why resource use and costs vary across 
international health care settings. The literature review suggested that when 
addressing this issue certain measurement issues arise (Table 6.15). To tackle these 
issues an empirical investigation has to use a database with certain features. In 
particular, sufficient patients and centres are required to identify reasons for resource 
use and cost variation. This database was judged to have sufficient patients and 
centres to allow for systematic reasons for variation to be identified at different levels. 
Resource use had to be collected in several health care settings using a consistent 
disaggregated methodology. Information on factors potentially associated with 
resource use and unit cost variation had to be available. In particular, suitable 
information on case-mix had to be collected at the level of the patient. The Biomed II 
stroke study had many of the features required for thoroughly examining the reasons 
for cost variation and was therefore judged an appropriate dataset for addressing the 
thesis' question. There are nevertheless, weaknesses in the dataset that should be 
recognised when interpreting the subsequent results. 
In this dataset approximately there were concerns about the potentially endogenous 
relationship between cost (or LOS) and survival. To address this an instrumental 
variable approach was considered, but this was rejected because it was not possible to 
identify an appropriate set of variables to use as the `instrument'. Instead, the main 
analysis in the thesis is limited to those patients surviving the stroke. This limits the 
generalisability of the resource use and cost analysis to those patients surviving up to 
three months post-stroke. 
In addition, information was not collected on health-related quality of life. Hence, it 
may not be realistic to assume that those centres that use fewer resources are 
producing stroke care in a more technically efficient way- indeed in some of the 
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centres using more resources those resources are being deployed to produce organised 
stroke care, which has been shown to improve outcomes. 
A societal perspective was not taken to cost measurement, it is therefore possible that 
those centres making less use of health and community service resources were using 
more inputs from patients and their carers. Some information was collected though on 
whether the patients' family helped the patient with activities of daily living, after 
their hospital discharge. Using these data, it was possible to compare at least family 
inputs across the centres, to see whether in some centres they seemed to be a 
substitute for hospital care. 
The Biomed II stroke study only included hospital-admitted stroke patients, and so 
excluded those patients managed in the community. There are differences in hospital 
admission rates following stroke across different European centres (Ricci et al. 1991; 
Tuomilehto et al. 1992), and this may partly explain why there are wide variations in 
the characteristics of the patients included in each centre. The implication for the 
methodological focus of this thesis-- to examine the reasons for cost variation across 
settings-- is that differences in patient characteristics across settings should be 
carefully considered, when attempting to understand reasons for cost variation. 
The resource use data were collected for 90 days post stroke. While the Biomed II 
stroke study originally intended to collect data on resource use, costs and outcomes 
for up to one year post stroke, this was only feasible for two of the study centres 
(Grieve et al. 2000). To assess resource use and cost variability across 13 centres, the 
data at three months post stroke were used. This underestimates the overall costs of 
stroke care especially in those centres where a sizeable minority of patients are still in 
hospital at 90 days post stroke. The data described in this chapter show that in the 
centres in UK, Denmark and Finland (2 and 3) a sizeable minority of patients were 
still in hospital at 90 days post stroke. As these centres were those with the highest 
overall LOS, by censoring the data at 90 days it is most likely that cost differences 
across the centres will be underestimated. 
The numbers of patients (n=1,298) and centres (n=13) included in the study will allow 
the relative importance of resource use and cost variation at either a patient or centre 
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level to be examined. However, there are insufficient centres in each country to allow 
cost variation across centres within a country to be explored. Only in Finland (three 
centres) and Lithuania (two centres) were there more than one centre per country. 
There was some variation amongst the Finnish centres, for example the LOS in the 
Finland 1 centre was approximately half that in the other two centres. However, for a 
thorough examination of reasons for resource use and cost variation within a country 
a dataset is required with many more centres and observations within a particular 
country. 
The data described also showed that within each centre, patients took various 
pathways through the system, varying in their use of hospitals within each centre, and 
wards within each hospital. It is recognised though, that there are insufficient data to 
model these different hierarchies within each centre when formally assessing the 
reasons for resource use and cost variation. The numbers of patients, centres, and 
countries covered by the database means that the subsequent analysis defines the 
hierarchy at two levels: patients clustered within centres. 
The literature review suggested that differences in technical, productive and scale 
efficiency across health care settings may be important in explaining cost variation. 
Previous studies have used data from many provider units to estimate efficiency levels 
across provider units (see Chapter 4). It is recognised that in this study there are 
insufficient centres to allow differences in technical and productive efficiency to be 
estimated. 
6.7 Conclusions 
In conclusion, the findings from the literature review provided the conceptual 
framework for the empirical investigation. The case study chosen for identifying 
reasons for cost variation across settings, was the Biomed II stroke study. It was 
possible to extend this study to consider reasons for cost variation across settings. In 
this chapter, the methodology and the resource use data for the empirical investigation 
are presented. These data show that there are wide variations in resource use 
following stroke, for example in hospital LOS, across the study centres. The 
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information collected on patient and contextual factors are used to generate 
hypotheses for why resource use varies across health care settings. The next chapter 
considers the measurement and analysis of unit costs and total costs. 
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Chapter 7: Measurement and analysis of unit 
cost differences across the centres 
7.0 Introduction 
The previous chapter described the methodology used to collect resource use data and 
provided an overview of the data collected for the thesis. The literature review 
highlighted that to understand variation in unit costs amongst settings it is important 
to disaggregate unit costs into resource inputs and factor prices (Chapter 2). The 
review suggested that differences in relative factor prices across countries might 
explain variation in the combination of factor inputs (e. g. relative levels of input from 
doctors or nurses) and the resources used (e. g. LOS) to produce health care (Chapter 
4). The empirical investigation therefore takes a disaggregated approach to unit 
costing. This chapter presents the methodologies used to measure unit costs. Price and 
volume indices are constructed to explore reasons for differences in unit costs across 
the study centres, and to consider the implications of these variations for differences 
in total costs per patient. The total costs per patient reported for each centre may also 
depend on the method used to convert local currencies into a common currency. This 
chapter highlights the methodological advantages and problems associated with 
different currency conversion factors. 
This chapter is split into six sections. The first section summarises the methodological 
issues involved in constructing price and volume indices, the second section discusses 
the suitability of different currency conversion factors, and the third section describes 
the methodology used to collect and calculate unit costs and total costs. The fourth 
section details the methods used to construct price and volume indices and a 
'technology specific' currency conversion factor. The fifth section presents the 
results: describing the unit costs, the price and volume indices, and the total costs. The 
final section discusses why the differences in price levels across the centres concerned 
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may exist and considers the implications for understanding cost variation across 
health care settings. 
7.1 Volume ratios, price and volume indices 
Volume ratios and price and volume indices can all be used to explore why 
differences in unit costs maybe observed across health care settings. 
7.11 Volume ratios 
A starting point for considering why unit costs may differ across health care settings 
is to compare the ratio of factor inputs used to produce a given level of output 
(Barnum and Kutzin 1993). For example, Hutton (2001) compares the number of 
antenatal care visits per health care professional across health care centres, to try and 
identify those centres that are more technically efficient. However, this static 
approach does not consider that firms in different settings, particularly across 
countries, may face different factor prices and this may be reflected in the chosen 
factor mix. 
7.12 Price indices 
Price indices have been widely used to compare prices across different time periods 
(see for example Boskin et al 1986), but their use in comparing prices across different 
settings is less well developed. This chapter examines the use of price bilateral price 
indices for comparing factor prices across countries. These indices compare the prices 
in each country to those in a reference country. A key issue to consider when 
developing a price index is how to weight the prices of the different goods or factor 
inputs (Bernt 2000). Studies in health economics that have used price indices have 
been criticised for ignoring the issue of weighting, and simply summing up the 
relative price levels of different good and services: i. e. implicitly giving each 
component equal weighting (US General Accounting Office 1992). Danzon and Chao 
(2000) used price indices to compare the price of pharmaceuticals across countries 
and found that previous conclusions that drugs' prices in the US were higher than 
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elsewhere, were invalid as they were based on biased and unweighted indices. Their 
work illustrates the importance of using appropriate volume weights and taking a 
representative sample of product prices for the sector concerned (Danzon and Chao 
2000, Danzon and Kim 1998). 
Laspeyres and Paasche price indices both use volumes to weight the price of goods or 
factor inputs (Call and Holahan 1983). A Laspeyres price index (Lp11(; e) can compare 
the factor prices in a comparator country to those in a reference country. Each set of 
factor prices is weighted by the volume of that factor input used in the reference 
country. A Laspeyres price index is therefore defined as in equation 1: 
m 
7, P: 9, 
Lprice_ Jm (1) 
PA i=1 
Where pi is the price in the reference country, p2 the price in the comparator country, 
ql the volumes in the reference country, q2 the volumes in the comparator country, all 
for factor inputs i.... m. 
A problem with the Laspeyres price index is that it ignores any substitution effects; 
the comparator country is assumed to use the same level of factor inputs as the 
reference country irrespective of any differences in relative factor prices. Instead, a 
Paasche index (Ppijce) can be used, which takes the volume of factor inputs used in the 
comparator country (q2) to weight the factor prices in both the reference and 
comparator countries (equation 2). 
m 
J= 1P: 
gs 
Ppricc_-- 
m 
(2) 
i p1q: 
For cross-country comparisons, the use of the Paasche index assumes that faced with 
the factor prices in the comparator country, the reference country would choose the 
comparator country's volume of inputs, that is the factor mix chosen would adjust to 
reflect the relative factor price. In reality, variables other than price may determine the 
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factor mix (see Chapter 4), so that even if the price of a factor input was relatively 
high in country A compared to country B, this would not necessarily lead to less use 
of the factor input. 
7.13 The Gerschenkron effect and the Fisher Price Index 
As Laspeyres and Paasche price indices use different volumes to weight price 
differences across countries, they may produce different results. The discrepancy 
between Laspeyres and Paasche price indices has been termed the Gerschenkron 
effect (Gerschenkron 1951), and is often summarised by the ratio of the Paasche to 
the Laspeyres price indices (Van Ark et al. 1999). Economic theory suggests that 
unless the elasticity of substitution is perfectly inelastic there will be correlation 
between different factor prices and different factor mixes, and that the Paasche/ 
Laspeyres ratio will therefore be less than one. This hypothesis is examined for each 
centre included in the empirical investigation by initially constructing both Laspeyres 
and Paasche indices and the Paasche/Laspeyres ratio. 
A common approach to price index construction is to regard estimates from the 
Laspeyres and Paasche indices as boundaries for the ideal index (Hill 1999). The 
Fisher index is then constructed by taking the geometric mean of the Laspeyres and 
Paasche price indices (Fisher 1922). Apart from taking the middle ground between 
these two extreme positions, the Fisher price index satisfies certain ideal properties 
defined by the economic theory of index numbers (Diewert 1999). In light of its 
desirable properties, the Fisher price index has been recommended for comparing 
prices between countries (Diewert 1999), and is used in this investigation to compare 
the relative prices across the centres concerned. The Fisher price indices are also used 
in the subsequent empirical investigation that assesses the effects of differences in 
factor price on resource use across the centres (Chapter eight). 
7.14 Volume indices 
The same indices can be used to compare the volume of factor inputs across different 
countries, weighting relative volumes by factor prices. So a Laspeyres volume index 
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(Lvolume) uses factor prices in the reference country as weights (equation 3), whereas 
the Paasche index (Pot. e) uses the comparator country's factor prices as weights 
(equation 4). The Fisher volume index takes the geometric mean of the two. 
mm 
1I pº4: lI P: q: Lvolume- 
mm 
(3) Pvolume (4) 
Pº R'º P: qº 
7.2 Conversion of factor prices to a common currency 
To compare costs across countries it is necessary to convert local currencies into a 
common currency (e. g. US dollars). A potentially important question this raises is: 
which method of currency conversion is most appropriate? One alternative would be 
to convert local currencies into US dollars using official exchange rates (OER). 
However, the problem with using OER is that they are only based on the exchange of 
traded goods and do not reflect the relative price of non-traded goods such as health 
care. OER do not reflect differences in overall purchasing power between countries 
(Kanavos and Mossialos 1999). They may partly reflect macroeconomic deficits or 
surpluses in the economies concerned. Currency speculation may also lead to a 
dramatic increase or decrease in a country's OERs. 
Purchasing Power Parity (PPP) indices have been developed to try to overcome these 
problems. The purpose of using a PPP index is to try to eliminate price differences 
between countries, and to permit international comparisons of the volume of services 
consumed or produced across countries. For example, cross-national comparisons of 
output are often conducted using PPPs to convert local measures of Gross Domestic 
Product (GDP), into a common currency, eliminating differences in price levels 
between the countries concerned. These GDP PPPs are calculated using prices of a 
`basket' of goods and services, chosen to represent overall consumption or production 
in the countries concerned. The price of this basket of goods is compared between the 
comparison country, say the UK, and the reference country (say the United States). So 
for example, if the basket of goods is worth $1 in the United States, the PPP index 
calculates the price in local currency of buying the same basket of goods and services 
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in the UK (say £0.65). The ratio of these prices 0.65/1=0.65 ($ GDP PPP) provides a 
measure of purchasing power in the UK compared to the US. This conversion factor 
can then be used to translate measures of output across the countries concerned 
adjusting for general cross-national differences in the prices of goods and services. In 
the empirical investigation for this thesis it is necessary to adjust for differences in 
factor prices. However, certain issues arise surrounding the choice of conversion 
factor, these are discussed below. 
7.21 Issues in the choice of currency conversion factor. 
Commonly used measures of PPP are the GDP PPPs (Schreyer and Koechlin 2002). 
These are based on a basket of goods and services that are representative of 
consumption across the whole economy. These measures of PPP have been used to 
compare national output and productivity across countries (OECD 1999). However, 
when comparing costs in a particular sector or industry across countries the GDP PPP 
index may be less appropriate; the basket of goods and services is not representative 
of consumption (or production) in a specific sector. In particular, the use of a general 
basket of goods and services may not be suitable in areas such as health care that are 
dominated by non-tradeable goods and services. Medical care PPPs have been 
constructed that attempt to adjust for differences in the relative prices of medical care 
across countries, and these were available for most of the countries covered by the 
empirical investigation4S. However, medical care PPPs have been seriously criticised 
for their heavy bias towards pharmaceutical services (Danzon and Chao 2000, 
Kanavos and Mossialos 1999) that makes them unlikely to be representative of health 
services more generally. Danzon and Chao (2000) also pointed out that the 
pharmaceutical component of the medical care PPP is based on small, 
unrepresentative samples for each country, and does not use volume weights at the 
product level to reflect the relative importance of different products. Kanavos and 
Mossialos (1999) cautioned against the use of medical care PPPs for making 
international comparisons and multinational economic evaluations have usually relied 
on GDP PPP indices to report costs across different countries, despite their limitations 
(see for example Willke et al. 1998). 
Medical care PPPs were not available for Latvia and Lithuania. 
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Another alternative is to construct technology specific PPPs using data from the 
study. This approach has been taken by other studies making international cost 
comparisons (Wordsworth and Ludbrook 2005, Hutton 2001). This approach uses a 
`basket' of factor inputs that are deployed in producing the output concerned. The 
factor prices for each of these inputs are then estimated for each country compared to 
those for a reference country. These price differentials are then weighted according to 
input volumes. The measure of volume used should not be that of either the reference 
or the comparison country, but ideally an average of the two (i. e. a Fisher price 
index). The resultant price index provides a `technology specific' measure of 
purchasing power in the comparison country compared to the reference country. 
Using this specific measure of PPP to convert unit costs to a common currency 
provides an international cost comparison adjusting for differences in the price of the 
specific inputs used to produce the output concerned. 
Any of these methods of currency conversion assumes that the local prices used for 
the basket of goods and services reflect opportunity costs. If some of the factor inputs 
in the `basket' of goods are not traded in a perfectly competitive market, prices may 
not be available and even if they are, they may not reflect opportunity cost. This is a 
potential problem whichever currency conversion factor is used. 
Subject to this caveat, GDP PPPs have the potential to represent general opportunity 
costs in the economy as a whole, as the `basket' of goods and services is taken to be 
representative of consumption or production across the whole economy. Converting 
costs using GDP PPPs can therefore provide a measure of the opportunity costs in 
each economy after adjusting for general price differences between countries. Using 
GDP PPPs to convert costs into a common currency therefore appears to be consistent 
with taking a broad, societal perspective to economic evaluation that emphasises the 
measurement of costs for a broad range of providers with resource use valued using 
general measures of opportunity cost (see Chapter 2). 
A more specific index, whether it is for medical or stroke care, can only provide a 
measure of purchasing power for the particular sector in question. Using this 
conversion factor to convert costs to a common currency is more likely to adjust for 
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cross-national price differences in the particular sector concerned, and isolate the 
effect of volume differences. However, the trade-off is that the costs observed will 
reflect a more narrow definition of opportunity cost, one that only considers the value 
foregone for the sector or technology in question. 
The literature review highlighted the need to maintain consistency with economic 
theory when estimating costs across countries (Chapter 2), and so the main analysis in 
this thesis uses GDP PPPs to compare costs (Chapter 8). However, it is recognised 
that using GDP PPPs means that there may be outstanding cross-national differences 
in the price of those inputs used to produce stroke care. To see the impact this has on 
the results, a stroke care PPP is also calculated, based on a subsample of the factor 
inputs used to produce stroke services in each centre. To examine how sensitive the 
cost analysis is to the choice of conversion factor, the cost analysis (both in this 
chapter and chapter 8) is repeated with costs converted using the stroke specific PPP 
index. 
7.22 Conversion factors for traded versus non-traded goods 
A final issue is whether different conversion factors should be applied to traded and 
non-traded goods. In theory, if OER are used for traded goods then prices should be 
equalised across countries. It therefore seems appropriate to use OER to convert the 
costs of traded goods, and just use PPPs (whether for stroke care or GDP) to convert 
the costs of non-traded goods. Indeed this is the approach that has been recommended 
by the WHO (Tan-Torres Edejar et al. 2003). However, both the World Bank and the 
OECD include traded and non-traded goods in the basket of goods used to calculate 
GDP PPPs (World Bank 2000, OECD 2000). It is therefore inconsistent to use these 
GDP PPPs just to convert the prices of non-traded goods. The empirical investigation 
uses GDP PPPs for all factor inputs in the base case analysis. By contrast, the stroke 
care PPPs are just calculated for non-traded goods, so where the cost analysis uses 
this conversion factor, OER are used to convert the prices of traded factor inputs. For 
completeness, a final cost comparison uses GDP PPPs for non-traded inputs and 
OERs for traded inputs (for further details see section 7.57). 
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7.3 Methodology used in the empirical investigation for measuring 
unit costs 
7.31 Overview 
Unit costs were collected for each hospital and community service provider in each 
centre. A major decision regarding the costing methodology was whether to collect 
unit costs at an aggregated or disaggregated level. For example, the study could have 
collected unit costs at an aggregated level by collecting information on the average 
cost per bed-day or per diem cost, and multiplying this through by the length of stay 
to give the overall cost of hospitalisation. However, the literature review suggested 
that the ideal unit costs would be those that approximated opportunity cost in each 
centre and used a consistent methodology across the study centres. Using aggregated 
unit costs has two main problems. It relies on the methods of cost allocation used by 
the finance departments in each centre. Using this methodology would have meant 
cost differences across the centres relate simply to differences in the way unit costs 
are allocated. In addition, the estimation of opportunity costs requires that the cost 
chosen represents the value of the physical resource in its next best use (Palmer and 
Raftery 1999). Using an aggregated unit cost does not reveal the physical resource 
inputs used, and makes it very difficult to assess whether the unit cost does represent 
opportunity cost. 
7.32 Unit costs of labour inputs 
The majority of the costs of stroke care come from the labour inputs used during 
hospitalisation (Forbes and Dennis 1995) so particular care was taken to approximate 
the opportunity costs of these inputs. For labour inputs, the study collected 
disaggregated unit costs using a common methodology in each centre. The input from 
each grade of health care professional involved in producing stroke care in each 
centre was estimated. A semi-structured questionnaire was used on site visits to each 
centre, and members of staff at each hospital were asked about their level of input 
(direct and indirect) for each ward on which stroke patients were managed (see 
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appendix 1)46. The total annual staff time for each grade of doctor, nurse and therapist 
on each ward was recorded. To provide an average level of input per occupied bed- 
day the total annual input for each grade of staff was then divided by the total annual 
number of occupied bed-days for the ward concerned. This average measure of input 
(in minutes per occupied bed-day), provides a useful measure for comparing resource 
intensity across the centres. The measures of labour inputs are used in the construction 
of price and volume indices to help interpret unit cost differences across the centres 
(see section 7.41). 
The average input for each grade of staff is also used to estimate the labour costs per 
day. These labour inputs would ideally be valued by a measure of factor price that 
approximates opportunity costs. A general difficulty with estimating opportunity costs 
is that they require the health care firm to choose the combination of factor inputs that 
minimises costs in the long-run. However, as the evidence in Chapter 4 revealed, 
health care firms do not tend to behave in a way consistent with long-run cost- 
minimisation. The health care firms may regard the costs of adjusting certain factor as 
too high or there may be a lack of incentive for decision-makers to take the long-run 
perspective. At best, health care firms' behaviour is consistent with short-run cost- 
minimisation. Hence, the factor inputs and factor prices observed may not be 
consistent with productive efficiency. 
A further problem in these centres was that the labour markets for health care 
professionals were not perfectly competitive and prices were not available for labour 
inputs. To approximate the opportunity costs, the costs of labour input were derived 
by dividing the total annual cost to the hospital of employing the relevant mid-grade 
health professional47, by the total number of hours worked, to give an average cost per 
hour48. Any additional payments to health care professionals from `under the counter' 
payments from patients or private work were excluded. The average cost per occupied 
bed-day was calculated for each grade of health care professional by multiplying their 
factor input (in hours per occupied bed-day) by their factor price (cost per hour). 
46 Care was taken to try and ensure a consistent definition of each grade of staff across the centres 
based on levels of training and years of experience. 47 The costs included the salary, overtime, and employers' National Insurance contributions. 48 These measure of factor price are used in the construction of the price and volume indices (section 
7.41). 
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The average labour cost per occupied bed-day was estimated by aggregating the 
average costs per occupied bed-day across all health care professionals. 
7.33 Investigation costs 
Apart from labour costs, the hospital costs included the costs of investigations, 
consumables, drugs and overheads. Information on the use of investigations was 
collected for each patient included in the database. The unit cost of each investigation 
was taken from the finance departments in each hospital and was established during 
interviews at each centre. These unit costs were based on the price charged to another 
public sector provider. This was felt to be the closest proxy to opportunity cost, as it 
did not include a profit to the organisation, and covered all appropriate cost 
components: staff time, reagent costs and overheads. During the interviews, it was 
important to establish that the same cost components were included in each centre. 
7.34 Drugs, consumables and overheads 
Individual patient data were not collected on the use of drugs, consumables or 
overheads. These are generally small cost items for stroke patients (Forbes and 
Dennis 1995). None of the centres included in the study provided high cost stroke 
drugs such as thrombolytics either routinely or as part of randomised controlled trials. 
The costs of drugs, consumables and overheads were therefore estimated as average 
costs per occupied bed-day. These costs per occupied bed-day were calculated by 
dividing the total annual inpatient expenditure for each category in each department 
by the total number of occupied bed-days. These costs were added to the staffing 
costs to give a total cost per occupied bed-day (or unit cost) for the relevant hospital 
wards in each centre. 
7.35 Unit Costs post hospital discharge 
To establish the unit costs associated with outpatient visits to clinicians and use of 
rehabilitation services, interviews were undertaken with a range of providers at each 
centre to again establish the staffing input used in providing care. These inputs were 
combined with information on the average cost of employing each member of staff to 
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give average staffing costs. Information on consumables, drugs and overheads was 
taken from the finance department in each centre and added to staffing costs to 
provide an average cost for each contact. For residential and nursing home care it was 
not possible to interview the providers concerned to estimate detailed costs. For these 
services, the charge (cost per day) to the National Health Service in each centre was 
used. Where there were several different service providers, the median cost of the 
item concerned was taken as the unit cost. 
7.36 Calculating total costs per patient 
For each patient total costs were calculated over the observation period of three 
months post-stroke. Investigation costs per patient were calculated by multiplying 
each patient's use of investigations by the unit cost. Other hospitalisation costs per 
patient (labour costs, consumables and overheads) were calculated by multiplying the 
length of stay on each ward by the appropriate cost per occupied bed-day, and 
summing these costs across each ward and hospital. These costs were added to the 
total cost of investigations, to give a total hospitalisation cost per patient. Total three 
months costs per patient were the sum of the hospitalisation, outpatient, community 
and institutional care costs. All costs were adjusted to a 1998 price base using price 
indices and converted into US dollars initially using GDP PPP indices (OECD 2000, 
World Bank 2000). 
7.4 Constructing the price and volume indices and currency 
conversion factors 
7.41 Price and volume indices 
The inputs used for the construction of the price indices were those deployed on the 
ward where most bed-days were used by the stroke patients in this study. This 
provided a consistent way of comparing factor inputs and factor prices across the 
study centres. To construct price indices, disaggregated data were required on factor 
inputs and factor prices, and these were available for labour costs, overall the main 
component of costs per occupied bed-day (see Table 7.1). 
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Within labour costs, nine factor inputs were used to construct the index, doctors' time 
(chief doctor, senior level doctor, mid-grade doctor, junior doctor), nurses' time (chief 
nurse, qualified nurse, unqualified nurse), therapists time (physiotherapist, OT, speech 
therapist). The French centre was chosen as the reference centre, as this centre has the 
median level of unit costs. Also, for the French centre each of the factor inputs 
described was used to produce stroke care. For most of the other centres at least one 
factor input was not used, and for these centres, the overall index was based only on 
the factor inputs present. The prices of each factor input were taken as the cost per 
hour ($ GDP PPP) of employing each grade of staff (see section 7.32). The Laspeyres, 
Paasche and Fisher price and volume indices were calculated for each centre, 
compared to the French centre. 
7.42 Constructing the stroke care PPP index for currency conversion and using 
this measure 
The Laspeyres, Paasche and Fisher indices were constructed as above using the same 
labour inputs except that prices were kept in each centre's local currency. The 
reference centre was again the French centre, where the price of labour inputs was 
reported in French francs. The resulting price indices gave the number of units of 
local currency required to buy one francs worth of factor inputs in the reference 
centre- the stroke care PPP. This provided a measure of purchasing power for each 
centre compared to the French centre. To allow comparison with GDP PPPs which 
were reported in US dollars, each of the stroke care PPPs were converted from French 
francs into US dollars using 1998 OER (5 francs to 1$US ) (OECD 2000). 
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7.5 Results 
The results section initially describes the unit costs for the main ward in each centre 
where stroke patients were managed (a more complete set of unit costs is provided in 
appendix 2). The following section uses price and volume indices to analyse why 
differences in unit costs are observed across the centres. The use of the indices is then 
extended to present the stroke care specific PPPs. Finally, the total costs per patient in 
each centre are described, using different conversion factors. 
7.51 Unit costs of hospital care 
The unit costs for the main resource use items are presented in Table 7.1, at the level 
of aggregation traditionally used in economic evaluations (see also appendix 2). The 
results show that there were wide variations in unit costs across the centres even after 
using the GDP PPP conversion factor to adjust for price differences. The average total 
cost per occupied bed-day ranged from $23 in the Latvian centre to $333 in the Italian 
centre. In particular, there were wide variations in the average costs per occupied bed- 
day of labour inputs, these ranged from $3 (Latvia) to $256 (Italy). Across all the 
centres, the labour inputs were the highest cost component, and constituted 57% of 
the overall cost per occupied bed-day. 
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Table 7.1: Unit costs: Average costs per occupied bed-day for each category of 
inputs (% of average total cost per occupied bed-day) [$ GDP PPPJ 
Centre Labour inputs Consumables Overheads total 
Latvia 3 12% 8 34% 12 52% 23 
Lithuania 2 10 21% 20 41% 18 37% 48 
Lithuania 1 10 20% 21 42% 19 38% 50 
Poland 39 35% 25 23% 47 42% 112 
Finland 3 80 72% 7 6% 25 22% 112 
Finland 1 83 53% 29 18% 45 29% 157 
France 128 74% 17 10% 28 16% 172 
UK 138 71% 17 9% 40 20% 194 
Finland 2 145 64% 22 10% 60 26% 227 
Denmark 130 56% 27 11% 77 33% 234 
Spain 83 35% 54 22% 102 43% 239 
Portugal 133 50% 53 20% 78 30% 263 
Italy 256 77% 15 4% 62 19% 333 
ALL 95 57% 24 15% 57 28% 167 
Further insights are provided when the unit costs are disaggregated further, into factor 
inputs and factor prices. An example of this is given for the level of input from a 
recently qualified doctor. The results suggested that while there was some variation in 
the use of this particular factor input there were particularly wide variations in factor 
price across the centres considered (Table 7.2). The level of input and associated 
factor price are compared below: 
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Table 7.2: Factor input and factor price: doctors' time49 
Factor input Factor Price 
(minutes/ bed-day) (cost per hour $ GDP PPP) 
Latvia 18 2 
Lithuania 2 13 4 
Lithuania 1 19 4 
Poland 28 10 
Finland 3 10 40 
Finland 1 18 19 
France 15 29 
UK 22 18 
Finland 2 NA NA 
Denmark 20 29 
Spain 20 31 
Portugal 15 33 
Italy 23 30 
NA: not applicable as this input was not used in Finland 2 centre. 
7.52 Price Indices 
Price indices provide a more comprehensive comparison of factor prices across the 
centres. The results showed that there were wide variations in the price of labour 
inputs between the Western and Eastern European centres (Table 7.3). This was after 
converting prices into US dollars using GDP PPPs which suggested that GDP PPPs 
did not adjust for differences in these relative prices between the Western and Eastern 
European countries. The results showed that there were wide variations in the price of 
labour inputs across these centres whichever measure of volume weighting was used. 
49 For a mid-grade doctor, that is someone who has the experience and training required for them to 
qualify as a specialist (e. g. neurologist) in the country concerned, but who does not have managerial 
responsibilities. 
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Within the Western European centres there were relatively small differences in factor 
prices, after PPP adjustment, and again the choice of index was not important. The 
differences in relative prices between the three Finnish centres were as wide as 
between the other Western European centres. 
Table 7.3: Price indices (S GDP PPP) for labour inputs in each centre compared 
to the French centre. 
Centre Laspeyres Rank Paasche Rank Fisher Rank 
Price index Price index Price index 
Latvia 0.07 1 0.07 1 0.07 1 
Lithuania 2 0.17 3 0.16 3 0.16 3 
Lithuania 1 0.15 2 0.14 2 0.15 2 
Poland 0.39 4 0.38 4 0.38 4 
Finland 3 1.18 12 1.21 12= 1.18 12 
Finland 1 0.74 5 0.77 5 0.75 5 
France 1.00 9 1.00 9= 1.00 8= 
UK 0.86 6 0.88 6 0.87 6 
Finland 2 1.18 13 1.21 12= 1.19 13 
Denmark 1.01 10 0.99 8 1.00 8= 
Spain 0.87 7 0.89 7 0.88 7 
Portugal 1.00 8 1.00 9= 1.00 8= 
Italy 1.08 11 1.08 11 1.08 11 
7.53 Gerschenkron effect 
The Paasche/Laspeyres ratio is less than one when the Gerschenkron effect exists i. e. 
there is input substitution according to factor price differences. In the majority of the 
centres, the Paasche/Laspeyres ratio was one or more, suggesting that the 
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Gerschenkron effect was not detected. Of the four centres where the Gerschenkron 
effect was detected, three were in Eastern Europe (Table 7.4). 
Table 7.4: Paasche/Laspeyres ratio for price of labour inputs in each centre 
Centre Paasche/Laspeyres ratio 
Latvia 1.00 
Lithuania 2 0.98 
Lithuania 1 0.93 
Poland 0.98 
Finland 3 1.04 
Finland 1 1.05 
France 1.00 
UK 1.01 
Finland 2 1.03 
Denmark 0.97 
Spain 1.02 
Portugal 1.00 
Italy 1.00 
7.54 Volume indices 
The volume indices showed that there was generally less variation across the centres 
in factor input use compared to factor price, in particular between the Western and 
Eastern European centres (Table 7.5). There was greater variation across the Western 
European centres in factor use compared to factor price. In particular, the Italian 
centre had a much higher level of labour input than the other centres. 
209 
Table 7.5: Volume indices for each centre's labour inputs compared to those In 
the French centre. 
Laspeyres 
volume 
index 
Rank Paasche 
volume 
index 
Rank Fisher 
volume 
index 
Rank 
Latvia 0.39 1 0.39 1 0.39 1 
Lithuania 2 0.78 4 0.73 4 0.75 4 
Lithuania 1 0.59 2 0.58 2 0.59 2 
Finland 3 0.67 3 0.70 3 0.69 3 
Poland 1.19 9= 1.17 9 1.18 9 
Finland 1 1.37 12 1.44 12 1.41 12 
France 1.00 6 1.00 6 1.00 6 
UK 1.22 11 1.24 11 1.23 11 
Finland 2 1.19 9= 1.22 10 1.21 10 
Denmark 1.15 8 1.12 8 1.14 8 
Spain 0.90 5 0.91 5 0.91 5 
Portugal 1.13 7 1.13 7 1.13 7 
Italy 3.11 13 3.11 13 3.11 13 
7.55 Comparison of conversion factors 
Table 7.6 presents the units of local currency required to buy a dollars worth of goods 
and services for each of the conversion factors discussed. The stroke care PPP is 
presented for the Fisher price index. The GDP PPP index showed that that far fewer 
units of currency were required to buy one dollars worth of good and services in the 
Eastern European countries, than suggested by the OER (Table 7.6). Compared to the 
GDP PPP, the stroke care PPPs were appreciably lower in the Eastern European 
centres. The prices of the labour inputs used in producing stroke care were relatively 
low compared to general prices in these economies. The most extreme example was in 
210 
the Latvian centre where the stroke care PPP was 1/15th that of the GDP PPP. The 
divergence between the OER, GDP PPP and stroke care PPP indices was much 
smaller for the Western European countries. 
Table 7.6: Units of each centre's local currency required to buy a US dollars 
worth of goods and services, for different conversion factors (all 1998 price base). 
OER ($) GDP PPP ($) Stroke care PPP ($) 
Latvia 0.50 0.30 0.02 
Lithuania 2 4.00 1.40 0.19 
Lithuania 1 4.00 1.40 0.17 
Poland 2.40 1.40 0.44 
Finland 3 5.37 5.89 5.76 
Finland 1 5.37 5.89 3.68 
France 5.00 6.10 5.00 
UK 0.60 0.60 0.43 
Finland 2 5.37 5.89 5.75 
Denmark 5.60 8.30 6.80 
Spain 124.70 117.90 85.12 
Portugal 151.00 119.40 103.62 
Italy 1628 1515 1346 
Sources: OECD (2000), World Bank (2000) The French centre was the reference centre for each 
conversion factor. 
7.56 Total costs per patient (GDP PPP) 
The mean total 3-month costs per patient, converted using GDP PPP are reported in 
Table 7.7. The mean cost per patient was $5,340. However, this ranged from $550 in 
the Latvian centre to $9,600 in the Danish centre. The Danish centre had both high 
factor prices (this chapter) and resource use (chapter six). Over all the centres, the 
majority of the costs were inpatient costs, however, in certain centres community care 
costs (France) and institutional care costs (Finland 3) were important, and appeared to 
substitute for hospital services. The reasons for variation in total costs across the 
centres are explored in chapter 8. 
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Table 7.7: Mean Total 3-month costs per patient (% of total costs) [$/PPP] 
(n=1298) 
Country Inpatient Outpatient Community Institutional Total costs 
costs costs care costs care costs 
Latvia 456 1 37 56 550 
(83) (0) (7) (10) 
Lithuania 2 1,357 10 24 47 1,438 
(94) (1) (2) (3) 
Lithuania 1 1,623 9 11 16 1,659 
(98) (1) (1) (1) 
Poland 3,283 31 700 58 4,072 
(81) (1) (17) (1) 
Finland 3 4,711 301 371 1132 6,515 
(72) (5) (6) (17) 
Finland 1 2,745 858 488 64 4,155 
(66) (21) (12) (2) 
France 4,681 119 1,052 352 6,204 
(75) (2) (17) (6) 
UK 8,672 294 223 122 9,311 
(93) (3) (2) (1) 
Finland 2 6,975 1,365 229 468 9,036 
(77) (15) (3) (5) 
Denmark 8,881 307 387 24 9,600 
(93) (3) (4) (0) 
Spain 1,965 245 326 27 2,805 
(70) (9) (12) (10) 
Portugal 3,893 1,451 44 17 5,405 
(72) (27) (1) (0) 
Italy 5,153 164 171 681 6,170 
(84) (3) (3) (11) 
ALL 4,526 323 298 203 5,340 
(85) (6) (6) (4) 
F statistic 40.17 26.70 13.98 8.76 50.32 
P value <0.001 <0.001 <0.001 <0.001 <0.001 
F statistic and p value are calculated based on OLS regression analyses with costs as the independent 
variables and dummy variables for each centre as independent variables. F statistic is calculated with 
13 parameters and 1285 degrees of freedom. 
7.57 Comparing total costs per patient in US dollars using different conversion 
factors 
In the base case analysis the total costs of stroke care were converted into US dollars 
using GDP PPPs. The sensitivity analysis then examined the impact of using different 
conversion factors. For resource inputs defined as tradeable, OER were used to 
convert costs into a local currency. For non-tradeable inputs GDP PPPs and then 
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stroke specific PPPs were used to convert costs into US dollarsSO. Ordinary least 
squares (OLS) regression analyses were used with total costs per patient as the 
dependent variables, and dummy variables for each centre as the independent 
variable, to compare each measure of total costs across the centres. The corresponding 
F statistics, p values and adjusted R2 are reported for each regression analysis. 
The impact of using each of these three approaches on the mean three month stroke 
costs for all the cases in the dataset is shown below (Table 7.8). The results show that 
using OERs to convert the costs of the tradeable factor inputs led to a greater 
divergence in the overall costs of care across the centres, compared to using the GDP 
PPP factor for all inputs (Table 7.8). However, using stroke specific PPPs led to a 
smaller divergence in costs between the Eastern and Western European centres. For 
example, the mean cost in the Polish centre based on the stroke specific PPP was 
$5,000, which was only just below the average across all the centres included in the 
study. The F statistic was lowest for the comparison of total costs across the centres 
that used the stroke specific PPP. This illustrates that more of the variability in total 
costs was explained at the centre level when this conversion factor was used, as 
differences in factor prices were reduced. 
Although using the stroke care PPP index led to smaller cost differences between the 
centres, residual differences in cost remain. The adjusted P. 2 was 0.28, which indicates 
the level of cost variation that was not explained by the dummy variables for centresr 
The following chapter considers why this outstanding cost variation exists. 
so Consumables and overheads were defined as tradeable and staff inputs as non-tradeable, though in 
reality some staff inputs may be tradeable between countries, and some non-staff inputs may be 
produced and consumed locally. 
In fact, the level of unexplained variation is higher when using the model that reduces overall cost 
differences between the centres. This apparently counter intuitive result is due to the level of 
unexplained variation that exists at an individual level, which increases when this conversion factor is 
used. This is illustrated by the higher standard deviations that surround the centre-level means when 
this conversion factor is used. 
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Table 7.8: Mean total cost (sd) in US$ for each case included in the dataset 
(n=1,298) for each conversion factor used. 
Centre Tradeables: GDP PPP Tradeables: OER Tradeables: OER 
Non-tradeables: GDP PPP Non-tradeables: Non-tradeables: 
Base case GDP PPP stroke 
PPP 
Latvia 550(370) 400(215) 1,374(955) 
Lithuania 2 1,438(919) 800(515) 3,134(3,401) 
Lithuania 1 1,659(711) 918(424) 3,973(2,325) 
Poland 4,072(2,303) 2,948(1,673) 6,017(3,552) 
Finland 3 6,515(3,215) 6,716(3,317) 6,833(3,366) 
Finland 1 4,155(2,565) 4,370(2,687) 5,589(3,535) 
France 6,204(5,015) 6661(5,333) 7,499(6,015) 
UK 9,311(7,983) 9,310(7,983) 11,841(10,213) 
Finland 2 9,036(5,815) 9,344(6,026) 9,484(6,119) 
Denmark 9,600(7,706) 10,938(8,789) 12,876(10,299) 
Spain 2,805(2,514) 2,755(2,466) 3,425(2,993) 
Portugal 5,405(4,353) 4,839(3,941) 5,504(4,396) 
Italy 6,170(2,565) 6,080(5,216) 6,302(6,080) 
ALL 5,340(5,884) 5,401(6,494) 6,906(7,246) 
F statistic 50.32 61.14 42.79 
P value <0.001 <0.001 <0.001 
Adjusted R2 0.31 0.36 0.28 
The F statistic is calculated with 13 parameters, and 1285 degrees of freedom. 
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7.6 Discussion 
The literature review emphasised the importance of using a disaggregated approach to 
costing, so that reasons for variations in unit costs could be explored (Chapter 2). The 
review also highlighted the importance of using a consistent method to measure unit 
costs in each health care setting (Chapter 2). This chapter presented the methods used 
to measure unit costs, and analysed reasons for unit cost differences. The method 
relied on the construction of price indices that have generally been applied to time 
series data, and have rarely been applied to comparing factor prices across health care 
systems (Danzon and Chao 2000). The results showed that the price of factor inputs 
varied widely between the Eastern and Western European centres. For example, when 
prices were converted using the GDP PPP conversion factor the price of factor inputs 
was 15 times lower in the centre in Latvia compared to the French centre. The 
corresponding differences in the volume of inputs between Western and Eastern 
European centres were relatively small (2.5 times lower in the Latvian centre 
compared to the French centre). There were differences in the volume of factor inputs 
amongst the Western European centres, but these were not explained by differences in 
relative prices. A technology specific PPP index was constructed which adjusts for 
differences in the prices of those factor inputs used to produce stroke care. Using this 
conversion factor reduced, but did not eliminate cost differences across the centres. 
For example, when the GDP PPP conversion factor was used, the mean total costs per 
patient were 20 times higher in the French centre than in the Latvian centre, but they 
were still 6.5 times higher when the stroke specific PPP was used. The outstanding 
cost differences across the centres may reflect differences in factor inputs, resources 
use (e. g. LOS) and case-mix; the next chapter consider these issues. 
There were large differences in factor prices between the Western and Eastern 
European centres which exceeded the differences in GDP per capita across those 
countries (Chapter 6). In particular, there were wide variations in the costs of labour 
inputs between the centres in Eastern and Western Europe. The large wage 
differentials suggest that the international labour market is not perfectly competitive 
in this sector. Labour economics predicts that faced with a relatively low wage in one 
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country, workers would migrate to another (Call and Holahan 1983), this process 
potentially leading to wage equalisation across the countries concerned, for workers 
with the same marginal productivity. These results suggest that restrictions in the 
labour market for health care professionals mean that the market is in a sustained state 
of disequilibrium. Governments in Western Europe may put in place regulations to 
limit the number of health care professionals recruited from Eastern European 
countries. Employers may lack information about the transferability of skills and the 
relative productivity of health care professionals from different countries. 
In Eastern European countries, wages may only be a small determinant of labour 
supply. As discussed in Chapter 4, there may be compensating differentials for health 
care professionals. The working conditions, the local environment and additional 
`perks' such as free child care or subsidised housing may all encourage a doctor in 
Eastern Europe to continue supplying labour in spite of the low wage. One limitation 
of the measure of factor price used is that it only considers the costs of labour to the 
public health care providers. In the Latvian centre, the doctors also worked in the 
private sector to complement their income. In ex-soviet countries `under the counter' 
payments from patients may also be prevalent (Thompson and Witter 2000, Ensor and 
Witter 2001, Ensor 2004). As part of the site visits to each centre, details were asked 
about these payments, but only in one centre (Latvia) were these acknowledged to 
exist, and even then they were estimated to be small52. It is possible though that the 
study underestimated the opportunity costs of these factor inputs, in the Eastern 
European centres and the true differences in opportunity costs between the Eastern 
and Western European centres may be less than observed in this study. It would 
appear unlikely though that the exclusion of these broader aspects of opportunity cost 
would fully explain the price differences observed. 
Other studies that have assessed labour costs in Eastern Europe have also found that 
wages are much lower than in Western European countries. The International Labour 
Organisation (ILO) found that within particular countries in Eastern Europe the 
relative wages of health care workers were low compared to those for colleagues in 
32 Estimates varies from 5% to 10% of the average monthly salary. 
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other sectors (International Labour Organisation 2002). For example, the ILO 
considered labour costs in the health sector in Lithuania and commented that: 
".. average salaries are very low (in Lithuania) compared to EU levels, and were only 
83% of the Lithuania national wage. " (ILO 2002, p6). 
Lower wages in the Eastern European centres may be a spill over from the incentive 
mechanisms that previously existed in these countries. Under the Soviet-style health 
care system, hospital budgets were generally fixed, and based on the number of beds 
(Sheiman 1994). Although budgets were fixed, costs rose, in response to inelastic 
demand for new drugs and investigations, bought at Western prices (Van Andel 
1997). Salaries for health care workers were paid out of the residual from the budget 
and fell, both in real terms and relative to professionals working in other sectors 
(Sheiman 1994, ILO 2002). In addition, there was a general perception in ex-soviet 
countries that workers in service sectors do not produce such a worthwhile output 
compared to their counterparts in manufacturing industry (Afford 2004). Labour 
market economics would predict that health care professionals would retrain and work 
in other sectors, but again a lack of mobility in the labour market coupled with 
uncertainty about economic prospects in the countries concerned, may have conspired 
to keep wages low. 
There was relatively little variation in relative factor price across the Western 
European centres, certainly when compared with pharmaceutical markets (Damon 
and Chao 2000, Danzon and Kim 1998) and manufacturing industries (Van Ark et al. 
1999). This may indicate that in these countries the labour markets in the health sector 
are more flexible and competitive, leading to similar prices for labour inputs across 
countries. In each of these centres, the hospitals concerned were public sector 
teaching hospitals, and there was evidence of transfer of health care professionals 
across the centres concerned. Interestingly, within Finland there were important 
variations in the price of inputs amongst the centres, illustrating that variability in 
factor prices may be important within as well as across countries. 
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Previous cross-national comparisons have found that factor substitution according to 
relative factor prices does occur both in manufacturing industry (van Ark et al. 1999) 
and in the use of pharmaceuticals (Danzon and Chao 2000). However, this 
investigation found that the measures of relative price were similar whether they were 
constructed using Laspeyres or Paasche price indices. This suggests that input 
substitution according to factor price (the Gerschenkron effect) in the pursuit of 
productive efficiency is generally not taking place. This may reflect a lack of 
incentive to produce efficiently in the centres concerned. While there were differences 
across the Western European centres in the use of factor inputs, these did not appear 
to reflect differences in factor price. These may instead reflect differences in the 
choice of technology or differences in case-mix across the centres concerned (see 
Chapter 6). For example, in the Italian centre, most patients were referred to a hi-tech 
acute stroke unit immediately post stroke, which had a much higher staff to bed ratio 
than equivalent wards in other centres. 
It should also be noted that the Gerschenkron effect was not detected amongst 
Western European centres where prices were similar but was detected between the 
Eastern European centres and the French centre where there were large differences in 
relative factor prices. Where there are smaller more subtle differences in relative 
factor prices, it may be more difficult to detect any correlation between relative factor 
prices and relative factor use. In addition, decision-makers in each centre may not 
have much control over the use of labour inputs. These may be set by regulations laid 
down by national governments. However, the local decision-maker may have more 
control over resource use measures such as LOS, and the level of factor price may be 
a factor the local decision-maker uses when deciding when to discharge the patient 
from hospital. The measures of relative price constructed in this chapter will therefore 
be used in the subsequent analysis of reasons for variations in LOS across the centres 
(Chapter 8). 
The unit costing tried to use a disaggregated and consistent methodology across the 
study settings. This was feasible for the measurement of labour inputs which formed 
an important component of the overall costs of stroke care. However, for some of the 
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resource inputs, in particular consumables and overheads it was not possible to use a 
disaggregated approach to cost measurement. Detailed data were not collected for 
these items for each patient, and this information was not available at site visits to 
each centre. For these cost elements, the method of cost allocation was based on 
methods used by financial departments in each centre. Attempts were made to try and 
standardise these methods based on recommendations in the literature that suggested 
allocating joint costs across different departments to the individual department and 
then to the individual bed-day, based on measures of relative use (Graves 2002). 
While cost variation across the centres for these items was generally lower than for 
labour inputs for certain centres these items comprised a high proportion of the total 
costs per bed-day, and were important in understanding cost variation. For example, 
in the Spanish centre, overhead costs were 43% of the cost per hospital bed-day. 
Overhead costs were 3.5 times higher in the Spanish centre than the French centre, 
whereas the costs per bed-day of labour inputs were 30% less than in the French 
centre. However, it is likely that some of the observed variability in the costs of 
overheads reflects differences in the methods used to allocate these costs. 
The method used to calculate a more specific currency conversion factor followed 
other attempts to construct technology specific PPPs and calculated bilateral price 
indices whereby prices in each centre are compared to those in a reference centre 
(Wordsworth and Ludbrook 2005, Hutton 2001). These indices are sensitive to the 
choice of reference centre (Diewert 1999). Instead, multilateral price indices can be 
developed whereby the prices in each country are compared to all other centres' 
prices (Diewert 1999). Multinational studies of cost and cost-effectiveness could use 
multilateral price indices, to adjust more fully for cross national price differences 
when estimating costs. 
Finally, a general problem with using price or volume indices is that they are 
commonly based on aggregated measures of input, rather than measures at an 
individual level. They therefore suffer from the same problems of all such aggregated 
measures in health care, namely that there is inadequate adjustment for case-mix and 
quality of inputs and outputs across the firms concerned. All the indices described rest 
219 
on the premise that the productivity of the factor inputs in each country is identical. 
Yet, as described in chapter 6, the case-mix, ward-type and outcomes of stroke care 
vary within and across the centres concerned, suggesting that there are potential 
variations in the quality of health care inputs. The indices also provide deterministic 
measures with no indication of the level of random variation that surrounds the use of 
factor inputs. Indices that are more appropriate would recognise these issues. 
However, the level of disaggregation used in constructing these indices already goes 
beyond the separate reporting of resource use unit costs required in economic 
evaluation, and has given further insights into why costs vary across health care 
settings. 
7.7 Conclusions 
To conclude, unit costs vary across the centres because of differences in factor inputs, 
but even greater differences in factor price. This has implications for the interpretation 
of costs converted using GDP PPPs, in that the observed cost differences between 
Eastern and Western centres partly reflect outstanding differences in factor prices. 
The variation in labour costs was studied in depth and was an important component of 
the costs of stroke care in each setting. Amongst the Western European centres there 
were wide variations in the use of labour inputs; these appear an important reason for 
the observed variation in the costs per bed-day across these centres. The use of 
different price indices suggested that factor price differences were not driving 
observed differences in factor use across the Western European centres. Although the 
cost measurement attempted to use a consistent method and measure opportunity 
costs in each setting, the study may have underestimated opportunity costs in the 
Eastern European centres. The factor price of labour inputs was based on the 
employees' wage and did not include 'under the counter' payments or `benefits in 
kind' (e. g. subsidised housing). While careful attempts were made to use a consistent 
methodology across the centres, the observed variations in unit costs may partly 
reflect differences across the centres in the way overhead costs were allocated. 
Nevertheless, the conclusion that important price differentials exist between the 
centres in Eastern and Western Europe is sufficiently large to appear robust to the 
caveats discussed. The next chapter examines the importance of factor price and other 
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variables in explaining the observed variations in resource use and total cost across 
the study centres. 
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Chapter 8: Assessing the variability of 
multinational resource use and cost data using 
OLS regression models compared to MLMs 
8.0 Introduction 
The data described in chapter six showed that there were differences between the 
resources used and the cost of producing stroke care across the 13 different European 
centres included in the empirical investigation. The literature review identified factors 
associated with resource use and cost variation across different geographical health 
care settings. These factors may be measured at different levels-- at the level of the 
patient, health care centre, or country concerned. For example, relative price, which is 
usually measured at the level of the health care centre or country concerned, may 
determine the relative level of resource use in different centres. Other factors that are 
associated with resource use differences, such as case-mix may operate at a patient- 
level (Wennberg 1984, McPherson et al. 1982, Phelps and Mooney 1993). Chapter six 
showed that there were important variations in patient and contextual factors across 
the centres included in the study. Chapter seven highlighted that relative factor prices 
and unit costs vary across the centres. There are therefore a priori reasons for using 
methods of analysis that recognise that factors associated with international resource 
use and cost variability, operate at different levels. 
However, studies in this area have generally used ordinary least squares (OLS) 
models (Willke et al. 1998, Coyle and Drummond 1998). These models assume that 
observations across patients are independent and have a common variance. This 
assumption would seem implausible when using data from different centres, as 
patients' resource use (or costs) within a particular centre may be more similar than 
that in different centres, for the reasons outlined. Furthermore, centre or national-level 
variables included in an OLS model are considered as if they were measured at a 
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patient-level, thus spuriously inflating the amount of information they supply. By 
contrast, multilevel models (MLMs) are able to incorporate the hierarchical structure 
of the data (in this case of patients within centres), and provide more appropriate 
estimates of patient and centre-level effects. MLMs have been recommended for use 
in health economics (Rice and Jones 1997), but despite the obvious intuitive appeal of 
using MLMs to assess multicentre resource use and cost data, they have not yet been 
used for this purpose. An important question to address is: does using MLMs rather 
than OLS models matter when analysing multicentre resource use and cost data? 
The aim of this chapter is to compare the use of OLS regression models and MLMs 
for assessing the reasons for multicentre resource use and cost variations. The Biomed 
II stroke dataset described in chapter six, is used for this purpose. Section 8.1 
summarises the methodology used to assess the reasons for international resource use 
and cost variation, and covers issues such as the choice of model specification, and 
the conversion factor used. Section 8.2 describes the different statistical models used 
in the analysis. Section 8.3 presents the results, and section four discusses their 
implications. 
8.1 Overview of methodology 
This chapter compares the use of OLS models and MLMs for estimating which 
factors are associated with length of hospital stay (LOS) and total cost. LOS was 
chosen as the resource use measure as it is the resource use variable that explains 
most of the variation in the costs of stroke care (Porsdal and Boysen 1999). The basic 
structure of MLMs and the rationale for their use in health care and health economics 
has been previously described (Chapter 5), so only a summary is provided here. In the 
context of this dataset, individuals (level-1 units) are nested within centres (level-2 
units). It is recognised that some of the variables defined at a centre-level are 
measured at a national level e. g. overall level of health care spending. These could 
have been considered as a separate level however there were insufficient centres in 
each country to include country as a separate, third level in the model. 
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8.11 Inclusion of variables for assessing resource use and cost variation. 
Chapter four outlined the variables included in the dataset, that have a clear 
theoretical rationale for explaining either resource use or cost variability. Some of 
these variables were measured at the patient-level such as case-mix or access to care. 
Other factors were measured at the centre or country level: relative factor price, 
budget constraints, incentives to health care providers, and patients. The decision 
about which of these variable to include in the model was also based on a priori 
reasoning rather than statistical significance. Certain variables were excluded from the 
models because there were clear theoretical reasons as to why their inclusion in a 
model explaining resource use or total cost was inappropriate. For example as 
Wagstaff (1989a) points out, variables such as bed-occupancy are directly correlated 
with resource use, and total cost, and were therefore excluded from the analysis. It 
was recognised that measures summarising the production processes in each centre, 
such as the access to neurologists and the use of rehabilitation hospitals, would be 
likely to be correlated with more general measures of health infrastructure such as the 
percentage of GDP spent on health care (% GDP/health). It was also desirable to 
choose higher-level variables that may have more general use outside the specific 
disease area. On this basis the context variables that seemed most appropriate were % 
GDP on health care, use of copayments, use of DRG system and for the resource use 
model, relative factor prices. As factor price and the use of substitutes to care is used 
in the calculation of total cost these variables were excluded from the total cost 
model. 
8.12 Distribution of cost variable 
MLMs usually assume that the errors terms are normally distributed. However, 
resource use and cost data are usually not normally distributed (Briggs and Gray 
1999). In this dataset, the resource use and total cost data used in this investigation are 
clearly not normally distributed (see appendix 4). In addition, the shape of the 
distribution of the data varies across the centres included in the analysis. For this 
investigation, the main interest is in the effect of covariates on LOS and total cost per 
patient. The initial analysis will use OLS models and MLMs that assume the residuals 
are normally distributed. When using regression models to analyse data it is possible 
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that although the raw data are skewed the residual is normally distributed after 
adjusting for covariates. However, given the highly skewed cost data, with 
distributions differing by centre it appears unlikely that the general assumption that 
the residuals are normally distributed is justified (appendix 4). Generalised linear 
models (GLMs) models have been recommended as an alternative for analysing cost 
data (Briggs and Gray 1999, Manning and Mullahy 2001), as a variety of non-normal 
distributions can be specified but, unlike data transformations in OLS regression, they 
make inferences about the mean cost directly (see Chapter 5). A particular type of 
GLM- the gamma model, can also be specified as having a different shape for 
different higher level units in the data hierarchy. This made the gamma model a 
potentially attractive alternative for the analysis of this dataset. 
8.13 Conversion factor used to convert local costs into common currency 
The previous chapter concluded that converting costs from local currencies into a 
common currency (US dollars) using GDP PPP, did not adjust for differences in 
relative price between the Eastern and Western European centres. Nevertheless, as 
GDP PPPs provide a more general measure of opportunity costs in each of the centres 
concerned the main cost analysis will use total costs converted using GDP PPPs. 
However, analysis tests the robustness of the conclusions to the choice of conversion 
factor, by using total costs converted using the stroke care PPP (derived in Chapter 7) 
in a sensitivity analysis. 
8.2 Statistical models used 
An OLS regression model takes the form: 
yj=ßo+ßjx, +e1; ei-Normal(0, o2) (1) 
where yi is the outcome variable for the ith individual, x, is an explanatory variable, 
with associated slope coefficient ßi. Ais the intercept and e1 , the error term which 
represents unexplained variability between individuals, is assumed to be normally 
distributed with a mean of zero. The OLS model assumes that the variance of the error 
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term is the same for all individuals. Extra explanatory variables can be included at 
either a patient or centre-level. Those representing centre-level covariates necessarily 
take the same value for all individuals in a particular centre. 
Moving to a MLM structure changes the way the unexplained variation, the random 
error term, is modelled. The most basic MLM, the random intercepts model, includes 
an additional term which represents the unexplained variation that exists across 
centres. Using subscripts i and j for the ith individual injth centre, the model may be 
written: 
yu =%+, Ql xy + u, + Ev; E, j- Normal(O, 02), uj - Normal(O, ý) (2) 
where A is a fixed quantity applying to all individuals, uj is a random variable with 
zero mean and constant variance (ý) which applies to all the cases in a particular 
centre, and ell is a random error term which represents the unexplained variation for 
individuals within a centre. uj indicates the effect of centre on the outcome variable, 
over and above that explained by the set of explanatory variables. The intercept for 
thejth centre (previously given as A) is now given as a fixed component ()%) plus a 
random component (uj). The model can be developed by including additional 
explanatory variables at the level of the individual or the centre. 
MLMs allow the effect of adding centre-level explanatory variables on the extent of 
unexplained variation between centres (ý) to be estimated. In addition, the degree of 
dependency amongst observations within each centre can be measured by the intra- 
class correlation coefficient (p) defined as j Q1(ß+02), This reflects the strength of 
`nesting' within the data hierarchy. 
A number of alternative GLMs were considered for the analysis. A gamma 
distribution model with random mean (0j) and random shape (c) parameters was 
chosen as it fitted the positively skewed LOS and cost data reasonably well: 
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yy - Gamma(O , o. ) , 9y =A+A xy + uj ; 
uu - Normal(0, T2), Oj - truncated Normal(µ, co2) (3) 
This `generalised linear mixed model' (GLMM) is a type of multilevel model similar 
to model 2 in that it allows for random centre effects (uff), but it accommodates 
positively skewed data by the use of a gamma rather than a normal distribution, 
allowing the gamma distributions to have different shapes in each centre. The shape 
parameters are restricted to be positive by using a normal distribution truncated at 
zero. 
8.3 Estimation 
An OLS regression model was fitted to estimate the effect of the patient-level 
variables identified in chapter six on the total length of hospital stay (LOS) (model 1). 
Variables were included if the literature review suggested they may be associated with 
LOS, and retained in the equation even if they did not reach conventional levels of 
significance. A series of diagnostic tests were performed for heteroscedasticity, 
multicollinearity and correct functional form. 
The analysis was repeated with normal MLM random intercepts (model 2) and 
gamma GLMM random intercepts (model 3). The normal model was estimated by 
restricted iterative generalised least squares in MLwiN (Rasbach et al. 2002), 
equivalent to restricted maximum likelihood. The gamma models were fitted using 
Markov chain Monte Carlo methods in WinBUGS (Gilks et al. 1996). The LOS 
analyses were then repeated also including centre-level variables (models 4-6). 
The models including patient and centre level variables were re-fitted with total cost 
as the dependent variable (models 7-9). The total costs used were those converted 
from local currencies into US$ using the GDP PPP index (see Chapter seven). As 
LOS is highly correlated with total cost, both in this dataset and more generally for 
stroke patients, the same factors were included in the models apart from the variables 
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for price index and care substitutes. The goodness of fit of the different cost models 
was compared using log-likelihoods, and plots of deviance residuals (Rasbach et al. 
2002). 
To test whether the conclusions were robust to the choice of conversion factor, the 
models were refitted with the costs converted from local currency into US dollars ($) 
using the stroke specific PPP index (models 10-12). 
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8.4 Results 
8.41 LOS models with patient-level variables 
The results from the OLS analysis suggested that most of the patient variables 
considered were associated with LOS (Table 8.1, model 1). The relationship between 
these factors and LOS was generally that anticipated by a priori reasoning. For 
example, LOS was higher for the more severe cases, i. e. those in coma, incontinent or 
paralysed at admission. There was an inverse relationship between age and LOS. As 
stated in Chapter 6 this appears inconsistent with more general literature that suggests 
age is positively associated with resource use mainly because of the closer proximity 
to death. However, in this dataset only patients surviving the stroke were included, 
and the inverse relationship only arises after adjusting for the other patient factors. So 
for survivors with a given case-mix, younger patients were more likely to stay in 
hospital longer than older patients. This may reflect the perception that younger 
patients have a greater capacity to benefit from inpatient hospital rehabilitation, 
although it should be noted that the effect of age on LOS was small and non- 
significant. The utilisation of community support was associated with reduced LOS 
indicating that this may be a substitute for hospital care. The adjusted R2 for the OLS 
model was 0.27, this showed that there was still a large element of unexplained 
variation. 
Compared to the OLS model, the normal random intercepts model (model 2) gave 
somewhat different coefficients and standard errors, and the estimated significance of 
the covariates changed accordingly. For example, both age and independence pre- 
stroke had smaller coefficients and were no longer significant, whereas paralysis had 
a larger estimated effect. The random intercepts model (model 2) fitted the data better 
than the OLS model as shown by the lower level of unexplained variation at a patient 
level (02) and the higher log-likelihood statistic. Model 2 estimated the level of 
unexplained variation, which existed across the centres. The results showed that the 
majority of the unexplained variation was among patients, rather than among centres, 
and the intra-class correlation coefficient (p) was 0.16. 
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Diagnostic testing for the OLS model suggested that severe multicollinearity was 
unlikely to exist; for example, the pairwise correlation coefficients between the 
explanatory variables did not exceed 0.6. Heteroscedasticity was detected for the OLS 
model (p<0.001 by the Cook-Weisberg test (Cook and Weisberg 1982)). 
Heteroscedasticity can be caused by using an incorrect functional form (Gujarati 
1988), and here the residuals were found to be non-normally distributed, with the 
shape of the distribution varying according to the health care centre (see appendix 4). 
The Ramsey reset test for functional form also suggested that the OLS model was 
misspecified (p=0.01). 
The analysis was therefore repeated using a gamma model with intercept and shape 
parameter varying by centre (Table 8.1, model 3). The estimated effect sizes and their 
associated standard errors differed somewhat from both the two previous models. For 
example, the coefficient for age was now larger and significant at the 5% level, 
whereas the coefficient for community support was no longer statistically significant. 
The log-likelihood statistic indicated that the gamma model fitted the data 
substantially better than either of the other two models. 
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Table 8.1: OLS model, MLM and GLMM estimating the effect of patient-level 
variables on length of hospital stay (LOS): coefficient (SE) 
Model 1: OLS Model 2: MLM Model 3: 
Normal, with 
GLMM 
random Gamma, with 
intercept random 
intercept 
Constant term 41.7 (5.5)** 29.5 (6.2)** 31.3 (4.8)** 
Patient variables 
Age -0.10 (0.06)* -0.08 (0.05) -0.13 (0.04)** 
Independent pre-stroke -6.04 (2.38)** -3.22 (2.32) -4.82 (2.22)** 
Living alone Reference Reference Reference 
Living with others -8.23 (1.55)** -5.07 (1.55)** -0.65 (1.13) 
Living in nursing home -10.85 (4.61)** -8.49 (4.44)* 4.37 (4.31) 
Incontinent 19.29 (1.55)** 18.81 (1.49)** 15.65 (1.63)** 
Paralysed 7.34 (1.56)** 8.48 (1.50)** 2.45 (0.81)** 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 5.35 (2.13)** 5.80 (2.04)** 6.82 (1.65)** 
Unknown stroke type -2.27 (1.73) -7.71 (2.45)** -3.67 (1.13)** 
Onset to admiss <6 hrs Reference Reference Reference 
Onset to admiss 6-24 -0.55 (1.58) 0.59 (1.52) 0.77 (0.89) 
hrs 
Onset to admiss 1-7 d -0.96 (1.80) -0.70 (1.73) 1.22 (0.96) 
Onset to admiss >7 d -1.33 (3.27) -0.85 (3.17) 0.28 (1.50) 
Ons. to admiss 10.17 (2.64)** 8.05 (2.60)** 6.39 (2.85)** 
unknown 
Family support -1.53 (1.39) 2.51 (1.49)* 2.46 (0.81)** 
Community support -4.06 (1.71)** -5.76 (1.68)** -0.20 (1.04) 
Random effects 
o2 (within centres) 522 470 442 
z2 (between centres) 87 (37) 85 (47) 
Log-likelihood -5896 -5845 -5267 
** p<0.05, *p<0.10, Ons: Onset, admiss: admission, hrs: hours, d: days. The log-likelihood statistic 
presents a measure of how well each model fits the data. R2 values were not available for the MLMs. 
231 
8.42 LOS models with patient, centre and national level variables 
The models were re-fitted including centre-level variables (Table 8.2). The results 
showed that the estimated direction of effect for these variables was that anticipated 
by theory: proxies for the presence of incentives to discharge patients earlier -a DRG 
system, patient copayments, or higher relative prices (Fisher price index) - were all 
associated with shorter LOS, whereas a higher proportion of GDP spent on health was 
associated with longer LOS. For the OLS analysis (model 4) each of these effects was 
statistically significant at the 5% or 10% level. Although the adjusted R2 (0.28) was 
higher than for the previous OLS model including just patient level variables, there 
was still substantial unexplained variation. 
The normal (model 5) and gamma random intercepts models (model 6) found that 
these centre-level variables were far from statistically significant. The coefficients for 
the centre-level variables were generally similar for the three models. So for example, 
whichever model was used, an increase in the proportion of GDP spent on health care 
of one percentage point was associated with an average increase in LOS of 6 days. 
The standard errors were much smaller for the OLS model which does not take into 
account the hierarchical structure of the data, and thus severely overestimated the 
significance of these variables. The gamma model had the highest log-likelihood, and 
therefore fitted the data best. 
The variance terms for both multilevel models showed that most of the unexplained 
variation was, again, at the level of the patient rather than the centre (/=0.18 for the 
normal random intercepts model). The MLMs which included centre and national 
level variables (models 5 and 6) had a similar extent of unexplained variation across 
centres, and a similar log-likelihood, compared to the models with just patient-level 
variables (models 2 and 3). This showed that, once the hierarchical nature of the data 
was recognised, these higher-level variables did not help explain the variability in 
LOS across centres. 
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Table 8.2: OLS model, MLM, GLMM estimating the effect of patient, centre and 
national-level variables on length of hospital stay (LOS): coefficient (SE) 
Model 4: OLS Model 5: MLM Model 6: GLMM 
Normal, random Gamma, with 
intercept random intercept 
Constant term 15.3 (7.8)* 4.7 (24.6) 12.6 (26.1) 
Patient variables 
Age -0.08 (0.05) -0.07 (0.05) -0.13 (0.04)** 
Independent pre-stroke -3.84 (2.37) -3.13 (2.32) -5.09 (2.19)** 
Living alone Reference Reference Reference 
Living with others -6.29 (1.59)** -4.98 (1.56)** -0.73 (1.11) 
Living in nursing home -7.03 (4.55) -8.38 (4.44)* 4.25 (4.19) 
Incontinent 19.28 (1.53)** 18.82 (1.49)** 15.57 (1.65)** 
Paralysed 7.64 (1.54)** 8.52 (1.51)** 2.31 (0.84)** 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 6.03 (2.10)** 5.84 (2.04)** 6.84 (1.63)** 
Unknown stroke type -3.22 (2.17) -7.82 (2.48)** -3.74 (1.12)** 
Onset to admiss <6h Reference Reference Reference 
Onset to admiss 6-24 h 0.36 (1.56) 0.64 (1.52) 0.69 (0.88) 
Onset to admiss 1-7 d -0.53 (1.78) -0.68 (1.73) 1.16 (0.97) 
Onset to admiss >7 d -2.65 (3.25) -0.87 (3.17) 0.21 (1.53) 
Ons. to admiss unknown 6.66 (2.64)** 7.90 (2.60)** 6.12 (2.83)** 
Family support 1.72 (1.48) 2.67 (1.49)* 2.46 (0.81)** 
Community support -6.37 (1.73)** -5.86 (1.69)** -0.31 (1.04) 
Centre and national 
variables 
% share GDP 5.71 (1.09)** 6.58 (5.13) 5.39 (5.53) 
DRG system -8.11 (1.77)** -6.16 (7.03) -4.96 (7.39) 
Price index -10.91 (2.58)** -10.79 (10.26) -9.60 (10.93) 
Copayment -3.82 (2.19)* -4.92 (9.68) -3.93 (10.30) 
Random effects 
oz (within centres) 502 470 369 
ý (between centres) 102 (42) 120 (97) 
Log-likelihood -5868 -5845 -5268 
** p<0.05, *p<O. 10 Ons: Onset, admiss: admission, hrs: hours, d: days 
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Figure 8.1 shows the deviance residuals from models 5 and 6 in the form of normal 
plots. If a model is appropriate, deviance residuals should approximately follow a 
normal distribution and will lie along the line of identity shown in the plots. For the 
normal MLM (model 5), the residuals show considerable positive skewness, in 
keeping with the positive skewness of the raw LOS data. The residuals from the 
gamma GLMM (model 6) 'show a much better behaviour, indicating the greater 
appropriateness of this model for these data and confirming the improvement in fit 
shown by the log-likelihoods. 
8.43: Total cost models with patient and centre-level variables 
The factors that were associated with LOS, were also associated with total cost (Table 
8.3). In the OLS model each of the centre and national level variables was 
significantly associated with total cost, and the direction of the effect was that 
predicted by economic theory: the presence of patient copayments or a DRG system 
were associated with lower mean costs, a higher proportion of GDP spent on health 
care was associated with higher total costs. 
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Figure 8.1: Quantiles of the standardised deviance residuals from length of 
hospital stay (LOS) plotted against the quantiles from a standard normal 
distribution. 
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Table 8.3: OLS model, MLM and GLMM estimating the effect of patient and 
centre and national-level variables on total cost ($/PPP) coefficient (SE) 
Model 7: OLS Model 8: MLM Model 9: GLMM 
Normal, random Gamma, random 
intercept intercept 
Constant -4470 (1432)** -6156 (4353) -2034 (6529) 
Patient variables 
Age -10.0 (10.8) -6.2 (10.8) -7.4 (2.6)** 
Independ pre-stroke -916 (478)* -831 (467)* -3985 (3679) 
Living alone Reference Reference Reference 
Living with others -1344 (316)** -1309 (309)** -20 (86) 
Living nurs home 412 (917) 0 (892) 994 (602) 
Incontinent 3657 (310)** 3561 (300)** 942 (176)** 
Paralysed 1709 (309)** 1811 (302)** 56(54) 
Ischaemic stroke Reference Reference Reference 
Haemorr. Stroke 985 (424)** 971 (411)** 182 (116)* 
Unkn. stroke type -2140 (385)** -1110 (497)** -244 (69)** 
Onset-ad < 6h Reference Reference Reference 
Onset-ad 6-24 h -125 (315) -141 (305) -5 (62) 
Onset to ad 1-7 days -400 (358) -500 (348) 39 (64) 
Onset to ad >7 days -740 (652) -300 (638) -54 (82) 
Onset to ad unkn. 1836 (531)** 2063 (523)** 419 (280)* 
Centre and national 
variables 
% share GDP 2042 (155)** 2200 (755)** 2218 (946)** 
DRG system -1688 (354)** -1475 (1259) -1860 (1560) 
Price index NA NA NA 
Copayment -1722 (405)** -1637 (1758) -1477 (2153) 
Random effects 
c2 (within centres) 20.5 x 106 19.1 x 106 18.3 x 106 
z2 (between centres) 3.6 (1.5) x 106 5.8 (4.4) x 106 
Log-likelihood -12761 -12731 -11800 
** p<0.05, *p<0.10, NA: not applicable, Independ: independent, Ons: Onset, ad: admission, haemorr: haemorrhagic, unkn: unknown, hrs: hours, d: days. Note that the family support and community 
support variables (Table 8.3) are excluded from this model, as variables representing care substitutes 
might be actual components of total cost. 
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The OLS model again severely underestimated the standard errors of the centre and 
national level variables, so that their significance was overstated. Model 8, which 
correctly recognised the hierarchical structure of the data, estimated that the only 
higher-level variable which was significantly associated with total cost was the % 
share of GDP spent on health care. Although the presence of patient copayments and 
a DRG system were each associated with a mean reduction in total cost of 
approximately $1,500, model 8 found that the standard errors surrounding these 
variables were large. Model 9 which incorporated the hierarchical structure of the data 
and used a more appropriate functional form which better fitted the data, again found 
that only % GDP spent on health was associated with total cost. Like the LOS models, 
the proportion of unexplained variability in total costs amongst patients was 
substantially higher than that across centres (p=0.16). 
8.44 Currency conversion factor 
In the base case analysis, the costs were reported using the GDP PPP conversion 
factor. However, using this conversion factor did not completely adjust for price 
differences across the centres concerned (Chapter seven). Some of the observed 
relationships between higher-level variables (in particular % GDP/health), and total 
cost may reflect the relationship with price, rather than resource use. To examine this 
further, in a sensitivity analysis the costs were converted from local currencies to US$ 
using stroke care PPPs, which reduced any price differences between the centres. The 
resulting cost models (10 to 12) therefore looked at the effect of factors (such as 
%GDP/health) on the overall level of resource use and hence total cost, rather than on 
resource use and factor price and hence total cost (Table 8.4). 
The results showed that even when stroke care PPPs were used to convert local costs 
into US dollars, the same factors were associated with total cost. This suggests that it 
is mainly through their influence on physical resource use rather than factor price that 
these variables are associated with total cost (Table 8.4). 
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Table 8.4: OLS model, MLM and GLMM estimating the effect of patient, centre 
and national-level variables on total cost ($/stroke care PPP) coefficient (SE) 
Model 10: OLS Model 11: MLM 
Normal, random 
intercept 
Model 12: GLMM 
Gamma, random 
intercept 
Patient variables 
Constant -6231(3478) -7,861(5,690) -3,803(4,768) 
Patient variables 
Age -25.8(13.4)* -10.3(13.6) -16.8(6.38)** 
Independent pre-stroke -1205(594)** -1090(587)* -1,140(483)** 
Living alone Reference Reference Reference 
Living with others -1527(392)** -1,623(389)** -156.9(190.1) 
Liv in nursing home 407(1139)** 17.3(1121) 1866(997)* 
Incontinent 4471(384)** 4458(377)** 2909(370)** 
Paralysed 2295(384)** 2304(380)** 270(122)** 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 1325(526)** 1242(516)** 715(299)** 
Unknown stroke type -1,576(478)** -1,757(622)** 446(172)** 
Ons to admiss < 6hr Reference Reference Reference 
Ons to admiss 6-24 hrs -154(391) -195(583) 4.30(144) 
Ons to admiss 1-7 days 424(445) . 655(438) 26.9(148) 
Ons to admiss >7 days -614(810) -590(802) -166(196) 
Ons to admiss unknown 2919(660)** 2,847(658)** 1338(638)** 
Centre and national 
variables 
% share GDP 2503(192)** 2528(812)** 2,292(822)** 
DRG system -2426(439)** -1558(1,365) -2,436(1145)** 
Price index NA NA NA 
Copayment -1743(503)** -1,925(1,893) -684(1,773) 
Random effects 
a2 (within centres) 31.6* 106 30.1 * 106 17.0* 106 
(between centres) 4.1(1.8)* 106 5.3(4.0)* 106 
Log-likelihood -13,400 -13,027 -12,100 
** p<0.05, *p<0.10, NA not app licable, ** p<0.05, *p<0.10 Ons: Onset, admiss: admission, hrs: hours, 
d: days. 
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8.5 Discussion 
This chapter presented the results of OLS regression models and MLMs for assessing 
factors associated with resource use and cost variation. The results showed that 
patient-level variables representing case-severity, access to care, and substitutes to 
care were significantly associated with resource use and total cost whichever model 
was used. 
Economic theory suggests that the presence of a DRG system, patient copayments and 
higher relative factor prices would, ceteris paribus be associated with shorter LOS. 
The OLS analysis found these factors were associated with significantly shorter LOS. 
However, the OLS analysis overestimated the precision of the centre and national- 
level associations, and therefore made incorrect inferences. The MLMs were more 
appropriate for analysing the multinational data, and led to different results. In 
particular, the MLMs showed that, once the hierarchical nature of the data was 
recognised, none of the higher-level variables predicted resource use and only the 
level of health care spending was associated with total cost. 
The reason for this is as follows (Goldstein 1995). In an OLS regression of, say, cost 
on % GDP/health, all 1298 patient costs are considered. Thus the regression line is 
very precisely estimated (Figure 8.2a). In a MLM regression, the correct hierarchical 
structure of the data is recognised, and essentially the mean cost in each of the 13 
centres is regressed on % GDP/health. The resulting regression line is imprecisely 
estimated (Figure 8.2b). In this example, the regression lines for the OLS and MLM 
analyses have a similar slope, i. e. the effect of % GDP/health on total cost is similar 
for each model. However the SE is much larger in the MLM since it involves a 
regression of 13 rather than 1298 points. 
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Figure 8.2: The relationship between cost and % GDP/health, based on (a) 
ordinary least squares regression, (b) multilevel modelling; 95% confidence 
interval for the regression lines shown. 
These results suggest that assessments of international resource use and cost variation 
should not rely on OLS analyses. While it might appear that only the OLS analysis is 
producing results that are supported by a priori reasoning, the statistical assumptions 
made are inappropriate. The OLS analysis assumes that the individual error terms are 
independent, and do not allow for any clustering in the data. Yet economic theory 
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suggests that where contextual factors such as input prices differ, this will lead, 
ceteris paribus to differences in resource use. Therefore, if centres A and B have 
different factors prices, the resource use for patients in centre A will be more similar 
to each other than to individuals within centre B. Thus, the OLS assumption that the 
error terms are independent would not be supported by economic theory in this 
context. MLMs acknowledge that hierarchies exist and in this context can allow for 
individuals to be clustered within centres. MLMs therefore provide a suitable 
framework for analysing why these differences exist as they estimate the effects of 
patient and higher-level factors correctly. These models provide a reasonable basis for 
investigating why costs might vary across centres. By uncovering the reasons for 
variability based on both economic and statistical rationale this analysis has, at least in 
this disease area and context, provided a list of reasons for cost variation. 
The use of economic theory proved complementary to statistical theory. The choice of 
variables for inclusion in the models was driven by economic theory, which also 
helped when interpreting the results. Table 8.5 presents a list of the hypotheses posed 
by the literature and the data, and tested in the analyses. For example, economic 
theory suggested that substitutes for hospital care such as family and community 
support should be included in the analysis and the results showed that the utilisation 
of these alternatives to hospital care were associated with reduced LOS. The 
specification of an appropriate statistical model allowed the relationship of each 
variable with LOS to be correctly estimated and interpreted. 
The results suggested that the proportion of GDP spent on health care (% GDP/health) 
was the only higher-level variable associated with total cost. However, this variable 
was not associated with the main resource use measure, LOS. The reason why % 
GDP/health was associated with total cost could be that this variable was correlated 
with the factor prices used to value the resource inputs. In the base case analysis these 
factor prices were converted into US$ using the GDP PPP index, which left residual 
price differences across the centres. To consider whether the association of % GDP/ 
health and total cost depended on the factor used to convert factor prices into US 
dollars, the analysis was repeated using a stroke care PPP index. Converting relative 
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prices using this index left only small differences in relative prices across the 
countries concerned. The results of this sensitivity analysis suggested that even when 
the prices used were relatively homogenous, the % GDP/ health variable was still 
significantly associated with total cost. This suggests that the main way in which % 
GDP/ health was associated with total costs was through its association with overall 
physical resource use, rather than through the correlation with relative factor prices. 
The % GDP/ health variable may therefore provide a reasonable starting point for 
deciding whether resource use and total costs are similar across centres. 
The % GDP/ health was included as a variable to provide a more general measure of 
health infrastructure in each country. For example, those centres with higher national 
levels of health care spending generally had more hi-tech equipment available, offered 
further rehabilitation options to stroke patients, and had neurologists leading care. It is 
likely the % GDP/ health variable summarises overall differences in the production 
processes across the centres, and could represent the effects of other variables not 
included in the analysis that summarise the different models of stroke care that exist 
across the centres concerned (Table 8.5). 
In a database with 13 centres it was not possible to use enough centre-level variables 
to identify which particular differences in the health care infrastructure across centres 
were associated with total cost differences. Nor was it possible to identify other centre 
or national-level variables that were associated with resource use and total cost. 
Further studies in different disease areas are required to extend this analysis and 
examine what other factors may, in different contexts be associated with resource use 
and cost variation. The analyses presented here could be expanded to define further 
levels of the hierarchy. For example, there is an economic rationale to suggest that 
patients in different wards within a centre, may face different incentives for discharge 
from hospital. Also, contextual factors may differ across health care centres within a 
country. In an international dataset with more centres, the approach presented here 
could be expanded to investigate which factors drive cost variation at a patient, centre, 
national or international level. Alternatively, the issue of cost variation could be 
explored in a national cost-effectiveness study, looking at variability amongst 
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different patients and health care providers. While the particular factors driving cost 
variation will differ according to the disease or the context, the methodological issues 
raised here would apply to any situation where the data may be regarded as 
hierarchical. 
In this dataset, there was some residual variation in resource use and costs across the 
health care centres. This may reflect some of the differences highlighted in the 
literature review, such as technical, productive or scale efficiency or level of uptake of 
new technology. However, the intra-class correlation coefficient (p), which reports the 
proportion of the variability at the centre-level, was relatively low (0.16). This shows 
that most of the residual variation was at the patient level and suggests that 
unmeasured differences in patient characteristics (such as unmeasured case-mix, 
socioeconomic status, or morbidity) may be important in explaining overall variation. 
Whilst p is useful for understanding the degree to which variability exists at different 
levels, it should not be used as a basis for accepting or rejecting the use of the MLM 
approach, Indeed the relative levels of unexplained variation may be conditional on 
the number of centres versus number of patients included in the analysis. As is clear 
from this study, OLS methods can be severely misleading even when p is small. 
Previous MLMs in health economics, in health services research and in other sectors 
such as education have assumed that the residuals are normally distributed (Carey 
2000, Goldstein 1995). This assumption is unlikely to hold when the variable of 
interest is total cost per patient. Although generalised linear models (GLMs) have 
been recommended and used for analysing cost data (Manning and Mullahy 2001, 
Barber and Thompson 2004), they have not previously been evaluated in hierarchical 
models for comparing costs across health care settings. This study demonstrated their 
use in analysing hierarchical cost data. The GLMM random intercept model with the 
gamma distribution fitted the data better than the MLM random intercept model 
which assumed a normal distribution. This suggests that GLMMs are an attractive 
alternative for analysing hierarchical resource use and cost data. 
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Economic evaluations are often criticised for lacking generalisability (O'Brien 1997), 
particularly as costs may differ between locations (Hoch et al. 2002). Despite this, 
economic evaluations rarely examine why costs vary across settings and the few 
studies which have considered this issue have relied upon OLS analysis (Willke et al. 
1998, Coyle and Drummond 1998). These results indicate that those studies which 
used OLS analyses to identify factors associated with resource use and cost 
differences, may have reached erroneous conclusions (Coyle and Drummond 1998). 
Other studies have used OLS to analyse variation in costs across centres (Willke et al. 
1998). While this approach allows valid conclusions to be drawn about the magnitude 
of cost variation across centres, it does not consider why costs and cost-effectiveness 
vary across health care settings. Similarly, while tests for interactions can assess 
whether there is significant variation across centres (Cook et al. 2003), they are not 
suitable for assessing the reasons for cost variability. MLMs allow more correct 
inferences to be made about which factors are associated with cost variation. This can 
help decision-makers assess the applicability of results to their local setting. In this 
study the higher-level variable which explained most cost variation was the national 
level of spending on health care. This variable could therefore be used, alongside 
patient-level variables, to predict stroke costs for centres outside the study. 
Previous multicentre costing studies have struggled to assess cost variation partly 
because unit costs have not been measured in each centre, and the costing 
methodology used has differed by location (Schulman et al. 1996). Although the case- 
study described was not a full cost-effectiveness analysis, it was chosen for this 
evaluation as it enabled cost variation to be carefully assessed. In particular, detailed 
resource use, unit costs and outcomes were collected in each centre using a consistent 
methodology. Thus any differences between the centres in observed cost, would be 
more likely to reflect real differences in resource use, and unit cost rather than 
differences in the methodology used. The numbers of patients and centres were 
reasonably similar to the numbers which could be recruited to an international 
economic evaluation, which made it a realistic setting for testing the usefulness of 
MLM versus OLS for assessing cost variation. MLMs could be applied to multicentre 
(national or international) economic evaluations, where the net-benefit is reported for 
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individual patients, and the incremental net-benefit of the new treatment is estimated 
using regression analysis (Manca et al. 2005, Hoch et al. 2002). 
8.6 Conclusions 
This chapter compared the use of MLMs with OLS regression models for identifying 
which factors were associated with resource use and cost variations across health care 
settings. By ignoring the hierarchical structure of the data the OLS models 
underestimated the standard errors associated with the higher-level variables and 
therefore overestimated their precision. MLMs correctly recognised the variance 
structure and found that none of the higher-level variables were associated with LOS. 
The only higher-level variable associated with total cost was the % GDP/health 
variable, which was a proxy for differences in health care infrastructure across the 
international settings concerned. The % GDP/health variable was still associated with 
total costs, when international differences in factor prices was adjusted for using the 
stroke specific PPP index. Patient factors were important in explaining variation in 
both LOS and total costs. However, the MLMs suggested that most of the variation 
left unexplained by the models was at a patient-level. The gamma model allowed for 
the skewed distribution of the data, and fitted the data best. The next chapter extends 
the comparison of MLMs and OLS regression analysis to estimate cost-effectiveness 
across different health care settings. 
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Chapter 9: Cost-effectiveness analysis 
9.0 Introduction 
The previous chapter suggested that considerable variation in health service costs can 
exist across health care settings, and that multilevel models (MLMs) can be more 
appropriate for identifying which factors are associated with cost variation across settings 
than ordinary least squares (OLS) regression models. This chapter compares the use of 
OLS models and MLMs for analysing multicentre cost-effectiveness data. These data 
may be hierarchical with patients clustered within centres, and centres clustered within 
countries. In this context, MLMs may be more appropriate than OLS models as their use 
may be more consistent with economic and statistical theory (see Chapters 4 and 5). This 
chapter assesses whether in practice the choice of statistical technique can have an 
important impact on the estimation of cost-effectiveness. 
Previous studies have considered whether the relative cost-effectiveness of various 
interventions varies across health care centres located in different countries (Willke et al. 
1998, Cook et al. 2003). Cook et al. (2003) found a lack of heterogeneity or variation 
across countries and concluded that pooling cost-effectiveness estimates across countries 
may therefore be appropriate. By contrast, Willke et al, (1998) found important 
differences in mean ICERs across the countries included in their study, and this limited 
the usefulness of just reporting an overall estimate of cost-effectiveness. However, both 
these studies lacked the statistical power needed to detect cross-national differences in 
cost-effectiveness, and neither study used MLMs to assess the variation in cost- 
effectiveness. 
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This chapter compares the use of OLS models with MLMs for analysing international 
cost-effectiveness data. As a suitable multicentre cost-effectiveness dataset is not 
available, the Biomed II dataset is extended to generate a multicentre cost-effectiveness 
dataset. It is recognised that by generating a dataset, it is not possible to identify factors 
that are associated with variation in cost-effectiveness. Instead, the aim of this chapter is 
to consider the potential impact of the choice of statistical technique on the results of a 
multicentre cost-effectiveness analysis. As with the cost analysis in chapter eight, the 
dataset covers 13 centres in 10 different countries. As there are insufficient centres in 
each country to have three levels in the MLM, two levels are used with patients nested 
within centres. The subsequent commentary discusses variability within and across 
centres. The context is multinational but the statistical principles could also be applied to 
cost-effectiveness data collected as part of a national multicentre study. 
This chapter is divided into five main sections, the first provides an overview of the 
relevant statistical issues involved in estimating cost-effectiveness in this context, the 
second describes the development of the dataset, the third describes the statistical models 
used, the fourth compares the results of the OLS models and MLMs for assessing cost- 
effectiveness, and the final section discusses and interprets the results. 
9.1 Relevant statistical issues in cost-effectiveness analysis (CEA) 
The previous chapter compared the use of OLS models with MLMs for analysing which 
factors were associated with LOS and total costs. These techniques are now compared for 
the analysis of cost-effectiveness data, which raises further statistical issues. In CEA, 
recent developments in the methodological literature have seen incremental net benefits 
(INB) and cost-effectiveness acceptability curves (CEAC) become the preferred measures 
of cost-effectiveness (Fenwick et al. 2004, NICE 2004), and both these methods of 
presenting the results of CEA are used in this chapter. Net benefits are most commonly 
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estimated on the costs scale and are then termed net monetary benefits (NMB) and are 
defined by Hoch et al. (2002) as: 
NMB, ='% E1-TC, 
where % is the societal willingness to pay for a unit of health gain, E; is the effectiveness 
of the intervention for individual i, TC1 is the total costs for individual i. When costs and 
outcomes are measured for each individual in an RCT, the NMB for each individual can 
therefore be calculated (Hoch et al. 2002). An OLS regression analysis can be used, with 
a dummy variable to estimate the effect of the intervention on net benefits-- the INB. The 
mean estimate of INB using this regression approach is equivalent to estimating the mean 
INB by estimating the difference between the mean NMB for the treatment group and the 
mean NMB for the control group in a standard net benefit analysis (Hoch et al. 2002). 
9.11 Using total or aggregated OLS regression analysis to estimate cost-effectiveness 
The main purpose of CEA is to provide the decision-maker with a relevant estimate of the 
cost-effectiveness of the intervention, i. e. one that can inform the resource allocation 
decision. A national decision-maker requires information that is relevant to the country 
concerned. However, the economic evaluation may be reliant on data collected from a 
multicentre RCT that recruits patients from several countries. The study may not have 
collected resource use data for each patient, or unit cost data in each health care setting. 
In this case, an aggregated regression analysis may be used to estimate an average 
measure of cost-effectiveness (e. g. the INB) across all the centres and countries in the 
study (see for example Johannesson et al. 1997). This approach has the advantage of 
maximising the power in the study to detect a positive INB, and produces a relatively 
precise estimate. The problem with this approach is that the overall estimate of cost- 
effectiveness may not be relevant to a national decision-maker. This approach ignores 
any variability in the mean or the distribution of the INB across the different centres or 
countries. This could lead to biased estimates of the INB, and the uncertainty that 
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surrounds it. Other techniques that can recognise the variability in the mean INB across 
different countries or centres therefore need considering. 
9.12 Centre-specific OLS regression analysis 
If resource use data for each patient and unit cost data for each centre are collected, then 
separate OLS analyses can be used to estimate INBs for each centre. While this approach 
provides specific unbiased estimates of the mean INB and its standard error, the analysis 
may lack power, and there may be insufficient cases in a particular centre or country to 
detect whether or not the mean INB is positive. It may also be regarded as statistically 
inefficient to base a decision on information collected solely from the setting most 
relevant to the decision-maker, without regard to the results in other centres, with 
potentially more cases. In reality, decision-makers are likely to be influenced by results in 
other contexts, which this model fails to acknowledge. 
9.13 Fixed effects meta-analysis 
To increase the statistical power needed to detect differences in NMB between the 
treatment and control groups in a multicentre RCT, it may be desirable to firstly estimate 
a mean INB for each centre, and then secondly to pool these results to estimate an overall 
INB using a fixed effects meta-analysis (Fleiss 1993). This increases the power of the 
analysis to detect differences between treatment and control groups. This method unlike 
the total OLS regression model recognises any differences in the distribution of the INB 
across the centres. However, both the total OLS model and the fixed effects meta-analysis 
assume that there is no variability in the mean INB across the centres, i. e, that there is no 
heterogeneity. 53 
53 Even though using the separate OLS models does allow for different treatment effects in each centre, this 
is not strictly heterogeneity as the different centre effects are not drawn from a distribution. 
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9.14 MLMs 
The assumption of no heterogeneity across the centres can be relaxed by moving to a 
MLM. A MLM can account for variability in the mean INB across centres by using the 
`random slope model' described in detail in chapter five. The random slope model allows 
a regression coefficient representing the effect of the intervention to vary randomly 
across the study centres. The MLM can either assume a common patient-level variance 
across the treatment centres, or each centre can be allowed to have a different variance. 
The MLM with different variances can be estimated in one stage, or alternatively could 
be estimated in two stages using a random effects meta-analysis (Fleiss 1993, Thompson 
and Sharp 1999). This approach is the same as under the fixed effects meta-analysis, with 
centre specific estimates derived first (stage one), but these effects are then combined, 
allowing for variability in the INB within and across the centres (stage two). Random 
effects meta-analyses are most commonly used to pool effectiveness data from individual 
studies measuring treatment effects (Thompson and Sharp 1999), but the technique can 
be used to pool data from different centres (Localio et at. 2001). The random effects 
meta-analysis or two stage model, is similar to the one-stage MLM with different 
variances in each centre described above (Higgins et al. 2001). 
Shrinkage estimates may be used in MLMs to improve the statistical efficiency of the 
individual centre's estimates. The use of shrinkage estimators aims to combine the 
advantages from using the overall mean estimate (additional power and using all 
information) and the centre-specific estimate (relevance). While shrinkage estimates may 
be appealing for the reasons outlined, they assume that the data are exchangeable 
(Spiegelhalter et al. 2000) (see Chapter 5 for a further discussion). In this context, this 
assumes that the INB for all the centres concerned are drawn from the same distribution 
i. e. there are no systematic differences in the INB across the centres. However, the 
evidence from the theoretical review and the cost analysis disputes this assumption (see 
Chapters 4 and 8). To address this, MLMs may use covariates to adjust for systematic 
differences across the centres, before using shrinkage estimates to give centre-specific 
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estimates. Again, this may be done in two ways, either as part of a one-stage MLM or 
using a meta-regression analysis (two stages). In a meta-regression analysis, the 
dependant variable in this context is the INB and centre or national-level factors can be 
included as independent variables to adjust for systematic differences across the centres. 
Section 9.3 formally defines these alternative models for analysing cost-effectiveness 
data, but firstly the methodology and data used to generate the cost-effectiveness dataset 
are presented. 
9.2 Development of the multicentre cost-effectiveness dataset 
The original dataset recorded the costs and outcomes of routine stroke care for 1757 cases 
in 13 centres in 10 countries (see chapter 6). The dataset did not include an appropriate 
intervention for conducting a cost-effectiveness analysis. Instead, in this chapter the 
original data from the observational study are used to generate an international cost- 
effectiveness analysis. A hypothetical `treatment' is defined by making several 
assumptions based on the results from the cost analysis (Chapter 8) and using the relevant 
literature on the effectiveness of interventions for stroke patients (Stroke Unit Trialists' 
Collaboration 2001). These assumptions are used to create a scenario that could arise 
when an economic evaluation is conducted alongside a multicentre RCT. The main 
features of this scenario are that the effectiveness of the `intervention' is assumed to be 
similar across the centres, and it is assumed the intervention costs are the same for each 
patient and centre. In Chapters 6-8 the morbidity costs of stroke care were found to differ 
widely across the health care centres. It is therefore assumed that the impact of the 
intervention on morbidity costs varies across patients and centres. 
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The main methodological standpoints are the same as in the observational study (see 
Chapters 6 and 7). Once again, a hospital and community health service perspective is 
taken to cost measurement. The cost-effectiveness analysis includes cost and outcomes 
up to three-months post-stroke, as this is the time-horizon over which these data were 
recorded. As information was collected on survival but not on health-related quality-of 
life (HRQoL), the outcome measure used in the CEA is life-years gained. 
9.21 Definition of the `control' and 'treatment' groups and assumptions about the 
treatment's effectiveness. 
The cost-effectiveness dataset is based on the original data from the 1757 patients 
included in the observational study (Chapter 6). It is assumed that 50% of these patients 
(n=878) have the costs and outcomes observed in the original empirical study. These 
patients therefore represent the `control' group or routine practice in each centre. The 
remaining patients (n=879) are assumed to have the intervention. This hypothetical 
treatment is defined broadly as a new pharmaceutical intervention for stroke that reduces 
mortality and morbidity. It is assumed that the treatment group has a reduction in all 
cause mortality at three months of 34%, i. e. that the odds ratio of death for treatment 
versus control is 0.66. The odds ratio is similar to that observed from comparing post- 
stroke mortality following care on a specialised stroke unit versus care on a general 
medical ward (Stroke Unit Trialists' Collaboration 2001). It is also assumed that the 
intervention reduces morbidity. However, in the absence of a suitable measure of 
morbidity, this aspect of the intervention's impact is not captured by the effectiveness 
measure, but it is included in the cost analysis (see section 9.23). 
9.22 Sampling from the observational data to achieve the assumed reduction in 
mortality. 
The original observational dataset with costs and outcomes recorded for 1757 cases is 
divided into two sub-samples, a `treatment' group and a `control' group. To achieve the 
lower mortality rate in the treatment group, more of the cases in the observational study 
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who are alive at three months are allocated to the treatment than to the control group. 
Similarly, a higher proportion of the cases that died are allocated to the control group. 
The numbers of cases according to vital status who need to be allocated to each group, to 
achieve the odds ratio of 0.66 in favour of treatment are given in Table 9.1. 
Table 9.1: 3-month mortality (N=1757) following treatment and control. N (%) 
Dead Alive 
Control 264 (30) 614 (70) 
Treatment 195 (22) 684 (78) 
Total 459 (26) 1298 (74) 
Odds ratio (95% CI) for 3-month mortality for treatment versus control: 0.66(0.53 to 0.82). 
The required numbers of cases are sampled for each group at random, from the cases in 
the observational dataset. The random sampling is over the whole cohort, with no 
stratification by centre. Each case could potentially be allocated to either treatment or 
control. The only constraints on the random sampling are that it has to achieve an odds 
ratio in favour of the treatment group of 0.66, and there have to be 879 patients in the 
treatment group, and 878 patients in the control group. This produces a single dataset 
with the required odds ratio for mortality, and equal numbers of patients in the treatment 
and control groups. For both the treatment and control groups, the mortality data are 
those observed in the observational study. 
Repeating this random sampling with the same constraints leads to different combinations 
of patients being allocated to the two groups, and would lead to different eventual 
estimates of cost-effectiveness. A concern is that the ensuing statistical analysis could be 
based on samples that have outlying observations and are `unrepresentative' of the likely 
combinations of patients in these two groups. The random sampling is therefore repeated 
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100 times to produce different 100 datasets. The dataset chosen for the analysis will be 
the one that has the mean measure of cost-effectiveness (see Section 9.24). 
9.24 Costing Assumptions 
The intervention itself is assumed to have a cost of $3,000 across all the patients and 
centres. It is recognised that making this assumption of uniform cost will lead to an 
underestimate of cost variability compared to an actual intervention. However, it is also 
assumed that the intervention reduces morbidity costs. For the `control' group the CEA 
assumes that costs are the same as in the observational study but for each case in the 
treatment group, the baseline morbidity costs are reduced by 40%sa. The rationale for this 
is that a successful intervention for stroke may result in less disability in addition to 
reducing mortality (Samsa et al. 1999), so assuming a reduction in morbidity costs would 
seem plausible. Previous international cost-effectiveness studies in other disease areas 
have suggested that those countries with higher absolute costs may experience a greater 
reduction in morbidity costs from an effective intervention, than those countries with 
lower baseline costs (Hull et al. 1981, Menzin et al. 1996). As the morbidity costs in the 
observational study varied across settings assuming that the intervention leads to a 
proportionate reduction in morbidity costs will lead to differences in the incremental 
costs of the intervention across the centres. 
9.24 Calculation of life years, net-benefits and incremental analyses 
The number of life years for the decedents is calculated by subtracting the date of stroke 
from the date of death, to give the number of days survived, and dividing this by 365. As 
the data are censored at three months post-stroke, patients alive at 90 days are not 
assumed to live any longer; these cases are therefore assumed to live for 90/365=0.25 life 
years. Similarly, no morbidity costs are included after three months post-stroke. By 
ignoring any impact the intervention has after three months, the CEA will underestimate 
sa This 40% reduction in morbidity costs is applied to decedents as well as survivors to simplify the 
analysis. However, it is recognised that this reduction in morbidity costs is less likely for patients who died. 
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the cost-effectiveness of the intervention. Net monetary benefits (NMB) are calculated 
for each individual i, by valuing their life years (LY) by the societal willingness to pay 
for a life year (X), and subtracting from this, the individual's total costs of care (TC): 
NMB, = A, LYY-TC1 
where A is the societal willingness to pay for a life year, LYi and TC; are the number of 
life years and total costs for individual i. A is initially set at $60,000 per life-year gained 
(LYG) across all the centres, though this value is varied in subsequent sensitivity 
analyses. 
OLS regression analyses are initially used to estimate the incremental effect of treatment 
on life years, total costs and NMB. The regression analyses each have a dummy variable 
for treatment group as an explanatory variable, and life years, total costs and NMB 
respectively as dependent variables. Using these regression models, the incremental 
effectiveness, incremental costs and incremental net benefits (INB) of the new treatment 
are estimated for each of the 100 costs and effects datasets. The mean INB varied across 
these different datasets, as each dataset had treatment and control groups with different 
mixes of patients. The dataset with the mean INB over the 100 datasets is therefore 
chosen for all the ensuing analyses. This choice was made to avoid basing the subsequent 
statistical analyses on a dataset with outlying observations. 
9.25 Description of the cost-effectiveness dataset. 
The cost-effectiveness dataset generated had a reasonably even distribution of treatment 
and control cases across the 13 centres, and could reflect the distribution of cases in a 
non-randomised treatment comparison (Table 9.2). 
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Table 9.2: Numbers (%) of treatment and control cases in each centre in the cost- 
effectiveness dataset. 
Centre N Control Treatment 
Portugal 108 53 (49) 55 (51) 
Spain 49 19(39) 30(61) 
Italy 136 68 (50) 68 (50) 
France 132 73 (55) 59 (45) 
Denmark 297 160 (54) 137 (46) 
Finland 1 95 52 (55) 43 (45) 
Finland 2 71 32(45) 39(55) 
Finland 3 43 20 (47) 23 (53) 
UK 108 51(47) 57(53) 
Poland 149 74 (50) 75 (50) 
Lithuania 1 80 43 (54) 37 (46) 
Lithuania 2 237 104 (44) 133 (56) 
Latvia 252 129(51) 123 (49) 
All cases 1757 878 (50) 879 (50) 
As the patients were selected for the treatment and control groups based on mortality, the 
case-mix for the treatment group was slightly less severe than for the control group 
(Table 9.3). For example, 39% of patients in the treatment group were incontinent at 
hospital admission compared to 42% of patients in the control group. 
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Table 9.3: Baseline Characteristics in treatment and control groups. 
Control Treatment All cases 
(N=878) (N=879) (N=1757) 
Unconscious 212(25%) 152 (17%) 364(21%) 
Incontinent 371(42%) 345 (39%) 716 (41%) 
Paralysis 706 (80%) 200 (80%) 351 (20%) 
The treatment was associated with an overall gain in life years at a small but non- 
significant additional cost. The mean INB when A was $60,000 per LYG was therefore 
positive and statistically significant at the 95% level (Table 9.4). 
Table 9.4: Life-years, total costs and INB, over 3-months post-stroke. 
Control Mean Treatment Mean Difference (tr-cont) 
(sd) (sd) Mean (95% CI) 
Life years 0.19(0.10) 0.20(0.09) 0.016 (0.007 to 0.024) 
Total costs ($) 4,362(5,427) 4,733(3,268) 371 (-48 to 789) 
ICER ($/life year) 23,187 
Overall INB ($) 582 (23 to 1142) 
(X=$60,000 per LYG) 
To summarise, a cost-effectiveness dataset was generated, based on the observational 
stroke dataset. The important features of the cost-effectiveness dataset were that it 
assumed that the intervention's effectiveness was similar across the centres, and that the 
intervention costs were the same. However, it was assumed that the intervention led to a 
40% reduction in morbidity costs, so that the impact of the intervention differs across 
individuals and centres. The overall mean INB estimated using OLS regression analysis 
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was positive and statistically significant. The next section defines the different OLS 
models and MLMs for estimating the relative cost-effectiveness of the intervention. 
9.3 Statistical models used in the CEA 
Each of the five models used in the CEA are defined below: 
9.31 Model 1: Aggregated or total OLS regression model 
In the most basic model, OLS regression can be used to estimate a single mean INB 
across all individuals and centres: 
yf =A+ Axi + &-; &- Normal(0,02) (model 1) i=1 .... 175 7 individuals 
where yr is the NMB for the ith patient, xi is an explanatory variable for treatment group, 
with the slope coefficient ßl, and ß is the intercept term. ß is a fixed effect that 
represents the NMB in the control group and X31 represents the INB from treatment. This 
model is sometimes known as an aggregated or a total regression model (Kreft and De 
Leeuw 1998). This model assumes that the INB is the same across all individuals and 
centres. The model therefore assumes that there is a common variance across the centres 
and no variability in the mean INB across the centres. 
9.32 Model 2: Centre-specific OLS models and fixed effects meta-analysis 
Using separate OLS models for each centre allows different mean INB and variances to 
be estimated for each centre (stage 1). 
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Thus for each jth centre each model provides an average NMB for the control group: %ßj, 
an average effect of treatment (the INB): /31j, and a centre-specific measure of the 
variance surrounding the residual: q2. 
yy=/ion+ßlßxy+&.; E; -Normal(O, a2) (model2) 
To estimate an overall effect a second stage may be used in the model, with the centre- 
specific estimates pooled across the centres using a fixed effects meta-analysis (stage 2). 
In this context a fixed effects meta-analysis assumes that the true INB in each centre is 
the same. To estimate the overall mean INB the means for each centre (j9 ,) are weighted 
(wj) according to the inverse of their variance (V) to give the overall mean estimate- fi 
AF =W1ß11 I where wj =1/V( 
ft1j) 
wý 
Those centres with a smaller variance surrounding their mean INB, are therefore given a 
higher weighting in calculating the pooled or overall mean INB. Therefore compared to 
the overall estimate from using the aggregated OLS, the results from the fixed effects 
meta-analysis move the overall mean towards those centres with smaller variancesss 
9.33 Model three: MLM with random slopes but common within-centre variance. 
A MLM can account for variability in the INB across centres by using a `random slope 
model'. The random slope model allows the regression coefficient representing the 
treatment effect or mean INB A, to vary randomly across the study centres. This requires 
that an additional error term, uj is included, which represents a different slope or 
treatment effect for each centre (see Chapter 5 for a detailed explanation). The mean INB 
for each centre is therefore A+ uj where ßi is the overall mean INB and uj the mean 
ss Note, in this context the difference with the overall estimate may be a subtle one, as the aggregated 
estimate will partly reflect the numbers of cases in each centre, and those centres with more cases may also 
be the centres with smaller variances. 
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difference in the INB for the individual jth centre. uu is assumed to be normally 
distributed with a mean of 0 and variance 2z. Just as with the random intercepts model 
(chapter 8) interest is in the size of the between-centre variance or level of heterogeneity, 
22. 
y; ý = , Oo; + (ßl + u; ) x,,. + eu ; Cy - 
Normal(0, a2) uj- Normal(0,,? ) (model 3) 
This MLM assumes that the mean INB for each centre is sampled from a normal 
distribution and that this distribution represents the TNB across all possible centres. Each 
centre is assumed again to have a different fixed intercept ßj, but a common variance c'. 
Shrinkage estimates can be used to shrink the centre-specific estimates in towards the 
overall mean (see Chapter 5). 
9.34 Model four: MLM with random slopes and different variances in each centre, 
estimated by either one-stage MLM, or two-stage MLM (random effects meta- 
analysis). 
MLMs do not necessarily have to assume a common patient-level variance across the 
treatment centres as in Model 3, and instead each centre can be allowed to have a 
different variance. This can be estimated in the one-stage model below where Q2 is the 
variance for the jth centre. 
yu =ßßj + (f31 + uj) xy + Cu; eu - Normal(O, Q 2) ur Normal(0, ý) (model 4) 
Alternatively, the same model can be estimated in two stages. In the first stage, the mean 
INBs (and their standard errors) are estimated for each centre. In the second stage, the 
mean estimates from each centre, are weighted to take into account the level of within 
centre, and between-centre variability (DerSimonian and Laird 1986) and then combined 
using the formula below to give an estimate of the overall random effect: 
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ýR=YWjAj 
E wj 
where ß; is the overall random effects estimate, Aj is the effect in the jth centre and 
w, is the weight given to the individual centre's INB. The weighting for each centre- w, 
is given by the inverse of the within centre and between-centre variances: 
i w; _ 
o, +a' 
This two-stage model is similar to the one-stage MLM described above (Higgins et at. 
2001). Shrinkage estimates are again used to provide estimates of the centre-specific 
mean INBs and their standard errors. 
9.35 Model five: MLM with different variances within and across centres with 
national-level covariates, estimated in either one stage or in two stages (meta 
regression). 
Model four can be expanded to include additional covariates to identify which factors are 
associated with variability in the INB. It is no longer assumed that the "true" estimates of 
INB are drawn from the same distribution with no systematic differences across the 
centres. Instead, the covariates included can be used to adjust for systematic differences 
across the centres. The extent to which adding national-level covariates can reduce the 
between-centre variability and improve the fit of the model can be investigated. The 
choice of national-level variable for this analysis was driven by the literature review and 
by the empirical costing work, which suggested that the proportion of GDP spent on 
health care (% GDP/health) was associated with variability in costs. The % GDP/health 
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variable was included as a categorical variable (low, medium and high %GDP/health)56. 
This allows cost-effectiveness to be analysed and presented for centres that fall into 
different strata of GDP spent on health care. Two categories of % GDP/health were then 
included as dummy variables, excluding a third, as the reference case. 
To investigate the effect of %GDP/health on the INH, an interaction with treatment was 
included for each of the %GDP/health dummy variables, as in the equation below: 
y;, =ß +(ß +u1)xg+A x, jzÜ+ß3xuwo+ey; (model 5) 
ey - Nonnal(0, q) ur Normal(0,22) 
where xu=1 if treated, 0 if control 
where zu=1 if medium % GDP/health, 0 otherwise 
where wu=1 if high % GDP/health, 0 otherwise 
yt represents the NMB across all cases, floj the intercept term is the average NMB in the 
control group with the reference level of %GDP/health, that is low % GDP/health. 81 
represents the INB for the low %GDP/health group, and the INB is allowed to vary 
randomly across the centres. A represents the additional effect of the medium % 
GDP/health group on INB, and ß represents the additional effect of high % GDP/health 
on INB. 
56 The % of GDP spent on health care was defined as low when <5.1%, medium between 5.1% and 5.5%, 
and high when % GDP/health >5.5. It is recognised that re-defining a continuous variable as a categorical 
variable is a simplification. 
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As with the previous MLM, a between-centre variance (uff) and an individual variance 
term (e, ) that is allowed to differ across the centres, are included in the model. The 
variance i now represents the residual variability in the NMB across the centres after 
adjusting for the covariates. 
This investigation of the effect of national-level covariates can also be done in two stages 
using a meta-regression model. Firstly, the mean and standard error of the INB are 
estimated in each centre, and secondly these estimates are used in a regression model 
with the mean INB in each centre as the dependant variable and the national-level 
variables as explanatory variables. Again, the two-stage meta-regression model should 
produce similar results to the one-stage MLM. 
9.4 Estimation 
OLS models and MLMs were fitted to estimate the effect of treatment on net monetary 
benefit- the INB. Treatment was defined as a dummy variable, with no treatment the 
reference category. The first OLS model was the aggregated or total regression model 
that estimated the effect of treatment over all cases and centres (model 1). The analysis 
was repeated fitting separate OLS regressions for each centre (model 2). The centre- 
specific INB and standard errors were pooled in a fixed effects meta-analysis to give an 
overall mean INB (model 2). 
Two MLMs (models 3 and 4) were fitted with normal random slopes representing 
variability in the treatment effect, across the different centres. Both models were fitted 
with a dummy variable for each centre, to give a different, but fixed intercept in each 
centre. Model 3 was fitted with a common variance across the centres and model 4 was 
fitted with a different variance for each centre. Model 4 was also estimated as a two-stage 
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model by using the centre-specific estimates from model 2 in a random effects meta- 
analysis. Model 5 was an extension of Model 4 and included interaction terms to examine 
the differential effect of %GDP/health on the INB (Model 5). This analysis was again 
repeated as a two- stage model by using the estimates from model 2 in a meta-regression 
(Model 5). In addition, to reporting the overall mean INB for each MLM, the centre- 
specific estimates of INB and their standard errors were reported using shrinkage 
estimates (models 3-5). 
The one-stage MLMs were estimated in MLwiN by restricted iterative generalised least 
squares (RIGLS), equivalent to restricted maximum likelihood (Rasbach et al. 2002), and 
using Markov chain Monte Carlo (MCMC) (Gilks et al. 1996). For each model residual 
deviances were reported which are equivalent to reporting -2*log likelihood and provide 
a measure of model fit. 57 Where one model was nested within another, the goodness of 
model fit was compared using a likelihood ratio test based on the difference in the 
residual deviance. The two-stage models were estimated by restricted maximum 
likelihood estimation in Stata 8.1 (Stata 2002). The DerSimonian and Laird test for 
heterogeneity was applied to the fixed and random effects meta-analyses (DerSimonian 
and Laird 1986). 
Finally, models 1-5 were re-fitted for a range of ceiling ratios; ?. was allowed to vary 
from $0 to $100,000 per life year gained (LYG). This enabled cost-effectiveness 
acceptability curves (CEACs) to be drawn that plot the probability that the intervention is 
cost-effective for different levels of the ceiling ratio (Fenwick et al. 2004). The 
probability that the intervention was cost-effective was estimated as 1-p/2, where p was 
the 2-sided value from the coefficient estimating the INB in each model (Hoch et al. 
2002). This is a Bayesian interpretation of probability i. e the probability that the 
intervention is cost-effective given the data (Briggs 1999). CEACs were presented for 
57 These measures of model fit are reported in preference to R= values as these were not available for the 
MLMs. 
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models 1 and 4, and the fixed effects meta-analysis based on the results of model 2. The 
models are summarised in the table below (Table 9.5). 
Table 9.5: Summary of the five models 
Modell Model 2 Model 3 Model 4 Model 5 
Aggregated Centre-specific MLM, same MLM MLM 
OLS OLS variance different different 
variances variances 
Model OLS OLS MLM MLM MLM 
Intercept fixed fixed fixed fixed fixed 
Variance common different common different different 
Slope common different/com random random random 
monSB 
Shrinkage no no yes yes yes 
Two-stage no yes, fixed no yes, random yes, meta- 
option effects meta- effects meta- regression 
analysis 59 analysis 
National- no no no no yes 
level 
covariates 
58 Different slopes were specified for the centre-specific estimates (stage 1), but then a common slope was 
assumed for the fixed effects meta-analysis (stage 2). 39 The centre-specific estimates from model 2 are also used in the random effects meta-analysis (model 4). 
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9.6 Results 
This results section starts by considering whether variability in INB within and across 
centres is an issue in this dataset, by presenting the results from models 1 and 2. The 
overall results of the first four models are then summarised and discussed. The CEACs 
are presented. Following this the impact of using shrinkage estimates on the centre- 
specific estimates of INB are described. Finally, the results from model 5, that uses a 
national-level covariate to try and adjust for systematic differences across the centres, are 
presented. 
9.61 Description of INB using OLS models (models 1 and 2). 
The results from the aggregated or total OLS model suggested that the overall INB was 
positive (p<0.05) (Table 9.6). However, the assumptions of no heterogeneity and 
common variance across all patients did not appear valid; heteroscedasticity was detected 
for the aggregated model (p<0.001 by the Cook-Weisberg test (Cook and Weisberg, 
1982) and the distribution of the residuals differed widely across the centres (appendix 5). 
The histograms also suggest that in some centres the patient-level residuals did not follow 
a normal distribution (appendix 5). The results from the regression analyses for each 
centre (model 2) showed that both the mean INB and the standard errors differed across 
the centres (Table 9.6, Figure 9.1). For most of the centres the treatment was not 
associated with a significant gain or loss in NMB; the confidence intervals surrounding 
the centre-specific mean INB mostly overlapped zero (Figure 9.1). 
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Table 9.6: OLS models estimating the overall INB (model 1), and the centre-specific 
INB (model 2) ['% =$60,000/LYG) 
Model Centre N Estimate (SE) 
1 All cases 1757 582 (285)** 
2 Portugal 108 959 (1109) 
2 Spain 49 620 (1806) 
2 Italy 136 -418 (966) 
2 France 132 1457 (883) 
2 Denmark 297 2177 (749)** 
2 Finland! 43 2001 (1061) 
2 Finland2 95 703 (902) 
2 Finland3 71 941 (1264) 
2 UK 108 1704 (1253) 
2 Poland 108 85 (789) 
2 Lithuania 1 80 -3089 (1123)** 
2 Lithuania 2 237 -1468 (659)** 
2 Latvia 252 -65 (842) 
** p<0.05 
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Figure 9.1: Centre-specific INBs (95% CI) from model 2 
9.62 Summary of overall estimates of INB for models 1-4 
The overall results from the first four models are summarised below (Table 9.7). The 
results show that the overall 1NB from model 2, derived from the fixed effects meta- 
analysis, was smaller and less significant than the INB estimated by the total regression 
model (model 1). Model 1 gave most weight to those centres with the most cases, 
whereas the fixed effects meta-analysis (model 2) gave most weight to those centre 
estimates with the lowest variances. The centres with the lowest variances were mainly 
those centres with the lower mean INBs. The standard errors surrounding the overall 
estimates from both OLS models were relatively small compared to models 3 and 4 as 
they ignored the heterogeneity in the INB across the centres. 
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Table 9.7: Summary of the overall INB estimated by models 1-4 
Modell Model 2 Model 3 Model 4 
Aggregated Centre- MLM, same MLM different 
OLS specific variance variances 
OLS 
Model OLS OLS MLM MLM 
Intercept fixed fixed fixed fixed 
Variance common different common different 
Slope common different/co random random 
mmon 
Mean INB (SE) 582(285) 345(263)60 430(406) 425(403) 
P value 0.04 0.19 0.29 0.29 
11.6(11.0)*105 10.5(11.4)*105 
Goodness of fit 35,544 35,320 35,378 35,308 
Deviance (MCMC) 
The MLMs (models 3 and 4) recognised the heterogeneity in the INB across the centres 
and therefore had much larger standard errors and p values for the overall mean INB, 
than either of the OLS models (Table 9.7). The overall mean INB for the MLMs was 
larger than estimated by the fixed effects meta-analysis (model 2), but smaller than from 
the aggregated OLS model. The MLMs estimates weighted each centre's estimate partly 
according to its own variance, so those centres with higher variance, mainly those with 
highest mean INBs, had their estimates down-weighted, so the overall mean INB was 
lower compared to model 1. However, the MLMs recognised that heterogeneity did exist 
across the centres, by weighting each centre's estimate according to the level of within 
and between-centre variance. The result was that when estimating the overall INB, the 
difference in the weighting given to each centre was smaller than for model 2. The down- 
60 The overall mean INB from model 2 is estimated using a fixed effects meta-analysis of the centre- 
specific results. 
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weighting of those centres with higher variances was therefore less extreme than for 
model 2 and therefore the effect sizes were larger. 
Estimating the MLMs using either the one or two-stage approaches produced similar 
estimates of mean INB, and between-centre variability61. The estimates from the MLMs 
assumed that there were high levels of between-centre variance, and the DerSimonian and 
Laird test for heterogeneity suggested that there was significant heterogeneity that was 
ignored in the fixed effects meta-analysis, and OLS models (Test for heterogeneity 
Q=29.773, p=0.003). The comparisons of goodness of fit showed that the MLM that 
allowed for different variances in each centre (model 4) had lower levels of residual 
deviance and fitted the data best. A likelihood ratio test, comparing the residual deviance 
between models 2 and 4, showed that model 4 fitted the data significantly better 
(p=0.002)62. The OLS model (model 2) that allowed for different variances across the 
treatment centres had lower residual deviances and therefore fitted the data better than 
either the MLM or OLS models that assumed a common variance across the patients in 
different centres (models 3 and 1). 
9.63 The impact of changing the threshold willingness to pay 
The analyses were repeated for each model for different thresholds of the ceiling ratio X. 
The CEAC plotted the probability the intervention was cost-effective against ). (Figure 
9.2). The MLM that recognised that heterogeneity existed and allowed for different 
variances (model 4) was the model that made the most appropriate assumptions. Using 
the aggregate OLS (model 1) underestimated the standard error and overestimated the 
treatment effect; this model therefore overestimated the probability that the intervention 
was cost-effective at all realistic levels of X. 
61 The results presented were those from using the MCMC estimation in MLwin. 62 The difference in residual deviance gives a chi-squared value of 18, which with 2 degrees of freedom 
gives ap value of 0.002. 
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Compared to the MLM (model 4) the fixed effects meta-analysis (model 2) 
underestimated the probability that the intervention was cost-effective at low levels of ?,, 
and overestimated the probability that it was cost-effective when ? was greater than 
$60,000 per LYG. 
The CEAC was steeper for the fixed effects estimate (model 2), and crossed the CEAC 
for the random effects estimate (model 4) at aI of just under $60,000 per LYG. The fixed 
effects estimate was determined by the level of within-centre variance and this changed 
with a,; where ) was low the centres with the lowest variances tended to have lower mean 
INB, the estimates from these centres were given higher weighting in the fixed (model 2) 
than the random effects model (model 4). However, as ? increased the variances 
increased most in those centres with lower net-benefits, these centres estimates were 
down-weighted more in the fixed than the random effects estimate, and consequently the 
overall estimate in the fixed effects model increased relative to the random effects 
estimate. The random effects estimate was less dependent on the within-centre variances, 
and hence the estimates were less sensitive to X. The more precise estimates for the fixed 
effects model (model 2) also caused the CEAC to be steeper than for the random effects 
model (model 4). 
A general problem with the CEACs plotted using the models considered above is that 
they assume a general value of ? for each decision-context. As this study included centres 
from countries at different stages of development it is unlikely that the same value of ? 
applies in each context. CEACs allow decision-makers to consider the probability that the 
intervention is cost-effective at various values of X. However, simultaneously changing 
the ceiling ratio in different decision contexts would make an overall CEAC very difficult 
to interpret. This issue is further considered in sections 9.65 and in the discussion (9.7). 
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Figure 9.2: CEACs for aggregate OLS model (model 1) vs fixed effects estimate 
derived from the centre-specific OLS regressions (model 2) vs MLM with random 
treatment effect (model 4) 
0. e ................................. 
p. o. e. 
0. e 
-- aggregated OLS (model 1) 
0.7 
p(cost -MLM (model 4) 
effective) 0. e iI fixed effects meta analysis for model 2 
0.5 ... 4............. / 
0.4 
0.3 i0.2 
I" 
0.1 ........... ......... 
1. 
0 
0 20000 40000 80000 80000 100000 120000 
7.. ($/LYG) 
9.64 The effect of shrinkage 
The mean INBs for each centre with 95% CI, are compared for models 2 and 4 to 
examine the effect of the shrinkage estimators used in model 4 (Figure 9.3). The results 
showed that, as anticipated the shrinkage estimators were closer to the overall mean, and 
the confidence intervals surrounding each estimator were narrower, indicating gains in 
statistical efficiency. Those centres estimates that changed most with shrinkage were 
those furthest from the overall mean and with the least precise results. 
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Figure 9.3: The effect of shrinkage: centre-specific and overall mean INB (95% CI) 
for fixed effects (model 2) and random effects (model 4) 
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9.65 Inclusion of national-level covariates- model 5 
The use of the shrinkage estimator assumes that those centres that diverge most from the 
random effects estimator are those that are the least precise. All the heterogeneity across 
the centres is therefore assumed to be random, and not due to systematic differences 
across the centres. However, the literature review and previous cost analyses suggested 
that certain factors, in particular the level of GDP spent on health care, are associated 
with differences in cost and potentially variation in INB across the centres. 
The results from model 5 showed that including the treatment by % GDP/health 
interaction terms improved the fit of the model (Table 9.8). The interaction terms were 
statistically significant and their inclusion reduced the level of unexplained variance at a 
276 
centre-level (the residual deviance is lower for model 5 than model 4). A likelihood ratio 
test showed that the model fit improved with the inclusion of the interaction terms 
(p = 0.04 )63. The mean INB for the reference group, those centres spending a low 
proportion of GDP on health care, was negative whereas those centres spending a 
medium or high level of GDP on health care had higher, positive, mean INBs. 
Table 9.8: Results from meta-regression analysis (model 5) estimating the effect of 
GDP/health on INB 
Coefficient Estimate (SE) 
Treatment -949(430) 
Treatment-covariate interactions 
Low GDP/Health*treatment reference 
Mid GDP/Health*treatment 2025(699)** 
High GDP/Health*treatment 2280(652)** 
1.21(3.6)* 105 
Deviance (MCMC) 35,302 
** p<0.05 
The figure below (Figure 9.4) used the estimates from model 5 to plot the estimated INB 
for each stratum of % GDP/health, alongside the centre-specific shrunken estimates of 
INB (model 4). The results show that the overall INB was significantly less than zero for 
the centres with low %GDP/health, and significantly greater than zero for those centres 
with medium or high levels of GDP spent on health care (Figure 9.4). 
63 Compared to model 4, model 5 had a reduction in the residual deviance giving a chi-squared of 6, with 2 
additional degrees of freedom. 
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Figure 9.4: Estimates of mean INB (95% CI) for each centre and overall estimates of 
mean INB (95% CI) for centres in countries spending low, medium and high % of 
GDP on health care (from model 5). 
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Model 5 was re-estimated for different levels of the ceiling ratio a,, and the results used to 
plot CEACs according to different strata of GDP spending on health care. The results 
show that for low GDP/health centres, the intervention was not cost-effective at different 
levels of X (Figure 9.5); for high GDP/health centres the intervention was cost saving and 
the intervention was cost-effective even if ?. was zero. For the mid GDP/health centres, 
the probability that the intervention was cost-effective was above 0.5 when ?. exceeded 
$25,000 per LYG. 
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Figure 9.5: CEACs based on estimates of INB from model 5, with adjustment for 
different levels of GDP/Health 
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9.7 Discussion 
The aim of this chapter was to examine whether using MLMs rather than OLS models to 
analyse multicentre cost-effectiveness data could lead to different results. The results 
showed that using an aggregated OLS model to report an overall measure of cost- 
effectiveness underestimated the uncertainty that surrounded the results. Using separate 
OLS models for each centre suffered from a lack of statistical power and pooling the 
estimates from these models in a fixed effects meta-analysis, ignored heterogeneity 
across the centres and overestimated the precision of the results. The MLMs, allowed for 
heterogeneity across the different centres and provided more accurate estimates of the 
uncertainty surrounding the results. The cost-effectiveness dataset used to compare the 
techniques was generated and further research using multicentre studies is required to 
compare MLMs with OLS regression analyses. The results presented here do though raise 
certain issues that need careful consideration when analysing multicentre cost- 
effectiveness data. 
The situation highlighted was where an intervention has the same cost and similar 
effectiveness across a range of centres, but has a differential impact on morbidity costs 
across centres. OLS regression analysis has recently been recommended for assessing the 
INB of one treatment alternative compared to another (Hoch et al. 2002), and could be 
applied to the situation described. However, using OLS regression analyses to estimate a 
single pooled mean INB does not appear appropriate in this context. This approach 
ignores differences in the mean and variance of the INB that may exist across centres. In 
this case study, compared to the MLM the aggregated OLS analysis overestimated the 
overall mean INB. It has been recently recommended that decision-makers choose the 
interventions that are on average relatively cost-effective (Claxton et al. 2002, Claxton 
1999), i. e. where the mean INB is positive. If OLS analyses fail to accurately estimate the 
mean INB, basing decision-making on these estimates could lead to the misallocation of 
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health care resources. There may be other circumstances where using OLS analysis to 
estimate mean INB may underestimate the cost-effectiveness of an intervention. For 
example, if the mean INB is lower in those centres with more patients, then the overall 
OLS regression analysis may underestimate the mean INB. 
While ignoring heterogeneity has an ambiguous impact on the mean estimate of cost- 
effectiveness the impact on the standard error surrounding the measure of cost- 
effectiveness is more generalisable. By ignoring heterogeneity, aggregated OLS analysis 
or fixed effects estimates based on centre-specific OLS analyses, underestimate the 
standard error surrounding the INB and overestimate the precision of the estimate. This 
would provide health care decision-makers with a false sense of certainty surrounding the 
overall result. The greater the uncertainty surrounding the mean estimate of cost- 
effectiveness, the higher the value of acquiring more information (Claxton 1999). So 
OLS analyses would overestimate the precision of the overall estimate of cost- 
effectiveness, and may understate the value of acquiring further information for assessing 
cost-effectiveness. 
Rather than using pooled OLS results, a decision-maker could use the separate OLS 
regressions for each centre, and base their decision on the most relevant result for their 
own setting. The main problem with using separate OLS analyses is that there is a lack of 
statistical power to detect whether differences in NMB exist between the interventions, 
and high levels of sampling variation therefore surround the results. In this case study 
only 3 out of the 13 centres had INBs that were statistically significant at the 5% level. 
Other international cost-effectiveness studies have concluded that there was a lack of 
statistical power to detect differences in cost-effectiveness according to the country 
concerned (Willke et al. 1998, Cook et al. 2003). A decision-maker in this situation is 
likely to consider the results from other centres, or the overall estimate, when deciding 
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which intervention is relatively cost-effective. This approach does not formally recognise 
the transfer of information from other centres, and does not use all the available data. 
The MLMs recognised the heterogeneity that existed across the centres, and adjusted the 
overall mean INB and standard error accordingly. The result was that compared to the 
overall estimates from the OLS analyses, the MLMs made a more accurate estimate of 
the mean INB and the sampling variation surrounding the result. The comparisons of 
model fit showed that the MLMs that recognised the differences in the mean and the 
variance of the INB across the centres, fitted the data best. 
In addition to providing an overall estimate of cost-effectiveness that recognises 
heterogeneity, MLMs can also provide shrunken estimates of centre-specific estimates 
and their standard errors. Those centres with outlying or imprecise estimates can borrow 
strength from those centres with more precise estimates. The centre-specific estimates are 
moved in towards the overall mean and are more precisely estimated compared to those 
based on the observed data. However, the use of shrinkage estimators highlights a 
potential problem with using MLMs in this context, in that the estimates from the 
individual centres are regarded as exchangeable: i. e. they are drawn from the same 
distribution (Spiegelhalter et al. 2000). In the context of multinational data the 
assumption that there are no systematic differences across the centres is contradicted by 
insights from economic theory summarised in the literature review (Chapter 4), and by 
the previous empirical results (Chapter 8). In particular, differences exist in budget 
constraints, factor prices and production processes across these health care settings; a 
priori reasoning would not appear to justify the assumption of exchangeability across all 
the health care centres. 
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To allow for these systematic differences across the centres additional covariates can be 
included in the MLM. The literature review identified several variables potentially useful 
for characterising differences across centres (Chapter 4), and one of these-the % of GDP 
spent on health care (%GDP/health) was chosen for this analysis based on the results of 
the cost analysis (Chapter 8). Compared to the basic MLM the inclusion of these 
covariates reduced the level of unexplained variability at a centre-level and improved the 
model fit. Presenting the overall results of the MLM for different strata of GDP spent on 
health care would therefore seem more appropriate, and the results for individual centres 
were reasonably comparable to the random effects estimate for the particular stratum of 
GDP spent on health care (%GDP/health). This model provides results that have more 
precise estimates than the centre-specific estimates, but does not make such strong 
exchangeability assumptions as using the overall random effects estimates or shrunken 
estimates without covariate adjustment. 
In multinational studies decision-makers in countries at different stages of development 
may face very different levels of X. In principle, a CEAC allows a decision-maker to see 
whether the results of a CEA are robust to different values of ?. However, although 
decision-maker in different countries can specify alternative values of X, incorporating 
these different values into a single CEAC, would make the overall CEAC very difficult to 
interpret. Instead, using the %GDP/health by treatment interaction in the regression 
models, allowed different CEACs to be drawn for different stratums of GDP/health. 
Using this approach assumed that the data, including the value of ? were exchangeable 
within, but not across different stratums of GDP/health. 
It cannot be concluded that the % of GDP spent on health care is the most appropriate 
variable for stratifying centres based on these results. The cost-effectiveness dataset was 
constructed making the assumption that the intervention reduced morbidity costs by 40%, 
and these morbidity costs were associated with the % of GDP spent on health care 
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(chapter 8). Hence, the association of the variable %GDP/heaith with INB was contrived 
through the design of this study, and would only apply to other cost-effectiveness studies 
bearing similar characteristics. Nevertheless, the approach illustrates how to relax the 
exchangeability assumption, and the potential importance of using a priori reasoning to 
stratify centres in a CEA. It also illustrates how MLMs can include covariates to try and 
reduce the level of unexplained heterogeneity across the centres. 
In other contexts, there may be strong a priori reasons for including different centre-level 
variables in a MLM for example, the presence of a DRG system, or the reimbursement 
method for physicians could in other circumstances be important variables. The choice of 
variables should be determined by a priori reasoning that uses theoretical principles when 
considering the likely variability in costs and cost-effectiveness for the settings and health 
care technologies in question. Theoretical reasoning would appear to provide stronger 
basis for choosing variables than simply identifying those variables that are statistically 
significant, which may just be an artefact of the dataset concerned. 
The analysis considered two alternative techniques for including covariates in MLMs. 
The first required the inclusion of covariate interactions with treatment. The second used 
a two- stage approach, with the centre-specific mean estimates regressed against the level 
of GDP spent on health care, in a meta-regression. Both approaches produced the same 
result, that in this example there was a differential INB according to the level of 
GDP/health. The two-stage meta-regression approach was easier to implement than the 
one-stage approach. However, the advantage of the one-stage approach is that it can be 
easily expanded to include patient-level covariates. This could be potentially useful when 
adjusting for baseline differences between treatment and control groups. For example, in 
this case study more patients were in coma at admission in the control group. The one- 
stage approach could easily be extended to include a treatment by coma interaction term 
to adjust for these differences. 
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MLMs have traditionally been used in other areas, e. g. education and the meta-analysis of 
clinical trials, but their use is relatively recent in health economics (Rice and Jones 1997). 
When developing a MLM to examine multinational cost-effectiveness data, this case 
study suggested it was important to avoid the assumption of common variance across the 
treatment centres, an assumption commonly made by MLMs in education (Goldstein 
1995) and recently in health economics (Carey 2000). In this example, the inter-patient 
variability clearly differed across the centres. Allowing the variance to differ across the 
centres improved the fit of the MLM, and should be considered during the analysis of 
multicentre cost-effectiveness data. 
One limitation of the MLMs developed in this chapter is that they assume the residuals 
are normally distributed. Whereas the histograms for the centre-level residuals showed 
that this assumption may be realistic (see appendix 5), this assumption appeared less 
tenable for the patient-level residuals, which at least in some centres, were clearly non- 
normally distributed (appendix 6). Instead, it was assumed that there were sufficient cases 
to invoke the central limit theorem and to presume that with the large numbers involved 
the normality assumption held. This has been shown to be reasonable for some cost 
datasets (Barber and Thompson 1998), and this assumption has also been made when 
analysing net benefits (Hoch et al. 2002, Manca et al. 2005). However, this work could be 
extended to investigate whether the hierarchical gamma models used in the cost analysis 
in Chapter 8, are also appropriate for analysing hierarchical cost-effectiveness data. 
Another alternative would be to investigate the use of the non-parametric bootstrap for 
analysing multicentre cost-effectiveness data. 
This cost-effectiveness analysis demonstrated that when the intervention leads to 
differences in morbidity costs across the centres, then the choice of MLM versus OLS 
regression analysis could make an important difference to the inferences drawn. 
Obviously, in multinational economic evaluations there may be other circumstances when 
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the difference in the results produced by the techniques is much smaller, for example 
when both the incremental costs and effects are similar across the centres. In other 
circumstances, drug prices might also differ across centres, leading to greater 
heterogeneity64. This chapter demonstrates the use of appropriate techniques for dealing 
with the heterogeneity that may exist across centres in a multicentre cost-effectiveness 
analysis. Few studies in the cost-effectiveness literature have used statistical techniques 
to test and adjust for differences across centres, when analysing cost-effectiveness. In a 
recent review, Barbieri et al. (2005) demonstrated that important differences in mean 
cost-effectiveness could exist across health care settings. However, this study did not 
provide any statistical measures of uncertainty or any formal tests of heterogeneity. 
Similarly Willke et al. (1998) demonstrated that important differences in the mean 
estimate of cost-effectiveness can exist across countries, however, the study lacked the 
power to detect whether these differences were statistical significant. Cook et al. (2003) 
used statistical techniques to report differences in the cost-effectiveness of simvastatin 
across several Scandinavian countries, and based on tests for heterogeneity concluded 
that there were not significant differences in the INB across the studies concerned. 
However, the tests for heterogeneity were underpowered, and they did not provide a 
strong basis for assuming that the INB did not vary across the countries concerned and 
that the overall INB was the appropriate measure of cost-effectiveness upon which to 
base decision-making. 
9.8 Conclusions 
To conclude, this chapter has shown that ignoring the hierarchical nature of multicentre 
cost-effectiveness data can lead to an inappropriate assessment of cost-effectiveness. The 
case study illustrated that by acknowledging the heterogeneity that exists across centres, 
MLMs can provide a more appropriate estimate of cost-effectiveness. MLMs also need to 
consider the systematic differences that exist across centres, using covariates suggested 
64 Countries may also differ in the outcome gains from an intervention, or the value of those outcome gains, 
Explicit consideration of these issues is outside the scope of this investigation which focuses on the impact 
of cost variation across settings on estimates of cost-effectiveness, 
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by economic theory. This chapter illustrated the issues raised when using these 
techniques for analysing a cost-effectiveness dataset. 
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Chapter 10: Discussion 
10.0 Introduction 
Economic evaluations are used in setting priorities in health care. For example, NICE use 
CEA to recommend which health care interventions the NHS in England and Wales 
should provide (NICE 2004). The use of CEA in decision-making has the potential to 
improve the efficiency of resource allocation in health care. However, this will only 
happen if these studies use sound methods, in particular if the costs used represent 
opportunity costs for the decision-context (Graves et al. 2002). Measuring opportunity 
costs is problematic and requires that costs reflect productive efficiency (Donaldson et al. 
2002). However, the observed costs of health care may vary across settings, for example 
hospitals in different geographical locations (Willke et al. 1998). It is unclear whether 
such variations reflect variations in productive efficiency, differences in contextual 
factors such as factor prices, or inconsistencies in costing methods. Unless studies 
disentangle the reasons for observed cost variation across health care settings CEA may 
continue to use costs that diverge from opportunity costs. 
The aim of this thesis is to assess why costs vary across health care settings, and the 
implications for the methodologies used in economic evaluation. The specific objectives 
stated in the introduction are: 
1. To assess how economic evaluations currently consider cost variation across 
settings. 
2. To generate hypotheses for why costs may vary across health care settings. 
3. To identify which factors are associated with variation in resource use and 
cost using MLMs and OLS regression models. 
4. To compare the use of OLS regression models to MLMs for analysing 
multicentre cost-effectiveness data. 
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The first section of this chapter considers the main findings from both the literature 
review and the empirical investigation in relation to each of these objectives. The second 
section reviews important methodological themes from the thesis alongside emerging 
issues in the literature. The third section discusses the limitations of the approach taken. 
10.1 Main findings from the thesis 
10.11 How does economic evaluation consider cost variation across settings? 
The literature review highlights that economic evaluations commonly ignore cost 
variation across settings at both the design and analysis stages. Health care providers in 
different settings may face different levels of factor prices, use various combinations of 
factor inputs and differ in the observed costs of producing health care programmes 
(Chapters 2 and 3). The review suggests that economic evaluations make fundamental 
decisions at the design stage that limit the consideration of these and other reasons for 
cost variation. For example, if studies only measure costs in one health care setting, it is 
unclear whether the costs measured are those of efficient production and therefore 
represent opportunity costs for the decision context concerned. Unless the costs used 
represent opportunity costs, the evaluations may make inaccurate estimates of the relative 
costs and cost-effectiveness of different health care interventions. The use of 
inappropriate cost estimates can hinder moves to improve the allocative efficiency of 
resource allocation. 
Recent multinational economic evaluations observed wide cost variations across health 
care settings, and found that ignoring this variation led to inaccurate estimates of cost- 
effectiveness (Chapter 3). However, these studies suffered from serious limitations. They 
did not use economic theory to pose hypotheses for why costs may vary. The studies 
failed to address measurement issues that pervade the comparison of costs across health 
care settings, and the analytical methods did not recognise the hierarchical structure of 
these cost data. 
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Studies are required that assess reasons why costs vary across health care settings, and 
identify circumstances where costs may depart from opportunity costs. An assessment of 
cost variation across settings can provide guidance on a number of methodological issues. 
For example, these studies can guide the numbers and characteristics of health care 
settings that an economic evaluation requires to help ensure that the costs collected 
represent opportunity costs for the decision context concerned. 
10.12 To generate hypotheses for why costs may vary across health care settings. 
a) Hypotheses generated from the literature 
The literature review generated hypotheses for why costs observed may vary across 
health care settings (Chapter 4). This review provided a conceptual framework for the 
ensuing empirical investigation. The production and cost function literature highlighted 
that firms could face different factor prices and therefore choose alternative input 
combinations whilst still minimising costs. However, the firm's ability to cost-minimise 
may depend on the health care context. For example, the level of labour input available to 
the health care firm may vary across countries because of differences in the national 
labour markets for health care professionals. Health care firms in certain countries may 
be more constrained in choosing the level of labour inputs required to maximise 
productive efficiency. Differences in patient factors in particular case-mix are also 
important in explaining cost variation across health care settings (Chapter 4). 
The literature review highlighted the problems involved in testing these hypotheses. The 
methodological guidelines for economic evaluation have not carefully considered the 
measurement issues that arise when comparing or using cost data collected from different 
health care settings (Chapter 2). For example, the guidelines are not prescriptive about the 
appropriate level of aggregation to use when measuring resource use or unit costs. 
However, where studies have taken an aggregated approach to cost measurement, it is 
unclear whether the same items are included in the unit costs or resource use measured in 
each health care setting (Chapter 3). An empirical investigation of cost variation across 
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health care settings needs to use a consistent method of cost measurement in different 
contexts. The review suggests that to reduce methodological inconsistencies across study 
settings a disaggregated approach to cost measurement is preferable. In addition, 
economic evaluations that considered cost variation across settings did not include 
sufficient cases or centres to identify systematic reasons for cost variation across health 
care settings (Chapter 3). A study comparing costs across settings should consider 
whether there are sufficient patients and settings to identify systematic cost differences. 
The review of the applied cost function literature emphasises the importance of adjusting 
for differences in case-mix, when comparing costs across health care settings (Chapter 4). 
Studies that estimated differences in efficiency across health care settings required data 
from many health care units. These studies therefore relied on administrative costing 
datasets and used the DRG system of case-mix classification, to adjust for case-mix 
differences across health care providers. Using these highly aggregated measures of case- 
mix meant that observed cost differences across health care settings could reflect 
unmeasured differences in the patient case-mix. Studies of cost variation across settings 
therefore need to use appropriate datasets that collect sufficiently detailed measures of 
patient case-mix to explore the role of differences amongst patients in explaining cost 
variation. 
b) Hypotheses from the dataset in the empirical investigation 
The case study used for the empirical investigation was a multinational stroke dataset 
comprising case-mix, resource use, and cost data on 1300 stroke admissions from 13 
centres in 10 European countries (Chapter 6). Detailed information on patient factors and 
resource use were measured for each patient for three months post-stroke. Information on 
unit costs and the characteristics of each centre and country were also collected (Chapters 
6 and 7). These data were used together with the findings from the literature review 
(Chapter 4) to pose hypotheses for cost variations. 
The resource use data illustrated that there were important differences in the way stroke 
care was provided across the study settings (Chapter 6). While each centre had an acute 
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hospital providing inpatient care, different alternatives to hospital care existed across the 
centres and the range of care alternatives available may be associated with differences in 
mean LOS across the centres. The access to and use of specialist technologies also varied 
across centres. In some settings, there was better access to specialist neurological 
services, or inpatient rehabilitation services. It was hypothesised that access to these more 
specialised technologies, led to a higher use of tests and investigations and higher health 
service costs. A national-level variable, the proportion of GDP spent on health care (% 
GDP/health), was proposed for inclusion in the subsequent regression analyses. This 
variable represented differences in the level of health care infrastructure across the 
countries concerned. There were also variations in patient factors such as case-mix across 
the centres and it was hypothesised that these differences may partly explain the observed 
variations in resource use and costs across the centres. 
The analysis of the unit cost data (Chapter 7) suggested that there were wide differences 
in factor prices across the centres, particular between those located within Eastern 
compared to Western Europe. These differences may arise because of inflexibilities in the 
European labour markets for health care professionals. There were also differences in the 
use of factor inputs that did not appear to reflect differences in relative factor prices. 
10.13. To identify which factors are associated with variability in resource use and 
cost using MLMs and OLS regression models. 
The review of economic concepts and statistical techniques highlighted some of the 
difficulties in identifying factors associated with cost variation (Chapters 4 and 5). 
Economic theory suggests that factors associated with cost variation operate at different 
levels. Statistical theory states that where data are hierarchical, using OLS regression 
analysis and ignoring the clustered nature of observations could lead to incorrect 
inferences about the reasons for resource use and cost variation. While the theoretical 
literature suggests that the choice of technique for analysing cost data might matter, the 
results from the empirical investigation provided an example of where the choice of 
technique did matter (Chapter 8). Using OLS regression analysis led to incorrect 
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inferences, in particular the significance of each of the higher-level variables was 
overstated. Once MLMs rather than OLS regression models were used to assess the 
reasons for cost variation, the only higher-level variable associated with cost variation 
was the % GDP/health. 
The % GDP/health variable may capture the effect of several factors that the data and the 
literature review suggested were likely to be associated with resource use, but which were 
not formally included in the regression equations. Insights from the literature review 
suggested that the % GDP/health variable was likely to represent differences across the 
centres in the quality of inputs, access to technology, and the national level of health care 
infrastructure. Those countries spending a high proportion of their GDP on health care 
are more likely to adopt new technologies, and ensure health professionals are highly 
trained. The descriptive data clearly suggested that in the Eastern and Southern European 
centres where the national levels of spending on health care were lower; there was less 
access to neurologists, organised stroke care, inpatient rehabilitation facilities and 
physiotherapists. It would therefore appear that there were different `models of stroke 
care' and that these models of care were associated with different costs. The variable % 
GDP/health therefore appeared to differentiate between these different models of care, 
and summarised the effect they had on costs. 
The MLMs confirmed that several other factors suggested by the literature review and 
data as likely to be associated with cost variation, were still statistically significant when 
an appropriate technique was used for assessing cost variation. More complex patient 
case-mix was associated with higher total cost, and the presence of care alternatives was 
associated with shorter LOS. The MLMs were therefore useful in identifying factors 
associated with systematic cost variations across the health care settings in the study. 
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10.14. Assessing the use of MLM compared to OLS for analysing multicentre cost- 
effectiveness data. 
The observational dataset used for the main aspect of the empirical investigation was 
extended to generate a multicentre cost-effectiveness dataset, comparing a new 
intervention for stroke patients to existing practice in each centre (Chapter 9). The 
analysis examined the implications of using a pooled OLS estimate to assess incremental 
cost-effectiveness compared to a MLM that allowed the relative cost-effectiveness of the 
intervention to vary across the health care centres. The results showed that the pooled 
OLS analysis provided an inaccurate, over precise estimate of relative cost-effectiveness 
compared to the MLMs. The MLMs recognised the heterogeneity that existed across the 
health care centres and gave a more accurate estimate of the mean cost-effectiveness of 
the intervention and the associated uncertainty. 
10.2 Central methodological themes emerging from the thesis 
The central methodological themes from the thesis fall under three main headings: the use 
of explicit a priori reasoning to identify reasons for cost variation, the use of MLM in 
health economics, and the methodological implications for economic evaluation. 
10.21 The use of a priori reasoning to identify reasons for cost variation 
This thesis used relevant strands from both microeconomic and statistical theory. The 
thesis found that the theoretical strands from these two disciplines were complementary 
to one another when identifying reasons for cost variation. The review of microeconomic 
theory found a priori reasons why costs may vary across health care settings (Chapter 4). 
Theory also suggests that systematic reasons for cost variation operated at different 
levels, for example at a patient, centre or national level. The cost data may therefore be 
clustered, for example within health care centres. Statistical theory states that where data 
are clustered using OLS regression analyses that assume observations are independent is 
inappropriate. MLMs recognise the data hierarchy and are more suitable for testing the 
hypotheses suggested by microeconomic theory in this context (Chapter 5). 
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Insights from production and cost function theory were used in the empirical 
investigation to choose the variables for inclusion in the cost functions. The cost 
functions specified cannot be regarded as the analogue of well-behaved production 
functions (Breyer 1987). There were insufficient patients or centres, to estimate isoquants 
and to test the extent to which each health care centre was exhibiting cost-minimising 
behaviour. However, the choice of independent variables was still made with recourse to 
economic theory, rather than resorting to an `anything goes' approach to cost function 
specification (Wagstaff 1989a). The variables included patient characteristics, the 
availability of substitutes for hospital care, incentives for the hospital to cost-minimise, 
and a measure for the level of health care infrastructure (% GDP spent on health care) in 
each country (Chapter 8). 
Insights from microeconomic theory were used when interpreting the results of the cost 
functions presented in the empirical investigation. The unexplained variations across the 
centres could relate to a number of factors excluded from the cost functions. These 
unexplained variations could reflect residual variations in patient factors, factor prices or 
differences in technical or productive inefficiency, as well as random variation across the 
centres (Chapter 8). 
The use of economic theory highlighted some of the measurement problems that arise 
when comparing unit costs across centres, particularly when those centres are drawn from 
economies at different stages of development. The use of the GDP Purchasing Power 
Parity indices to convert local currencies into US dollars was unlikely to reflect the 
relative opportunity cost of each input in each of the centres concerned. It must also be 
acknowledged that there was variability in the quality of inputs and outputs across the 
study centres. While the % GDP/health variable may have captured some of these effects, 
these factors may also have explained the residual differences found to exist at a centre- 
level (Chapter 7). 
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10.22 Issues arising when using MLMs in health economics 
MLMs have been used for some time in the statistical literature and have been widely 
used in research and policy-making in education (Goldstein 1996). Despite their 
conceptual advantages, prior to the commencement of this thesis MLMs had rarely been 
used in health economics (Rice and Jones 1997). The empirical analysis in this thesis 
demonstrated the use and appropriateness of MLMs for analysing international cost and 
cost-effectiveness data. Recent work by Manca et al. (2005) showed that similar 
advantages exist for using MLMs compared to OLS regression models when analysing 
cost-effectiveness data collected in multicentre trials in a single country. 
When applying the standard MLMs traditionally used in the education and HSR literature 
to the analysis of cost and cost-effectiveness variation, two key issues emerged that 
warrant further discussion: the skewed nature of the cost variable, and the assumption of 
exchangeability. MLMs commonly assume that the residuals from the regression 
equation are normally distributed. However, cost data are often highly skewed, and 
methods that assume either the raw data, or the residual from a regression equation are 
normally distributed, may not be appropriate. GLMs have been recommended for 
analysing non-hierarchical cost data as they can allow for the skewed distribution of the 
data whilst still reporting the arithmetic mean costs required by decision-makers (Barber 
and Thompson 2004). This thesis used GLMMs as they allow for the hierarchical 
structure of the cost data and a skewed distribution function can be chosen. Within the 
group of GLMMs the gamma model chosen allowed for the distribution of the cost data 
to vary by centre (Chapter 8). This model would seem particularly useful for analysing 
hierarchical cost data. An alternative model that also allows for the skewed nature of cost 
data is the non-parametric bootstrap. This model has been applied to clustered data in an 
educational context (Carpenter et al. 2003), but its use in analysing hierarchical cost data 
has yet to be tested. 
MLMs also rest on the assumption that data are exchangeable, that is they are drawn 
effectively at random, from the same distribution. This assumption has been made by 
another study that used shrinkage estimates in MLMs (Manca et al. 2005), to move 
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centre-specific estimates of incremental cost-effectiveness in towards the overall, random 
effects mean estimate. These models regard the variability between centres as random 
rather than attributable to systematic differences. However, in this thesis both the 
theoretical review (Chapter 4) and the empirical investigation (Chapter 8) suggested there 
were systematic cost variations across the centres included in the study. This thesis 
avoided categorising cost variation across settings as `random' and instead identified 
systematic reasons for cost variation. Before assuming that the cost-effectiveness data are 
exchangeable, the analysis included covariates to allow for systematic variations in costs 
across the centres (Chapter 9). As Spiegelhalter et al. (2000) point out: 
"... where there are known reasons to suspect specific units are systematically different, 
then these reasons need to be modelled.. " (Spiegelhalter et al. 2000, p21). 
This thesis therefore argues in favour of using covariates to adjust for systematic 
differences in costs and cost-effectiveness across health care settings, before making the 
assumption of exchangeability. After making these adjustments, it is more likely that the 
data can be assumed exchangeable across the health care settings, i. e. drawn from the 
same distribution. 
10.23 Methodological Implications for economic evaluation 
The literature review found gaps in the advice given on how CEA should be designed, 
analysed and presented. The empirical investigation has provided some potential 
solutions to the methodological issues raised relating to cost variation across settings. 
These solutions are described below and listed in Table 10.1. 
a) Insights for the design of economic evaluations 
There is little guidance available for those designing CEA alongside multicentre RCTs on 
the number of settings that should be included in the costing study, the characteristics of 
the study centre or the level of aggregation that should be used for cost measurement 
(Chapter 2). A further concern is whether it is necessary to measure costs in all centres or 
countries. Multinational studies have measured costs in a single country and generalised 
the results to other countries or measured country-specific unit costs, but combined these 
297 
with trial wide measures of resource use (Chapter 3). More recently, studies have 
measured country-specific resource use and unit costs (Willke et al. 1998). The 
guidelines for economic evaluation fail to offer advice on which study design is most 
appropriate. 
This thesis found that there was potentially wide variation in both resource use and unit 
costs across study centres (Chapters 6 and 7). In a multinational study, it may not be 
appropriate to simply collect costs in one setting or to pool cost results across settings. 
Also while it may be easier for analysts to measure unit costs, but not resource use in 
each centre, the findings in this study, highlight the importance of measuring resource use 
in a range of international health care setting. 
Basing estimates of total cost on resource use estimated from an atypical sub-sample of 
the countries recruited to a multinational study may generate inaccurate and misleading 
results. Taking this approach ignores systematic differences across the settings that may 
partly reflect differences in productive inefficiency. Basing cost estimates on an `average' 
measure of resource use or unit cost is unlikely to represent opportunity costs in any 
particular decision context. Analysts should consider estimating resource use and unit 
costs in more centres than is currently the norm in economic evaluations. The use of 
MLMs reveals the need to have data available from enough centres to enable the effects 
of higher-level variables to be estimated with adequate precision. One preferred strategy 
is therefore to undertake costing sub-studies on a random selection of patients from all 
centres, rather than on all patients from only selected centres. Studies can then consider 
why any observed variations in costs exist across settings. This can allow analysts or 
decision-makers in different countries to identify which cost estimates are most likely to 
approximate opportunity costs in their decision-making context. Estimating the resource 
use and unit costs in many health care setting would help identify the opportunity costs of 
each health care programme in each decision context. 
Once studies have identified factors that are associated with cost variation this can inform 
the design of future CEA. If the level of health care spending is found more generally to 
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be associated with total or incremental costs, then a multinational study could select 
centres likely to represent opportunity costs in countries with high, medium or low levels 
of spending on health care. Decision-makers in each of these settings could then base 
their decisions about relative cost-effectiveness on relevant cost data. 
The methodological guidelines reviewed were not specific about the level of 
disaggregation that should be employed when estimating resource use or unit costs. In 
this study, a highly disaggregated approach was taken to resource use and unit cost 
measurement, particularly for labour costs. Factor inputs and factor prices were measured 
for each labour input, in each centre. Collecting these disaggregated data provided further 
insights into why costs varied across settings, in this case differences in wage rates across 
countries were found to be particularly important. This disaggregated approach meant 
that indices could be used to summarise differences in relative and absolute prices, and 
technology-specific purchasing power parity (PPP) indices were constructed. The use of 
technology specific PPPs showed that the main results were not sensitive to the choice of 
conversion factor. Other international costing studies have also taken a disaggregated 
approach to cost variation and constructed technology specific PPPs to test the robustness 
of their results to the choice of conversion factor (Hutton 2001, Wordsworth and 
Ludbrook 2005). 
Although there were advantages associated with taking a disaggregated approach the 
opportunity costs of this use of research resources must be recognised. Taking a detailed 
approach limits the number of settings where the study is able to collect cost data. An 
extreme alternative would be to collect cost data across many different settings using 
highly aggregated, routinely collected data. The main problem with this approach is that 
methodological inconsistencies, in particular in the measurement of costs would limit the 
study's ability to detect systematic cost variations (Schulman et al. 1998). On balance, 
this thesis advises against using a highly aggregated approach certainly in a multinational 
context, where methodological differences in cost measurement across settings appear an 
important problem. 
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Table 10.1: Summary of the issues related to cost variation across settings that arise 
during the conduct of CEA and proposed solutions 
Issue Raised Proposed solution 
Study Design 
0 No centres for resource use or unit 
cost measurement? 
" Choice of centres for resource use 
or unit cost measurement? 
0 Multinational studies: measure resource 
use, unit costs in several countries. 
0 Use higher-level factors for example % 
GDP on health care in international studies 
" Appropriate level of aggregation in " Further disaggregation into factor price 
resource use or unit cost and factor inputs, useful. 
measurement? 
Study analysis 
" How to pool resource use, unit cost " Pooled data using OLS regression can 
or total cost data across settings? 
" How to analyse cost data to allow 
for differences in the mean and the 
distribution of costs across settings? 
" How to adjust the cost parameters 
in a model to estimate cost- 
effectiveness in different settings? 
Presentation of study results 
" How to present context specific 
results in multicentre studies? 
" How to use statistical methods to 
make results more representative of 
the decision context? 
" How to consider the extent to which 
the results are generalisable? 
lead to misleading results. 
" MLMs provide accurate estimates of 
mean cost-effectiveness and associated 
precision. 
" Use relationships between patient and 
higher-level factors and total costs. 
" Use shrinkage estimates after adjusting 
for systematic differences. 
" Random effects estimate provides a 
potentially more generalisable estimate. 
" Centre and country-level covariates can 
be used to provide limits on 
generalisability/ assist with transfer of 
results. 
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b) Insights provided for the analysis of cost data 
The review of the guidelines found that little attention has been given to how resource use 
and cost data should be analysed to take account of variation in costs and cost- 
effectiveness across settings (Chapter 2). The empirical investigation compared methods 
for identifying reasons for cost variation across settings. An important finding from this 
investigation was that when OLS regression analyses were used to identify factors 
associated with international cost variation, they overestimated the statistical significance 
of the centre and national-level variables (Chapter 8). Previous studies that used OLS 
regression analysis to compare costs across health care settings did not recognise the 
hierarchical nature of cost data (Coyle and Drummond 1998, Willke et al. 1998) and may 
have overestimated the statistical significance of centre-level variables associated with 
cost variation (Coyle and Drummond 1998). MLMs provided more accurate estimates of 
the effects of the centre and national-level variables and their standard errors. This thesis 
therefore recommends the use of MLMs for identifying reasons why costs may vary 
across health care settings (Chapter 8) 
The problems associated with analysing skewed hierarchical cost data were examined. 
Previous studies suggested that GLMs are attractive for analysing non-hierarchical cost 
data (Manning and Mullahy 2001, Barber and Thompson 2004). This thesis suggests that 
GLMMs are attractive for analysing cost data that are both skewed and hierarchical 
(Chapter 8). 
OLS regression models and MLMs were compared for analysing mutticentre cost- 
effectiveness data in an international context. The results showed that pooling results 
across settings using OLS regression analysis may lead to inaccurate mean estimates of 
cost-effectiveness and an underestimation of uncertainty. Using OLS analyses to estimate 
cost-effectiveness separately for each setting, suffered from a lack of statistical power 
(Chapter 9). The problem of a lack of statistical power also pervades recent suggestions 
to use tests for heterogeneity in this context (Cook et al. 2003). MLMs would appear the 
more appropriate alternative for analysing hierarchical cost-effectiveness data. The 
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overall estimates from a random effects model provides an accurate estimate of the 
overall cost-effectiveness and the uncertainty that surrounds it. 
c) Insights for the presentation of results 
The presentation of study results should incorporate the different forms of uncertainty 
that surround the mean estimates of cost-effectiveness and much progress has been made 
on methods for accounting for sampling variation in economic evaluation (Briggs and 
Gray 1999, Fenwick et al. 2004). Recent developments in this area have acknowledged 
the heterogeneity that may exist across patient groups, and sub-group analysis is now 
recommended for CEA that are submitted to NICE in the UK (NICE 2004). However, 
less attention has been given to understanding variations across settings. The evidence 
from this and other recent studies suggests that there are systematic variations in costs 
across settings (Willke et al. 1998, Coyle and Drummond 1998, Manca et al. 2005) and 
this cost variation should be recognised alongside other forms of uncertainty in the 
presentation of results. 
One way of highlighting this cost variation across settings would be to present setting 
specific cost-effectiveness results, however, there may be insufficient power in the study 
to do this, and this is an inefficient use of available information. The results from the 
empirical investigation suggested that using the centre-specific shrinkage estimates from 
the MLMs may be an appropriate way of presenting variation across settings (Chapter 9). 
However, a fundamental assumption that has not been challenged by other studies using 
MLMs (Manca et al. 2005) is that the data are exchangeable across the settings 
concerned, i. e. that they are drawn from the same distribution. This assumption was not 
plausible for this case study, as both the theoretical review and empirical analysis of cost 
data suggested that there were a priori reasons for expecting systematic variations in 
incremental cost-effectiveness across the study settings. This thesis therefore 
recommends that before making the exchangeability assumption, covariates (in this case 
% GDP/health) are used to adjust for systematic variations across health care settings. 
The use of covariates can highlight contexts where adopting a new intervention may not 
improve productive efficiency. This can help ensure that subsequent attempts to compare 
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the cost-effectiveness of interventions across different disease areas do not include 
inefficient alternatives (Chapter 9). 
If there are systematic cost variations across settings, this has implications for the 
generalisability of a study's results. In the economic evaluation literature statements 
about the generalisability of results across health care settings tend to be made without 
recourse to economic theory or evidence (Mason 1997). The mean estimate of cost- 
effectiveness is usually assumed to apply to all health care settings within the study 
setting, and to generalise to health care settings not included in the study. The results 
from this study suggested some limits to the generalisability of cost and cost- 
effectiveness results across health care settings. 
Covariates can be used to provide boundaries for the generalisability of cost-effectiveness 
results. These boundaries may help decision-makers in countries not represented by 
centres in the study to assess whether the results of the CEA apply to their decision 
context. The cost-effectiveness results presented in this thesis would be inaccurate if the 
results for those countries with high or medium levels of spending on health care were 
transferred to those countries with relatively low levels of spending on health care 
(Chapter 9). The costs in the study context would be highly unlikely to represent 
opportunity costs in the decision context. Instead, the random effects mean estimates for 
each stratum of GDP spent on health care (high, medium, low) could be applied to other 
centres that fall within the same stratum of GDP spending on health care. The use of 
covariates therefore provides a `rule of thumb' for deciding which result is most 
. appropriate for a centre outside the study 
65 
Rather than arguing that the % of GDP spent on health care is the variable to use when 
generalising results in other multinational studies, this thesis presents a methodology for 
65 Clearly, care still has to be taken as there may be countries that meet the criteria for low or high levels of 
GDP spending on health care, that have very different characteristics to the countries participating in this 
study. It may be helpful to use the range of health care spending observed amongst countries included in 
the study to place upper and lower boundaries on the contexts that the results from such a study could be 
applied to. In addition, other data on covariates suggested in the literature review as being associated with 
costs, may be compared between centres included in the study and those in the new decision context to 
assess whether the result can be regarded as transferable. 
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considering cost variation that could be more generally applied. In particular, using 
MLMs to identify the covariates that are associated with cost variation, could further 
understanding of cost variation across health care settings. The literature review provided 
a list of covariates potentially associated with cost variation, and in other contexts these 
covariates, may provide an appropriate basis for deciding when the results of an 
economic evaluation can be generalised to different decision contexts. 
The focus of this study was on improving the methods of cost and cost-effectiveness 
estimation where patient-level data are available. However, the literature review also 
highlighted that cost variation across settings is important in the context of model-based 
economic evaluations (Chapter 3). Little guidance exists on how models should consider 
cost variation across countries although models have been suggested as a panacea for 
problems of generalisability (Drummond and Davies 1991). Models have been used to 
`adapt' costs collected in one setting to another (Drummond and Davies 1991). Often 
there is little basis for the way costs have been adapted, beyond the use of expert 
opinions' on the likely differences in resource use. Instead the covariates identified in this 
thesis could be used in a cost-effectiveness model to transfer the results of a cost analysis 
to a different country. This thesis argues that even if a cost-effectiveness model is used to 
transport costs across settings, the transfer of costs should be based on theoretical and 
empirical insights, and not according to commentators' speculations. 
10.23 Methodological Implications for the broader cost function literature 
In their forward to the Handbook of Health Economics Culyer and Newhouse (2000) 
highlight the importance of importing ideas from other disciplines to health economics, 
but also of exporting findings from health economics to inform other disciplines, While 
the main contribution of this thesis has involved transferring ideas from microeconomics 
and statistics into economic evaluation, there are also findings from this thesis that can be 
exported to the more general literature on cost functions. 
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The cost function literature has been dominated by studies estimating variations in 
technical, productive and scale inefficiency across health care settings (Cowing and 
Holtmann 1983, Wagstaff 1989b, Jacobs 2000, Hollingsworth 2003). These studies have 
concentrated on cost variability at the level of the health care setting; patient-level cost 
variation has been largely ignored. This is true of studies using non-frontier estimation 
techniques (such as OLS models), but also of studies using frontier estimation techniques 
(such as deterministic OLS, DEA, and SFA). These studies have relied on routinely 
collected, highly aggregated datasets (Chapter 5). Disaggregated datasets with sufficient 
observations at both a patient and centre level have not been available. 
The results presented suggest that differences in patient characteristics are important in 
explaining resource use and cost differences across health care settings. The use of 
MLMs found that unexplained variation at a patient-level was much larger than at a 
centre-level. Carey (2000) used a MLM to assess patient and centre-level cost variability 
amongst health care providers in the US, and came to similar conclusions. Ignoring the 
measurement issues posed by inter-patient variation therefore appears to be an important 
omission. Previous studies could have made inaccurate inferences about the effect of 
contextual factors such as incentives to cost-minimise on levels of inefficiency (Conrad 
and Strauss 1983, Cowing and Holtmann 1983). 
When assessing reasons for inefficiency further consideration should be given to 
capturing variation across patients. As more disaggregated cost datasets become available 
in health care, it would seem desirable to extend existing techniques for measuring 
efficiency to allow for variability at different levels of the data hierarchy. Both SFA and 
DEA have been recently applied to panel datasets that allows for variability over time to 
be examined (Jones 2000), and this may in itself reduce the impact of ignoring 
unexplained patient variation. However, based on the results of this thesis, extending the 
use of DEA and SFA to include patient-level variation would appear highly desirable. 
305 
10.3 Limitations 
The case study used in the thesis was an observational costing study covering 13 centres 
in 10 different countries. The study did not include sufficient patients or centres to 
formally test some of the hypotheses emerging from the literature review. For example, it 
was not possible to examine whether differences in technical or productive efficiency 
explained cost variation across settings. To estimate efficiency requires the use of a 
frontier estimation method, rather than one based on a measure of central tendency. 
Frontier estimation techniques tend to require the use of datasets with many observations 
at a centre level, which are only available from routine highly aggregated datasets. The 
use of a disaggregated dataset was able to assess some of the measurement issues that 
pervade the analysis of aggregated datasets, and should be regarded as complementary to 
more aggregated analyses. 
The use of disaggregated data allows the thesis to tackle some but not all of the 
measurement issues involved in comparing costs. The cost analysis did not allow for 
differences across the centres in patients' outcomes. Production function theory 
highlights that if the inputs used in the production function of health care change, then 
outcomes may also vary. Previous work undertaken as part of the empirical study found 
that survival differed across the centres after adjusting for patient factors (Grieve et al. 
2001a). The problem with incorporating survival into the cost function was that it led to 
difficulties in the interpretation in the cost function. Differences in cost across the centres 
could lead to differences in survival or vice versa. The pragmatic solution taken to this 
problem was that the main analysis in the thesis only included those patients who 
survived for at least three months post-stroke (Chapters 6-8). Any conclusions regarding 
the reasons for cost variation only therefore apply to this group of patients. 
The cost-effectiveness analysis (Chapter 9) did include both survivors and decedents. 
This analysis considered the use of MLMs for analysing hierarchical cost-effectiveness 
data. The scope of the analysis was limited to considering the impact of cost variation 
across settings on the relative cost-effectiveness of a new technology. However, the 
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relative effectiveness of health care interventions may also vary across health care 
settings. Indeed, even if there is no differential effect in clinical effectiveness according 
to setting, there may still be important differences in the value of a given effect across 
different cultures. The estimates presented in this thesis therefore do not capture the full 
implications of variability between health care settings on the relative cost-effectiveness 
of different health care interventions. 
The empirical investigation used cost data for a particular disease -- stroke care in a 
certain context -- care for hospital-admitted stroke patients in different European centres. 
Previous research found wide variations in the way hospital-admitted stroke patients were 
managed across different European centres (Beech et al. 1996, Wolfe et al. 1999). The 
patient factors that this thesis found are associated with resource use and total cost 
variation are particular to this disease area and context and should not be regarded as 
generalisable to other disease areas or geographical locations. While the country-level 
variable, the % of GDP spent on health care, might be associated with international cost 
variation in other contexts, further studies are required to identify factors associated with 
cost variation more generally. By contrast the conceptual framework, based on using 
microeconomic theory to generate hypotheses and testing these hypotheses using MLMs 
would appear transferable to other disease areas and contexts. 
A central argument in this thesis is that to understand reasons for cost variation across 
settings, it is necessary to use a consistent costing methodology in each health care 
setting. In general, the disaggregated approach taken did enable measurement problems to 
be identified rather than concealed. However, some of the residual variations at both 
patient and centre-level may reflect problems in applying consistent methods in each 
international setting. In particular, the allocation of overheads in each setting relied on the 
methods used in each finance department, and this may partly explain some of the 
observed variations in unit costs. A further problem was that none of the conversion 
factors used allowed the costs reported in a common currency to represent the 
opportunity costs of those resources in each health care setting. 
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The thesis used MLMs to distinguish between cost variations at a centre as opposed to a 
patient-level. The choice of two levels in the models was a pragmatic one, based on the 
numbers of patients, and centres included in the study. Ideally, the analysis would have 
included separate levels for centres and countries. However, there were insufficient 
centres within each country to allow for this third level in the hierarchy. In studies 
including more centres in each country, the analytical methods presented here could be 
extended to analyse variation at more than two levels. More complex MLMs could be 
estimated that recognise the clustering of observations within individuals, individuals 
within particular care areas e. g. wards, wards within centres, centres within regions, and 
regions within countries. 
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Chapter 11: Conclusions 
11.0 Contribution of this thesis 
The overall contribution of this thesis was to raise awareness about the way costs are 
currently measured and analysed in economic evaluation. The thesis identified particular 
problems with the way CEAs currently consider cost variation across health care settings. 
The thesis highlighted that existing approaches to cost variation across health care 
settings are inconsistent with economic and statistical theory, and can lead to inaccurate 
estimates of costs and cost-effectiveness. Basing decision-making on inaccurate 
assessments of cost-effectiveness can move the allocation of health care resources away 
from the target of allocative efficiency. 
CEAs that recognise cost variation across health care settings can provide a stronger basis 
for decision-making. This thesis exposed the methodological problems associated with 
previous attempts to examine cost variation across settings. The major contribution of the 
thesis was to develop a more appropriate methodology for identifying reasons for cost 
variation across settings and the implications for economic evaluations. This approach 
had three important methodological strands, each of which contributed to existing 
literature in this area. 
Firstly, microeconomic theory was used to pose hypotheses for the reasons for cost 
variation. Previous studies have tended to disregard theory when analysing cost variation 
across settings. This thesis demonstrated the use of microeconomic theory for identifying 
factors associated with cost variation across settings. For example it highlighted that costs 
may vary because of differences in patient factors or centre-level factors such as factor 
prices. 
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Secondly, the literature review found that previous studies took a highly aggregated 
approach to cost measurement. This approach disregarded measurement issues that arose 
when comparing costs across settings. An important contribution of this thesis was to 
present a disaggregated approach to cost measurement that could disentangle the reasons 
for cost variation across international health care settings. Price and volume indices 
originally developed on time series data, were applied to a different context: to examine 
the role of price and volume differences in explaining cost variation across health care 
settings. The empirical investigation used a disaggregated multinational stroke dataset to 
investigate whether the a priori reasons suggested by theory did explain systematic cost 
variations across settings. The investigation demonstrated that there were wide 
differences in factor prices across the centres, particular between those located within 
Eastern compared to Western Europe. The thesis illustrated that taking a more 
disaggregated approach offered clear insights into the reasons for cost variation across 
international health care settings. 
Thirdly, the thesis demonstrated the use of statistical techniques that recognised the 
hierarchical structure of international cost and cost-effectiveness data. The use of MLMs 
in health economics was previously recommended. However, recent cost and cost- 
effectiveness analyses have not used MLMs and have tended to rely on OLS regression 
analyses that disregard the inherently hierarchical structure of these data. Statistical 
theory states that where data are hierarchical, using OLS regression analysis that ignores 
the clustered nature of observations can lead to incorrect inferences. While the theoretical 
literature suggested that the choice of technique for analysing cost data might matter, the 
results from the empirical investigation provided an example of where the choice of 
technique did matter. Using OLS regression analysis led to incorrect inferences, in 
particular the significance of each of the higher-level variables in explaining cost 
variation was overstated. Once MLMs rather than OLS regression models were used to 
assess the reasons for cost variation, the only higher-level variable associated with cost 
variation was the proportion of GDP spent on health care. The empirical investigation 
also demonstrated that in an evaluative context, OLS regression analysis can lead to 
inaccurate estimates of the mean incremental cost-effectiveness, and the associated 
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uncertainty. The thesis used a generated international cost-effectiveness dataset to 
demonstrate that MLMs were also appropriate for analysing between-centre differences 
in cost-effectiveness. A further contribution of the thesis was to highlight that the 
assumptions made when using MLMs in other sectors such as education or health 
services research, may not be appropriate for analysing cost or cost-effectiveness data. In 
particular, MLMs typically assume that the residuals are normally distributed, an 
implausible assumption when analysing skewed cost data. The use of generalised linear 
mixed models (GLMM) was found to be more appropriate, and proved attractive for 
analysing cost data that were both skewed and hierarchical. The thesis also highlighted 
that when analysing multinational cost-effectiveness data it was important to challenge 
the assumption that the data were exchangeable. The methodology presented emphasised 
the use of national-level covariates to adjust for systematic differences across health care 
settings when estimating cost-effectiveness. 
In summary, the major contribution of this thesis was to raise concerns about the way 
costs are measured and analysed in CEA. This thesis extended previous studies by 
demonstrating the use of a method rooted in economic and statistical theory for 
identifying reasons for systematic variation across health care settings. This method can 
be applied to multicentre cost and cost-effectiveness analysis. It is proposed that by 
recognising variation across health care settings, studies can provide more accurate 
estimates of cost and cost-effectiveness and the associate levels of uncertainty, and 
therefore provide a stronger basis for health care decision-making. 
11.1 Areas for further research 
In addition to making contributions to knowledge in this area, this thesis identified areas 
that are worthy of further research. 
The scope of this thesis was limited to the assessment of cost variation across settings. It 
is plausible that if resource use varies across health care settings, then there may also be 
differences in outcomes. Ideally, an economic evaluation would identify factors 
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associated with variation across settings in outcomes, costs and incremental cost- 
effectiveness. To assess variations in these parameters, studies need to assess cost- 
effectiveness across sufficient health care settings. 
While the focus of the empirical contribution was on observational cost data collected in 
a multinational context, the underlying methodological concerns raised by ignoring cost 
variation across health care settings may apply more generally, for example to national 
multicentre CEA. MLMs would also appear useful for assessing variation in this context. 
Indeed, Manca et al. (2005) have suggested that MLMs are appropriate for assessing 
variation in cost-effectiveness across different health care centres within a country. 
Further work, across more disease areas and contexts, is required to improve 
understanding of variations in costs, outcomes and cost-effectiveness using the 
methodologies presented in this thesis. This research could examine for example whether 
costs and cost-effectiveness vary if the interventions' costs are measured in a setting 
treating a high volume as opposed to a low volume of patients. 
This thesis highlighted that CEAs often fail to consider the choice of centres for cost 
measurement. The empirical investigation suggested that in an international context there 
may be wide variations across centres in resource use, unit costs and total costs. Hence, in 
this context the choice of centre for costing purposes could have an important impact on 
the results. Further research is needed to establish why costs in particular centres may 
diverge from opportunity costs. 
Finally, there is scope for considering further the measurement issues that arise when 
when estimating productive efficiency. It appears that practical constraints rather than 
conceptual reasoning have led the cost function literature to avoid considering inter- 
patient variability and inconsistency of cost measurement across settings. As economic 
evaluations continue to collect data alongside multicentre studies it may become more 
feasible to use techniques for measuring efficiency on more disaggregated datasets. Also, 
if the quality of routine datasets improve and have more consistent cost estimates and 
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collect more detailed data on patient case-mix, it may become worthwhile using these 
datasets to identify reasons for cost variation. 
11.2 Policy implications. 
The use of economic evaluation in policy-making can make the allocation of scarce 
health care resources more efficient. However, if economic evaluations provide results 
that are inaccurate or irrelevant to the decision-maker concerned, then their use may lead 
to further allocative inefficiency. This thesis argues that ignoring cost variation across 
health care settings leads to inaccurate results. Also, without information on why costs 
vary across settings, a decision-maker may be unable to assess how the results from a 
study can be applied to their particular context. Policy-makers may therefore ignore the 
results of economic evaluations or inappropriately apply them to their local context. 
In several countries, decisions on the use of health care technologies are based, at least in 
part on the use of CEA. In England and Wales NICE now makes recommendations to the 
NHS on the use of health care technologies. It is clear from the methodological guidelines 
NICE issues that such decisions should be based on soundly conducted studies with 
particular attention given to the uncertainty that surrounds the studies' results (NICE 
2004). Yet the guidelines do not give advice on how uncertainty that arises from cost 
variation across settings should be recognised or dealt with. The results in this thesis 
suggested that there can be systematic reasons why costs vary across health care settings. 
The thesis proposes methods for measuring, analysing and interpreting this variation. In 
particular it suggests that policy-makers should take great care before transferring results 
from different countries, for use in their own jurisdiction. Decision-makers should be 
aware that multinational economic evaluations that ignore cost variation across settings 
may produce inaccurate estimates and may not lead to appropriate health policy 
decisions. The use of covariates to stratify the results of cost-effectiveness analysis may 
allow decision-makers in countries not represented by a study to assess the relevance of 
their results to the local context. 
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This thesis illustrates a methodological approach that can encourage economic 
evaluations to provide results that are more relevant to policy-making. It highlights the 
potential importance of considering cost variation when making decisions about health 
care priorities. It may also help researchers to think about placing boundaries on the 
generalisability of their results. Just as developments such as the cost-effectiveness 
acceptability curve have been useful for communicating sampling uncertainty to policy- 
makers, so the use of MLMs, may help demonstrate where there are systematic variations 
in costs and cost-effectiveness across settings. 
In summary, an important aim of health policy makers is to improve the efficiency of 
resource allocation. To move towards this goal policy-makers require economic 
evaluations that use appropriate methodologies. This thesis provides an approach that can 
identify reasons why costs vary systematically across health care settings. Using this 
approach can improve the methods used in costing studies. The thesis argues that if future 
economic evaluations use this approach this can improve the conduct of cost and cost- 
effectiveness analyses so that these studies provide a sounder basis for health policy- 
making. 
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Appendix 1: Biomed 2: resource use and costing questionnaire 
This questionnaire lists the resource and cost data that we need to collect during our 
fieldwork visits to centres. We have also indicated who is likely to supply these data 
based on our experiences in United Kingdom hospitals. Please modify the contact list if 
you think that it is more appropriate for us to obtain the data from an alternative source. 
The focus of the costing exercise will be the main study hospital so most of our visit will 
concentrate on getting information from cost centres at this hospital. However, where a 
substantial amount of care is provided at more than one hospital site (as in Dijon where 
patients are transferred to a rehabilitation unit), we will need to visit these other hospitals 
to collect the information required. 
The questionnaires will be completed at the meetings we will have during our visit. We 
are distributing copies of the questionnaire now, to help centre co-ordinators plan our 
visits, and to give staff adequate warning of the type of data we need. 
(1) Background information 
Contact: the centre co-ordinator 
9A confirmation of the wards where the major stroke care provision is. 
9 An update on data collection at the centre 
9A discussion of concerning more detailed study in this centre (see section 8) 
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(2)Cost category: Nursing costs 
Contact: Nurse Managers at the wards providing the majority of care for stroke 
patients. 
(e. g. general medicine, elderly care, neurology, intensive care unit etc) 
" The total number of beds on the ward. 
" The number of occupied bed days used per year and the current occupancy of the 
ward. 
" The number of occupied days per year used by stroke patients. 
" The nursing levels on each of these wards in terms of whole time equivalents by 
grade/ type of nurse (during night shift/ day shift). 
" The role of each type/grade of nurse in the care of patients and the qualifications and 
experience that they need before they can be employed in that role. 
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(3) Cost category: Doctors' costs 
Contact: Representatives from the main clinical specialities involved in the care of 
stroke patients. 
9 The total number of clinical staff available for inpatient and non-inpatient care (all 
patients) in terms of whole time equivalents by grade or clinical sessions by grade. 
9 The total number of beds that the inpatient staff cover (all patients). 
" The total number of clinical staff available for the inpatient and non-inpatient care of 
stroke patients (measured in terms of whole time equivalents by grade). 
" The role of each type/grade of clinician in the care of patients and the qualifications 
and experience that they need before they can be employed in that role. 
" The proportion of time spent by clinicians on clinical duties (as opposed to lecturing, 
research etc). 
(4)Cost category: Investigation costs 
Contact: Heads of departments providing CT scans, MRI, anglography, doppler 
and Echocardiogram services 
9 The average cost of providing each of these scans 
" For a CT scan the average staff time involved in conducting a scan and the type of 
equipment used. 
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(5) Cost category: Cost of therapy 
Contact: Physiotherapists/ Occupational therapists 
" The total number of therapists by grade/type available for inpatient and non-inpatient 
therapy (all patients). 
" The number of beds covered by the therapists 
" The number of hours that a therapist works per week. 
" The role of each type/grade of therapist in the care of patients and the qualifications 
and experience that they need before they can be employed in that role. 
0 The options for rehabilitation for stroke patients post discharge 
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(6) Cost category: Overall cost per hospital day 
Contact: A representative of the hospital finance department 
" The average cost per month of each grade of the following: 
(salary + any additional costs which employers have to pay) of all: 
nurses 
doctors 
therapists 
" The total inpatient and non-inpatient expenditure of the hospital over the most recent 
financial year. 
" The total number of occupied bed-days in the whole hospital during the most recent 
financial year 
The total inpatient spending in the department most relevant to stroke patients (e. g. 
neurology) on the following areas 
" Drugs 
" Consumables (e. g. surgical equipment, bandages etc) 
" Food 
" Transport 
" Maintenance (repairs to machinery etc) 
" Administration (secretarial costs, management costs both direct to the department 
or allocated from the central hospital) 
" Cleaning 
" Porters (people who move the patients from place to place) 
" Energy (Gas, electricity, water) 
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(7) More detailed study 
Contact: Centre co-ordinator. 
9 In order to find out more detailed information on the resource use associated with 
stroke care we would like if possible to look at the notes of patients with the project co- 
ordinator. The purpose of this study is to collect information on: 
" Staff contacts 
" Investigations 
" Drugs 
" To facilitate this, please could you have 10 sets of medical records available for us to 
look at with you on the site visit for patients who are about to be discharged or have been 
discharged from the study hospital. 
(8)Cost category: Other hospitals 
If stroke patients who are included in the Biomed centre are likely to be treated as 
inpatients at local/ rehabilitation hospitals we will need visit these centre and repeat the 
exercise there. 
(9)Cost category: Services in the community 
Contact: Centre co ordinator and representative from community rehabilitation facilites. 
" To discuss rehabilitation and other services which are available place in the 
community 
" Possibly to pilot a3 month questionnaire looking at resource use in the community 
353 
(10) General 
In addition to the above, we would be grateful for any other data that are routinely 
available which describe services used by stroke patients or the costs of stroke in your 
hospital or locality. 
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Using multilevel models for assessing the variability 
of multinational resource use and cost data 
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Summary 
Multinational economic evaluations often calculate a single measure of cost-effectiveness using cost data pooled 
across several countries. To assess the validity of pooling international cost data the reasons for cost variation across 
countries need to be assessed. Previously, ordinary least-squares (OLS) regression models have been used to identify 
factors associated with variability in resource use and total costs. However, multilevel models (MLMs), which 
accommodate the hierarchical structure of the data, may be more appropriate. This paper compares these different 
techniques using a multinational dataset comprising case-mix, resource use and cost data on 1300 stroke admissions 
from 13 centres in 11 European countries. OLS and MLMs were used to estimate the effect of patient and centre- 
level covariates on the total length of hospital stay (LOS) and total cost. MLMs with normal and gamma 
distributions for the data within centres were compared. The results from the OLS model showed that both patient 
and centre-level covariates were associated with LOS and total cost. The estimates from the MLMs showed that 
none of the centre-level characteristics were associated with LOS, and the level of spending on health was the centre- 
level variable most highly associated with total cost. We conclude that using OLS models for assessing international 
variation can lead to incorrect inferences, and that MLMs are more appropriate for assessing why resource use and 
costs vary across centres. Copyright Q 2004 John Wiley & Sons, Ltd. 
Keywords multilevel modelling; multinational studies; costing methodology; economic evaluation 
Introduction 
An increasing number of economic evaluations are 
being conducted on a multinational basis [1-6]. 
For example, RCTs often recruit patients from 
several countries and calculate an average measure 
of the effectiveness of the new intervention across 
the study centres. Multinational economic evalua- 
tions have then used these trial data, combined 
with a pooled measure of the incremental cost, to 
calculate a single, global measure of cost-effective- 
ness [4,5]. This practice has been criticised as unit 
costs, resource use and patient outcomes may all 
vary across countries [I]. To understand the 
implications of this variability on the design, 
analysis and interpretation of multinational cost- 
effectiveness studies, further research is needed on 
why these parameters vary across health care 
settings. 
A good starting point for assessing why cost- 
effectiveness varies across health care settings, is to 
examine why resource use varies, since resource 
use is associated with total costs and outcomes. 
Previous work has suggested that reasons for 
resource use variability may operate at different 
levels. For example Raikou et al. argue [7] that 
*Correspondence to: Health Services Research Unit, London school of Hygiene and Tropical Medicine, Keppel Street, London 
WCIE 7HT, UK. E-mail: richard. grieve@lshtm. ac. uk 
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relative price, which is usually measured at the 
level of the health care centre or country con- 
cerned, is likely to be important in determining the 
relative level of resource utilisation in different 
centres. The practice variations literature suggests 
that patient-level variables, in particular case-mix, 
are associated with resource use differences [8-10]. 
To investigate the accuracy (or inaccuracy) of 
pooling data across different health care settings, 
the extent to which these different factors are 
associated with variations in resource use needs to 
be investigated. The approach can then be 
extended to examine differences in cost and cost- 
effectiveness across settings. 
The reasons for variability should be assessed 
using appropriate analytical methods. Studies in 
this area have generally used ordinary least- 
squares (OLS) models [1,11]. These models assume 
that observations across patients are independent 
and have a common variance. This assumption 
would seem unlikely to hold when using data from 
different centres, as patients' resource use (or 
costs) within a particular centre may be more 
similar than that in different centres. Furthermore, 
centre-level variables included in an OLS model 
are considered as if they were measured at a 
patient level, thus spuriously inflating the amount 
of information they supply. By contrast, multilevel 
models (MLMs) are able to incorporate the 
hierarchical structure of the data (that is, of 
patients within centres), and provide more appro- 
priate estimates of patient and centre-level effects. 
MLMs have been recommended for use in health 
economics [12], but despite the obvious intuitive 
appeal of using MLMs to assess multinational 
resource use and cost data, they have not yet been 
used for this purpose. 
The aim of this paper is to compare the use of 
MLMs and OLS models for assessing the reasons 
for international resource use and cost variations. 
These methods are illustrated using an observa- 
tional costing study which included patient and 
centre-level data from 13 centres in 11 different 
European countries. 
Methods 
This study compares the use of OLS models and 
MLMs for estimating the extent to which factors 
are associated with length of hospital stay and 
total cost, The basic structure of MLMs and the 
Copyright 0 2004 John Wiley & Sons, Ltd. 
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rationale for their use in health care and health 
economics has been previously described (12-14], 
so only a summary is provided here. In our context 
of multinational data, patients (level-1 units) are 
nested within centres (level-2 units). 
Models 
An OLS regression model takes the form 
Yr = ßo + ßtx! + ej, et - Normal (0, a2) 
where y1 is the outcome variable for the ith patient, 
x1 is an explanatory variable, with associated slope 
coefficient ßI. ßo is the intercept and s,, the error 
term which represents unexplained variability 
between patients, is assumed to be normally 
distributed with a mean of zero. The OLS model 
assumes that the variance of the error term is the 
same for all patients. Extra explanatory variables 
can be included. One representing a centre-level 
covariate (z, say) necessarily takes the same value 
for all patients in a particular centre 
yt 2 ßo + ßIx, + ß2zi + er, ej - Normal (0, a2) 
Moving to a MLM structure changes the way the 
unexplained variation, the random error term, is 
modelled. The most basic MLM, the random 
intercepts model, includes an additional term 
which represents the unexplained variation that 
exists between centres. Using subscripts i and j for 
the ith patient in jth centre, the model may be 
written as 
yu = ßo + ß, xU + uj + eU, eU N Normal (0, ax), 
uj - Normal (0,, r 2) 
where ßo is a fixed quantity applying to all 
patients, uj is a random variable with zero mean 
and constant variance (s) which applies to the 
patients in centre j, and e, is a random error term 
which represents the unexplained variation for 
patients within a centre. uj indicates the random 
effect of centre on the outcome variable, over and 
above that explained by the set of explanatory 
variables. The intercept for the jth centre (pre- 
viously given as ßo) is now given as a fixed 
component (ßo) plus a random component (uj). 
The model can be developed by including addi- 
tional explanatory variables at the level of the 
patient. The regression coefficients (such as ßI) can 
also be allowed to vary between centres, but we do 
not use such `random slopes' models in this paper. 
health Icon. 14: 185-196 (2005) 
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Multilevel Models 
A centre-level explanatory variable, taking the 
value zJ for centre J, can be included as 
YýJ = ßo +ßAxJ +ß2zJ + uJ+ 80, 
ey- Normal (0, v2), uJ - Normal (0, s2) 
The variance r2 now represents the residual 
variability between centres not explained by the 
covariates [15]. Hence MLMs allow the effect of 
adding centre-level variables on the extent of 
unexplained variation between centres to be 
estimated. In addition, the degree of dependency 
between observations can be measured by the 
intra-class correlation coefficient (p) defined as 
p ., r2/(12 + a2). This reflects the strength of 
`nesting' within the data hierarchy. 
The basic MLM above assumes that the errors 
terms are normally distributed. However, resource 
use and cost data are usually not normally 
distributed [16]. Generalised linear models 
(GLMs) models have been recommended for 
analysing cost data [Barber JA, Thompson SG. 
Multiple regression of cost data: use of generalised 
linear models. J Health Serv Res Policy 2004, in 
press], as a variety of non-normal distributions can 
be specified but, unlike data transformations in 
OLS regression, they make inferences about the 
mean cost directly. A number of alternative GLMs 
were considered for our analysis. A gamma 
distribution model with random mean (8d), and 
different shape (0) parameters for each centre, 
was chosen as it fitted the positively skewed LOS 
and cost data reasonably well: 
yu -Gamma (Ou, ßßj), Ou ßo + ßixu + uj, 
uj ý Normal (0, i2) 
This 'generalised linear mixed model' (GLMM) is 
a type of multilevel model similar to model 2 in 
that it allows for random centre effects (uj), but it 
accommodates positively skewed data by the use 
of a gamma rather than a normal distribution, 
allowing the gamma distributions to have different 
shapes in each centre. Again this can be extended 
to include centre-level covariates zy. 
yu - Gamma (8u, Ij), 
9U = ßo + ßlxU + ß2zß + uJ, uj - Normal (0, t2) 
Data 
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costs and outcomes of different ways of providing 
stroke care across 13 centres in 11 different 
European countries. The methodology and main 
results have been reported elsewhere (18,19]. 
Briefly, the study centres recruited patients pro- 
spectively who had suffered a first-ever stroke and 
attended each of the study centres over a 1-year 
period during 1996--1997. Data were collected for 
3 months post-stroke. 
Patient-level variables 
Designated investigators at each centre completed 
standard forms to record patient-level variables 
[20]. Data were collected on patient characteristics 
(sex, age, pre-stroke living conditions); stroke 
severity measures (incontinence during the first 
week after stroke, dysphasia, paralysis at hospital 
admission) and stroke subtype (cerebral infarction, 
intra-cerebral haemorrhage, or unspecified stroke). 
The use of hospital and community services was 
recorded for three months post-stroke. The unit 
costs of each resource use item were collected in a 
consistent and disaggregated manner at each 
centre on site visits [18]. For example for labour 
inputs, the costs per hour of employing each grade 
of health care professional were measured, and 
multiplied by the level of labour inputs (hours per 
occupied bed-day) to give the labour costs per bed- 
day. Unit costs were initially reported in local 
currencies (1998 prices) and then converted into 
US dollars using the purchasing power parity 
(PPP) index to adjust for differences in the 
opportunity cost of resources across the economies 
concerned [21-23]. Finally, total 3-month costs 
($/PPP) were calculated for each patient. 
The main outcome measure for the original 
study was survival post-stroke, but for this 
analysis patients who had died during the 3 
months post-stroke were excluded. This was 
because our focus was on comparing methodolo- 
gies for assessing resource use and cost data, rather 
than trying to assess the role of outcome in 
understanding resource use differences. Some 
patient-level variables for the patients included in 
the analysis (n- 1298) are presented in Table 1. 
Centre-level variables 
The case-study used to compare these methods Data on centre-variables potentially associated 
was an observational study which compared the with resource use differences were obtained from 
Copyright ® 2004 John Wiley & Sons, Ltd. health Econ. 14: 185-196 (2005) 
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Table 1. Summary of patient-level variables 
R. Grieve et at. 
Centre N Mean (sd) 
LOS (days) 
Mean (sd) 
total cost 
(US $/PPP) 
Mean (sd) 
age (years) 
% paralysed % incontinent 
Spain 32 7.8 (6.3) 2805 (2514) 72.3 (8.4) 84 28 
Portugal 73 13.0 (14.2) 5405 (4353) 64.4 (11.5) 84 25 
Latvia 145 18.7 (11.1) 550 (370) 62.7 (10.0) 82 12 
Italy 109 20.2 (23.0) 4155 (2565) 74.2 (11.0) 81 40 
Finland 1 37 19.1 (20,2) 6170 (5293) 72.9 (9.4) 65 19 
France 105 24.2 (27.5) 6203 (5015) 70.9 (17.6) 69 18 
Lithuania 1 62 28.0 (13.5) 1439 (919) 69.9 (11.1) 89 25 
Poland 92 25.5 (15.9) 1659 (711) 69.6 (11.6) 95 20 
Lithuania 2 186 26.5 (16.5) 4072 (2303) 66.9 (10.5) 68 16 
Denmark 246 37.0 (33.7) 9311 (7983) 67.6 (13.9) 70 33 
UK 73 39.3 (33.8) 6515 (3215) 71.3 (11.8) 67 26 
Finland 2 81 36.5 (31.1) 9599 (7706) 70.1 (11.6) 74 35 
Finland 3 57 37.4 (29.0) 9036 (5815) 80.8 (7.3) 60 42 
Total 1298 27.3 (25.6) 5340 (5884) 69.3 (12.6) 77 26 
reviewing the literature, and visiting the centres 
concerned. The variables used in the analysis 
are presented in Table 2, and defined as follows: 
the level of health spending was taken as the 
proportion of Gross Domestic Product (% GDP) 
spent on public health care; the reimbursement 
system for acute hospital costs was defined as 
being either a global budgeting or a diagnosis- 
related group (DRG) system; the level of patient 
co-payment for acute care was recorded for 
each centre, and defined as a categorical (Yes/ 
No) variable. 
International price indices were constructed 
to estimate differences in the relative price of 
health inputs across the centres. Labour input 
prices were used to construct the indices as 
labour costs make up the majority of total stroke 
care costs [24]. Laspeyres price indices were 
calculated which weight the relative price of 
each input by the reference centre's resource 
volumes [25]. The French centre was taken 
as the reference centre as it had the median level 
of unit costs. Paasche indices were also con- 
structed which weight relative prices by each 
comparison centre's resource volumes [25]. The 
geometric mean of the Laspeyres and Paasche 
indices was calculated to give the Fisher price 
index [25]. The Fisher price index was used as the 
relative price variable in the analysis, and is 
presented in Table 2. 
Copyright © 2004 John Wiley & Sons, Ltd. 
Estimation 
An OLS regression model was fitted to estimate 
the effect of patient-level variables on the total 
length of hospital stay (LOS) (model 1). Variables 
were included if there was an a priori reason 
that they were likely to be associated with LOS, 
and were retained in the equation even if they did 
not reach conventional levels of significance. A 
series of diagnostic tests were performed for 
heteroscedasticity, multi-colinearity and correct 
functional form. The analysis was repeated 
with normal MLM random intercepts (model 2) 
and gamma GLMM random intercepts 
(model 3). The normal model was estimated by 
restricted iterative generalised least squares in 
MLwiN [30], equivalent to restricted maximum 
likelihood. The gamma models were fitted using 
Markov chain Monte Carlo methods in 
WinBUGS [31]. The LOS analyses were then 
repeated also including centre-level variables 
(models 4-6). Finally, each of the models with 
patient and centre-level variables were re-run with 
total cost as the dependent variable (models 7-9). 
For the total cost models price index was not 
considered as an independent variable as it is likely 
to be highly correlated with total cost. The 
goodness of fit of the different cost models was 
compared using log-likelihoods, and plots of 
deviance residuals [31], 
Health Econ. 14: 185-196 (2405) 
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Table 2. Summary of centre and country-level variables 
189 
National Method of Patient Unit costs Fisher Public Health reimbursement co-payment acute Price index Expenditure for acute for acute care (relative to 
(% share of GDP) hospital care? ($/PPP) French centre) 
Spain 5.4 Global budget No 239 0.88 
Portugal 5.2 DRG No 263 1.00 
Latvia 3.9 DRG Yes 23 0.07 
Italy 5.7 DRG No 333 1.00 
Finland 1 5.3 Global budget No 157 0.75 
France 7.3 DRG Yes 172 1.00 
Lithuania 1 5.1 DRG No 48 0.16 
Poland 4.7 Global budget No 112 0.38 
Lithuania 2 5.1 DRG No 50 0.15 
Denmark 6.8 Global budget No 234 1.00 
UK 5.6 Global budget No 194 0.87 
Finland 2 5.3 Global budget No 227 1.19 
Finland 3 5.3 Global budget No 112 1.18 
Sources: OECD Health Data 2001 [26], European Observatory on Health Care systems [27-29], Grieve et al. 1191 
GDP, Gross Domestic Product: DRG, Diagnostic Related Group. 
Results 
(i) LOS models with patient-level variables. The 
results from the OLS analysis suggested that most 
of the variables considered were associated with 
LOS (Table 3, model 1). Compared to the OLS 
model, the normal random intercepts model 
(model 2) gave somewhat different coefficients 
and standard errors, and the estimated significance 
of the covariates changed accordingly. For exam- 
ple, both age and independence pre-stroke had 
smaller coefficients and were no longer significant, 
whereas paralysis had a larger estimated effect. 
The random intercepts model (model 2) fitted the 
data better as shown by the lower level of 
unexplained variation at a patient level (a2) and 
the higher log-likelihood statistic. In addition, 
model 2 provided an estimate of the level of 
unexplained variation which existed between the 
centres. The results showed that the majority of 
the unexplained variation was among patients, 
rather than among centres, and the intra-class 
correlation coefficient (p) was 0.16. MLMs with 
random slope parameters were also fitted to the 
data, but as the results did not alter appreciably 
from the random intercepts model they -are not 
presented here. 
Diagnostic testing for the OLS model suggested 
that severe multi-colinearity was unlikely to exist, 
for example, the pairwise correlation coefficients 
between the explanatory variables did not exceed 
0.6. Heteroscedasticity was detected for the OLS 
model (p <0.001 by the Cook-Weisberg test [32]). 
It can be caused by using an incorrect functional 
form, and here the residuals were found to be non- 
normally distributed. The analysis was therefore 
repeated using a gamma model with intercept and 
slope parameter varying by centre (Table 3, model 
3). The estimated effect sizes and their associated 
standard errors differed somewhat from both the 
two previous models. For example, the coefficient 
for age was now larger and significant at the 5% 
level. The log-likelihood statistic indicated that the 
gamma model fitted the data substantially better 
than either of the other two models. 
(ii) LOS models with patient and centre-level 
variables. The models were re-fitted including 
centre-level variables (Table 4). The results showed 
that the estimated direction of effect for these 
variables was that anticipated by theory: proxies 
for the presence of incentives to discharge patients 
earlier -a DRG system, patient co-payments, or higher relative prices (Fisher price index) - were all 
associated with shorter LOS, whereas a higher 
proportion of GDP spent on health was associated 
with longer LOS. For the OLS analysis (model 4) 
each of these effects was statistically significant at 
the S or 10% level, However, the normal (model 5) 
and gamma random intercepts models (model 6) 
found that these centre-level variables were far 
Copyright ® 2004 John Wiley & Sons, Ltd. Health icon. 14.185-196 (2005) 
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Table 3. OLS, MLM and GLMM models estimating the effect of patient-level variables on length of hospital stay (LOS): coefficient (SE) 
Model 1: OLS Model 2: MLM 
Normal, with 
random intercept 
Model 3: GLMM 
Gamma, with 
random intercept 
Constant term 41.7 (5.5)** 29.5 (6.2)** 31.3 (4.8)"` 
Patient variables 
Age -0.10 (0.06)* -0.08 (0.05) -0.13 (0.04)** Independent pre-stroke -6.04 (2.38)** -3.22 (2.32) -4.82 (2.22)** Living alone Reference Reference Reference 
Living with others -8.23 (1.55)" -5.07 (1.55)** -0.65 (1,13) Living in nursing home -10.85 (4.61)** -8.49 (4.44)* 4.37 (4.31) Incontinent 19.29 (1.55)** 18.81 (1.49)** 15.65 (1.63)** 
Paralysed 7.34 (1.56)** 8.48 (1.50)** 2.45 (0.81)** 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 5.35 (2.13)" 5.80 (2.04)** 6.82 (1.65)** 
Unknown stroke type -2.27 (1.73) -7.71 (2.45)** -3.67 (1.13)** 
Onset to admission <6 h Reference Reference Reference 
Onset to admission 6-24h -0.55 (1.58) 0.59 (1.52) 0.77 (0.89) 
Onset to admission 1-7 days -0.96 (1.80) -0.70 (1.73) 1.22 (0.96) 
Onset to admission >7 days -1.33 (3.27) -0.85 (3.17) 0.28 (1.50) 
Onset to admission unknown 10.17 (2.64)"" 8.05 (2.60)** 6.39 (2.85)** 
Family support -1.53 (1.39) 2.51 (1.49)* 2.46 (0.81)** 
Community support -4.06 (1.71)** -5.76 (1.68)** -0.20 (1.04) 
Random effects 
c2 (within centres) 522 470 442 
s2 (between centres) 87 (37) 85 (47) 
Log-likelihood -5896 -5845 -5267 
"p <0.05. 
"p <0.10. 
from statistically significant. Although the coeffi- 
cients for the centre-level variables were generally 
similar for the three models, the standard errors 
were much smaller for the OLS model. The OLS 
model does not take into account the hierarchical 
structure of the data, and thus severely over. 
estimated the significance of these variables. The 
gamma model had the highest log-likelihood, and 
therefore fitted the data best. 
The variance terms for both multilevel models 
showed that most of the unexplained variation 
was, again, at the level of the patient rather than 
the centre (p-0.18 for the normal random 
intercepts model). The MLMs which included 
centre-level variables (models 5 and 6) had a 
similar extent of unexplained variation between 
centres, and a similar log-likelihood, compared to 
the models with just patient-level variables (models 
2 and 3). This showed that, once the hierarchical 
nature of the data was recognised, these centre- 
level variables did not help explain the variability 
in LOS between centres. 
Figure 1 shows the deviance residuals from 
models S and 6 in the form of normal plots. If a 
model is appropriate, deviance residuals should 
approximately follow a normal distribution and 
will lie along the line of identity shown in the plots. 
For the normal MLM (model 5), the residuals 
show considerable positive skewness, in keeping 
with the positive skewness of the raw LOS data. 
The residuals from the gamma GLMM (model 6) 
show a much better behaviour, indicating the 
greater appropriateness of this model for these 
data and confirming the improvement in fit shown 
by the log-likelihoods in Table 4. 
(iii) Total cost models with patient and centre- 
level variables. The results for total costs (Table 5) 
showed that the OLS models again severely 
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Table 4. OLS, MLM and GLMM models estimating the effect of patient and centre-level variables on length of hospital stay (LOS): coefficient (SE) 
Model 4: OLS Model S. MLM 
Normal, with 
random intercept 
Model 6: GLMM 
Gamma, with 
random intercept 
Constant term 15.3 (7.8)* 4.7 (24.6) 12.6 (26.1) 
Patient variables 
Age -0.08 (0.05) -0.07 (0.05) -0.13 (0.04)** Independent pre-stroke -3.84 (2.37) -3.13 (2.32) -5.09 (2.19)** Living alone Reference Reference Reference 
Living with others -6.29 (1.59)** -4.98 (1.56)** -0.73 (1.11) Living in nursing home -7.03 (4.55) -8.38 (4.44)* 4.25 (4.19) Incontinent 19.28 (1.53)** 18.82 (1.49)** 15.57 (1.65)** 
Paralysed 7.64 (1.54)** 8.52 (1.51)** 2.31 (0.84)** 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 6.03 (2.10)** 5.84 (2.04)** 6.84 (1.63)** 
Unknown stroke type -3.22 (2.17) -7.82 (2.48)** -3.74 (1.12)*" Onset to admission <6h Reference Reference Reference 
Onset to admission 6-24h 0.36 (1.56) 0.64(l. 52) 0.69 (0.88) 
Onset to admission 1-7 days -0.53 (1.78) -0.68 (1.73) 1.16 (0.97) 
Onset to admission >7 days -2.65 (3.25) -0.87 (3.17) 0.21 (1.53) 
Onset to admission unknown 6.66 (2.64)** 7.90 (2.60)** 6.12 (2.83)** 
Family support 1.72 (1.48) 2.67 (l. 49)* 2.46 (0.81)** 
Community support -6.37 (1.73)** -5.86 (1.69)** -0.31 (1.04) 
Centre variables 
% share GDP 5.71 (1.09)"* 6.58 (5.13) 5.39 (5.53) 
DRG system -8.11 (1.77)*" -6.16 (7.03) -4.96 (7.39) 
Price index -10.91 (2.58)`* -10.79 (10.26) -9.60 (10.93) 
Copayment -3.82 (2.19)* -4.92 (9.68) -3.93 (10.30) 
Random effects 
a2 (within centres) 502 470 369 
s2 (between centres) 102 (42) 120 (97) 
Log-likelihood -5868 -5845 -5268 
'"P<0.05. 
0p <0.10. 
underestimated the standard errors of the centre- 
level variables, so that their significance was 
overstated. Model 8, which correctly recognises 
the hierarchical structure of the data, estimated 
that the only centre-level variable which was 
significantly associated with total cost was the % 
share of GDP spent on health care. Model 9 which 
incorporated the hierarchical structure of the data 
and used a more appropriate functional form 
which better fitted the data, again found that only 
% GDP was associated with total cost. Like the 
LOS models, the proportion of unexplained 
variability in total costs between patients was 
substantially higher that between centres 
(p = 0.16). 
Discussion 
This study compared the use of OLS and MLMs 
for assessing which factors were associated with 
international resource use and cost variation. The 
results showed that the OLS analysis severely 
overestimated the precision of the centre-level 
associations, and made incorrect inferences. 
MLMs were more appropriate for analysing the 
multinational data, and led to different results. In 
particular, whereas the OLS analyses found that 
all the centre-level variables considered were 
associated with resource use and total cost, the 
MLM analysis showed that, once the hierarchical 
nature of the data was recognised, none of these 
Copyright © 2004 John Wiley & Sons, Ltd. Health Econ. *4: 185-196 (2005) 
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Figure 1. Quantiles of the standardised deviance residuals from length of hospital stay (LOS) plotted against the quantiles from a 
standard normal distribution 
variables predicted resource use and only the level 
of health spending was associated with total cost. 
The reason for this is as follows [15]. In an OLS 
regression of, say, cost on % GDP, all 1298 patient 
costs are considered. Thus the regression line is 
very precisely estimated (Figure 2a). In a MLM 
regression, the correct hierarchical structure of the 
data is recognised, and essentially the mean cost in 
each of the 13 centres is regressed on % GDP. The 
resulting regression line is imprecisely estimated 
(Figure 2b). In this example, the regression lines 
for the OLS and MLM analyses have a similar 
slope. However, the SE is much larger in the MLM 
since it involves a regression of 13 rather than 1298 
points. OLS regression models also give incorrect 
results for the effects of patient-level variables 
because of differences between centres which are 
not accounted for in the analysis -a bias due to 
confounding. MLMs avoid this bias. 
Economic evaluations are often criticised for 
lacking generalisability [33], particularly as costs 
may differ between locations [34]. Despite this, 
economic evaluations rarely examine why costs 
vary across settings and the few studies which have 
considered this issue have relied upon OLS 
analysis [1,11]. Our results indicate that those 
studies which used OLS analyses to identify 
factors associated with resource use and cost 
Copyright ® 2004 John Wiley & Sons, Ltd. 
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differences may have reached erroneous conclu- 
sions (I I]. Other studies have used OLS to analyse 
variation in costs across centres (1]. Whilst this 
approach allows valid conclusions to be drawn 
about the magnitude of cost variation between 
centres, it does not consider why costs and cost- 
effectiveness vary across health care settings. 
Similarly, whilst tests for interactions can assess 
whether there is significant variation across centres 
[35], they are not suitable for assessing the reasons 
for cost variability. MLMs allow correct inferences 
to be made about which factors are associated with 
cost variation. This can help decision-makers 
assess the applicability of results to their local 
setting. In this study the centre-level variable 
which explained most cost variation was the 
national level of spending on health care. This 
variable could therefore be used, alongside patient- 
level variables, to predict stroke costs for centres 
outside the study. This illustrates how MLMs can 
be used to improve generalisability. 
Using MLMs to assess cost variation could also 
assist in the design of multinational economic 
evaluations. Currently, multinational evaluations 
often only measure costs for a subsample of 
centres recruited to the overall study [1-6]. The 
choice of centres for the costing sub-study is 
usually based on pragmatic grounds, rather than 
IJealth Ecan, It 185-196 (2005) 
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Table 5. OLS, MLM and GLMM models estimating the effect of patient and centre-level variables on total cost: 
coefficient (SE) 
Model 7: OLS Model 8: MLM 
Normal, with 
random intercept 
Model 9: GLMM 
Gamma, with 
random intercept 
Constant -4470 (1432)** -6156 (4353) -2034 (6529) 
Patient variables 
Age -10.0 (10.8) -6.2 (10.8) -7.4 (2.6)*' Independent pre-stroke -916 (478)* -831 (467)* -3985 (3679) Living alone Reference Reference Reference 
Living with others -1344 (316)** -1309 (309)** -20 (86) Living in nursing home 412 (917) 0 (892) 994 (602) 
Incontinent 3657 (3l0)** 3561 (300)** 942 (176)** 
Paralysed 1709 (309)** 1811 (302)** 56 (54) 
Ischaemic stroke Reference Reference Reference 
Haemorrhagic stroke 985 (424)** 971 (411)** 182 (116)* 
Unknown stroke type -2140 (385)** -1110 (497)'"` -244 (69)** Onset to admission <6h Reference Reference Reference 
Onset to admission 6-24h -125 (315) -141 (305) -5 (62) Onset to admission 1-7 days -400 (358) -500 (348) 39 (64) 
Onset to admission >7 days -740 (652) -300 (638) -54 (82) Onset to admission unknown 1836 (531)** 2063 (523)""'' 419 (280)* 
Centre variables 
% share GDP 2042 (155)** 2200 (755)** 2218 (946)** 
DRG system -1688 (354)** -1475 (1259) -1860 (1560) 
Price index NA NA NA 
Copayment -1722 (405)** -1637 (1758) -1477 (2153) 
Random effects 
oZ (within centres) 20.5 x 106 19.1 x 106 18.3 x 106 
r2 (between centres) 3.6 (1.5) x 106 5.8 (4.4) x 106 
Log-likelihood -12761 -12731 -11800 
"p <0.05. 
"p <0.10. 
NA not applicable. 
on any rational basis. Instead factors identified as 
being associated with total costs could be used to 
choose where best to measure costs. For example, 
if the level of health care spending is associated 
with total or incremental costs, then centres could 
be selected which were broadly representative of 
countries with high, medium or low levels of 
spending on health care. Decision-makers in each 
of these settings could then base their decisions 
about relative cost-effectiveness on relevant cost 
data. Perhaps more importantly, the use of MLMs 
reveals the need to have data available from 
enough centres to enable the effects of centre-level 
variables to be estimated with adequate precision. 
One preferred strategy is therefore to undertake 
costing sub-studies on a random selection of 
patients from all centres, rather than on all 
patients from only selected centres. 
Apart from correctly estimating coefficients and 
standard errors for patient and centre-level vari- 
ables, the MLM approaches provide additional 
information. In particular, the extent of residual 
variation is reported at both patient and centre 
level. For this dataset there was some residual 
variation in resource use and costs across the 
health care centres, which may reflect differences in 
technical or scale efficiency. However, the intra- 
class correlation coefficient (p), which reports the 
proportion of the variability at the centre-level, 
was relatively low (0.16). This shows that most of 
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Figure 2. The relationship between cost and % share of GDP, based on (a) ordinary least-squares regression, (b) multilevel 
modelling; 95% confidence interval for the regression lines shown 
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the residual variation was at the patient level and 
suggests that unmeasured differences in patient 
characteristics (such as socioeconomic status) may 
be important in explaining overall variation. 
Whilst p is useful for understanding the degree to 
which variability exists at different levels, it should 
not be used as a basis for accepting or rejecting the 
use of the MLM approach. As is clear from the 
examples in this paper, OLS methods can be 
severely misleading even when p is small. 
Previous MLMs in health economics have 
assumed that the residuals are normally distrib- 
uted [14]. This assumption is unlikely to hold when 
the variable of interest is total cost per patient, or a 
measure of cost-effectiveness such as incremental 
net-benefit. Although generalised linear models 
(GLMs) have been recommended and used for 
analysing cost data [Barber, 2003, [17]], they have 
not previously been evaluated in hierarchical 
models for analysing cost or cost-effectiveness 
data. This study demonstrated their use in analys- 
ing hierarchical cost data. The GLMM random 
intercept model with the gamma distribution fitted 
the data better than the MLM random intercept 
model which assumed a normal distribution. This 
suggests that GLMMs are an attractive alternative 
for analysing multinational resource use and cost 
data. 
Previous multicentre costing studies have 
struggled to assess cost variation partly because 
unit costs have not been measured in each centre, 
and the costing methodology used has differed by 
location (6]. Although the case-study described 
was not a full cost-effectiveness analysis, it was 
chosen for this evaluation as it enabled cost 
variation to be carefully assessed. In particular, 
detailed resource use, unit costs and outcomes 
were collected in each centre using a consistent 
methodology. The numbers of patients and centres 
were reasonably similar to the numbers which 
could be recruited to an international economic 
evaluation, which made it a realistic setting for 
testing the usefulness of MLM versus OLS for 
assessing cost variability. The technique could be 
applied to multicentre (national or international) 
economic evaluations, where the net-benefit is 
reported for individual patients, and the incre- 
mental net-benefit of the new treatment is esti- 
mated using regression analysis [35,36]. To fully 
test the use of MLMs for multicentre economic 
evaluations, future studies are needed which 
measure resource use and unit costs in more 
centres using consistent costing methodologies. 
Copyright ® 2004 John Wiley & Sons, Ltd. 
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